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“Man’s mind is his basic tool of survival. Life is given to him, 
survival not. His body is given to him, its sustenance is not. 
His mind is given to him, its content not. To remain alive, he 
must act, and before he can act he must know the nature 
and purpose of his action. He cannot obtain his food without 
a knowledge of food and of the way to obtain it. He cannot 
dig a ditch -or build a cyclotron- without a knowledge of his 
aim and of the means to achieve it. To remain alive, he must 
think.”
Ayn Rand, 
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Chapter 1
General introduction and outline of thesis
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The immune system is typically divided into innate and adaptive immunity. T- 
and B-lymphocytes mediate the adaptive immune responses, while monocytes, 
macrophages, neutrophils, and NK-cells are considered to be the main cellular 
effectors of innate immunity. It is generally thought that only the adaptive immune 
responses can build immunological memory, while this property is missing from 
the cells of innate immune responses. However, this paradigm has recently been 
challenged. In recent years there is increasing evidence showing that also the 
innate immune system possesses adaptive characteristics (1). Interestingly, in non-
vertebrates and even plants, both lacking an adaptive immune system, it has already 
been known for several decades that a memory response can be built, protecting from 
secondary infections (2). Interestingly, in contrast to adaptive immune responses, 
the innate immune memory (also called trained immunity) is not strictly specific, as 
infection with one pathogen often also protects from other non-related pathogens 
(3). The molecular substrate for the induction of trained immunity has been shown to 
be epigenetically regulated (4). 
 During the last few years it was shown that human monocytes and macrophages 
can build trained immunity after certain infections or vaccinations. When monocytes 
are exposed in vitro for 24h to microbial structures such as β-glucan  (a component 
of the Candida albicans cell wall) or muramyl dipeptide (MDP) or to the tuberculosis 
vaccine BCG, and a week later restimulated with non-related pathogens, they display 
a significant increase in cytokine production (5, 6). This non-specific memory was 
shown to be the result of a rearranged epigenetic landscape of these cells. Improved 
DNA accessibility due to histone modifications leads to increased capacity of the 
cells to respond with gene transcription (6-8). Also in mice, an in-vivo challenge with 
β-glucan protected from a subsequent S. aureus challenge (5, 9, 10), and infection 
with cytomegalovirus improved effector function of NK-cells (11). Similar effects were 
reported in vivo in young infants vaccinated with Bacillus Calmette-Guérin (BCG), 
who showed non-specific protection from all-cause mortality, mainly as a result of 
reduced mortality due to neonatal sepsis and respiratory tract infections (12, 13). To 
further assess this effect of BCG vaccination, and to determine whether this could be 
the result of modulation of the innate immune system, healthy volunteers received 
the BCG vaccine and ex-vivo cytokine responses of PBMCs were assessed at later 
time points. In this well-controlled setting, innate cytokine production was increased 
after vaccination as a result of epigenetic reprogramming in myeloid cells (6). 
 Taking these data together, this shows that the innate immune system is able to 
adapt through functional and epigenetic reprogramming, a process termed trained 
immunity or innate immune memory (1, 14). Trained immunity can be considered an 
important host defense mechanism contributing to and mediating the maturation of 
the innate immune system of infants and mediating protection after certain infections 
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or vaccinations. On the other hand, one should however not underestimate that when 
induced inappropriately, trained immunity might also play a role in the pathogenesis 
of autoinflammatory diseases or atherosclerosis (1, 14, 15). Better understanding of 
the molecular mechanisms of trained immunity is crucial for designing novel more 
effective vaccines, as well as developing new ways of immunotherapy and targeting 
inflammatory disorders (1). 
 In this thesis I will examine in the first place the immunomodulatory effect of the 
BCG vaccine on the innate immune system in humans. So far it was only shown 
that BCG vaccination increases cytokine production by epigenetic modulation 
of monocytes. Whether this indeed results in an infectious-disease protective 
phenotype and whether this can be applied in e.g. immune compromised patients, 
will be examined in the first part of this thesis. In the second part of this thesis 
I will investigate the mechanisms that underlie the induction of trained immunity, 
with a focus on the interaction between immune and metabolic pathways. Since, 
by understanding which molecular mechanisms are important for the induction of 
trained immunity, these pathways could specifically be enhanced or inhibited to 
induce or inhibit trained immunity in certain disease processes.
Induction of trained immunity by BCG in humans
As BCG is a live-attenuated vaccine it cannot be used in patients with immune 
deficiencies. In order to tackle this problem, I will assess the immunomodulatory 
potential of γ-irradiated BCG (γBCG): can it induce similar specific and trained 
immunological memory as the normal BCG vaccine? I therefore γ-irradiated the 
vaccine and tested its ability to induce trained immunity. In Chapter 2 I will examined 
the capacity of γBCG to induce trained immunity in vitro, as well as in vivo in a 
vaccination trial in healthy volunteers. Furthermore, in Chapter 3 I will investigate 
the capacity of γBCG to restore immune function in an experimental human model of 
LPS-induced tolerance (immunoparalysis), used as a model for sepsis. 
 WHO recommends high-dose vitamin A supplementation in countries at risk of 
vitamin A deficiency (16). Observational data suggest that vitamin A might have non-
specific effects itself as well, just as seen for BCG (17). In Chapter 4 I will therefore 
assess the non-specific effects of vitamin A on monocytes and macrophages and 
examine whether vitamin A influences the induction of trained immunity by BCG. 
This might give important clues for vitamin A supplementation policy and future trials. 
 It is hypothesized that BCG-induced trained immunity can protect against infections 
with non-related pathogens, based on the observational data and the immunological 
results so far. In order to test this hypothesis in a controlled setting, in Chapter 5 we 
will use yellow fever vaccination as a human infection model, as vaccination with this 
live-attenuated vaccine will result in viraemia. Healthy volunteers will be vaccinated 
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with placebo or the BCG vaccine and a month later challenged with the yellow fever 
vaccine. The in-vivo effects of BCG on a viral infection will be assessed, and how 
these correlate with the in-vivo induction of trained immunity. This would be the first 
trial examining the link between the induction of trained immunity and an infection in 
an in-vivo human situation.  
 In Chapter 6 I will review the (potential) non-specific effects of all commonly 
administered vaccines and discuss the potential effects of changes in the current 
schedule. 
Mechanisms for the induction of trained immunity: the interaction between 
immune and metabolic pathways
In recent years it has become clear that cellular metabolism is crucial for the 
functional state of immune cells (18). This started with the observation that different 
lymphocyte subsets display markedly different activation of metabolic pathways (19, 
20). Once a T-cell becomes activated it shows high rates of both glycolysis and 
oxidative phosphorylation (OxPhos) and mainly metabolizes glucose to lactate (21, 
22). Memory T-cells on the other hand rely more on lipid synthesis by mitochondrial 
citrate production. Citrate is subsequently used to produce triacylglycerides (TAGs) 
for degradation by β-oxidation to fuel OxPhos via acetyl-CoA production (23). 
This in contrast to regulatory T-cells that use exogenously derived fatty acids to 
fuel β-oxidation and OxPhos (24). Later studies show that different macrophages 
subtypes also display distinct metabolic pathways. The anti-inflammatory (M(IL-4) or 
formerly M2) macrophages rely on OxPhos (25, 26) and show increased β-oxidation 
of fatty acids (27), while pro-inflammatory (M(IFNγ) or formerly M1) macrophages 
largely depend on glycolysis with disruption of the tricarboxylic acid (TCA) cycle (28, 
29).
 A metabolic switch from OxPhos to glycolysis resulting in more lactate production, 
called the Warburg effect, was first described in highly metabolic active cancer 
cells (30). A similar switch was found to be essential in the induction of β-glucan 
trained monocytes (31). The benefit from the Warburg effect lies in the fact that 
glycolysis can be more strongly upregulated than OxPhos. Therefore, the Warburg 
effects results in a faster production of ATP, which is essential in activated cells 
(30). Under such circumstances the TCA cycle is no longer used catabolically, but 
only to shift citrate towards production of acetyl-CoA necessary for production of 
phospholipids and cholesterol. Glucose consumption and lactate production by 
β-glucan-trained monocytes and macrophages is increased, whereas oxygen 
consumption is significantly decreased compared to control macrophages (31). 
Transcriptional and epigenetic (H3K4me3 and H3K27ac) analysis of β-glucan-
trained monocytes revealed that genes in the Akt/mTOR/HIF-1α signaling pathway 
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and several metabolic pathways, especially glycolysis, were highly induced (7, 31). 
Inhibiting these pathways at several levels, or making use of myeloid cell specific 
Hif-1α knockout mice, abrogated induction of trained immunity both at cytokine and 
epigenetic level (31).
 In the second part of this thesis I will examine additional metabolic changes 
induced during activation of trained immunity, since for example from the field of 
cancer metabolism it is very well know that other metabolic pathways apart from 
glycolysis play important roles for changes in cellular phenotype. In this second 
part I will also assess the metabolic changes in immune tolerance in human 
sepsis, an almost unexplored field, which could give important clues for potential 
‘immunometabolic therapy’. 
 Whether metabolic changes occur in BCG-induced trained immunity is unknown, 
just as the potential interaction with epigenetic changes. In Chapter 7 potential 
metabolic changes in BCG-induced trained immunity are being studied, just as the 
concurrently occurring epigenetic changes. Furthermore, I will assess whether these 
changes also take place in vivo in humans after BCG vaccination, translating our 
previous findings into a more clinically relevant condition. 
 An interesting and relatively new field of research is metaboloepigenetics, where 
the influence of metabolites or metabolic pathways on the epigenome is being 
assessed. This, as certain metabolites can serve as donors (e.g. acetyl CoA) or 
cofactors (e.g. α-ketoglutarate) in epigenetic modulations (32, 33). In Chapter 8 I 
will therefore examine whether glutamine metabolism and TCA cycle metabolites 
play a role in the induction of trained immunity by β-glucan. Hence, examining 
other ways of modulating the induction of trained immunity. Apart from glutamine 
metabolism and the TCA cycle, also the cholesterol synthesis pathway is highly 
induced in β-glucan-induced trained immunity. In Chapter 9 I will examine whether 
this induction is essential for the induction of trained immunity and we assess the 
role of intermediates in this pathway, in this process. In addition, we will examine 
whether modulation of the cholesterol synthesis pathway could be the underlying 
mechanism in the pathophysiology of hyper-IgD syndrome (HIDS). In other words, 
whether trained immunity could be the cause of the pro-inflammatory profile of the 
monocytes of these patients and therefore causing the disease symptoms. This 
approach could give new insights into the pathophysiology of this disease, and 
therefore open a new therapeutic avenue. 
 Apart from trained immunity, metabolic changes could also play a role in 
innate immune tolerance. Although, this is a completely unexplored field. Immune 
tolerance can be considered as the opposite of trained immunity, as monocytes and 
macrophages become less responsive due to epigenetic changes. This is a well-
known cause of mortality in sepsis patients at intensive care units. As metabolic 
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changes play a role in trained immunity, it is likely that the same is true for innate 
immune tolerance. This might lead to hypotheses for therapeutic options in innate 
immune tolerance. In Chapter 10 I will examine the metabolic changes in monocytes 
in in-vitro induced immune tolerance and in monocytes from septic patients and 
assess whether they can be reversed. 
 Also in the tumor microenvironment macrophages are reprogrammed, resulting 
in long-term changes in the phenotypes of the macrophages. As a result of exposure 
to the tumor and to the changed microenvironment, tumor-associated macrophages 
might also undergo epigenetic and metabolic changes that are essential in this 
reprogramming. These changes are examined and discussed in Chapter 11 in a 
model for thyroid cancer, again also exploring potential therapeutic interventions. In 
Chapter 12 I will give an overview of all known metabolic pathways essential for the 
induction of trained immunity and summarize the chapters of the second part of this 
thesis. 
 Finally, I will discuss the findings presented in this thesis in Chapter 13 and 
give an overview of important future experiments to be performed and the potential 
clinical applications of innate immune memory. 
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Part I
Trained Immunity induced 
by BCG

Chapter 2
Long-term in-vitro and in-vivo effects of 
γ-irradiated BCG on innate and adaptive 
immunity
Rob J.W. Arts*, Bastiaan A. Blok*, Peter Aaby, Leo A.B. Joosten, Dirk de Jong, Jos 
W.M. van der Meer, Christine S. Benn, Reinout van Crevel, Mihai G. Netea. 
*These authors contributed equally to this work
J Leukoc Biol 2015;6:995-1001
Chapter 2
  20 | 
ABSTRACT
BCG vaccination is associated with a reduced mortality from non-mycobacterial 
infections. This is likely to be mediated by a combination of innate immune memory 
(‘trained immunity’) and heterologous effects on adaptive immunity. As such, BCG 
could be used to boost host immunity, but not in immunocompromised hosts, as it 
is a live-attenuated vaccine. We therefore assessed whether inactivated γ-irradiated 
BCG (γBCG) has similar potentiating effects. In an in-vitro model of trained immunity, 
human monocytes were incubated with γBCG for 24h and restimulated after 6 
days. Cytokine production and the role of pattern recognition receptors and histone 
methylation markers were assessed. The in-vivo effects of γBCG vaccination were 
studied in a proof-of-principle trial in 15 healthy volunteers. γBCG induced trained 
immunity in vitro, via the NOD2 receptor pathway and upregulation of H3K4me3 
histone methylation. However, these effects were less strong than those induced 
by live BCG. γBCG vaccination in volunteers had only minimal effects on innate 
immunity, whereas a significant increase in heterologous Th1/Th17 responses was 
observed. γBCG induces long-term training of innate immunity in vitro. In vivo, γBCG 
induces mainly heterologous effects on the adaptive immune system, while effects 
on innate cytokine production are limited. 
Long-term Effect of γBCG on Immunity 
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 2The live-attenuated Bacillus Calmette-Guérin (BCG) vaccine protects against 
extrapulmonary infection with Mycobacterium tuberculosis and against leprosy (1, 
2).  In addition, mounting evidence shows that vaccination with BCG also has non-
specific protective effects: early administration of BCG vaccination at birth leads to 
reduced child mortality, mainly as a result of reduced neonatal sepsis, respiratory 
infections, and fever (3-5). Furthermore, BCG is used in patients with bladder cancer 
to induce immune stimulating effects and slow tumor progression (6) and the vaccine 
is also being investigated for potential protective effects against atopic diseases (7). 
Two main effects have been suggested to mediate the non-specific effects of BCG 
vaccination: potentiating effects on adaptive immune responses (‘heterologous 
immunity’) and epigenetic reprogramming with functional priming of human 
monocytes (‘trained immunity’) (8-10). Upon stimulation with non-mycobacterial 
pathogens of cells isolated from BCG-vaccinated individuals, both the adaptive and 
the innate immune system demonstrate a primed status and are able to react faster 
and more efficient to a secondary (and non-related) stimulus (8, 9, 11). 
 A major drawback of BCG being used for eliciting these effects clinically, is that 
it is a live microorganism that cannot be used for vaccination in immunodeficient 
individuals (e.g. HIV-infected, post-sepsis immunoparalysis), who are the group of 
patients most likely to benefit from such effects (12). Vaccination with γ-irradiated 
BCG (γBCG) could be an attractive alternative, in case that the γBCG would 
demonstrate similar potentiation of heterologous and/or trained immunity. In this 
study we investigated the non-specific long-term in-vitro and in-vivo effects of γBCG 
on the innate and adaptive immune responses.
MATERIALS AND METHODS
Subjects - The in-vitro experiments were performed on cells isolated from healthy 
blood donors. For the in-vivo BCG vaccination study, fifteen healthy individuals 
(age range 20-34 years, 9 female and 6 male) were included after they had given 
informed consent between November and December of 2013. One volunteer was 
lost to follow-up after 8 weeks, because she moved abroad, therefore the time point 
3 months after vaccination contains only data of 14 volunteers. Blood was drawn 
before, and 2 weeks, and 3 months after vaccination with 0,075mg γBCG. The 
study was approved by the Arnhem-Nijmegen Medical Ethical Committee and was 
registered at ClinicalTrials.gov as NCT02259608.
γ-Irradiation - Vials with live-attenuated BCG (Statens Serum Institut, Denmark) 
were irradiated in the original packaging with an average dose of at least 30kGy (13, 
14) in a JS6500 Tote Box Irradiator. γ-irradiation was performed by Synergy Health 
Ede B.V., Ede, The Netherlands. The inactivated BCG was cultured for 6 weeks to 
confirm inactivation.
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In-vitro monocyte stimulation - For the in-vitro model of trained immunity, 
PBMCs were isolated by density gradient using Ficoll-Paque of buffy coats from 
healthy volunteers (Sanquin, Nijmegen), after which monocytes were obtained by 
1h adherence and washing in 96-well flat-bottom culture plates (5x10^5 PBMCs 
per well in 100µl volume). Monocytes were stimulated for 24h with either RPMI 
(control culture medium), live-attenuated BCG (10µg/ml, Statens Serum Institut, 
Denmark), heat-killed BCG (1h at 100oC), or γBCG. In some experiments the 
histone methyltransferase inhibitor MTA (1mM, Sigma-Aldrich, MO, USA) or a 
demethylase inhibitor pargyline (3µM, Sigma), or Bartonella quintana LPS (a potent 
TLR4 antagonist (15), 20ng/ml) was added. After 24h, cells were washed with PBS 
to remove the stimuli and cells were rested in RPMI 1640 supplemented with 10% 
human serum for 6 days. On day 7 monocytes were restimulated with different stimuli 
including E. coli LPS (10ng/ml, Sigma), Pam3Cys (10µg/ml, EMC microcollections, 
Tuebingen, Germany) or heat-killed Staphylococcus aureus (1x10^7 organisms/ml, 
clinical isolate). In TLR4-blocking experiments cells were restimulated with PolyI:C 
(50µg/ml, Invivogen, San Diego, CA, USA) and flagellin (5µg/ml, Sigma) to assess 
non-TLR4 driven cytokine responses. After 24h, supernatant was collected and 
cytokines were measured by ELISA. 
PBMC isolation and ex-vivo stimulation of leukocytes isolated from the 
vaccinated volunteers - Isolation and stimulation was performed as described 
before (8, 9). Briefly, PBMCs were isolated from the healthy volunteers before and 
after BCG vaccination by density centrifugation of Ficoll-Paque and diluted to a 
concentration of 5x10^6/ml. 100µl/well was added to 96-well plates and cells were 
incubated for 24h (IL-6, TNFα, IL-1β), 48h (IFNγ) or 7d (IL-17, IL-22) with RPMI, 
sonicated Mycobacterium tuberculosis H37Rv (1µg/ml), heat-killed Candida albicans 
(1x10^6/ml, strain UC820) or Staphylococcus aureus (1x10^6/ml) in the trial. 
Cytokine Measurements - Cytokine measurements were performed in the 
supernatants using commercial ELISA kits from R&D Systems (TNFα, IL-1β, IL-
17 and IL-22; Minneapolis, MN, USA) or Sanquin (IL-6, IFNγ; Amsterdam, The 
Netherlands). 
Chromatin immunoprecipitation - To assess epigenetic markers associated with 
inflammatory changes, monocytes (10x10^6 cells/well in 2ml volume) were cultured 
in vitro in 6-well plates. Cells were stimulated for 24h with RPMI or γBCG (10µg/ml), 
after which the stimuli were washed away. After resting for 6 days in culture medium, 
the control and γBCG-primed cells were harvested and fixed in methanol-free 
formaldehyde 1%. Afterwards, cells were sonicated and immunoprecipitation was 
performed using antibodies against H3K4me3 (Diagenode, Seraing, Belgium). After 
ChIP, DNA was processed further for qPCR analysis. Samples were analyzed by a 
comparative Ct method in which myoglobulin was used as a negative control and H2B 
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were used for this analysis: myoglobulin forward AGCATGGTGCCACTGTGCT; 
myoglobulin reverse GGCTTAATCTCTGCCTCATGAT; H2B forward 
TGTACTTGGTGACGGCCTTA; H2B reverse CATTACAACAAGCGCTCGAC; 
TNFA forward GTGCTTGTTCCTCAGCCTCT; TNFA reverse 
ATCACTCCAAAGTGCAGCAG; IL6 forward AGGGAGAGCCAGAACACAGA; IL6 
reverse GAGTTTCCTCTGACTCCATCG.
Statistical analysis - Differences were analysed using Wilcoxon signed-rank test or 
Mann-Whitney U test where applicable. All calculations were performed in Graphpad 
prism 5 (CA, USA). p < 0.05 was considered statistically significant. Data are shown 
as means ± SEM.
RESULTS
Inactivated BCG induces trained immunity in vitro
Preincubation of monocytes with live BCG and inactivated γBCG led to a significant 
2- to 4-fold increase in IL-6 and TNFα production upon restimulation with LPS one 
week later, compared to preincubation with culture medium only (Figure 1A,B). 
Cytokine production directly after BCG stimulation did not differ between the different 
Figure 1. BCG and γBCG priming of monocytes increases cytokine production upon restimulation 
with LPS. (A,B) Adherent monocytes from healthy volunteers were incubated with γBCG (A), live BCG 
(B) or RPMI for 24h, then washed with PBS and rested for 6 days. On day 7 monocytes were rechallenged 
for 24h with LPS or culture medium. Cytokine production in supernatant was assessed with ELISA. (C,D) 
Training cells with live-attenuated, heat-killed and γBCG increased IL-6 (C) and TNFα (D) production upon 
stimulation with LPS compared to priming with medium. Cytokine levels in RPMI restimulated samples 
were all below detection limit. Wilcoxon matched pairs signed rank test. To compare fold changes between 
live BCG and γBCG the Mann-Whitney U test was used. (n≥6, * p < 0.05).
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forms of BCG (data not shown).  Inactivation of BCG by γ-irradiation or heat-killing 
had similar effects as live BCG, although in a lower magnitude (Figure 1C,D). 
Training of monocytes with γBCG is NOD2 dependent and not TLR4 depen-
dent
To address the role of TLR2, TLR4 and NOD2 in BCG-induced trained monocytes, 
the following experiments were performed. Firstly, blocking of TLR4 or TLR2 by the 
addition of a potent TLR4 inhibitor (LPS derived from Bartonella quintana)  or an 
αTLR2 antibody during pre-incubation with live BCG and γBCG did not significantly 
influence the magnitude of trained immunity (Figure 2A-D). Addition of B. quintana 
LPS alone did not lead to priming of cytokine responses (data not shown). Secondly, 
previous studies have shown an important role for NOD-like receptor 2 in the 
immune recognition of BCG and the induction of trained immunity by live BCG (8). A 
potential role of NOD2 for the induction of trained immunity by γBCG was validated 
by experiments showing that monocytes isolated from NOD2-deficient patients 
(homozygous for the 3020insC; rs2066847 mutation) have decreased induction 
of trained immunity when preincubated with γBCG and restimulated with LPS or 
Pam3Cys (Figure 2E,F). 
γBCG induces epigenetic changes in histone methylation
Pre-incubation of monocytes with live BCG and γBCG led to a significant upregulation 
of histone trimethylation at the histone 3 lysine 4 (H3K4) position of the TNFA and IL6 
promoters, a histone mark previously associated with trained immunity. The effect of 
live BCG was stronger than that of γBCG (Figure 3A and B). The importance of histone 
methylation for the induction of trained immunity was further demonstrated by the 
inhibition of both live BCG and γBCG effects by the addition of a methyltransferase 
inhibitor MTA during the preincubation period. In contrast, the demethylase inhibitor 
pargyline had no effects on monocyte training (Figure 3C and D).
Vaccination with γBCG induces heterologous immunity, but no trained im-
munity in vivo
A group of healthy volunteers were vaccinated with γBCG to assess its effect on both 
innate and adaptive immune responses. γBCG vaccination significantly increased 
the production of innate immune cytokine IL-1β and IL-6 induced by M. tuberculosis, 
but not by the other microbial stimuli, showing that vaccination with inactivated BCG 
has only minimal effects on innate immune responses (Figure 4). 
 In contrast, heterologous immune responses represented by the production of 
IFNγ and IL-22 was significantly upregulated 2 weeks and 3 months after vaccination 
with γBCG compared to baseline, when restimulation was performed with either S. 
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Figure 2. Training with γBCG is dependent on the NOD2-receptor. (A,B) TLR4 was blocked during 
priming with live BCG and γBCG by use of LPS derived from B. quintana, one week later cells were 
rechallenged with flagellin and polyI:C. Blocking of TLR4 gave a non-significant increase of IL-6 (A) and 
TNFα (B) production upon restimulation with flagellin. Depicted are fold changes compared to no training 
(n=5). TLR2 was blocking during priming with live BCG and γBCG by use of an αTLR2 antibody. One 
week later cells were rechallenged with LPS. (C,D) Blocking of TLR2 did not significantly influence IL-6 
(C) and TNFα (D) production upon restimulation with LPS. Depicted are fold changes compared to no 
training (n=5). (E,F) Adherent monocytes from NOD2-deficient patients and healthy controls were used 
in the in-vitro training model. Macrophages from NOD2-deficient patients did not show increased IL-6 (E) 
and TNFα (F) production upon restimulation with LPS, Pam3Cys and S. aureus one week after training, 
whereas cells from healthy controls showed an upregulation of cytokine production. Cytokine levels in 
RPMI restimulated samples were below detection limit. Depicted is fold of change compared to no training 
(n=4 patients vs. 4 controls). Mann-Whitney U test was used for analysis of TLR4 blocking.
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aureus or C. albicans, demonstrating strong non-specific heterologous effects of 
γBCG (Figure 4). Surprisingly, the specific effect of γBCG was relatively weak, as the 
upregulation of IFNγ production after M. tuberculosis stimulation was only marginally 
increased (Figure 4). As prevaccination IFNγ response to M. tuberculosis was low 
in all volunteers (which makes pre-exposure to mycobacterial antigens unlikely), 
this finding argues that γBCG cannot be used as a tuberculosis vaccine, as it will 
probably not induce enough immunological protection, as shown previously (16). 
After vaccination, cells of the volunteers were still capable to respond ex vivo to 
training by γBCG (Figure S1).
 Several studies have shown that among BCG-vaccinated children, those having 
a BCG scar have better survival than those without a scar (17, 18). But since all 
but one of the γBCG-vaccinated volunteers had developed a scar 3 months after 
vaccination, we were not able to perform such an analysis. 
Figure 3. Training induced by γBCG is epigenetically mediated. (A,B) Adherent monocytes were 
trained in vitro with γBCG. On day 6 cells were harvested and processed for chromatin immunoprecipitation. 
qPCR was performed on ChIPed DNA. Depicted is H3K4me3 % of total input for the IL6 (A) and TNFA 
promoter (B). Preincubation with γBCG led to increased H3K4me3 of TNFA and IL6 promoter region. 
Wilcoxon matched-pairs signed rant test. (n=8, * p < 0.05, ** p < 0.01).
(C,D) In a separate set of experiments, the histone methyltransferase inhibitor MTA or the demethylase 
inhibitor pargyline were added during the first 24h, while incubating with γBCG. One week later monocytes 
were rechallenged using LPS. Incubation with MTA abrogated the induction of IL-6 (C) and TNFα (D) after 
training with live BCG and γBCG, whereas incubation with pargyline did not lead to an altered cytokine 
response. Depicted are fold changes compared to no training. Mann-Whitney U test. (n=6, * p < 0.05).
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DISCUSSION
In the present study we assessed the capacity of γBCG to stimulate heterologous 
and trained immunity, the two immunological mechanisms hypothesized to mediate 
the protective non-specific effects of BCG vaccination. While γBCG induced trained 
immunity in an in-vitro experimental model, this effect was less strong compared to 
the live-attenuated BCG vaccine. In line with this, vaccination of healthy volunteers 
with γBCG had only limited effects on innate immunity. However, γBCG strongly 
potentiated heterologous Th1 and Th17 immunity, suggesting that this approach 
may have clinical applications. 
 A large body of epidemiological studies, as well as a number of randomized 
clinical trials, reported significant non-specific protective effects of BCG vaccination 
(3-5, 17-19). While very beneficial in young children, and potentially also in the 
elderly (20), BCG vaccination cannot be used in patients with immune deficiencies 
due to the fact that it contains live microorganisms. It would therefore be useful 
to explore alternative approaches that would avoid the danger of a disseminated 
infection in an immunocompromised host, and also decrease side effects as 
lymphadenitis in healthy persons, while retaining heterologous beneficial effects on 
Figure 4. Vaccination of Healthy volunteers with γBCG induces heterologous immunity, but no 
trained immunity. Healthy volunteers were vaccinated with γBCG. PBMCs were collected before and 
after vaccination, and stimulated ex vivo with sonicated M. tuberculosis, heat-killed S. aureus or C. 
albicans. Cytokine production was assessed by ELISA in supernatants. γBCG vaccination increased 
only the MTB-induced innate cytokine responses (A-C), while strongly increasing heterologous T-helper 
responses represented by IFNγ (D) and IL-22 (F) production.  Cytokine level in RPMI-stimulated samples 
was all below detection level. Depicted are fold changes as compared to prevaccination. Wilcoxon 
matched-pairs signed rank test. (* p < 0.05, ** p < 0.01).
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infection susceptibility. We thus hypothesized that γ-irradiation of BCG, which kills 
the microorganism while preserving the structure of the cell wall, may be a viable 
alternative to the live vaccine.
 The results of the in-vitro and in-vivo experiments reported here demonstrate a 
consistent pattern when comparing γ-irradiated and live BCG. In in-vitro models of 
trained immunity, γBCG was able to induce priming of monocytes towards increased 
cytokine production, but the effect was weaker than that of live BCG. As previously 
demonstrated with live vaccine (8), γBCG induced these effects in a NOD2-dependent 
manner, and were mediated by histone methylation at the level of H3K4. However, 
these effects were not strong enough to induce an effective trained immunity in vivo 
in all the volunteers: the innate immune responses were largely unaffected when 
assessed in the entire group, with the exception of M. tuberculosis-induced IL-1β 
and IL-6. 
 There are several possible reasons for the low effects of γBCG on trained 
immunity in vivo. Firstly, we cannot exclude that subtle changes of mycobacterial cell 
wall were induced during irradiation, and that may result in partial loss of biological 
activity. Differential effects of live and inactivated forms of BCG on TLR2 signalling 
and pro-inflammatory cytokine release have been noted in vitro before, showing 
a more potent effect of live BCG compared to inactivated forms (21). Secondly, 
in-vivo replication of BCG may be needed in order to release enough bacterial 
products (such as peptidoglycans that are recognized by NOD2) that would induce 
immunostimulatory effects at distance (22, 23).  Finally, another possibility might be 
that the administered dose of γBCG, which was identical with that of the live vaccine, 
should have been increased in order to insure the same effect as observed with the 
live BCG vaccine. Multiple subsequent vaccinations could represent an alternative 
strategy to obtain the desired effect. 
 In contrast to the effects on the innate immune system, γBCG vaccination induced 
strong heterologous effects on the Th1 and Th17 response, as demonstrated by 
the clear increase in the production of IFNγ, IL-22 and to some extent IL-17 upon 
stimulation of cells from vaccinated individuals with unrelated pathogens. Protective 
heterologous effects of infections and vaccinations have been described before, for 
example in mouse models where it has been shown that priming with one virus can 
enhance cytokine production and clearance of a second non-related virus (24, 25). In 
addition, immunizing mice with live BCG has been shown to enhance immunity against 
vaccinia virus, which was dependent on IFNγ production by CD4 cells (26). Human 
vaccination with live-attenuated BCG has been shown to enhance Th1 responses of 
other vaccinations as well (27). As a possible mechanism for heterologous effects on 
adaptive immunity, it has been shown that naturally occurring CD8+ T-lymphocytes 
expressing memory markers are able to rapidly produce vast amounts of IFNγ upon 
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 2incubation with IL-12, which could be boosted by co-incubation with IL-18, all in 
absence of a pathogen (28, 29). In addition, specific CD8+ T-lymphocytes were 
also shown to produce IFNγ during an infection with a nonrelated pathogen (30), 
and also CD4+ T-lymphocytes can produce IFNγ upon stimulation with IL-12 in an 
antigen-independent manner (31, 32). Similar mechanisms have been envisaged 
for the increased Th17 response: PstS1, a mycobacterial lipoprotein that has the 
same positive effect as BCG in a bladder cancer mice model (33), is able to induce 
an antigen-independent amplification of the IFNγ and IL-17/IL-22 response. When 
PstS1 induced memory CD4+ T-lymphocytes were incubated with activated DCs, in 
absence of a pathogen, increased production of IFNγ, IL-17 and IL-22 by the memory 
T-lymphocytes was observed, which was partly dependent on IL-6 production of the 
DCs (34). These studies demonstrate several putative mechanisms through which 
heterologous Th1 and Th17 responses to non-related pathogens can be boosted 
after vaccination with γBCG. In our study we unfortunately have not analysed which 
type of cell was the main producer of IFNγ or IL-17/22 in the ex-vivo stimulation 
experiments. However, it can be hypothesized that memory T-cells induced by γBCG 
vaccination are the source of increased Th1/Th17 responses upon stimulation with 
a non-related pathogen. Future studies are warranted to evaluate these biological 
processes in human volunteers with γBCG vaccination. 
 In conclusion, in this study we report that γBCG induces strong heterologous 
effects on Th1/Th17 immunity, and these effects could be harnessed for the therapy 
of immunocompromised patients. Although probably not useful in HIV-infected 
patients with very low CD4 counts, in other clinical situations in which T-lymphocytes 
are still present (such as post-sepsis immunoparalysis, HIV-infected patients with 
CD4 counts higher than 200/mm3), vaccination with γBCG may represent a novel 
strategy to boost the immune system and increase the resistance of the host to 
infections, thus potentially limiting morbidity and mortality in these vulnerable groups 
of patients. Although vaccination with the standard dose of γBCG induced only 
poorly trained immunity in vivo, higher or repeated dosages may represent additional 
possible strategies to be explored in the future to increase the efficacy of this novel 
approach. 
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Figure S1. (A,B) Adherent monocytes of γBCG vaccinated volunteers were ex-vivo primed with γBCG or 
RPMI for 24h and after 6 days of resting restimulated with LPS. Production of IL-6 (A) and TNFα (B) was 
determined in the supernatant, showing that monocytes of the healthy volunteers ex vivo can be trained 
by γBCG both before and after γBCG vaccination . Cytokine levels in RPMI restimulated samples were 
below detection level. Wilcoxon matched-pairs signed rank test. (* p < 0.05, ** p < 0.01).
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ABSTRACT
Bacille Calmette-Guérin (BCG) vaccine exerts non-specific immunostimulatory 
effects, and may therefore represent a novel therapeutic option to treat sepsis-
induced immunoparalysis. We investigated whether BCG vaccination modulates 
the systemic innate immune response in humans in vivo during experimental 
endotoxemia. We used inactivated γ-irradiated BCG vaccine because of the potential 
risk of disseminated disease with the live vaccine in immunoparalyzed patients. In 
a randomized double blind placebo-controlled study, healthy male volunteers were 
vaccinated with γ-irradiated BCG (n=10) or placebo (n=10) and received 1 ng/kg 
lipopolysaccharide (LPS) intravenously on day 5 after vaccination to assess the in-
vivo immune response. Peripheral blood mononuclear cells were stimulated with 
various related and unrelated pathogens 5, 8 to 10, and 25 to 35 days after vaccination 
to assess ex-vivo immune responses. BCG vaccination resulted in a scar in 90% 
of vaccinated subjects. LPS administration elicited a profound systemic immune 
response, characterized by increased levels of pro- and anti-inflammatory cytokines, 
hemodynamic changes, and flu-like symptoms. However, BCG neither modulated 
this in-vivo immune response, nor ex-vivo leukocyte responses at any time point. In 
conclusion, γ-irradiated BCG is unlikely to represent an effective treatment option to 
restore immunocompetence in patients with sepsis-induced immunoparalysis.
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Sepsis is a clinical condition that represents a major medical challenge due to its 
high mortality rate. Related to this, it is a major clinical challenge also because it 
may be difficult to diagnose in due time, and difficult to treat. Previous adjunctive 
therapeutic strategies, aiming to treat sepsis by inhibition of pro-inflammatory 
mediators have failed, likely related to the recent insight that the majority of septic 
patients do not succumb to the initial pro-inflammatory “hit”, but die at a later time-
point in a pronounced immunosuppressive state (1-3). This so-called ‘sepsis-induced 
immunoparalysis’ results from counter-regulatory anti-inflammatory pathways that 
are activated simultaneously with pro-inflammatory mechanisms (2-4). This renders 
patients unable to clear the initial infection and increased vulnerable to secondary 
infections (2, 3, 5). As a consequence, reconstitution of immunocompetence is 
emerging as a new and promising therapeutic target to improve outcome in sepsis 
patients (2, 3, 6, 7).
 Bacille Calmette-Guérin (BCG) is the most widely used vaccine worldwide. 
In addition to protection against tuberculosis (8), both observational studies 
and randomized clinical trials have shown that BCG vaccination is associated 
with beneficial effects on other infectious diseases as well. In this regard, early 
administration of BCG vaccination leads to strongly reduced infant mortality, 
mainly as a result of lower incidence of neonatal sepsis, respiratory infection, and 
fever (9-15).  These non-specific effects of BCG are suggested to be mediated by 
two mechanisms: potentiation of adaptive immune responses against unrelated 
pathogens, so-called ‘heterologous immunity’ (16), and epigenetic functional 
reprogramming of innate immune cells to an enhanced phenotype, a process 
described as ‘trained immunity’ (17-20). The latter process is characterized by 
enhanced production of pro-inflammatory cytokines by monocytes that have been 
previously primed by BCG, and is apparent upon stimulation with either specific 
or unrelated pathogens (17, 21). In line with this, mononuclear cells isolated from 
healthy volunteers and stimulated with unrelated pathogens show enhanced innate 
immune responses after BCG vaccination (17), and some of these effects even 
persist for up to one year (21). These effects largely rely on innate immune cells, 
as BCG vaccination enhances resistance against Candida infection and increased 
lipopolysaccharide (LPS)-induced cytokine production in splenocytes of mice lacking 
T- and B-cells (17).  
 Considering its potentiating effects on host defense, BCG could represent a 
therapeutic option to prevent or treat sepsis-induced immunoparalysis. Nevertheless, 
as patients with sepsis have an increased susceptibility to secondary infections, 
vaccination with live BCG may be associated with unwarranted risks for dissemination 
(22). As recent data showed that γ-irradiated BCG has similar potentiating effects 
on trained immunity in vitro (23), but does not present any risk for infection, this 
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inactivated form of BCG represents a clinically relevant alternative in these patients. 
However, the effects of BCG vaccination on the immune response in humans have 
hitherto only been shown ex vivo (17, 21). It has yet to be established whether these 
findings can be extrapolated to the human in-vivo situation, because ex-vivo data 
might not always reflect in-vivo responses (24, 25). The human endotoxemia model, 
in which healthy volunteers are administered a low dose of LPS, represents a unique 
model to study modulation of the systemic inflammation in humans in vivo in a safe, 
highly standardized, and reproducible manner (26).
 The aim of the present study was to investigate the effects of vaccination with 
γ-irradiated BCG on the systemic innate immune response in adult males in vivo 
during experimental endotoxemia. 
 
MATERIALS AND METHODS
Subjects - After approval from the Arnhem-Nijmegen Ethics Committee, 20 healthy 
non-smoking male volunteers gave written informed consent to participate in this 
study that was registered at ClinicalTrials.gov as NCT02085590. Subjects were 
screened before the start of the experiment and had a normal physical examination, 
electrocardiography, and routine laboratory values. Exclusion criteria were febrile 
illness during the 2 weeks before start of the study, prior BCG vaccination, any 
vaccination other than BCG within 3 months before start of the study, and a tuberculin 
skin test within 1 year prior to the start of the study. Throughout the study period, 
subjects were not allowed to take any drugs, including acetaminophen, and were 
asked to refrain from alcohol and caffeine 24h, and from food 12h before the start 
of the endotoxemia experiment. All study procedures were conducted in accordance 
with the declaration of Helsinki including current revisions and Good Clinical Practice 
guidelines. 
Study design and procedures - We performed a randomized double-blind 
placebo-controlled study. The study design is schematically depicted in Figure 1. 
For reasons detailed in the introduction, γ-irradiated (and therefore inactivated) 
BCG vaccine was used in this study. Irradiated BCG was cultured for 6 weeks using 
Mycobacteria Growth Indicator Tubes according to Dutch national guidelines to 
confirm inactivation, and no growth was observed. Subjects were randomly assigned 
to receive either 0.075 mg (0.1 ml) γ-irradiated BCG-vaccine intracutaneously (BCG-
vaccine SSI; Statens Serum Institut, γ-irradiation (25-30 kGy) performed by Synergy 
Health Ede, The Netherlands; n=10) or 0.1 ml placebo (BCG-reconstitution fluid: 
Sauton; Statens Serum Institut; n=10) in a double-blind fashion. Five days after 
vaccination, all subjects received an intravenous injection of LPS (lipopolysaccharide 
derived from Escherichia coli O:113, Clinical Center Reference Endotoxin, National 
Institutes of Health (NIH), Bethesda, MD), 1 ng/kg. Endotoxemia experiments were 
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conducted as described previously (25). Heart rate (three-lead electrocardiogram), 
blood pressure, respiratory rate, and oxygen saturation (pulse oximetry) data were 
recorded from a Philips MP50 patient monitor every 30 seconds by a custom in-
house-developed data recording system. LPS-induced flu-like symptoms (headache, 
nausea, shivering, muscle and back pain) were scored every 30 min on a six-point 
Likert scale (0 = no symptoms, 5 = worst ever experienced), resulting in a total score 
of 0–25 points. After the endotoxemia experiment, additional blood samples were 
drawn on days 8-10 and days 25-30 after vaccination. During the last visit, BCG scar 
formation was measured by an independent research nurse (to maintain blinding) 
using a centimeter ruler. 
Cytokine Measurements - To analyze plasma cytokines, ethylenediaminetetraacetic 
acid (EDTA) anticoagulated blood was centrifuged at 2,000xg at 4°C for 10min 
immediately after withdrawal, and plasma was stored at -80°C until analysis. 
Concentrations of TNFα, IL-6, IL-8, IL-10, IL-1β, IL-1 receptor antagonist (IL-1RA), 
MCP-1, and IFNγ were measured in plasma batch-wise using a Luminex assay 
according to the manufacturer’s instructions (Milliplex; Millpore, Billerica, MA, USA).
Leukocyte counts and differentiation - Analysis of leukocyte counts and 
differentiation was performed in EDTA-anticoagulated blood using routine analysis 
methods also used for patient samples (flow cytometric analysis on a Sysmex XE-
5000).
Peripheral mononuclear cell stimulation assays - The mononuclear cell fraction 
was isolated by density centrifugation of EDTA-anticoagulated blood, diluted 1:1 
in pyrogen-free saline over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). 
day 1 
vaccination 
•  γ-irradiated BCG (n=10) 
•  placebo (n=10) 
LPS (1 ng/kg i.v.) 
between days 8-10 between days 25-35 time (days) 
plasma cytokines 
time (hours) 
hospitalization 
Continuous monitoring 
prehydration 
ex vivo stimulations 
day 6 
-2 -1 0 1 2 3 4 5 6 7 8 
plasma cytokines 
ex vivo stimulations 
Figure 1 - Experimental design. BCG: Bacille Calmette-Guérin; LPS: lipopolysaccharide.
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Isolated cells were washed twice in PBS and resuspended in culture medium (RPMI, 
Invitrogen, Carlsbad, California, USA) supplemented with 50μg/ml gentamicin, 2mM 
glutamax, and 1mM pyruvate. Cell counts were performed in a Coulter counter 
(Coulter Electronics). A total of 5x10^5 mononuclear cells in 100μl were added 
to round-bottomed 96-well plates (Greiner) with RPMI, sonicated Mycobacterium 
tuberculosis (MTB) (1μg/ml, strain H37Rv), Escherichia coli lipopolysaccharide 
(LPS; 1ng/ml; Sigma-Aldrich, St. Louis, MO, USA), heat-killed Staphylococcus 
aureus (1x10^6 microorganisms/ml, clinical isolate), or heat-killed Candida albicans 
(1x10^6 microorganisms/ml, strain UC820). After 24h (for determination of TNFα, 
IL-1β, and IL-6) or 48h (for determination of IFNγ and IL-10) of incubation, plates 
were centrifuged and supernatants were stored at -20°C until analysis. Cytokines 
were measured batch-wise using commercially available ELISAs (R&D Systems, 
MN, USA and Sanquin, Amsterdam, The Netherlands) according to the protocols 
supplied by the manufacturers. 
Calculations and Statistical Analysis - Data are represented as median and 
interquartile range or mean and SEM, based on their distribution (calculated by 
the Shapiro–Wilk test). The area under the curve (AUC) of cytokine levels during 
experimental endotoxemia, representing an integrated measure of the cytokine 
response, was calculated using time points 0-8h post-LPS. Comparisons were 
made using Mann-Whitney U tests (non-normally distributed data, between-group 
comparisons) or repeated measures two-way ANOVA (normally distributed data, 
where the time factor represents differences across both groups over time and 
the interaction factor represents between-group differences over time). Ex-vivo 
cytokine data were log-transformed to obtain a normal distribution. A p-value ˂ 0.05 
was considered statistically significant. Calculations and statistical analyses were 
performed using Graphpad Prism version 5.0 (Graphpad Software, San Diego, CA, 
USA).
RESULTS
Baseline characteristics
No differences in baseline characteristics between both groups were present (Table 
1). γ-irradiated BCG vaccination resulted in a scar at the vaccination site in 9 out 
10 subjects (median (range) size of 6 (1-9) mm). In the placebo group, 1 subject 
developed a small scar (1 mm). BCG vaccination did not result in fever or other 
clinical symptoms and no serious adverse events occurred during the trial. 
Hemodynamic parameters and symptoms
LPS administration resulted in a typical increase in heart rate and flu-like symptoms, 
and a decrease in mean arterial blood pressure (MAP) in all subjects, with no 
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differences between groups (Figure 2). 
Plasma cytokines and circulating leukocyte counts
BCG-vaccination did not result in increased plasma levels of any of the measured 
cytokines in the days following vaccination (Figure 3). As expected, administration of 
LPS resulted in a sharp increase in plasma levels of the pro-inflammatory cytokines 
TNFα, IL-6, IL-8 and MCP-1, as well as the anti-inflammatory cytokines IL-10 and 
IL-1RA (Figure 3). However, no differences were observed between the BCG and 
placebo groups. Similar to previous human endotoxemia studies (27), plasma 
levels of IL-1β and IFNγ were below the lower detection limits in the majority of the 
subjects at most time points. In some subjects and/or time-points, very low levels 
(approximately 10 pg/mL) were found, but no clear patterns over time or differences 
between groups were observed.  
 As described earlier, scar size differed substantially between BCG-vaccinated 
subjects, which might represent vaccination efficacy, and is associated with non-
specific beneficial effects of BCG (28, 29). Therefore, we stratified the BCG-
vaccinated group according to scar size (≤5 mm, n=5; >5 mm, n=5). These stratified 
analyses did not reveal notable differences in cytokine responses either (Figure S1). 
After LPS administration, transient leukocytosis developed, reaching maximum 
levels at t=8h, with no differences between groups (mean ± SEM of BCG and placebo 
groups, respectively: 10.2 ± 0.7 vs. 9.7 ± 0.7 x 10^9/L, p=0.62). At the first visit 
after the endotoxemia day (day 8-10), leukocyte numbers were normalized in both 
groups (5.2 ± 0.4 vs. 5.7 ± 0.6 x 10^9/L in the BCG and placebo groups, respectively, 
p=0.50). 
Cytokine production by peripheral blood mononuclear cells 
Five days after vaccination with BCG or placebo, but before LPS administration 
in vivo, there were no differences between groups in ex-vivo cytokine responses 
Figure 2 - Blood pressure, heart rate, and symptoms during experimental endotoxemia in subjects 
vaccinated with γ-irradiated BCG or placebo. Data are expressed as mean±SEM (n=10 per group). 
P-values calculated using repeated measures two-way analysis of variance (ANOVA). MAP: mean arterial 
pressure; HR: heart rate; bpm: beats/min.
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induced by specific (Mycobacterium tuberculosis) or unrelated (LPS, Staphylococcus 
aureus, and Candida albicans) pathogens or stimuli (fold change data (compared 
with baseline) of IFNγ, TNFα, and IL-1β are depicted in Figure 4, and fold change 
data of IL-6 and IL-10 in Figure S2. Absolute values of all cytokines are depicted 
in Figure S3). Similar to previous endotoxemia experiments (25, 30), 4h after LPS 
administration, an overall profound decrease in ex-vivo cytokine production was 
observed, indicative of immunoparalysis. BCG vaccination did not influence the 
development or magnitude of immunoparalysis. Likewise, no differences between 
groups in ex-vivo cytokine responses to any of the pathogens or stimuli were found 
on days 8-10 and 25-35 after vaccination. Of note, LPS-induced production of IFNγ, 
as well as LPS- and Mycobacterium tuberculosis-induced production of IL-10, was 
absent in many subjects and very low in others. Therefore, the endotoxemia-induced 
decrease in ex-vivo cytokine production was less noticeable and did not always 
reach statistical significance for these combinations. Staphylococcus aureus- and 
Candida albicans-induced IL-10 production was absent in virtually all subjects and 
was therefore not analyzed. 
DISCUSSION
In the present study, we demonstrate that γ-irradiated BCG vaccination does not 
influence the LPS-induced innate immune response in adult males in vivo five 
Figure 3 - Plasma cytokine concentrations in subjects vaccinated with γ-irradiated BCG or 
placebo. In the panels A-D, median values of pro-inflammatory cytokines TNFα, IL-6, IL-8, and MCP-1 
are depicted while in panels E and F median values of anti-inflammatory cytokines IL-10 and IL-1RA are 
shown (n=10 per group). Panels G-L depict median ± interquartile range of area under curve (AUC) the 
respective cytokines (n=10 per group, Mann-Whitney U test).
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days later. Furthermore, no effects of BCG vaccination on cytokine production of 
leukocytes stimulated ex vivo with specific and unrelated pathogens were observed. 
As all measured parameters were similar between groups, we can conclude that five 
days after vaccination, γ-irradiated BCG has no effect on the innate immune system 
and therefore does not induce trained immunity. This is evident from both the lack of 
an effect on LPS-induced plasma cytokine levels in vivo, as well as from the similar 
ex-vivo innate cytokine responses (TNFα, IL-1β, IL-6, and IL-10) against unrelated 
pathogens five days after vaccination in both groups. Previous epidemiological 
studies have shown that scar formation after vaccinia or BCG vaccination is 
associated with improved survival, possibly related to improved resistance against 
infections (28, 29). Therefore, we stratified subjects based on scar size, but no 
effects were found in these analyses either.  Furthermore, no effects indicative of 
trained immunity induction were found at later time-points, ranging from 8-10 days to 
25-35 days after vaccination.
 Our results are different from previous studies that used the live-attenuated BCG 
vaccine (17, 21) instead of the γ-irradiated BCG. There are several reasons and/
or limitations of the present study that might explain these differences. First and 
foremost, we used γ-irradiated BCG in the present study because our target treatment 
Figure 4 - Ex-vivo cytokine production. Production of IFNγ, TNFα, and IL-1β by peripheral blood 
mononuclear cells stimulated ex vivo with Mycobacterium tuberculosis (MTB), LPS, Staphylococcus 
aureus (SA), and Candica albicans (CA) of subjects vaccinated with γ-irradiated BCG or placebo. Data 
expressed as median and interquartile range of the fold change compared with day 1 (before vaccination) 
(n=10 per group). p-values calculated using repeated measures two-way analysis of variance (ANOVA) 
on log transformed data. Day 6 was the endotoxemia experiment day.
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population consists of immunoparalyzed septic patients who may be at risk for 
disseminated mycobacterial infection (22). We hypothesized that γ-irradiated BCG 
would be effective in inducing trained immunity in vivo because recent unpublished 
data of our group showed that γ-irradiated BCG exerts monocyte training in vitro. 
Furthermore, previous in-vitro studies showed that monocytes could be trained with 
live BCG, as well as with the inert NOD2 ligand MDP (17), highlighting that live BCG 
persistence is not mandatory for inducing trained immunity in vitro. Nevertheless, 
inactivating the vaccine could have reduced or abrogated the “training capacity” of 
BCG. While live vaccines can replicate and/or disseminate in the host’s body and 
thereby trigger the immune response to a greater extent, inactivated vaccines only 
activate immune responses locally (31). Although the scar formation in γ-irradiated 
BCG-vaccinated subjects indicates a local immune response, it could be envisioned 
that possible training effects of γ-irradiated BCG are much less sustained and 
widespread, and thus less pronounced. Along these lines, it was demonstrated 
that two and four weeks after vaccination with live BCG, 83 and 50% of individuals 
still displayed viable BCG at the vaccination site (32), respectively, indicative of a 
relatively long-lasting “active infectious pool” of bacteria (or their products) and/or 
cytokines that trigger a variety of responses. This is likely not relevant for the in-vitro 
situation, where cells are continuously exposed to bacteria and/or their products 
irrespective of whether they are alive or inactivated. Also, others have shown that 
viable bacteria elicit more potent immune responses compared to killed bacteria, due 
to recognition of so called ‘vita-PAMPs’ such as prokaryotic mRNA by innate immune 
cells (33). The absent effects of γ-irradiated BCG on ex-vivo cytokine responses to 
stimulation with M. tuberculosis further substantiate the hypothesis that γ-irradiation 
results in functional inactivation of BCG, resulting not only in abrogation of trained 
immunity but also of “classic” specific protection against M. tuberculosis.  
 Secondly, the timing of the interventions in our study might have precluded effects 
of γ-irradiated BCG. We chose to assess in-vivo and ex-vivo responses already five 
days after vaccination, in order to assess potential short-term effects that may be 
most relevant during sepsis. We hypothesized that this period would be sufficient to 
induce trained immunity based on the fact that in-vitro training by BCG only takes 
one day and that non-specific beneficial effects of BCG-vaccination in neonates were 
already apparent within 3 days (15). Nevertheless, in previous studies enhancing 
effects of BCG on leukocytes were found 2 weeks, 3 months, and one year after 
vaccination (17, 21). No earlier time-points were assessed in these earlier studies. 
 Thirdly, we only included young male volunteers in this study. There are 
considerable differences in the cytokine response to LPS between males and 
females (34). This is likely influenced by menstrual cycle-related hormonal variations 
that can affect the immune response. Because we wanted our study population to 
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be as homogenous as possible, we therefore included only males, analogous to 
virtually all of our previous endotoxemia studies. This might have biased our results, 
because the majority of the studies on non-specific effect of the BCG vaccine point 
to important sex-differential non-specific effects, and often the most pronounced 
effects were observed among females (12, 35, 36). Non-specific effects may also 
vary with age, nevertheless, live BCG exerted profound effects in a similarly aged 
study population (17, 21).  
 Fourthly, possible training effects of γ-irradiated BCG on monocytes in the long-
term might have been obscured by the LPS administration five days after vaccination. 
BCG-induced trained immunity has been shown to be mediated through epigenetic 
reprogramming of monocytes (17). Interestingly, exposure to LPS results in opposite 
epigenetic changes in monocytes and/or macrophages (20). Therefore, possible 
training effects induced by γ-irradiated BCG might have been nullified by the LPS 
administration. 
 Fifthly, the human endotoxemia model employed in this study is relatively mild 
and does not replicate the severe sepsis-induced immunoparalysis observed 
in actual patients. Therefore, although unlikely based on the complete absence 
of effects in the present study, we cannot exclude the possibility that γ-irradiated 
BCG exerts immunomodulatory effects in a true model of immunoparalysis or in 
immunoparalyzed septic patients.
 Finally, our study is limited by the fact that, apart from medical history, we did 
not screen for previous exposure to Mycobacterium tuberculosis. We chose not to 
perform a tuberculin skin test since this could trigger trained immunity effects on 
its own which would confound our study results. However, the infectious pressure 
of tuberculosis in the Netherlands is very low (37), and this possibility is unlikely to 
explain the absent effects of γ-irradiated BCG.  
 In view of the points raised above, a study using live BCG and possibly other 
timing of the interventions could be considered. While such as study would be 
warranted to elucidate the mechanisms behind the important nonspecific beneficial 
effects of BCG vaccination in neonates (9-15), it may be less relevant with regard to 
sepsis patients, in which the use of live BCG vaccine would be associated with too 
high risks.
CONCLUSIONS
γ-irradiated BCG does not modulate the in-vivo innate immune response in adult 
male volunteers five days after vaccination. Furthermore, vaccination did not induce 
trained immunity ex vivo. Therefore, γ-irradiated BCG is unlikely to represent a viable 
treatment option to restore immunocompetence in patients with sepsis-induced 
immunoparalysis. 
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Figure S1 - Area under curve (AUC) of plasma concentrations of pro-inflammatory cytokines TNFα, 
IL-6, IL-8, and MCP-1, and anti-inflammatory cytokines IL-10 and IL-1RA in subjects vaccinated with 
γ-irradiated BCG stratified according to vaccination scar size (≤5 mm or >5 mm, n=5 per group). Data are 
presented as median ± interquartile range of the respective cytokines. p-values calculated using Mann-
Whitney U test.
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Figure S2 - Production of IL-6 and IL-10 by peripheral blood mononuclear cells stimulated ex vivo with 
Mycobacterium tuberculosis (MTB), LPS, Staphylococcus aureus (SA), and Candica albicans (CA) of 
subjects vaccinated with γ-irradiated BCG or placebo. SA- and CA-induced IL-10 production was absent 
in virtually all subjects and was therefore not analyzed. Data expressed as median and interquartile range 
of the fold change compared with day 1 (before vaccination) (n=10 per group). p-values calculated using 
repeated measures two-way analysis of variance (ANOVA, time and interaction terms) on log transformed 
data. Day 6 was the endotoxemia experiment day.
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Figure S3 - Production of IFNγ, TNFα, IL-1β, IL-6, and IL-10 by peripheral blood mononuclear cells 
stimulated ex vivo with Mycobacterium tuberculosis (MTB), LPS, Staphylococcus aureus (SA), and 
Candica albicans (CA) of subjects vaccinated with γ-irradiated BCG or placebo. Data expressed as 
median and interquartile range (n=10 per group). Day 6 was the endotoxemia experiment day. For 
statistical analyses, see Figures 4 and Figure S2, which depict the same data expressed as fold change 
compared with day 1.
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ABSTRACT
Epidemiological studies suggest that vitamin A supplementation (VAS) has long-
lasting immunomodulatory effects. We hypothesized that all-trans retinoic acid 
(ATRA) inhibits inflammatory cytokines in a model of trained immunity in monocytes, 
by inducing epigenetic reprogramming through histone modifications. We used an 
earlier described in-vitro model of trained immunity, in which adherent monocytes of 
healthy volunteers were incubated for 24h with BCG in the presence or absence of 
ATRA. After washing the cells, cells were incubated for additional 6 days in culture 
medium, were thereafter restimulated with microbial ligands, and cytokine production 
was assessed. ATRA inhibited cytokine responses upon restimulation of monocytes, 
and this effect was exerted through increased expression of SUV39H2, a histone 
methyltransferase that induces the inhibitory mark H3K9me3. H3K9me3 at promoter 
sites of several cytokines was upregulated by ATRA, and inhibition of SUV39H2 
restored cytokine production. In addition to H3K9me3, the stimulatory histone mark 
H3K4me3 was downregulated by ATRA at several promoters of cytokine genes. We 
can therefore conclude that ATRA inhibits cytokine production in models of direct 
stimulation or BCG-induced trained immunity, and that these effects are mediated 
by histone modifications.
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Vitamin A is a collective term for several essential nutrients, which can be obtained 
from the diet either as retinyl esters or as carotenoids. The liver stores vitamin A as 
esters, which can be converted into retinol and distributed through the whole body 
carried by retinol binding protein. Once reaching its target tissue, retinol is converted 
into the biological active form of vitamin A, retinoic acid. Retinoic acid can bind to one 
of the three retinoic acid receptors (α, β, γ), that form a heterodimer with a retinoic X 
receptor to bind a response element and promote transcription of the target genes 
(1). 
 Vitamin A plays an important role in the immune system, influencing both the 
innate and the adaptive immune system (2). In innate immunity, retinoic acid mainly 
inhibits cytokine production of monocytes, macrophages and dendritic cells, and 
regulates cell differentiation (2-4). 
 WHO recommends high-dose vitamin A supplementation (VAS) in countries 
at risk of vitamin A deficiency; it is estimated that this intervention reduces overall 
child mortality by 24% (5). However, the effect of VAS may not always be beneficial. 
Attempts to extend the beneficial effect of VAS to infants by providing VAS at birth 
have shown conflicting results (6), with some studies showing a tendency for 
higher mortality, in particular in females in the second half of infancy (7, 8). Several 
studies have also noted interactions between VAS and routine vaccinations, with 
a potential negative effect of vitamin A in females who receive diphtheria-tetanus-
pertussis vaccine (DTP) (9, 10). These results suggest that the effect of vitamin 
A supplementation may not merely be a question of restoring vitamin A levels to 
normal levels, but that these high-dose supplements may have long-lasting effects 
on the immune system (11).
 Therefore, it is important to elucidate the potential long-lasting effects of vitamin 
A on the immune system. An increasing number of studies support the concept 
that BCG vaccination has beneficial heterologous effects and can reduce overall 
child mortality in low-income countries due to protection from sepsis and respiratory 
infections (12, 13). It has been proposed that these non-specific effects of BCG 
vaccine are mediated via training of the innate immune system: a non-specific 
priming of innate immune function exerted through epigenetic reprogramming. 
Recently, we have shown that vaccinating healthy volunteers with BCG leads to long 
term epigenetic changes in monocytes, which lead to higher cytokine response upon 
stimulation with a nonrelated pathogens (14, 15). 
 Until now, studies have mainly focussed on short-term effects of all-trans retinoic 
acid (ATRA) on innate immune cells, showing inhibitory effects on the induction 
of inflammation in human and rodent PBMCs and monocytes (16-20). Several 
mechanisms have been proposed for these effects, among which the downregulation 
of TLR2 (but not TLR4) expression (20), or inhibition of ERK/MAPK pathway and 
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nuclear translocation of NF-κB, the latter as a result of STAT-1 repression (18, 
19, 21). ATRA has also been found to downregulate PGE2 production in mouse 
peritoneal macrophages (3) and adding retinoic acid to human monocytes inhibited 
differentiation, maturation and function of dendritic cells (22, 23). However, the 
long-lasting effects of vitamin A have been little studied, and whether epigenetic 
reprogramming is the underlying cause of these functional changes is unknown. 
 We therefore hypothesised that vitamin A could induce epigenetic changes in 
innate immune cells, leading to long-term immunomodulatory effects on the immune 
system. To examine this hypothesis we assessed in the present study the in-vitro 
effect of ATRA (the most common vitamin A metabolite) on the function of monocytes/
macrophages both in direct stimulation assays and in an experimental model of 
BCG-induced trained immunity. 
MATERIALS AND METHODS
Monocyte stimulation - Monocyte isolation and the experimental model of trained 
immunity was performed as described previously (15, 24). In short, adherent 
monocytes were incubated at 37oC with different concentrations of ATRA (dissolved 
in pure ethanol, Sigma-Aldrich, MO, USA) with or without BCG (SSI, Denmark, 5μg/
ml). After 24h, the supernatant was discarded and cells were washed once with 
200μl warm PBS. Then cells were incubated for 5 days in 200μl RPMI with 10% 
human serum, which was changed once during incubation. At day 6 the cells were 
restimulated with Escherichia coli LPS (serotype 055:B5, Sigma-Aldrich, 10 ng/ml), 
or RPMI as a control and after 24h supernatants were stored at -20oC until ELISA 
experiments were performed to assess cytokine production.
 For the inhibition experiments, 1h before addition of ATRA, monocytes were 
preincubated with the SUV39H2 inhibitor chaetocin (50μmol/l, Sigma-Aldrich).
Cytokine measurement - Cytokine production was determined in supernatants 
using commercial ELISA kits for IL-1RA, TNFα (R&D systems, MN, USA) and IL-6, 
IL-8, IL-10 (Sanquin, Amsterdam, The Netherlands) following the instructions of the 
manufacturer.
mRNA expression - For quantitative RT-PCR (qPCR), adherent monocytes 
were incubated in 24-well plates (Corning) with ATRA for 4h or 24h, after which 
supernatant was discarded and TRIzol Reagent (Invitrogen) was added. For re-
stimulation experiments, 12-well plates were used. The experiment was performed 
as described above. On day 6 cells were restimulated with LPS for 4h and then 
stored in TRIzol for assessment of mRNA transcription. Total RNA purification was 
performed and concentrations of RNA were assessed using a Nanodrop (Thermo 
Fisher Scientific, MA, USA). Isolated RNA was reverse transcribed into cDNA using 
iScript cDNA Synthesis Kit (Bio-Rad, CA, USA). qPCR was performed by using the 
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SYBR Green method on a RT-PCR machine (OneStep, Applied Biosystems, CA, 
USA). The primers used (Biolegio, Nijmegen, Netherlands) can be found in Table S1. 
Samples were analysed by the ΔΔCT method, using HPRT as a housekeeping gene. 
Western blots - Adherent monocytes were incubated in 6-well plates with different 
concentrations of ATRA. After 20h cells were lysed and stored at -20oC. The amount 
of protein was assessed using a BCA assay (Thermo Fisher Scientific) and equal 
amounts of protein were loaded to 7.5% gels. The separated proteins were transferred 
to a nitrocellulose membrane (GE-healthcare), which was treated with a signal 
enhancer (Thermo Fisher Scientific) before it was blocked in 5% milk (Campina, 
The Netherlands). Rabbit polyclonal antibodies against SUV39H2 (Santa Cruz, TX, 
USA) and actin (Sigma) were used to determine the protein expression, which were 
visualized using SuperSignal West Femto Substrate (Thermo Fisher Scientific) and 
ECL (GE Healthcare), respectively. Normalised expression was analysed by Image 
Lab Sofware 5.0 (Bio-Rad, CA, USA).
ChIP analysis - Detailed methods have been described before (25). In short, 
adherent monocytes were incubated in 6-well plates (Corning) for 24h with 1nM of 
ATRA or RPMI and treated as described above. At day 6 cells were fixated in 1% 
formaldehyde (Thermo Fisher Scientific) and stored at 40C in PBS until sonication 
was performed (Bioruptor, Diagenode, Belgium). Sonicated chromatin was stored 
at -80oC until further analysis. Half of the chromatin of 1x10^6 cells was incubated 
overnight with an H3K9me3 antibody (Diagenode, 1µg) to yield only H3K9me3 
positive chromatin and the other half was used as total input. DNA from both samples 
was purified over DNA purification columns (Qiagen, NJ, USA) and qPCR was 
performed to determine the percentage of H3K9me3 DNA for cytokine promoters 
(see Table S1), with ZFN274_3UTR as a positive control and GAPDH as a negative 
control.
Gene accessibility - This was assessed by the EpiQ Chromatin Analysis kit (Bio-
rad). In short, cells were cultured in duplicate for 6 days and then treated (or not) with 
DNase. DNA was isolated over purification columns and qPCR was performed as 
described above using a control and reference gene provided by the manufacturer. 
Calculations were performed as suggested by the manufacturer.  
Statistical analysis - Differences were analysed using a paired t-test, Wilcoxon 
signed-rank test, or one-way Anova where applicable, in Graphpad prism 5 (CA, 
USA). p < 0.05 was considered statistically significant. Data are shown as means ± 
SEM.
RESULTS AND DISCUSSION
ATRA priming downregulates cytokine production by macrophages
Preincubation of monocytes during the first 24h with ATRA inhibited the capacity of 
Chapter 4
  54 | 
macrophages to release cytokines upon stimulation with LPS on day 6 in a dose-
dependent manner (Figure 1A,B). The control and trained monocytes restimulated 
with RPMI did not display any cytokine production. No difference in effect of ATRA 
between male and female volunteers was found (data not shown). 
 Cell death was excluded as an explanation for the observed effects, as LDH 
release and Annexin V/PI staining, demonstrating cell death, were only induced using 
the highest concentrations of ATRA (Figure S1). Therefore, we used a low dose of 
1nM in all 7-day experiments. In a separate analysis, using various differentiation 
markers, it was found that ATRA does not induce differentiation of monocytes 
towards an M1, M2 or DC phenotype (Figure S2). 
Figure 1 - ATRA 
downregulates cytokine 
production. 
(A,B) Monocytes that were 
incubated for 24h with 
different concentrations 
of ATRA, followed by a 
washing step thereafter, 
showed lower production 
of IL-6 and TNFα upon 
24h restimulation with 
LPS at day 6. (C-G) 
This downregulation 
was not specific for 
LPS restimulation, nor 
cytokine specific. The 
RPMI restimulated cells 
did not show any cytokine 
production. (H-L) The 
inhibition of cytokine 
production by ATRA (1nM) was caused by decreased gene transcription, as lower mRNA levels of 4h 
after LPS restimulation were observed. (M,N) Training of monocytes with BCG for 24h potentiated the 
response of the cells to LPS 6 days later. Adding ATRA during the first 24h inhibited the stimulating effect 
of BCG on LPS-induced cytokines. (n=6, * p < 0.05, ** p < 0.01, *** p < 0.001).
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 In order to assess whether the effects of ATRA were specific to LPS restimulation 
and for IL-6 and TNFα production, macrophages were restimulated for 24h with 
different ligands or pathogens and additional macrophage-derived cytokines were 
measured. It was shown that ATRA reduces cytokine production of both pro- and 
anti-inflammatory cytokines to all ligands (Figure 1C-G). Upon restimulation with 
LPS on day 6, qPCR demonstrated that the decrease of cytokine production was a 
result of lower transcription (Figure 1H-L).
ATRA inhibits the training effect of BCG on the innate immune system
Monocytes trained by BCG in an in-vitro 7-day culture system, produced more 
cytokines upon restimulation on day 6 with LPS (Figure 1M,N) compared to cells 
cultured without BCG (Figure 1A,B), as previously described (15). Adding ATRA to 
BCG during the first 24h of monocyte priming, inhibited the potentiating effect of 
BCG on restimulation with LPS, in a dose-dependent manner (Figure 1M,N). 
ATRA enhances expression of histone methyltransferase SUV39H2
As incubation of monocytes for 24h with ATRA has an effect on the cytokine 
production 6 days later, and as ATRA is known to modulate epigenetic marks in 
other cells (26-28), it is likely that epigenetic mechanisms play a role in this long-
lasting effect of ATRA. Two important inhibitory histone marks are the methylation 
of histone 3 at lysine 9 or 27 (H3K9 or H3K27) (29). We firstly determined whether 
transcription of one of the methyltransferases inducing methylation of H3K9 or H3K27 
was induced upon stimulation of monocytes with ATRA. mRNA was isolated after 
4h and 24h stimulation of monocytes with 1μM of ATRA: qPCR analysis of several 
methyltransferases showed a 2-fold induction of mRNA production of SUV39H2, 
a methyltransferase inducing trimethylation of H3K9 (H3K9me3) (Figure 2A). In 
contrast, the expression of other methyltransferases was not influenced by ATRA. 
The increase of gene expression was accompanied by increased SUV39H2 protein, 
measured by Western blot, showing a dose dependent increase upon stimulation 
with ATRA (Figure 2B,C). The exact mechanism through which ATRA causes an 
increase of SUV39H2 remains to be assessed in future studies. As ATRA binds to 
the retinoic acid receptor, a nuclear receptor which can bind DNA at a response 
element, it is conceivable that ATRA could exert a direct effect to the transcription of 
SUV39H2. However, an indirect effect via other intermediates cannot be excluded 
without further studies (1). 
ATRA leads to increased H3K9me3 and decreased H3K4me3 at the promoter 
sites of cytokines
To determine whether ATRA indeed leads to a long-term increase of H3K9me3,
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Figure 2 - ATRA induces transcription and production 
of SUV39H2. (A) Monocytes were incubated for 4h or 
24h with 1μM of ATRA, after which mRNA was isolated 
and the production of methyltransferases inducing 
methylation of H3K27 (EZH2) or H3K9 (others) was 
determined. Only the transcription of SUV39H2, which 
induces H3K9me3, was significantly upregulated. (n=6, 
* p < 0.01). (B) Monocytes were incubated for 20h with 
different concentrations of ATRA. Then cells were lysed 
and SUV39H2 production was assessed by Western 
blot showing an increased production of SUV39H2 while 
using higher concentrations of ATRA. (C) Average of 
normalised SUV39H2 expression by Western blot of 5 
independent representative experiments. (* p < 0.05, ** 
p < 0.01 vs both RPMI/EtOH).
monocytes were incubated with ATRA for 24h, 
after which they were washed and incubated 
in culture medium. When DNA was isolated 
6 days later, chromatin immunoprecipitation 
and PCR assessment showed a significant 
increase of H3K9me3 at the gene promoters 
of the cytokines measured (Figure 3A), 
and this increase was also found at day 10 
(Figure S3). As for TNFA gene, all primers 
covering almost the whole promoter showed 
an increase in H3K9me3, for the other 
promoters (IL6, IL8, IL10, IL1RA) only one primer was used, showing the same 
effect (Figure 3A). 
 There are several arguments for a relevant role of SUV39H2 in the observed 
increase of H3K9me3 by ATRA. Firstly, SUV39H2 is a histone methyltransferase 
that specifically induces H3K9me3. H3K9me3 is traditionally considered a strong 
repressive mark, which creates constitutive heterochromatin, a highly inactive form 
of chromatin that is both long-lasting and difficult to reverse. In contrast, H3K27me3 
and H3K9me1/2 result in facultative heterochromatin, which is more easily reversible 
(29, 30). As the mRNA level of other methyltransferases was not upregulated, we 
did not investigate H3K27me3 and H3K9me1/2, but we cannot exclude a potential 
role of these or other epigenetic marks as well. Secondly, H3K9me3 is associated 
with recruitment of heterochromatin protein 1 (HP1), which in turn can induce DNA 
methylation by recruitment of DNA methyltransferases (31). Furthermore, it has 
also been shown that ATRA itself can modulate DNA methylation status in different 
cell types (26, 32-34). Therefore, it seems plausible that DNA methylation status of 
cytokines genes can play a role as well in the inhibitory effect of ATRA. 
 Interestingly, we did not observe a complete gene silencing (Figure 1), although 
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Figure 3 - ATRA caused an increase of H3K9me3 and decrease of H3K4me3 at the promoter sites 
of cytokines. (A,B) Monocytes were incubated for 24h with 1nmol/L of ATRA. At day 6 DNA was isolated 
to determine the amount of H3K9me3 at the promoter sites of IL6, IL8, IL10, IL1RA and TNFA. For TNFA 
5 primers were used to cover whole promoter region, as no clear differences were seen, only one primer 
was used for the other cytokines. ATRA significantly increased the repressive H3K9me3 mark at the 
promoters of the genes of interest and decreased the activating histone mark H3K4me3. (n=6, * p < 0.05). 
(C) Also gene accessibility was determined at the promoters. Accessibility of GAPDH (the reference 
gene) was set at 100% and accessibility of the cytokine promoters was assessed relative to GAPDH. A 
decreased accessibility in ATRA primed cells was observed. (n=5, * p < 0.05, ** p < 0.01).
H3K9me3 was upregulated. This might be due to an incomplete upregulation of 
H3K9me3 at the pro-inflammatory promoter sites. But it could also be a result of 
the HP1 paradox, which shows that genes bound by HP1 (which traditionally has 
a repressive signature) can be transcriptionally active (35). The specific underlying 
mechanism has not been elucidated, but in myoblasts/myocytes it was shown that 
HP1α is able to recruit JHDM3A, a H3K9 demethylase, which would lead to gene 
activation (36). However, this is less likely to occur for ATRA as H3K9me3 remained 
upregulated at day 10 (Figure S3). Furthermore, it was shown that H3K9me3 may 
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suppress or activate gene transcription in cancer cells, depending on the DNA 
methylation profiles, the site of H3K9me3, and other histone marks present (37). 
Also the sub form HPγ has been proposed to play a role in transcription activity, as it 
can be both present in eu- and heterochromatin (38). Hence, more study is needed 
to elucidate the precise role of DNA methylation and HP1 recruitment in this context. 
 Furthermore, until now we have only looked at repressive histone marks. However, 
BCG has already been shown to prime monocytes by inducing epigenetic changes by 
increasing H3K4me3 at pro-inflammatory cytokine promoters, both in vitro and in vivo 
(15). As ATRA also decreased the cytokine production of BCG trained macrophages, 
we also determined the effect of ATRA on H3K4me3. Therefore, monocytes were 
incubated with ATRA for 24h and at day 6 H3K4me3 at cytokine promoters was 
determined. It appeared that for IL8, IL10 and IL1RA a decrease of H3K4me3 was 
present in ATRA-primed macrophages. For IL6 and TNFA no significant differences 
were found (Figure 3B). This shows that the downregulation of cytokine production 
by ATRA is not solely dependent on H3K9me3 and supports the hypothesis that 
ATRA can also influence other epigenetic marks, and that the downregulation of 
cytokine production is a result of a complex interplay of these changes. 
 To finally show that the overall effect of epigenetic changes induced by ATRA 
results in more dense chromatin, gene accessibility at the promoter sites was 
assessed by DNase treatment. At day 6 of the culture protocol, cells primed with 
ATRA showed a decreased gene accessibility, in line with the observed epigenetic 
changes (Figure 3C).
Inhibition of SUV39H2 can partially restore cytokine production and epigene-
tic changes
Finally, we wanted to assess whether methylation of H3K9 is indeed involved in the 
effects of ATRA, by blocking it with the SUV39H2 inhibitor chaetocin. When chaetocin 
was added for the 24h incubation period with ATRA +/- BCG, it restored cytokine 
responses upon restimulation of the cells, suggesting a causative role for SUV39H2 
in the inhibition of cytokine production by ATRA (Figure 4A,B), which was due to 
restored transcription (Figure 4C,D). To validate the mechanism, we additionally 
showed that chaetocin reversed the increase of H3K9me3 at the promoters of IL6 
and TNFA induced by ATRA. This effect was present in both macrophages and BCG-
trained macrophages (Figure 4E,F, and S4). 
 Interestingly, we also observed that H3K9me3 was downregulated by BCG 
training of the cells: this suggests that a combination of increased activation markers 
(e.g. H3K4me3) and decreased repression markers (e.g. H3K9me3) contribute to 
monocyte training by BCG, and this should be assessed in other models of trained 
immunity as well. 
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 The epigenetic reprogramming induced by ATRA that leads to a decreased 
cytokine production as shown in the present study may account at least partially for 
the contrasting effects on mortality reported in epidemiological studies of VAS (11). 
BCG vaccination has opposite immunological effects to ATRA (15) and is associated 
with strong reductions in all cause mortality (12, 13). Our observations support the 
hypothesis that BCG vaccination and VAS interact (39). It is still speculative to directly 
link our in-vitro ATRA experiments with in-vivo VAS, but it could be hypothesized that 
VAS also leads to long-term downregulation of cytokine production, and -depending 
on the situation- this could have harmful of beneficial effects. Thus, our findings 
could help explain why VAS may increase overall mortality in some situations. 
Figure 4 - Inhibition of 
cytokine production 
induced by ATRA and 
epigenetic changes are 
restored by a SUV39H2 
inhibitor. (A-D) When 
chaetocin, a SUV39H2 
inhibitor, was added during 
the first 24h incubation of 
monocytes with ATRA and/
or BCG, the production of 
IL-6 and TNFα upon LPS 
restimulation at day 6 was 
restored (A,B), as a result of 
restored transcription (C,D). 
(n=6, * p < 0.05, ** p < 0.01). 
(E,F) Also the increase of 
H3K9me3 induced by ATRA 
was restored by incubation 
with chaetocin in both the 
normal and BCG-trained 
macrophages (n=3). See 
Figure S4 for H3K9me3 
assessed using additional 
TNFA primers.
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Nevertheless, to truly assess the long-term effects of VAS on the innate immune 
system a study should be performed with immunological endpoints, e.g. ex-vivo 
monocytes stimulations and determination of epigenetic changes at different time 
points before and after VAS. 
 In conclusion, short-term exposure of human monocytes to ATRA results in long-
term immune inhibition characterized by lower cytokine responses upon stimulation 
with a second stimulus. These immunomodulatory effects of ATRA are induced by a 
decreased H3K4me3 and an activation of the histone methyltransferase SUV39H2, 
which increases H3K9me3 at the promoter sites of several cytokines, leading to 
epigenetic reprogramming and inhibition of gene transcription. 
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Figure S1 - Lower 
concentrations of ATRA do 
not induce apoptosis.
Monocytes were incubated for 
24h with different concentrations 
of ATRA or EtOH as a solvent 
control. After 24h incubation 
LDH was measured by a 
cytotox 96 cytotoxicity assay in 
the supernatant following the 
instructions of the manufacturer 
(Promega, WI, USA). At 
different time points cells were 
harvested, stained for Annexin 
V-FITC and PI (Biovision, CA, 
USA) and measured on a 
flowcytometer (Coulter Cytomics 
FC500, Beckman Coulter) to 
determine apoptosis. Depicted 
is the percentage of Annexin V 
positive or double positive cells. 
There was no direct cell toxicity 
as shown by non-increased LDH 
levels. And in the lower ATRA 
concentrations no delayed 
apoptosis was seen. Therefore, 
for the 7-day experiments a 
dose of 1nM was used.
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Figure S2 - ATRA does not cause a predominant M1, 
M2 or DC phenotype. Monocytes were incubated for 24h 
with 1nmol/L of ATRA. At day 6 cells were stored in TRIzol 
and mRNA isolation was performed. qPCR was performed 
on the reverse transcribed cDNA. None of the M1, M2, or 
DC markers was significantly up- or downregulated. iNOS 
transcription, as a marker for M1 differentiation, was too low 
in both the RPMI and ATRA primed cells and is therefore not 
depicted in the figure. (n=6).
Figure S3 - Epigenetic 
time course. Monocytes 
were incubated for 
24h in the presence or 
absence of 1nM ATRA. 
At different time points 
(also before incubated 
with ATRA or RPMI, 
marked by 0) cells 
were harvested and 
DNA was isolated to 
determine H3K9me3 
at the promoters of IL6 
and TNFA. (n=4, * p < 
0.05). H3K9me3 was 
not upregulated during 
the first 3 days. At day 6 
ATRA primed cells had a 
higher H3K9me3 at the 
promoter sites of IL6 and 
TNFA. The upregulation 
of histone methylation 
remained present at day 
10.
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Figure S4 - Additional primers for assessing H3K9me3 for the TNFA promoter (extra 
to Figure 4E,F). Additional parts of the TNFA promoter H3K9me3 were assessed, and this 
induction could also be inhibited by chaetocin. This accounts for both the normal and BCG-
trained monocytes. (n=3)
Chapter 4
  64 | 
qPCR experiments
Gene 5’-3’ sequence
Forward Reverse
HPRT CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA
IL6 AACCTGAACCTTCCAAAGATGG TCTGGCTTGTTCCTCACTACT
TNFA CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG
IL8 ACTGAGAGTGATTGAGAGTGGAC AACCCTCTGCACCCAGTTTTC
IL18 TGTCGCAGGAATAAAGATGGCT CCTTGGTCAATGAAGAGAACTTGGT
IL10 CAACCTGCCTAACATGCTTCG TCATCTCAGACAAGGCTTGGC
IL1RA GAAAATCCAGCAAGATGCAA GTCCTTGCAAGTATCCAGCA
SUV39H1 CCTGCCCTCGGTATCTCTAAG ATATCCACGCCATTTCACCAG
SUV39H2 TCTATGACAACAAGGGAATCACG GAGACACATTGCCGTATCGAG
SETDB1 AGGAACTTCGGCATTTCATCG TGTCCCGGTATTGTAGTCCCA
SETDB2 TGCTCTGGTGCTTGTCTGATG TGCATGTCGTCTTTGGAAGTG
EHMT1 GCTGTGTGAAAACCGAGCTG TCCGCTATCCGAGTTAGTGTG
EHMT2 CTGTCAGAGGAGTTAGGTTCTGC CTTGCTGTCGGAGTCCACG
EZH2 GGACCACAGTGTTACCAGCAT GTGGGGTCTTTATCCGCTCAG
TLR2 GAATCCTCCAATCAGGCTTCTCT GCCCTGAGGGAATGGAGTTTA
TLR4 GGCATGCCTGTGCTGAGTT CTGCTACAACAGATACTACAAGCACACT
iNOS TTCAGTATCACAACCTCAGCAAG TGGACCTGCAAGTTAAAATCCC
ARG1 GATTCCCGATGTGCCAGGATT GCCAATTCCTAGTCTGTCCACTT
CD163 TGAAGACTCTGGATCTGCTGA GAACTGGTGACAAAACAGGCA
CD83 AAGGGGCAAAATGGTTCTTTCG GCACCTGTATGTCCCCGAG
HLA-DRB1 CGGGGTTGGTGAGAGCTTC AACCACCTGACTTCAATGCTG
DC-SIGN TCAAGCAGTATTGGAACAGAGGA CAGGAGGCTGCGGACTTTTT
ChIP experiments
Gene 5’-3’ sequence
(promoter) Forward Reverse
GAPDH CACCGTCAAGGCTGAGAACG ATACCCAAGGGAGCCACACC
ZNF274_3UTR AAGCACTTTGACAACCGTGA GGAGGAATTTTGTGGAGCAA
IL6 TCGTGCATGACTTCAGCTTT GCGCTAAGAAGCAGAACCAC
TNFA1 AGAGGACCAGCTAAGAGGGA AGCTTGTCAGGGGATGTGG
TNFA2 CAGGCAGGTTCTCTTCCTCT GCTTTCAGTGCTCATGGTGT
TNFA3 GTGCTTGTTCCTCAGCCTCT ATCACTCCAAAGTGCAGCAG
TNFA4 TGTCTGGCACACAGAAGACA CCCTGAGGTGTCTGGTTTTC
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TNFA5 AGCCAGCTGTTCCTCCTTTA TTAGAGAGAGGTCCCTGGGG
IL8 TGGCAGCCTTCCTGATTTCT ACATAGGAAAACGCTGTAGGTCA
IL18 ATGCACTGGGAGACAATTCC CTCCCTCCACCTTCTTCCTC
IL10 GGGACAGCTGAAGAGGTGGA CCTCAAAGTTCCCAAGGAGC
IL1RA AGCATATGCAAAAGCCACGG ATGTGCAGAGCCTGTCTTGG
Table S1. Primers
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ABSTRACT
Bacillus Calmette-Guérin, the vaccine against tuberculosis has been shown to have 
non-specific beneficial effects against other infections than tuberculosis. We have 
previously shown that the BCG is able to induce trained immunity by epigenetically 
reprograming human monocytes, which results in higher cytokine responses to non-
mycobacterial stimuli after vaccination. However, no earlier studies have demonstrated 
a direct effect of BCG on a human infection in a controlled setting. The present 
study demonstrates that BCG vaccination reduces yellow fever vaccine viraemia 
after vaccination. Reduction of viraemia is highly correlated with the upregulation 
of IL-1β production to non-mycobacterial pathogens after BCG vaccination, but not 
to the specific IFNγ response to stimulation with the virus. Furthermore, epigenetic 
analysis of monocytes reveals that also in vivo broad epigenetic changes are induced 
in monocytes, suggesting that the genome-wide changes lead to epigenetic and 
functional reprogramming responsible for the nonspecific beneficial effects of BCG. 
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Bacillus Calmette-Guérin (BCG) is a live-attenuated vaccine that protects against 
miliary tuberculosis, tuberculous meningitis, and leprosy, and has now been used for 
almost a century (1, 2). Interestingly enough, the BCG vaccine also has non-specific 
protective effects. Several observational studies have shown that vaccination at 
birth results in reduced child mortality (3-6). In two later randomized controlled trials, 
these beneficial effects of BCG could be reproduced, and the reduced mortality 
appeared to be mainly due to protection against neonatal sepsis and respiratory 
infections (7-9). Also in several mouse infection models (summarized in (10)) 
prior BCG vaccination has shown to protect from mortality. Lastly, BCG is used as 
immunotherapy in cancer, as BCG installations in bladder cancer induce immune 
stimulating effects that slow tumor progression (11).
 The exact mechanism on how BCG exerts these non-specific protective effects 
remains partially unknown. Two types of mechanisms have been suggested to 
mediate these effects. Firstly, by inducing CD4 and CD8 memory cells that can be 
activated in an antigen-independent way, a process called heterologous immunity is 
triggered by BCG (12-14). Secondly, BCG also induces epigenetic reprogramming of 
human monocytes, which results in a more pro-inflammatory phenotype, a process 
called trained (innate) immunity (15, 16). 
 Despite these data, no earlier studies have demonstrated a direct effect of BCG 
on a human infection in a controlled setting. In this manuscript we use vaccination 
with the live-attenuated yellow fever vaccine as a model of viral infection in humans. 
Using this model, we investigate the impact of BCG vaccination on the virologic and 
immunological parameters after yellow fever vaccine administration, in a first study 
assessing the impact of BCG in a controlled human infection. 
 
METHODS
Subjects and BCG and yellow fever vaccine vaccination - Healthy men (age 
range 19-37 years) were recruited to participate in this trial. 30 healthy individuals 
were included in between February and November of 2015. Volunteers were at 
baseline randomly assigned to receiving either BCG (SSI, Denmark) or placebo (the 
diluent used to dissolve BCG in) and vaccinated in a double-blind fashion. A month 
later all volunteers received the yellow fever vaccine (Stamaril, Sanofi Pasteur). 
Blood was drawn before BCG/placebo and yellow fever vaccination and 3, 5, 6, 14, 
and 90 days after yellow fever vaccination. One of the volunteers in the BCG group 
already had a protective yellow fever titer before yellow fever vaccination, so he 
was excluded from all yellow fever analysis data. The study was approved by the 
Arnhem-Nijmegen Medical Ethical Committee, NL50160.092.24.
PBMC and monocyte isolation - Isolation and stimulation was performed as 
described before (15, 17). Briefly, PBMCs were isolated by density centrifugation 
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of Ficoll-Paque (GE healthcare, UK). Cells were washed twice in PBS and 
resuspended in RPMI culture medium (Roswell Park Memorial Institute medium; 
Invitrogen, CA, USA) supplemented with 50μg/ml gentamicin, 2mM Glutamax 
(Gibco), and 1mM pyruvate (Gibco) and diluted to a concentration of 5x10^6/ml. 
100µl/well was added to 96-well plates and cells were incubated for 24h or 7d with 
RPMI, sonicated Mycobacterium tuberculosis H37Rv (5µg/ml), heat-killed Candida 
albicans (1x10^6/ml, strain UC820) or Staphylococcus aureus (1x10^6/ml, clinical 
isolate). Supernatants were collected after 24h or 7d and stored at -20oC.
 Monocyte isolation was performed after the PBMC isolation step, by MACS 
isolation with CD14 positive magnetic beads (MACS Miltenyi) according to the protocol 
of the manufacturer.  1x10^6 monocytes were stored in Trizol (Life technologies) and 
all remaining monocytes were fixed in 1% methanol-free formaldehyde and stored in 
PBS before sonication, after which chromatin was stored at -80oC.
Cytokine Measurements - Cytokine measurements were performed in the 
supernatants using commercial ELISA kits from R&D Systems (TNFα, IL-1β, IL-
17 and IL-22; Minneapolis, MN, USA) or Sanquin (IL-6, IFN-γ; Amsterdam, The 
Netherlands). Circulating cytokines after yellow fever vaccination were determined 
in plasma. Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood was 
centrifuged at 2,000xg at 4°C for 10min immediately after withdrawal, and plasma 
was stored at -20°C until analysis. Concentrations of TNFα, IL-6, IL-8, IL-10, IL-1β, 
IL-1 receptor antagonist (IL-1RA), IFNα and IFNγ were measured in plasma using 
a Luminex assay according to the manufacturer’s instructions (Milliplex; Millpore, 
Billerica, MA, USA). 
Chromatin immunoprecipitation (ChIP) - Purified monocytes before and after BCG 
vaccination were fixed with 1% formaldehyde (Sigma-Aldrich) at a concentration 
of approximately 15x10^6 cells/ml. Fixed cell preparations were sonicated using 
a Diagenode Bioruptor Pico sonicator using 5 cycles of 30s on, 30s off. One µg 
of chromatin (approx. 0.5-1 x 10^6 cells) was incubated with dilution buffer, 12µl 
protease inhibitor cocktail and 1µg of H3K27ac antibody or H3K27ac (Diagenode) 
to a final volume of 300µl, and incubated overnight at 4oC with rotation. Protein A/G 
magnetic beads were washed in dilution buffer with 0.15% SDS and 0.1% BSA, added 
to the chromatin/antibody mix and rotated for 60min at 4oC. Beads were washed with 
400µl buffer for 5min at 4oC with five rounds of washes. After washing, chromatin 
was eluted using 200µl elution buffer for 20min. Supernatant was collected, 8µl 5M 
NaCl, 3µl proteinase K were added and samples were incubated for 4h at 65oC. 
Finally, samples were purified using Qiagen Qiaquick MinElute PCR purification Kit 
and eluted in 20µl elution buffer. Further prepartion of the samples and the data 
analysis was performed as described in Chapter 9.
Statistical analysis - Differences were analyzed using Wilcoxon signed-rank test or 
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Figure 1 - BCG induces trained 
immunity in vivo. (A) Healthy 
volunteers randomly received 
BCG or placebo vaccination. 
Before vaccination and 1 
month later, blood was drawn 
and PBMCs were isolated 
and restimulated ex vivo. (B) 
Fold increases (compared to 
baseline) of IL-1β, TNFα, and 
IL-6 production to LPS, M. 
tuberculosis (MTB), and C. 
albicans are shown. (n=15 per 
group, * p <0.05 BCG vs placebo, 
# p < 0.01 ## p < 0.01 baseline vs 
1 month, Mann-Whitney U test). 
(C) Unsupervised clustering 
analysis of cytokines measured 
(IL-1β, TNFα, IL-6, and IL10 after 
24h and IL-17, IL-22, IFNγ after 7 
days ex vivo incubation with LPS, 
MTB, S. aureus, or C. albicans.
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Mann-Whitney U test where applicable. All calculations were performed in Graphpad 
prism 5 (CA, USA). p < 0.05 was considered statistically significant. Data are shown 
as means ± SEM.
 
RESULTS
BCG induces trained immunity in vivo
We have shown before that BCG is able to increase ex-vivo cytokine responses to 
non-related pathogens of PBMCs 2 weeks and 3 months after vaccination (15, 17). 
We assessed the BCG effects on cytokine production a month after vaccination, with 
inclusion of a placebo group to account for potential timing-related effects. We were 
again able to show significant increases in cytokine production 1 month after BCG 
vaccination, which for most stimuli and cytokines were significantly higher than the 
placebo vaccinated volunteers (Figure 1A,B, S1). However, the induction of trained 
immunity was highly variable between individuals. To assess whether the induction 
of production of different cytokines upon different stimuli was correlated (e.g. is 
a higher induction of IL-6 to LPS correlated with a higher IL-1β production upon 
MTB stimulation), we performed an unsupervised cluster analysis. When the fold 
increases of cytokine production 1 month after BCG vaccination were compared, 
a cluster of innate cytokines and a second cluster of T-helper 1/17 lymphocyte 
cytokines becomes apparent. Within the cluster of innate cytokines, the induction of 
IL-1β and IL-6 production is highly related (Figure 1C). 
BCG vaccination lowers yellow fever viraemia
Yellow fever vaccine viraemia was determined by RT-PCR on day three, five, and 
seven post-vaccination. Viraemia was highest at day five, as previously reported by 
others (18) (Figure 2A,B). When viraemia was compared between the volunteers 
that received BCG or placebo, the group vaccinated with BCG showed a significantly 
lower amount of circulation virus compared to the group that received placebo 
(Figure 2B). This was also reflected by the amount of circulating cytokines in plasma, 
which were significantly higher in the volunteers that received placebo (Figure 2C). 
Importantly, when yellow fever neutralizing antibodies were measured at three 
months post vaccination, no differences were found between the two groups (Figure 
2D), showing that BCG vaccination did not have deleterious effects on yellow fever 
serology, despite the diminished viraemia. In addition, BCG vaccination did not 
change the specific cellular response to YFV as measured by IFNγ production by 
PBMCs (Figure S2). 
 To determine whether the induction of trained immunity, as measured by induction 
of ex-vivo cytokine responses, was correlated with the amount of circulating yellow 
fever virus, Spearman correlations between viraemia and all measured cytokines 
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were calculated. The fold-increase in TNFα and IL-6 production showed a weak 
correlation with viraemia. In contrast, the potentiation of IL-1β production capacity 
after BCG vaccination was strongly correlated with a lower viraemia (Figure 3A). 
Among the other cytokines, the induction of IL-10 upon stimulation with C. albicans 
also displayed a negative correlation with viraemia (Figure 3A). Interestingly, 
the induction of the specific cellular responses to YFV by BCG as measured by 
IFNγ production by PBMCs did not correlate with the viraemia (Figure 3A). When 
comparable correlation analysis were performed for the induction of yellow fever 
neutralizing antibody titers, no clear pattern was seen (Figure 3B). 
Figure 2 - BCG vaccination lowers yellow fever vaccine viraemia. (A) Post-vaccination viraemia was 
determined by PCR three, five and seven days after yellow fever vaccine. (B) Relative viraemia amounts 
by setting CT 40 as reference 1 are day 3, 5, and 7 post-vaccination. (*<0.05, Mann-Whitney U test). (C) 
Circulating cytokines were determined five days post vaccination in plasma. IL-1β and IL-10 were below 
detection limit in almost all samples. (*<0.05, **<0.01, Mann-Whitney U test). (D) Yellow fever neutralizing 
antibodies were determined 90 days post yellow fever vaccination.
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BCG vaccination results in epigenetically different monocytes
Monocytes from seven donors were analyzed by ChIP sequencing to determine the 
distribution of H3K27ac at ‘baseline’ (before BCG vaccination, day -28) and ‘BCG 
1 month’ (1 month after BCG vaccination, day 0), in order to examine whether also 
in vivo in humans BCG is able to induce a different epigenetic phenotype. In order 
to compare whole genome H3K27ac profiles of the different donors at the two time 
points, correlation plots based on sequencing reads were performed (Figure 4A). 
Based on all H3K27ac peaks, a separation of the samples at baseline and after 
BCG vaccination is seen. Correlation between the samples becomes only clearer 
when specifically analyzing peaks that are highly induced in at least one donor, or 
specifically analyzing differences between peaks before and after BCG vaccination 
(Figure 4A, S3A). Both displaying the 646 peaks showing differences between 
baseline and BCG in a heat map and a principal component analysis (PCA) figure 
show clear differences between the two time points (Figure 4B,C). When specifically 
analyzing peaks related to promoters, a comparable effect is seen (Figure S3B,C). 
Finally, when the genes near the 646 differential peaks are analyzed by pathway 
analysis, several important signaling and inflammatory related pathways are 
significantly differently regulated (Figure 4D, Table S1,2). Interestingly, genes as 
AKT1, MAPKs and PIK3 related genes that have been shown to be major regulators 
in β-glucan-induced trained immunity appear to be also important in BCG-induced 
trained immunity (19, 20). 
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Figure 3 – Induction of IL-1β negatively correlates with 
yellow fever viraemia.  (A) Fold induction of cytokine 
production 1 month after BCG vaccination (as shown in 
Figure 1B) are compared with yellow fever viraemia at 
day five post vaccination (as shown in Figure 3B). The 
Spearman correlation coefficients and their p values are 
shown. Panel (ii) and (iii) show an example of fold increase 
(a month after BCG vaccination) of IL-1β by C. albicans 
stimulation correlated with yellow fever viraemia (CT-
values) and of IFNγ by YFV stimulation.  (C) Fold induction of cytokine production 1 month after BCG 
vaccination (as shown in Figure 1B) are compared with yellow fever titer 90 days post vaccination (as 
shown in Figure 3D). The spearman correlation efficients and their p values are shown. 
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Figure 4 – Genome-wide H3K27ac analysis of BCG exposed monocytes. Monocytes from seven 
donors were analyzed by ChIPseq to determine the distribution of H3K27ac at ‘baseline’ (before BCG 
vaccination, -28d) and ‘BCG 1 month’ (1 month after BCG vaccination, 0d). (A) Correlation plot based on 
sequencing reads at (i) all H3K27ac peaks, (ii) peaks dynamic in at least one donor after BCG exposure, 
and (iii) peaks dynamic between the baseline and BCG 1 month groups (p <0.05, FC >1.5). (B) Heat map 
of 646 peaks showing differences between baseline and BCG exposed groups. (C) Principal component 
analysis of the same peaks. (D) Top pathways associated with genes near the 646 differential peaks and 
names of genes associated with inflammation and cytokine signaling.
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DISCUSSION
In this study we demonstrate for the first time that BCG has beneficial non-specific 
effects in a controlled model of human infection. In addition, we described the 
effects of BCG vaccination on cytokine production by PBMCs to related and non-
related stimuli, and in a subset of individuals we demonstrate broad changes in the 
epigenetic programming of monocytes.
 We have reported previously that the BCG vaccine is able to induce non-specific 
effects by showing increased cytokine production of PBMCs to non-specific stimuli 
after BCG vaccination (15, 17). We have now reproduced these effects, although we 
also show an important inter-individual variation in the induction of trained immunity. 
It was previously suggested that development of a scar after BCG vaccination 
could be used as a marker for non-specific effects and childhood survival (3, 21). 
However, all BCG-vaccinated volunteers developed a scar with a comparable size 
(0.5-0.7cm), and thus it is unlikely that scar development is a strong correlate of 
protection. A single nucleotide polymorphism in the autophagy gene ATG2b was 
shown to reduce the ability to induce trained immunity (22). However, screening the 
15 BCG vaccinated volunteers revealed only one volunteer with a mutant genotype, 
and thus is this also insufficient to explain the lack of response in some volunteers. 
Although responders and non-responders could be identified, the current knowledge 
on genetic factors influencing the induction of trained immunity by BCG is insufficient 
to explain the distribution we observed here. To answer this question a cohort study 
with larger numbers of volunteers being vaccinated with BCG is warranted to assess 
the effect of other genetic polymorphisms on the induction of trained immunity by 
BCG.
 Apart from just the change in cytokine production, we have now also shown 
that BCG vaccination can reduce yellow fever viraemia. Beneficial effects of BCG 
vaccination on resistance to viral infections have been reported in observational 
studies. In two randomized controlled trials there was a reduction in mortality from 
lower respiratory infection in children (often of viral origin) (7, 8) and in a case control 
study in children beneficial effects on the incidence of respiratory syncytial virus 
were found (23). Also in an Indonesian trial, repeated BCG vaccination in elderly 
subjects (60-75 years) reduced upper respiratory tract infections (24). Interestingly, 
when determining whether induction of trained immunity in our study measured by 
cytokine production upon stimulation with non-related pathogens is correlated with 
the protective effects of BCG vaccination on yellow fever viraemia, it appears the 
induction of especially the fold increase of IL-1β production was a good correlate of 
protection. In contrast, no such effect was observed for the specific cellular function 
as measured by IFNγ production of PBMCs after YFV stimulation. Because only 
circulating monocytes were thoroughly assessed in this study, effects of other innate 
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immune cells (e.g. NK-cells) on lowering yellow fever viraemia after BCG vaccination 
cannot be excluded.
 When assessing pathways related to the changed peaks after BCG vaccination, 
several important signaling and cytokine/chemokine pathways become apparent. 
This shows that also in vivo BCG is able to induce a different cellular phenotype 
of monocyte by changing the epigenetic landscape. When comparing the current 
epigenetic profiles to the epigenetic analysis that we have performed before on 
in-vitro β-glucan-trained macrophages, noticeable similarities are found. In the 
β-glucan-trained macrophages acluster of genes (M5) was defined as being most 
significantly regulated: immune response, cytokine and chemokine activity were the 
major regulated pathways in this cluster (19). Comparable regulated pathways were 
now also found in monocytes from in-vivo-trained healthy volunteers. Furthermore, 
we have shown before that the PI3K/Akt pathway is important in the induction of 
trained immunity by β-glucan and also by BCG in vitro (20, 25): this pathway is now 
shown to be epigenetically regulated in-vivo by BCG vaccination. Hence, the clear 
changes induced in in-vitro induced trained immunity can also be observed in the 
in-vivo vaccination model. 
 In conclusion, we show that the BCG vaccine is able to induce a pro-inflammatory 
phenotype in circulating monocytes, and is able to reduce the amount of circulating 
yellow fever virus after administration of the yellow fever vaccine. The demonstration 
that BCG vaccination is indeed able to improve the outcome of infection in humans 
opens the gates for new treatment strategies using trained immunity in severe 
infections.   
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Table S1 – >3SD Dynamic H3K27ac peaks in at least one donor after BCG exposure. Genes (and 
related pathways) related to peaks that are at least 3 standard deviations dynamic in one of the volunteers 
after BCG vaccination.
Table S2 – Dynamic H3K27ac peaks FC > 1.5, p < 0.05 after BCG exposure. Genes (and related 
pathways) related to peaks with a fold change of at least 1,5 with p < 0.05 after BCG vaccination.
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Figure S1, related to Figure 1B - Healthy volunteers randomly received BCG or placebo vaccination. 
Before vaccination and 1 month later blood was drawn and PBMCs were isolated and ex vivo restimulated. 
Fold increases (compared to baseline) of IL-10, IFNγ, IL-17, IL-22 production to LPS or PHA, M. 
tuberculosis (MTB), C. albicans, and S. aureus are shown. (n=15 per group, * p < 0.05 BCG vs placebo, 
# p < 0.01 ## p < 0.01 baseline vs 1 month, Mann-Whitney U test).
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Figure S2, related to Figure 2,3 – IFNγ production of PBMCs upon stimulation with the yellow fever 
vaccine (YFV). PBMCs were isolated at the mentioned days post yellow fever vaccination and ex vivo 
stimulated for 7d with the YFV. Fold increases (compared to baseline) are displayed.
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Figure S3, related to Figure 4 – Genome-wide H3K27ac analysis of BCG exposed monocytes. 
Monocytes from seven donors were analyzed by ChIPseq to determine the distribution of H3K27ac at 
‘baseline’ (before BCG vaccination, -28d) and ‘BCG 1 month’ (1 month after BCG vaccination, 0d). (A) 
Correlation plots showing the relationship between the different donors and exposures by Pearson, 
based on sequencing reads at (i) all H3K27ac peaks, (ii) peaks dynamic in at least one donor after BCG 
exposure, and (iii) peaks dynamic between the baseline and BCG 1 month groups (p <0.05, FC >1.5). 
Based on all H3K27ac peaks, we see mixing of the baseline and BCG samples, which suggests little 
global change in H3K27ac in response to BCG. However, based on significantly different peaks (iii) we 
observe clear separation between baseline and BCG exposed monocytes. (B) Heat map of differentially 
regulated genes (p < 0.05, FC > 1.5) related to promoters. (C) Box plots of down and upregulated peaks 
after BCG vaccination.
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ABSTRACT
An increasing body of evidence shows that the innate immune system has adaptive 
characteristics that involve a heterologous memory of past insults. Both experimental 
models and proof-of-principle clinical trials show that innate immune cells such 
as monocytes, macrophages and NK-cells can provide protection against certain 
infections in vaccination models independently of lymphocytes. This process is 
regulated through epigenetic reprogramming of innate immune cells and has been 
termed ‘trained immunity’. It has been hypothesized that induction of trained immunity 
is responsible for the protective non-specific effects induced by vaccines such as 
BCG, measles vaccination, and other whole-microorganism vaccines. In this review 
we will present the mechanisms of trained immunity responsible for the long-lasting 
effects of vaccines on the innate immune system.
Non-specific Effects of Vaccines
| 85
 6
Traditionally the host defense against invading pathogens is divided into innate and 
adaptive immunity. The innate immune system, relying on monocytes, macrophages, 
neutrophils, dendritic cells and NK-cell as its cellular effectors, recognizes pathogens 
using pattern recognition receptors (PRR; e.g. TLRs, NLRs, CLRs, RIGI-helicases) 
that bind pathogens associated molecular patterns (PAMPs) on pathogens. This 
results in a rapid activation of host defense: cytokine and chemokine production, 
phagocytosis, reactive oxygen/nitric oxide species production and other antimicrobial 
killing mechanisms, as well as antigen presentation to the adaptive immune system 
(1, 2). Since the innate immune system is considered not to possess immunologic 
memory, its actions are seen as being non-specific and to induce an identical effect 
upon every encounter with a pathogen. The adaptive immune system that consists of 
T- and B-lymphocytes, acts through specific recognition of antigens by lymphocytes, 
which induces memory cells that will greatly enhance the response to a later infection 
with a similar pathogen. Classical vaccination is based on this adaptive immune 
mechanism. Since the activation of lymphocytes and generation of memory cells is 
a slow process (days to weeks), vaccination is used to induce a ‘safe/controlled’ first 
activation of the immune system that will result in a specific memory and will protect 
the vaccinated host from secondary infection with the pathogen against which it was 
vaccinated (3).
 Recent data challenge however the paradigm that innate immunity is completely 
devoid of adaptive characteristics. Non-specific beneficial effects of vaccines on 
mortality and morbidity due to infections have been increasingly reported, which 
could not be explained solely by adaptive immunity (4). In both observational studies 
and randomized controlled trials it was shown that BCG reduced overall mortality, 
mainly by a decrease in lower respiratory infections and sepsis (further discussed 
below). Since this effect seems to be established within days, this is more consistent 
with an effect on innate immunity than on adaptive immunity. Moreover, studies in 
plants and non-vertebrates that totally lack adaptive immunity, have also shown 
protective host immune responses in models of vaccination or after certain infections 
(reviewed in (5)). These observations led to the hypothesis that certain infections 
or vaccines are able to induce reprogramming of the innate immune responses, 
leading to non-specific protection to reinfection, a process named trained immunity 
(5, 6) (Figure 1). 
Trained immunity: a de facto innate immune memory
An important model to study the mechanisms mediating trained immunity (TRIM) is 
the protection to reinfection induced by Candida albicans or its cell-wall component 
β-glucan. It was shown that mice infected with a nonlethal C. albicans infection had 
a lower mortality from a lethal C. albicans infection 7 days later. This protective 
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effect appeared to be T/B-cell independent, as Rag1-deficient mice were still 
partially protected (7), just as SCID mice in a BCG-induced trained immunity model 
(discussed below) (8). In contrast, CCR2-deficient mice in which myeloid cells are 
trapped in the bone marrow lost all protection: this demonstrates that only the loss of 
both innate immune effects (trained immunity) and adaptive memory (through loss 
of antigen-presenting cell function) leads to a complete inactivation of the protective 
effects induced by BCG. In an in-vitro experimental model, monocytes primed with 
β-glucan displayed a reprogramming of their function, among which an increased 
pro-inflammatory cytokine response to secondary stimuli. This appeared to be 
mediated by a dectin-1-Raf1 pathway and led to increased methylation of histone 
activation markers such as H3K4me3 and transcription of the TNFA and IL6 genes 
upon stimulation with (non-) related pathogens (7). Subsequently, inhibition of histone 
methyltransferases inhibited these effects, demonstrating a role of this epigenetic-
based mechanism for induction of innate immune memory, a conclusion supported by 
genome wide changes in H3K4me3, H3K4me1 and H3K27Ac (7, 9). Other microbial 
components were also shown to induce long-term reprogramming of innate immune 
responses. It should be noted, however, that the functional reprogramming of innate 
immune cells can result in an enhanced response after restimulation, as seen for 
Candida, but can also result in a reduced responses, indicative of tolerance, as 
seen for LPS (Figure 1) (9). On the other hand, one could also argue that it would be 
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Figure 1 - Long-term effects of vaccines on innate immune function. Upon vaccination, the innate 
immune system becomes activated by the vaccine. The stimulation of innate immunity can lead to long-
term effects leading to an increase response to a (non-related) infection. For example, BCG vaccination 
leads to training of innate immunity and a more effective host immune response, accompanied by a 
reduced mortality due to non-related infections. On the contrary, a previous infection with a Gram-negative 
microorganism and endotoxemia can lead to immunotolerance and a decreased response to an infection.
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more appropriate to depart from the view that one particular training stimulus would 
induce either increase or decrease of cell function: in fact it can be observed that 
each of these stimuli induces at the same time upregulation of certain genes, while 
downregulating others (10).
 Pathway analysis of the transcriptome and epigenome profiles of trained 
monocytes demonstrated a central role for the mTOR-pathway and glycolysis for 
induction of innate immunity. Similar to activated lymphocytes (11) or cancer cells (12) 
a shift in glucose cellular metabolism from oxidative phosphorylation towards aerobic 
glycolysis (known as the Warburg effect), was necessary for the function of trained 
cells (13). Hence, trained immunity is induced through epigenetic reprogramming of 
the transcriptional programs, as well as a through a switch in the cellular metabolism 
of glucose that insures the energy sources for the cells. 
 The capacity to induce trained immunity has been reported for BCG vaccination 
too (8, 14). Furthermore, other vaccines have also been shown to have long-lasting 
effects on all-cause mortality, and it has been hypothesized that they induce innate 
immune training effects (15). In the present review we will focus on the non-specific 
effects of vaccines and the evaluation of their capacity to induce trained immunity 
and heterologous immune effects. 
BCG 
The BCG vaccine is a live-attenuated vaccine against tuberculosis that is derived 
from the causative agent of bovine tuberculosis, Mycobacterium bovis. Its protective 
effect against tuberculosis differs greatly between different populations and different 
forms of tuberculosis (16). This is mostly attributed to different rates of priming with 
environmental mycobacteria which would nullify the additional protective effect of 
BCG vaccination (reviewed in (17)).
Non-specific effects on mortality and morbidity
In addition to its specific protective effect against tuberculosis, BCG has been shown 
to possess several non-specific effects. BCG-induced potent non-specific effects 
during therapy for bladder cancer (18), topical therapy for common and genital warts 
(19-21), diffuse cuteneous leishmania (22), and even as treatment for asthma or 
type 1 diabetes (23, 24). In addition, reports from the 1950s and 1960s showed that 
BCG vaccination or stimulation with other mycobacterial proteins (25) protect against 
infection with Staphylococcus aureus, Salmonella enteritidis, M. fortuitum (26, 27), 
Yersinia pestis (28), Klebsiella pneumonia (29), Salmonella enteritidis, Schistosoma 
mansoni (30), herpes simplex and vaccinia virus (31), Leishmania Major (32) and 
tumors (33) in mice, with effects that lasted up to 11 months after vaccination. A small 
number of studies have also reported increased susceptibility to Salmonella typhi, or 
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Eberthella typhosa after BCG vaccination (34-36). 
 Early human observational data are also available to support the hypothesis that 
BCG induces important non-specific effects. After the introduction of BCG vaccination 
in the province of Norrbotten in Sweden in 1931, mortality in the BCG-vaccinated 
children in the first year of life was 6.6% compared to 22.2% in the non-vaccinated, 
an effect that was too big to be due only to the protection to tuberculosis (37). A year 
later, in 1932, the Pasteur Institute reviewed their safety data on BCG vaccination 
and showed a mortality of 7.0% among vaccinated, compared to 15.3% among 
non-vaccinated children (38).  Several trials performed in the 1940s and 1950s in 
the USA and the UK show decreased overall mortality in children vaccinated with 
BCG (reviewed in (39)). More recent observational studies also showed similar non-
specific protective effects by BCG (40). Several observational studies performed 
in West-Africa showed that BCG vaccination (as determined by vaccination card, 
tuberculin test, or scar formation) was associated with a decreased overall mortality, 
with mortality ratios ranging from 0.41 to 0.55 (41-43), and similar protective 
effects of BCG were observed in several Asian countries (44, 45). Apart from these 
observational data, two randomized controlled trials have been performed to study 
the non-specific effects of BCG. In a first trial, 2320 low-birth-weight children (who 
normally will not receive BCG vaccine until they have gained enough weight), were 
randomized to receive BCG at birth or a delayed BCG vaccination. A mortality 
rate ratio of 0.49 (0.21-1.15) was shown after 3 days and 0.55 (0.34-0.89) after 4 
weeks in favor of the BCG-vaccinated neonates. The effect was most prominent in 
children with the lowest birth weight (<1.5kg) and was mainly due to fewer cases of 
neonatal sepsis, respiratory infections, and fever (46). A similar effect was observed 
in a smaller trial (47). A case-control study performed in this population found a 
beneficial effects of BCG vaccination on the incidence of acute lower respiratory 
tract infections and infection with respiratory syncitial virus. This effect was more 
marked in girls compared to boys (48). Revaccination of children aged 19 months 
to 5 years with low or no reactivity to tuberculin skin test did not have effects on 
overall mortality. Though this may have been due to the fact that many children 
received DTP afterwards; in children who had received all their DTP vaccines before 
enrolment, revaccination with BCG was associated with a mortality rate ratio of 0.36 
(0.13- 0.99) (49).
Non-specific immunological effects of BCG
The beneficial non-specific effects of BCG vaccination have been proposed to 
be mediated by two types of mechanisms: lymphocyte-mediated heterologous 
effects, or by innate trained immunity. Cross-reactivity of T-lymphocytes, a process 
termed ‘heterologous immunity’ (50), has been long proposed to mediated some 
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of the non-specific effects of vaccines. Heterologous immunity has been especially 
well described in virus infections, and it has been shown in mice that BCG can 
protect against infection with vaccinia virus through a mechanism dependent on 
T-cell receptor signaling and IFNγ production in CD4 cells (51). In an experimental 
model in hamsters, BCG vaccination increased the lytic activity of peritoneal cells 
against herpes simplex infected cells, an effect dependent on non-adherent Thy1.2+ 
cells (52). Furthermore, it has been shown that CD4 and CD8 memory cells can be 
activated in an antigen-independent manner, and they can therefore boost both Th1 
and Th17 responses upon secondary non-related infections (53-58). Interestingly, 
BCG revaccination of two year old children in Guinea Bissau resulted in lower TNFα 
and higher IL-10 responses to LPS, PHA and PPD (59), an effect that might be 
dependent on Treg induction by the second BCG vaccination, as it was shown that 
mice that were presensitized with mycobacteria developed more Treg induction 
and higher IL-10 response upon subsequent vaccination with BCG (60). Also, BCG 
vaccination has been shown to enhance the antibody titer and T-cell responses to 
other vaccines such as hepatitis B, polio and pneumococcal conjugate vaccination 
(61, 62)
 In addition to heterologous immunity, experimental and epidemiological data point 
to long-term effects of BCG on the innate immune responses. A mice study showed 
that BCG/PPD-activated macrophages were able to produce more H2O2 and were 
better capable in killing Candida albicans (63). Also SCID mice (lacking functional 
lymphocytes), showed an increased survival from Candida sepsis and less fungal 
outgrowth after BCG vaccination, with spleen monocytes producing more TNFα upon 
ex-vivo restimulation (8). BCG vaccinated B-cell deficient mice were as effectively 
protected from S. mansoni infection as the wild type controls (64). Administration 
of muramyldipeptide (MDP), which is a constituent of mycobacterial cells walls, 
confers protection against infection with vaccinia virus and herpes simplex virus in 
mice, and this effect was mediated by peritoneal macrophages and not dependent 
on IFNγ (31). Mice vaccinated with BCG show increased resistance against malaria 
infection, which was associated with increased transcription of antimicrobial proteins 
compared to non-vaccinated mice (65).  
 In humans, BCG vaccination was shown to induce potentiation of the activity of 
NK-cells  (22, 66), and the protective effect of BCG vaccination on disseminated 
candidiasis was partially dependent on NK-cells (66). Compared to cord blood 
monocytes from unvaccinated babies, cells from vaccinated infants showed 
increased expression of granulysin and perforin upon stimulation (67). In a trial in 
Guinea Bissau with 467 low-birth-weight newborns, ex-vivo cytokine production was 
upregulated upon stimulation with several TLR agonists (68), and an association of 
the number of M1 vs. M2 macrophages for the risk of recurrence after intravesical 
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BCG therapy supports an important role of innate immune cells for the non-specific 
effects of BCG (69). An increase in antimicrobial peptide production in infants 
vaccinated with OPV and BCG was also observed in a human observational study 
(70).
Molecular mechanisms behind the non-specific effects of BCG on trained 
immunity
Little is known regarding the molecular mechanisms mediating trained immunity 
induced by BCG vaccination. In a human vaccination trial, BCG resulted in an 
increased pro-inflammatory cytokine response of monocytes for up until three 
months after vaccination, upon ex-vivo stimulation with M. tuberculosis, S. aureus, 
or C. albicans. This was accompanied by a small increase of the activation markers 
CD11b, TLR4 and CD14. The increased cytokine production was a result of higher 
mRNA expression, which was accompanied by an increased H3K4me3 at the IL6 
and TNFA promoters (8). However, these effects mostly reversed 12 months after 
vaccination, arguing that trained immunity is shorter lived than classical adaptive 
immune memory. In addition, in an in-vitro model in which monocytes are trained 
for 24h with BCG and restimulated one week later, it was shown that trained 
immunity induced by BCG was dependent on the recognition by the NOD2 receptor, 
as monocytes of NOD2-deficient patients could not be trained. Moreover, BCG-
induction of trained immunity in-vitro was inhibited by the addition of the histone 
methyltransferase MTA (8), suggesting that epigenetic changes at the level of 
histone methylation play an important role. These effects of trained immunity by 
BCG in vivo were shown to wane after one year, while heterologous effects on Th1 
and Th17 responses were still visible at this timepoint (14). Finally, the induction of 
trained immunity by BCG was shown to be dependent on autophagy (71). Moreover, 
SNPs in autophagy genes were correlated with clinical outcome of bladder cancer 
patients that were treated with BCG instillations, hinting to the fact that the effect of 
BCG on bladder carcinoma might also be mediated by the innate immune system. 
An overview of the molecular mechanisms responsible for the induction of trained 
immunity by BCG is presented in Figure 2.
YELLOW FEVER VACCINE
The yellow fever vaccine (YFV) is a live-attenuated vaccine that in developed 
countries is only administered to travelers going to yellow fever endemic countries. 
In contrast, in many countries in Africa, South and Middle America YFV is part of 
the routine vaccination program (72). Vaccination with YFV results in viraemia three 
to seven days after vaccination, which results in a life-long immunity against yellow 
fever, making the YFV one of the most effective vaccines in use (73). Although no 
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prospective clinical trials have been performed, observational studies may suggest 
that YFV exerts potent non-specific effects. In an observational study (2007-2011) 
where the effect on overall mortality of live and live plus inactivated vaccines was 
compared, subjects (9-23 months old) where vaccinated with measles vaccine with 
or without a pentavalent vaccine containing DTP, H. influenzae type B and hepatitis 
B vaccine. In the last few years of the study the YFV was added to the vaccination 
program. Although confounding factors between the periods with and without YFV 
may have influenced the results, mortality declined after introduction of the YFV from 
15.2 to 7.0 for the 6 months follow up, and from 18.2 to 9.2 for 12 months follow up 
(74). 
Non-specific immunological effects of YFV
Interestingly, non-specific immunological effects of YFV have also been reported. 
When human volunteers were vaccinated with the YFV and 7, 15 and 30 days after 
vaccination isolated neutrophils, monocytes and NK-cells were restimuled ex vivo 
with the YFV, a higher TNFα signal in the unstimulated cells and a higher IL-10 
production in both unstimulated and stimulated cells was observed up until 30 days 
after vaccination. NK-cells did not show any difference for IFNγ, but IL-4 production 
Figure 2 - Molecular mechanisms of trained immunity induced by BCG. During the uptake and 
digestion of BCG by the monocytes and macrophages, autophagy plays an important role. In the 
autophagolysosome compartment BCG is digested, with the release of MDP that activates NOD2. 
Through a signaling cascade that remains to be deciphered, NOD2-dependent signals induce epigenetic 
reprogramming such as H3K4 trimethylation, that is responsible for relaxing the chromatin and increasing 
gene transcription.
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was significantly decreased in the non-stimulated cells, still 30 days after vaccination 
(75). In a similar vaccination study, an increased amount of pro-inflammatory 
monocytes (defined as CD14+CD16+HLA-DR++) was observed after YFV, which 
fits with the upregulated cytokine staining (76). Changes induced by YFV in NK-
cells were determined in a vaccination study in 8 volunteers, showing a significant 
upregulation of TLR3 and TLR9 expression on NK-cells until 10 and 7 days after 
vaccination, respectively. Interestingly, minor changes in TLR3 and TLR9 were 
seen up to 60 days post vaccination. Activation markers such as CD69 and HLA-
DP,PQ,DR were significantly higher expressed until 10 days post vaccination and 
especially the latter remained on average higher expressed until 60 days (77, 78). 
In conclusion, mounting evidence suggests that YFV induces long-term activation of 
monocytes and NK-cells.
Molecular mechanisms behind the non-specific effects of YFV
The YFV is recognized by TLR7, RIG-I helicases, and potentially TLR9 (79, 80). 
Regarding the molecular events induced by YFV, it has been demonstrated that this 
signals via a TLR9-PI(3)K-mTOR-p70S6K pathway, which leads to, among others, 
activation of mTOR (80). Transcription data showed that hexokinase 3 (HK3, a rate 
limiting enzyme in the glycolysis pathway), is still upregulated 60 days after YFV (13, 
81). Further, in an infectious model in which rhesus macaques were infected with 
the viscerotropic yellow fever virus, an upregulation of several epigenetic regulators 
of histone methyltransferase activity was reported (82). In a different study, two 
histone modulators were upregulated in the first week after vaccination: HIST1H1C 
and HIST1H4C (81). These data were not mirrored by whole-blood transcriptome 
analysis, presumably due to the fact that neutrophil-related signatures would likely 
mask effects on the minority monocyte and NK-cell populations (83, 84) and also sex 
differential effects were not taken into account in these analyses, possibly masking 
potential effect (85). 
INFLUENZA VACCINE
Influenza vaccination is done with either live or inactivated vaccines that consists 
of three or four influenza strains which may differ each new season, depending on 
the strains that are predicted to be most common during the influenza season. In 
many high-income countries the inactivated vaccine is given annually to people with 
a higher risk for complications of influenza (e.g. chronically ill, elderly, weakened 
immune system) or health care workers (86), whereas the live-attenuated vaccine it 
is recommended also to children in the US.
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Non-specific immunological effects of influenza vaccine
14 and 28 days after vaccination with an inactivated influenza vaccine, PBMCs were 
isolated and ex-vivo stimulation with LPS, M. tuberculosis, C. albicans and S. aureus 
was performed. This showed a tendency for increased TNFα and IL-6 production, 
whereas IL-1β, IFNγ and IL-10 production was downregulated (87). A similar trend 
was observed in a trial in which both older (>65 years) and younger (21-30 years) 
individuals were vaccinated with inactivated influenza vaccine. Blood was drawn 
before and 2, 7 and 28 days after vaccination, showing an increase in IL-6 and TNFα 
staining of CD14+CD16- and CD14+CD16+ monocytes in the younger volunteer 
group. In contrast in the older individuals an increase in IL-10 intracellular staining 
was observed in both types of monocytes (88). In another trial, healthy volunteers 
were vaccinated with a live-attenuated influenza vaccine. Four, seven and 11 weeks 
after vaccination PBMCs were stimulated ex vivo with the vaccine and cytokine 
production was assessed. A decrease in IL-10 production was observed, while the 
production of pro-inflammatory cytokines was decreased at 4 and 11 weeks post-
vaccination, with a slight increase at 7 weeks. No explanation for the difference 
between the results at 7 and 11 weeks was proposed by the authors (89). 
 Influenza vaccine is known to be recognized by TLR7 (90), but not much is 
known regarding the mechanisms through which influenza vaccine modulates 
innate immunity. However, potentiation of NK-cell function is probably one of the 
most relevant. In this respect, it has been shown that influenza is a potent stimulator 
of NK-activity, and that it increases the number of CD69+ spleen NK-cells (78). In 
a model of spontaneous metastasis of 4T1 breast tumor, when resection of the 
primary tumor was combined with an inactivated influenza vaccination, a reduced 
amount of metastases was observed. This effect could be reversed by depleting NK-
cells (78). In humans who were vaccinated with the inactivated influenza vaccine, 
an upregulation of CD69 expression, an increase of NK cytotoxicity (78), and an 
upregulation of NKp46+ and 2B4+ NK-cells was shown, which lasted until 14 days 
after vaccination with the live-attenuated vaccine (91). 
VACCINIA
Vaccinia virus belongs to the family of Poxviridiae, genus Orthopoxvirus, and has 
been used extensively to vaccinate against smallpox, the very severe disease 
caused by the related variola virus. Vaccination campaigns with vaccinia were 
very successful, leading to the eradication of smallpox in 1977. Vaccinia induced 
protection against smallpox is thought to rely on the induction of neutralizing 
antibodies and the generation of memory T-cells (92). Two observational studies 
on the non-specific effect of vaccinia on overall mortality have been performed in 
Guinea-Bissau. Adults were screened for the presence of a vaccinia scar and this 
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was associated with a decrease in overall mortality ranging from 40 to 80% (93, 94). 
Also, vaccinia vaccination has been linked with protection against melanoma and 
non-Hodgkin lymphoma (95-97).
Non-specific immunological effects of vaccinia
The epidemiological observation is complemented by a number of experimental 
studies in animals. Peritoneal cells and spleen cells from hamsters vaccinated with 
vaccinia showed an increased ex vivo cytotoxic activity towards cells infected with 
herpes simplex virus (HSV) (52, 98). For peritoneal cells this effect was mediated 
by a Thy1.2-positive fraction, and not by adherent macrophages, pointing to the fact 
that lymphoid cells are most likely involved (52). In the spleen cells however this 
effect was shown to be dependent on a Thy1.2-negative cell population, consistent 
with vaccinia activation of NK-cells (98). 
 Vaccinia has been also shown to modulate the cytokine production capacity. An 
increase of IFNγ, IL-6 and TNFα production was found when spleen cells of vaccinia-
challenged mice were cultured with vaccinia-infected cells compared to spleen cells 
from naive mice. The IL-6 and TNFα production was shown to be dependent on 
the adherent cells, compatible with monocytes and macrophages, whereas IFNγ 
production was dependent on both CD4 and adherent cells. Interestingly, when 
spleen cells from vaccinia-challenged mice were stimulated with HSV-infected cells, 
a strong increase in IL-6 and TNFα, but not IFNγ, production was noted, indicative of 
non-specific stimulation (99). The upregulation of pro-inflammatory cytokine release 
to unrelated stimuli seems to be present after in vivo, but not in vitro, infection with 
vaccinia virus. Dendritic cells show a decreased production of IL-6 and TNFα upon 
LPS and poly(I:C) stimulation when infected with vaccinia in vitro compared to mock 
infection, but increased production of these cytokines to LPS stimulation when cells 
are isolated from mice infected in vivo (100, 101). Other effector mechanisms of 
innate immune activation are also influenced by vaccinia infection since murine 
peritoneal cells harvested two weeks after vaccinia challenge showed increased 
production of reactive oxygen species when stimulated both with zymosan and 
with whole heat-killed C. albicans, this effect lasted for three weeks after vaccinia 
infection (102). 
 Since several studies point to a role of TLR2 in the innate immune recognition 
of vaccinia and engagement of TLR2 by Pam3CSK4 has been shown to prime 
ROS production in murine and human macrophages, this effect could potentially be 
mediated by TLR2 activation by vaccinia (103, 104). However, TLR2 stimulation in 
this study lead to decreased cytokine responses, and therefore it is unlikely to fully 
account for the effects of vaccinia. Interestingly, stimulation of TLR2 in hematopoetic 
stem cells (HSPCs) leads to alteration in the functional phenotype of progenitor 
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monocytes and macrophages (104). One could speculate that TLR2 recognition of 
vaccinia in HSPCs could therefore lead to phenotypic changes that account for the 
observed epidemiological long-term non-specific effects.
Molecular mechanisms behind the non-specific effects of vaccinia
The in-vivo effects of vaccinia challenge in humans have been characterized in a 
gene expression study in which PBMCs were isolated from 24 healthy volunteers 
before and 3 days, 6 days and 55 days after vaccination. Most of the genes that were 
differentially expressed showed the greatest modulation 6 days after vaccination. 
However, a large number of genes were still differentially expressed 55 days after 
vaccination, including several genes related to innate immune function. On the 
early time points after vaccination a striking upregulation of monocyte/macrophages 
specific markers was observed such as CD63 and CD16, as well as NK-specific 
genes such as KLRB1 and ZAP70. Interestingly, expression of IL8 and its receptor 
CXCR2 were both upregulated 55 days after vaccination, as well as IL18 and 
ARID5A, which stabilizes IL-6 and leads to increased IL-6 production in vivo. Several 
genes involved in cell metabolism which have been shown to be upregulated in 
models of trained immunity (e.g. HIF1A transcription factor) were also increased 55 
days after vaccinia challenge (83).
MEASLES VACCINE
Measles vaccination is part of worldwide vaccination programs, sometimes 
incorporated in the measles-mumps-rubella vaccine.  Protection against measles 
infection after vaccination is thought to rely on both humoral and cellular adaptive 
responses (105). Apart from its specific effect against measles infection, numerous 
observational studies from low-income countries and a randomized trial from have 
shown that measles vaccination is associated with decreased overall mortality 
and morbidity (106-108).  Furthermore, a study from the Gambia has shown that 
nasopharyngeal carriage of S. pneumoniae and  H. influenzae is decreased after 
measles and YFV vaccination compared to before vaccination (109). 
Non-specific immunological effects of measles vaccine
Natural measles infection is well known to induce immunosuppression, which is 
mainly thought to be dependent on lymphocyte depletion and silencing (110, 111). 
Inhibitory effects of measles vaccination on immune responses have been reported 
as well (112, 113). Interestingly, wild-type measles virus and vaccine strains are 
recognized differentially by monocytes, with wild-type measles virus being recognized 
by TLR2 (114) whereas for recognition of vaccine strains TLR3 and RIG-I seem 
to be of importance (115-117). This difference in innate immune recognition could 
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point to the fact that natural measles infection and measles vaccination might have 
differential effects on non-specific immunological responses. Several studies have 
assessed non-specific responses ex vivo before and after measles vaccination. 
Ovsyannikova et al. reported that after measles vaccination the ex-vivo production 
of both innate (IL-6, TNFα) and adaptive (IFNγ, IL-2) cytokines upon PHA stimulation 
is decreased during two weeks after vaccination. However, 30 days post vaccination 
levels of IL-6, IFNγ and IL-2 are increased compared to baseline. After a second 
measles vaccination, a different pattern was seen with increased IL-6, TNFα, and 
IFNγ responses lasting until 2 weeks postvaccination (118). Pabst et al. compared 
cellular recall responses to tetanus toxoid (TT) and Candida antigen, and cytokine 
production of PBMCs upon stimulation with PHA before and after (14, 22, 30 and 38 
days) primary measles vaccination in infants. Two weeks after measles vaccination 
a transient drop in cellular recall responses to TT and candida antigen was seen, 
but IFNγ response to PHA was significantly increased 14 and 38 days after measles 
vaccination (119). Likewise, Hussey et al. found decreased lymphoproliferative 
responses to PHA 2 weeks and 3 months after primary and secondary vaccination 
with the Schwarz strain of measles vaccine, but an increased concentration of the 
macrophage activation marker neopterin 2 weeks after vaccination (120). In contrast, 
Jensen et al. compared ex-vivo cytokine responses to a panel of non-specific 
stimuli before and six weeks after measles vaccination and found no influence 
on innate (TNFα, IL-10) or adaptive (IFNγ, IL-13, IL-5, IL-17) cytokine production 
(121). Overall, vaccination with measles seems to induce a transient suppression of 
lymphoproliferative responses, but a slight increase in innate immune responses as 
measured by non-specific cytokine production.
OTHER VACCINES
In addition to the several vaccines detailed above for which a relatively abundant 
amount of information is available with regard to their non-specific immunological 
effects, similar data, although less detailed, is known for other vaccines. For HPV 
vaccination it has been shown that 2 weeks after primary and secondary vaccination 
an increased expression of NK-activation markers NKG2D, NKp30 and NKp46 is 
observed, as well as increased expression of ILT2 (negative regulatory receptor) on 
monocytes (122).
 One of the most controversial discussion in the literature concerns DTP vaccination, 
for which deleterious effects on mortality have been reported by some, albeit not all, 
researchers. One could speculate that these effects may at least partly be explained 
by an effect on the innate immune system. Several observational studies performed 
in environments with high pediatric mortality have shown increased overall mortality 
in the period in which DTP vaccine is the most recently administered vaccine. This 
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effect was more pronounced in girls compared to boys (42, 123, 124). Similarly, an 
increase in the incidence of intestinal infection with rotavirus and C. parvum was 
observed in girls who had received DTP as most recent vaccination (125, 126). Also, 
in a murine study vaccination with DTP resulted in increased pathology and mortality 
when mice where challenged with RSV one week after immunization. This effect 
was more pronounced with purified pertussis toxin, and in an experiment with an 
adoptive transfer of spleen cells, not dependent on CD4 or CD8 T-cells (127).
 In the light of the beneficial non-specific effects of BCG vaccine which may be 
exerted through trained immunity, it could be speculated that DTP might have an 
opposite effect on the innate immune system compared to BCG, inducing  functional 
reprogramming of the immune system predisposing for increased susceptibility to 
infections. However, whether this is true and how DTP -or its adjuvant (alum)- exerts 
this effect remains to be demonstrated. 
FUTURE PESPECTIVES
The potential of vaccines to have non-specific effects on diseases other than the 
primary target infection is increasingly recognized as a very important phenomenon, 
as seen in the recommendation of the WHO SAGE working group which argues for 
the need for more studies to investigate the non-specific effects of vaccines (128). 
Given the evidence accumulated so far, it is likely that many of the non-specific 
effects of vaccines are at least in part mediated by reprogramming of the innate 
immune system. 
 This conclusion has several implications that warrant further research into the 
effects of vaccination on the innate immune system.
 Firstly, by taking into account these beneficial (and sometimes maybe deleterious) 
non-specific effects of vaccines, there is potential for a more rational design of 
vaccination policies, by delivering vaccines in an order that confers the maximum 
beneficial effects and protection against off-target diseases during childhood (40).
 Secondly, if currently used vaccines with strong beneficial non-specific effects 
but moderate specific protective effects, such as BCG, are to be replaced by newer 
vaccines that confer a greater specific protective effect, these new vaccines should 
also be evaluated for their non-specific effects. The old vaccine should not be 
withdrawn and substituted by a new vaccine without evaluation of the effect of this 
change on overall mortality.
 Thirdly, the non-specific effects of vaccines that have been phased out of 
vaccination policies due to the eradication of their target disease, such as vaccinia 
(worldwide), BCG (developed world), or perhaps in the future polio vaccine and 
measles vaccine, could still have beneficial effects without protecting against their 
target diseases. These potential beneficial effects should be investigated, because 
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these vaccines might still confer benefits even if their respective target-diseases 
have been eliminated.
 Fourthly, many adjuvants which are used to enhance the adaptive immunological 
response to vaccination against infections, and more recently cancer, act through 
activation of the innate immune system. Further research is warranted to identify 
innovative approaches for the design of novel classes of vaccines that combine 
effective induction of adaptive immune responses with elicitation of innate immune 
memory (trained immunity). 
 Fifthly, with increasing life span, immunosenescence is a growing problem, which 
may be alleviated by use of vaccines which induce innate immune training. 
 Finally, the study of the beneficial non-specific effects of vaccines might lead 
to the development of new strategies to use them in patient groups suffering from 
immunodeficiencies, who cannot be vaccinated with live vaccines.
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ABSTRACT
The protective effects of the tuberculosis vaccine BCG on unrelated infections are 
thought to be mediated by long-term metabolic and epigenetic reprogramming of 
innate immune cells such as the monocytes, a process termed trained immunity. 
Here we show that BCG induction of trained immunity in monocytes is accompanied 
by a strong increase in glycolysis and to a lesser extent glutamine metabolism, both 
in an in-vitro model and after vaccination of mice and humans. Pharmacological 
and genetic modulation of rate-limiting glycolysis enzymes inhibits trained immunity, 
changes which are reflected by effects on the histone marks (H3K4me3 and 
H3K9me3) underlying BCG-induced trained immunity. These data demonstrate that 
a shift of the glucose metabolism towards glycolysis is crucial for the induction of 
the epigenetic and functional changes underlying BCG-induced trained immunity. 
The identification of these pathways may be a first step towards novel vaccines that 
combine immunological and metabolic stimulation. 
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The live-attenuated Bacillus Calmette-Guérin (BCG) vaccine confers protection 
against severe forms of Mycobacterium tuberculosis infection, whilst having a limited 
effect against pulmonary tuberculosis (1, 2). In addition to its effects on tuberculosis, 
it has also been shown that vaccination with BCG leads to non-specific protective 
effects against non-related infections and mortality. In observational studies in West 
Africa it was shown that the presence of a BCG scar or PPD positivity are associated 
with reduced child mortality (3, 4). Furthermore, in two randomized controlled trials, 
early administration of BCG vaccination reduced child mortality, mainly as a result 
of less neonatal sepsis and lower respiratory infections (5-7). BCG is also used 
to treat bladder cancer and appears to be beneficial in several other diseases, 
such as warts, leishmaniasis and asthma (8-10). As further proof of its non-specific 
protective effects, BCG was shown to protect mice against lethal candidiasis (11), 
and interestingly, this protective effect was also present in SCID mice, therefore 
showing that this non-specific protection is T- and B-cell independent (12). It was 
found that these effects are mediated by functional and epigenetic reprogramming 
of innate immune cells such as monocytes, macrophages and NK-cells, a process 
termed ‘trained immunity’ (13, 14).
 We have recently demonstrated that induction of trained immunity by fungal 
components such as β-glucan leads to a shift of cellular metabolism from oxidative 
phosphorylation towards glucose fermentation (15, 16). This is a process mediated 
through the Akt/mTOR/HIF-1α pathway that is crucial for an effective induction of 
trained immunity (15, 16). Similar observations on the importance of metabolic 
changes during immune cells activation have been made by others: pro-inflammatory 
(e.g. M(IFNγ)) macrophages are characterized by increased glycolysis and lactate 
production, whereas the more anti-inflammatory (e.g. M(IL-4)) macrophages seem to 
rely on oxidative phosphorylation, fatty acid uptake and β-oxidation (17). In contrast 
monocytes from patients suffering from sepsis-induced immunoparalysis show 
reduced pro-inflammatory cytokine production with a defective capacity to mount 
glycolysis and β-oxidation (18). 
 So far however, no data have been reported regarding cellular metabolism in 
BCG-induced trained immunity. In this study we have used in-vitro and in-vivo (both 
mice and human) models of trained immunity (12) to assess the changes in cellular 
metabolism pathways that underlie BCG-induced trained immunity and its effects 
on cytokines and epigenetic (histone) changes. Deciphering the role of metabolic 
pathways for the non-specific effects of BCG vaccination may lead to a better 
understanding of the induction of trained immunity and how modulation of cellular 
metabolism pathways may be used to boost the effect of vaccines. 
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MATERIALS AND METHODS
Monocyte isolation and training experiments - Buffy coats from healthy donors 
were obtained after written informed consent (Sanquin blood bank, Nijmegen, The 
Netherlands and Hospital de Braga, Braga, Portugal). PBMC isolation was performed 
by dilution of blood in pyrogen-free PBS and differential density centrifugation 
over Ficoll-Paque (GE healthcare, UK). Cells were washed twice in PBS and 
resuspended in RPMI culture medium (Roswell Park Memorial Institute medium; 
Invitrogen, CA, USA) supplemented with 50μg/ml gentamicin, 2mM Glutamax 
(Gibco), and 1mM pyruvate (Gibco). In some experiments glutamax was replaced 
with 2mM or 1mM L-glutamin (Sigma-Aldrich, St. Louis, MO, USA). Subsequently 
monocyte isolation was performed by hyperosmotic density gradient centrifugation 
over Percoll (Sigma). Afterwards cells were washed once with PBS. Monocytes 
were counted and adjusted to 1×10^6 cells/ml. A 100μl volume was added to flat 
bottom 96-well plates (Corning, NY, USA) and cells were let to adhere for 1h at 37oC; 
subsequently a washing step with 200μl warm PBS was performed to yield maximal 
purity. Monocytes were incubated with culture medium only as a negative control or 
5μg/ml of BCG (SSI, Denmark) for 24h (in 10% pooled human serum). Cells were 
washed once with 200μl of warm PBS and rested for 5 days in culture medium with 
10% human pooled serum. Medium was changed once on day 3 of incubation. On 
day 6, cells were restimulated for 24h with 200μl RPMI, or Escherichia coli LPS 
(serotype 055:B5, Sigma-Aldrich, 10 ng/ml, after which supernatants were collected 
and stored at -20oC. In some experiments, cells were pre-incubated (before BCG 
training) for 1h with 100nM Wortmannin (Sigma), 10nM rapamycin (Sigma), 50μM 
BPTES (Sigma), 100μM 6-aminonicotinamide (Sigma), 11mM 2-deoxyglucose 
(Sigma), 0,3mM metformin, 3μM potassium dichloroacetate (DCA, Sigma), 1mM 
AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, Brunschwig 
chemie), 10nM torin 1 (R&D systems, MN, USA), 1μM oligomycin (Sigma). 
Cytokine, lactate, glucose, and NAD+ measurements - Cytokine production was 
determined in supernatants using commercial ELISA kits for TNFα (R&D systems) 
and IL-6 (Sanquin, Amsterdam, The Netherlands) following the instructions of the 
manufacturer. Lactate, glucose and NAD+/NADH concentrations were measured 
using Fluorometric Quantification Assay Kits (Biovision, CA, USA).
Metabolite measurements - 10x10^6 Monocytes were trained in 10cm-Petri dishes 
(Greiner) in 10ml-medium volumes. At day 6 cells were detached from the plate with 
versene (Life Technologies) and counted. At least 1 million cells were lysed in 60μl 
0.5% Triton-X in PBS. Metabolite concentrations were determined by assay kits for 
fumarate, glutamate, malate, or acetyl-CoA (all Sigma) following the instruction of 
the manufacturer. 
Western blots - Monocytes were cultured as described above and after 4h (Akt) or 
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6 days (mTOR) cells were lysed and stored at -80oC. Total protein amounts were 
determined by BCA assay (Thermo Fisher Scientific) and equal amounts of proteins 
were loaded on precasted 4-15% gels (Biorad, CA, USA). The separated proteins 
were transferred to a nitrocellulose membrane (Biorad), which was blocked in 5% 
BSA (Sigma). Incubation overnight at 4oC with rabbit polyclonal antibodies against 
p-Akt, p-mTOR, p-S6K, p-4EBP1 (Cell Signaling, Danvers, MA, USA), and actin 
(Sigma) were used to determine the protein expression, which was visualized using 
a polyclonal secondary antibody (Dako, Belgium) and SuperSignal West Femto 
Substrate (Thermo Fisher Scientific) or ECL (Biorad).
mRNA extraction and RT-PCR - Cells were cultured as described above. On day 6 
mRNA was extracted by Trizol (Life technologies), according to the manufacturer’s 
instruction and cDNA was synthesized using iScript reverse transcriptase (Invitrogen). 
Relative expression was determined using SYBR Green method (Invitrogen) on an 
Applied Biosciences Step-one PLUS qPCR machine and the values are expressed 
as fold increases in mRNA levels, relative to those in non-trained cells, with HPRT 
as a housekeeping gene. Primers are listed in Table S1.
Chromatin immunoprecipitation - 10x10^6 Monocytes were trained in 10cm-
Petri dishes (Greiner) in 10ml-medium volumes. Cells were isolated and trained as 
described above. After resting for 5 days in culture medium, the cells were harvested 
and fixed in 1% methanol-free formaldehyde. Afterwards, cells were sonicated 
and immunoprecipitation was performed using antibodies against H3K4me3 and 
H3K9me3 (Diagenode, Seraing, Belgium). DNA was isolated with a MinElute PCR 
purification kit (Quiagen) and was further processed for qPCR analysis using the 
SYBR green method. Samples were analyzed by a comparative Ct method according 
to the manufacturer’s instructions. The primers are listed in Table S1.
Assessment of glycolysis and oxygen consumption by Seahorse methodology 
- 10x10^6 Monocytes were trained in 10cm-Petri dishes (Greiner) in 10ml-medium 
volumes as described above and after 6 days detached with Versene (ThermoFisher 
Scientific) from the culture plates. 1x10^5 cells in triplicate were plated to overnight-
calibrated cartridges in assay medium (RPMI with 0.6mM glutamine, pH adjusted 
to 7.4. For OCR also 5mM glucose and 1mM pyruvate was added) and incubated 
for 1h in a non-CO2 corrected incubator at 37
oC. Oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) were analysed using a cell mito stress 
(OCR) or glycolysis stress test (ECAR) kit in a XFp analyser (Seahorse bioscience, 
Copenhagen, Denmark) with final concentrations of 1μM oligomycin, 1μM FCCP, 
0,5μM Rotenone/Antimycin A, 10mM glucose, and 50mM 2-DG.
 For mouse ex-vivo Seahorse analyses, splenocytes were collected from either 
BCG-vaccinated or control mice and plated 4x10^5 cells/well in RPMI medium 
supplemented with 10% FBS. At 12h cell were analysed with a 96XFe analyser to 
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assess ECAR and OCR as above described.
Animal experiments - This article conforms to the relevant ethical guidelines 
for animal research. The research was approved by the institutional animal care 
committee of the Italian Ministry of Health (N° 220/2010-B) and the handling of mice 
was conducted in compliance with European Community Directive 86/609 and the 
U.S. Association for Laboratory Animal Care recommendations for the care and use 
of laboratory animals.
 Briefly, C57BL/6 female mice were supplied as specific pathogen-free mice by 
Charles River (Calco, Lecco, Italy) and were maintained in specific-pathogen-free 
conditions. Food and water were available ad libitum. Five week-old mice were 
vaccinated or not with a single dose of BCG (5x10^6 CFU in 200µl PBS) injected 
i.v. Five mice were used for each experimental mouse group. Seven days after BCG 
vaccination, mice were sacrificed by cervical dislocation, according to the ethics 
requirements and spleens were aseptically collected. Single cell suspension were 
prepared in PBS by mechanic dissociation (Gentle Macs dissociator) and applied 
to Falcon 2360 cell strainers (BD Discovery Labware, San Diego, CA) before to be 
used in Seahorse experiments. 
NMR and amino acid experiments - Amino acids were quantified by high-
performance liquid chromatography (HPLC) in a Gilson UV/vis_155 detector (338nm) 
after precolumn derivatization with ortho-phthalaldehyde (OPA with methanol 
≥99.9%, potassium borate 1M pH=9.5, and 2-mercaptoethanol ≥99.0%) 1:5 (Sigma 
Aldrich). Culture supernatants were filtered by Acrodisc 13mm syringe filters with 
0.2μm supor membrane (Pall Corporations, USA). Inorganic mobile phase pH=7.8 
was composed by Na2HPO4.2H2O3 50mM:propionic acid 250mM (1:1) mixture 
(Merck, Germany) with acetonitrile HPLC grade in water (10:2:13). Organic mobile 
phase was composed by acetonitrile, methanol and water (3:3:4) (HPLC grade, 
HiPerSolv Chromanorm, VWR Chemicals, USA). All mobile phases for elution were 
degasified for 30 minutes previously to analysis. Amino acids were quantified using 
the Gilson Uniprot Software, version 5.11 accordingly to standard solutions were 
prepared in MilliQ water (Millipore, Germany).
 For NMR spectroscopy, methanol/water extracts and cell culture supernatants 
were analyzed. The aqueous and chloroform extracts were dried in a SpeedVac 
Plus system. The aqueous extract was suspended in 600μL D2O with 0.262mM of 
TSP-d4 as chemical shift indicator and the organic extract in 600 μL CD3Cl. To 
550μL of cell culture media were added 50μL D2O, with a TSP-d4 final concentration 
of 0.262mM.
 The samples were analyzed at 25°C by 1H-NMR and by 2D 13C-1H- heteronuclear 
single quantum coherence (HSQC) spectroscopy in a UltrashiedTM 800 Plus 
(Bruker) operating at 800.33MHz, equipped with a TXI-Z H C/N/-D (5mm) probe. 
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The 1H-NMR pulse sequence used has a NOESY-presaturation (noesygppr1d) with 
irradiation at the water frequency (ns 124, TD 64K, SW 20 ppm, d1 4s, d8 0.01s); 
while in the 13C-1H-HSQC was used the hsqcetgpsisp2 pulse sequence (ns 16, TD1 
512, TD2 2K, SW2 16ppm, SW1 165ppm, d1 1s). The chemical shifts in aqueous 
sample were referred to TSP. Spectra were acquired and processed using TopSpin 
3.2 software (Bruker); assignments were made by comparison with chemical shifts 
found in the literature for metabolic intermediates and Human Metabolome Database 
(www.hmdb.ca). The quantifications of the signals were performed by integration of 
the peaks in the 1H-NMR spectra and of the volumes in the 13C-1H-HSQC spectra, 
using the resonance due to the TSP as reference. 
Ex-vivo studies in humans - BCG vaccination trial: Twenty healthy volunteers 
were vaccinated with the BCG vaccine (SSI, Denmark) after informed consent was 
obtained. Before and two weeks and three months after vaccination, blood was 
drawn and PBMCs were isolated and ex vivo stimulated with M. tuberculosis, S. 
aureus, or C. albicans. 24h supernatants were used to determine lactate production 
and PBMCs stored in Trizol to determine gene expression. The study was approved 
by the Arnhem-Nijmegen medical ethical committee (NL31936.091.10). Primary end 
points and detailed methods were published before (12).
 Metformin clinical trial: Twelve healthy non-obese volunteers with good kidney 
function and devoid of metabolic disorders received increasing amounts of metformin 
for a total of five days (1000mg on day 1, 2000mg on day 6). Blood sampling was 
performed one day before start of metformin (day 0), directly after metformin intake 
(day 6), on day 9 and on day 20 for ex-vivo training of isolated monocytes. The study 
was approved by the Arnhem-Nijmegen medical ethical committee (NL47793.091.14). 
Both studies were conducted in accordance with the Helsinki Declaration.
Genetic analysis - For the genetic studies, we investigated genetic variation in 
two cohorts of healthy Dutch volunteers described previously (19-21): one cohort 
of 65 volunteers (cohort 1) collected in 2011, and a second cohort of 49 volunteers 
collected in 2015 (cohort 2). In both cohorts we performed ex-vivo trained immunity 
experiments. Volunteers were between 23-73 years old, and consisted of 77% males 
and 23% females. Monocytes were cultured in vitro as described above. SNPs in the 
database for MTOR, HK2, PFKP, GLS and GLUD1/2 were selected to analyze their 
effect on IL-6 and TNFα production upon LPS restimulation after BCG training. SNP 
information was extracted from a genome-wide Illumina Infinium single-nucleotide 
polymorphism (SNP) array (22). Linkage disequilibrium was calculated according to 
the methods of Machiela and Chanock. (23)
Statistics - Ex-vivo and in-vitro monocyte experiments were performed at least 6 
times and analyzed using a Wilcoxon signed-rank test or one-way Anova, where 
applicable. A P-value below 0.05 was considered statistically significant. All data 
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were analyzed using Graphpad prism 5.0 (La Jolla, CA, USA). * p < 0.05, ** p < 0.01. 
Data are shown as means ± SEM. 
RESULTS
Glucose is a main energy source for BCG-trained monocytes
To assess glycolytic rate, a well-established in-vitro method of trained immunity was 
used (12, 24). Human monocytes were incubated for 24h with BCG or RPMI as 
a medium control, and restimulated after a subsequent 5 days of rest with LPS 
(or RPMI) for 24h (Figure 1A). Glycolytic rate was assessed by measuring glucose 
consumption from the medium, lactate production was used to measure the 
fermentative capacity, 24h after LPS stimulation. Both glucose consumption and 
lactate release were increased, reflecting induction of glycolysis (Figure 1B). The 
ratio of lactate:glucose in BCG-trained macrophages was close to two, suggesting 
that these cells use glucose as the major source of lactate, whereas in non-trained 
macrophages (showing a higher ratio) other substrates were used as well (Figure 
1B, S1). As further proof, priming with BCG significantly increased incorporation of 
13C in lactate during the 24h of restimulation with LPS (Figure 1B, S2A,B), while 
incubating with 13C-labed glucose. Incorporation of 13C-labels was also increased 
in rybosyl-1, which is suggestive of an induction of the pentose phosphate pathway 
(Figure S2C). Assessment of BCG-trained monocytes on day 6 (prior to restimulation) 
using Seahorse technology showed an increased basal and maximal extracellular 
acidification rate (ECAR), as a measure of lactate production. Interestingly however, 
the oxygen consumption rate (OCR, as a measure for oxidative phosphorylation) 
was also increased (Figure 1C, S3A). This is different compared to β-glucan trained 
macrophages, which have shown a classical Warburg effect (with increased glycolysis 
and decreased oxidative phosphorylation) (16). These data were validated in mice, 
where BCG led to an upregulation of ECAR and OCR in splenocytes one week after 
vaccination (Figure 1D, S3B). 
 Besides glucose, other metabolites can be used for energy and carbon 
metabolism. We therefore assessed amino acid utilization at several time points, 
Figure 1 – Role of glucose metabolism for the induction of BCG-induced trained immunity. (A) 
Graphical outline of the in-vitro methods. (B) Monocytes were incubated for 24h with culture medium 
or BCG, then let to rest for 2 days and stimulated for 24h with LPS in medium with 13C-labeled glucose. 
Glucose consumption from the medium, lactate production, and their ratios were determined. Also 
incorporation of the 13C-label in lactate was determined (n=3,  * p < 0.05, student t test). (C) Monocytes 
were incubated for 24h with culture medium or BCG. At day 6 (prior to restimulation) extracellular 
acidification rate (ECAR) and oxygen consumption rate (OCR) were determined by Seahorse. (n=6,  * p 
< 0.05, Wilcoxon signed-rank test). (D) Mice were vaccinated with BCG. After 7 days splenocytes were 
isolated and ECAR and OCR were determined by Seahorse. (n=6,  * p < 0.05, ** p < 0.01, Mann-Whitney 
U test). (E) Monocytes were incubated for 24h with culture medium or BCG. At day 6 (prior to restimulation) 
intracellular concentrations of glutamate, fumarate, malate and acetyl-CoA were determined. (n=6,  * p < 
0.05, Wilcoxon signed-rank test).
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but none were significantly increased (Figure S4). Interestingly, intracellular 
concentrations of glutamate and malate (but not fumarate), metabolites that can be 
produced from glutamine, were increased. In contrast, concentrations of acetyl CoA, 
a central metabolite linking glycolysis and fatty acid metabolism with TCA cycle, 
were not modulated by BCG training (Figure 1E).
Metabolic changes and trained immunity are dependent on activation of the 
Akt/mTOR pathway
We previously showed that the shift towards a higher glycolytic rate in β-glucan-
induced trained monocytes is dependent on the Akt/mTOR pathway (16). Supporting 
a similar pathway in BCG-induced trained immunity, we found that monocytes that 
were primed for 2h with BCG showed an increased Akt phosphorylation (Figure 
2A). Inhibition of Akt by wortmannin during the first 24h of BCG training abrogated 
the increase in cytokine production by LPS restimulation at day 6, confirming the 
essential role of Akt for induction of trained immunity (Figure 2B). BCG-induced 
training of monocytes also led to phosphorylation of mTOR and its targets S6K and 
4EPB1 as determined at day 6 (Figure 2C), and inhibition of mTOR and glycolysis 
by rapamycin, torin, AICAR, and 2-deoxyglucose during BCG training abrogated 
the increased cytokine production (Figure 2D). Similar effects were observed with 
addition of metformin that has more broad metabolic effects on both glycolysis and 
oxidative phosphorylation (Figure 2D). Addition to the medium of dichloroacetate 
(DCA), which inhibits pyruvate dehydrogenase kinases and thus shifts glucose 
metabolism towards the TCA cycle (25)) abrogated induction of cytokine production. 
In contrast, the inhibition of the electron transport chain by the complex V inhibitor 
oligomycin did not have an effect on the induction of trained immunity (Figure 2E). 
Inhibition of glutamine metabolism by BPTES also abrogated cytokine production 
(Figure 2F). Decreasing glutamine concentration in the medium also inhibited 
induction of cytokine production after restimulation with LPS (Figure 2G), showing 
Figure 2 – Akt/mTOR activation and induction of BCG-induced trained immunity. (A) Monocytes 
were incubated for 2h with BCG or medium control and phosphorylated Akt was assessed by Western 
Blot and quantified. (n=5,  * p < 0.05, Wilcoxon signed-rank test). (B) Monocytes were incubated for 24h 
with culture medium or BCG, with or without wortmannin. At day 6, after restimulation with LPS, IL-6 and 
TNFα concentrations in the supernatants were measured. (n=6,  * p < 0.05, Wilcoxon signed-rank test). 
(C) Monocytes were incubated for 24h with culture medium or BCG. At day 6 (prior to restimulation) 
phosphorylation of mTOR, S6K, and 4EBP1 was assessed by Western Blot and quantified. (n=5,  * p < 
0.05, Wilcoxon signed-rank test). (D-F) Monocytes were incubated for 24h with culture medium or BCG, 
with or without the metabolic modulators of glycolysis/mTOR (D), TCA/OxPhos (E), glutamine metabolism 
or PPP (F). At day 6, IL-6 and TNFα production were determined in the supernatants after restimulation 
with LPS. (n=6,  * p < 0.05, Wilcoxon signed-rank test). (G) Monocytes were incubated for 24h with culture 
medium or BCG. Culture media with 2, 1, or 0 mM of L-glutamine were used. At day 6, IL-6 and TNFα 
production in the supernatants were determined after restimulation with LPS. (n=6,  * p < 0.05, Wilcoxon 
signed-rank test).
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that glutamine utilization is essential for the induction of trained immunity. Inhibition 
of the pentose phosphate pathway by 6-aminonicotinamide had no effect on the 
induction of training (Figure 2F). Thus, the Akt/mTOR pathway, that in turn drives 
glucose and glutamine metabolism, is crucial for BCG-induced trained immunity.
Epigenetic regulation of metabolism
To further assess how glucose and glutamine metabolism are regulated in BCG-
trained monocytes and macrophages, mRNA expression of mTOR and four essential 
enzymes in glycolysis and glutamine metabolism were determined at day 6 after 
BCG training. mTOR and all four enzymes were upregulated in trained monocytes 
prior to restimulation (Figure 3A). To investigate whether this increased expression 
was a result of epigenetic changes, histone 3 trimethylation of lysine 4 (H3K4me3) 
and lysine 9 (H3K9me3) were determined. Both these two histone marks have been 
previously shown to be important in BCG-induced trained immunity, with H3K4me3 
being a histone mark denoting open chromatin and increased gene transcription, 
while H3K9me3 is a repressor mark (12, 26, 27). H3K4me3 was indeed found 
significantly increased at the promoters of MTOR, HK2, and PFKP, and the decrease 
of H3K9me3 was even more pronounced, also for GLS and GLUD (Figure 3B). 
When monocytes were trained with BCG an increase of H3K4me3 and decrease of 
H3K9me3 was found at the promoters of TNFA and IL6, just as seen before (26). 
However, when BCG training was inhibited with metabolic inhibitors of glutamine 
metabolism (BPTES) or mTOR/glycolysis (rapamycin) the epigenetic changes at the 
promoter site of TNFA and IL6 were reversed to the baseline status (Figure 3C,D). 
This shows that the epigenetic and metabolic changes are intertwined and highly 
dependent on each other.
Induction of glycolysis is crucial for trained immunity following BCG vaccina-
tion of human volunteers
We next examined whether the increased ex-vivo cytokine production 2 weeks and 
3 months following BCG vaccination (12) was accompanied by increased glycolysis. 
This indeed seemed to be the case as shown by higher lactate concentrations in 
supernatants (Figure 4A), and higher expression of HK2 and PFKP in PBMCs, 
isolated from BCG-vaccinated individuals. Expression of GLS and GLUD, involved 
in glutamine metabolism, was not significantly affected by BCG vaccination, but 
there was a possible trend towards higher expression at three months (Figure 4B). 
To examine these pathways in vivo we next administered metformin, an AMPK-
activator (and mTOR inhibitor), to healthy volunteers for five days and examined 
ex-vivo induction of trained immunity with BCG (as shown in Figure 1A). Use of 
metformin inhibited induction of trained immunity by BCG, as shown by a temporary 
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Figure 3 – Epigenetic and metabolic regulation in BCG-induced trained immunity. Monocytes were 
incubated for 24h with culture medium or BCG. At day 6 (prior to restimulation): (A) mRNA expression of 
MTOR, and two rate limiting enzymes in glycolysis (HK2, and PFKP) and glutamine metabolism (GLS, 
and GLUD) were determined. (n=6,  * p < 0.05, Wilcoxon signed-rank test). (B) DNA was isolated and 
H3K4me3 and H3K9me3 were determined at promoter sites of MTOR, HK2, PFKP, GLS, and GLUD. 
(n=6,  * p < 0.05, Wilcoxon signed-rank test). (C,D) H3K4me3 (C) or H3K9me3 (D) were determined 
at promoter sites of TNFA and IL6. During the first 24h inhibitors of glutamine metabolism (BPTES) or 
mTOR/glycolysis (rapamycin) were added. (n=6,  * p < 0.05, Wilcoxon signed-rank test).
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Figure 4 – The role of glycolysis in proof-of-principle clinical trials in human volunteers. (A) In a 
human BCG vaccination trial healthy volunteers were vaccinated with BCG and at baseline and after 2 
weeks and 3 months, PBMCs were ex vivo restimulated and lactate concentrations in the supernatants 
were assessed (12). (n=19,  * p < 0.05, Friedman test, and Dunns post test). (B) In the same vaccination 
trial expression of HK2, PFKP, GLS, and GLUD were determined in PBMCs. (n=6,  * p < 0.05, Wilcoxon 
signed-rank test). (C) In a separate human metformin trial, healthy volunteers were treated for 6 days with 
an increasing dose of metformin. At baseline (day 0), directly after completed metformin treatment (day 
6), and 3 days (day 9), and 14 day (days 20) after metformin treatment, monocytes were isolated and ex 
vivo trained with BCG (as shown in Figure 1A). TNFα and IL-6 production after 24h restimulation with LPS 
were determined at day 7, and lactate production was assessed prior to restimulation (day 6). (n=11,  * p 
< 0.05, Wilcoxon signed-rank test).
Genetic validation for a role of glycolysis pathway in trained immunity
As a final step we examined whether genetic variation in metabolic pathways 
affected in-vitro training of monocytes by BCG: if glycolysis and glutaminolysis are 
important for the induction of trained immunity, then genetic variation of rate limiting 
enzymes in these pathways should modulate trained immunity. In order to determine 
this, the effects of single nucleotide polymorphisms (SNPs) in MTOR, HK2, PFKP, 
GLS and GLUD1/2 on induction of IL-6 and TNFα after LPS restimulation of BCG-
trained macrophages were determined in a first cohort (n=65), and significant 
associations were confirmed in a second cohort (n=49). SNPs in MTOR showed 
modulation of trained immunity, but as numbers of the homozygous genotypes were 
small and several MTOR SNPs were in linkage disequilibrium it is hard to draw 
strong conclusions on the causative SNP (Figure S5). Three GLUD SNPs were not 
associated with induction of cytokine production, and the effect observed in one of 
the two GLS SNPs (rs7564529) was not validated in the second cohort. However, 
three SNPs in HK2 and one SNP in PFKP significantly modulated the induction 
of trained immunity, and this effect was validated in the second cohort (Figure 5). 
Given the rate-limiting role of these enzymes for glycolysis, these findings support 
the essential role of glycolytic rate for the induction of trained immunity. 
Immunometabolism and BCG
| 119
 7
decreased induction of cytokine responses and lactate production upon secondary 
stimulation (Figure 4C).
DISCUSSION
BCG-induced trained immunity results in an increased responsiveness of monocytes 
and macrophages, with effector functions such as cytokine production and reactive 
oxygen species release being increased upon secondary stimulation with non-
related pathogens. Earlier studies have shown that trained immunity is caused by 
epigenetic rewiring at chromatin level (12). In this paper we show that the change 
in inflammatory profile and the underlying epigenetic changes are dependent on 
changes in cellular metabolism, with an increase in glycolysis as central hallmark, 
but also with upregulation of glutamine metabolism and oxidative phosphorylation. 
Furthermore, these metabolic changes were also epigenetically mediated, hence 
showing a complex interaction between immunometabolic pathways and epigenetic 
modifications. 
 The importance of cellular metabolism during immune cell activation has received 
Figure 5 - The effect of SNPs in glycolytic genes on the induction of trained immunity by BCG. 
Blood was drawn of healthy volunteers in 2011 (cohort 1) and 2015 (cohort 2) and SNPs were determined. 
Adherent monocytes were cultured in vitro as described in Figure 1A. 3 SNPs in HK2 (rs2229621 and 
1807090 in linkage disequilibrium, R2=0.936) and 1 SNP in PFKP were found to affect the production of 
IL-6 and TNFα in the supernatants upon LPS restimulation after BCG training in both cohorts. (* p < 0.05, 
Wilcoxon signed-rank test).
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a lot of attention in the last years. Already in the beginning of last century Otto Warburg 
showed that tumor cells displayed a higher rate of glycolysis and less oxidative 
phosphorylation compared to normal cells, a process called Warburg effect (28). 
More recently a similar pattern has been described during activation of immune cells, 
such as for pro-inflammatory M(IFNγ) macrophages and activated lymphocytes (29, 
30). Moreover, not only glucose metabolism, but also other metabolic pathways play 
important roles in reprogramming and polarizing cells, with fatty acid oxidation and 
oxidative phosphorylation being essential for anti-inflammatory M(IL-4) macrophage 
polarization (31), and glutamine metabolism with succinate accumulation involved in 
IL-1β production (32). Recently it was shown that the increase in glycolysis in LPS-
activated BMDM was also a result of altered activity of transcription factors, with a 
shift from Myc to Hif-1α dependent transcriptional regulation (33).  
 In the present study we demonstrate that cellular metabolism reprogramming is a 
central process involved in induction of trained immunity by BCG vaccination as well. 
BCG is the most widely used vaccine worldwide, and many epidemiological studies 
have demonstrated its capacity to protect against non-mycobacterial infections as 
well (5, 6). We have recently shown that BCG is a potent inducer of trained immunity: 
understanding the pathways that contribute to this effect of BCG is thus crucial 
for understanding the induction of trained immunity in humans, and potentially to 
design novel approaches for vaccination and immunotherapy in patients. Through a 
complementary approach combining in-vitro experiments, BCG vaccination in mice, 
BCG proof-of-principle studies in humans, and genetic validation, we demonstrate a 
crucial role for the Akt/mTOR pathway inducing high glycolytic rate for the induction 
of trained immunity. In addition, glutamine metabolism is also necessary for a full 
effective activation of trained immunity. In a model with β-glucan induced trained 
immunity, also a long-term increase in glycolysis (and pro-inflammatory phenotype) 
was shown, which was also dependent on mTOR/HIF-1α pathway (16). Interestingly 
however, in β-glucan induced trained immunity a clear Warburg effect was seen, 
with high glycolytic rate but a decreased oxidative phosphorylation (16). In contrast, 
BCG-induced trained immunity induced both glycolysis and an increase in oxygen 
consumption, arguing that different metabolic programs can be induced by various 
training stimuli. Nevertheless, when electron transport chain complex V was 
inhibited by oligomycin no effect on cytokine production was observed and when 
glucose metabolism was shifted from lactate production to the TCA cycle (by DCA) 
a decrease in induction of cytokine production was observed. This demonstrates 
that glycolytic rate and lactate production are more important for induction of trained 
immunity than oxidative phosphorylation, and mitochondrial metabolism could be 
associated with carbon and not energy metabolism highlighted by the relevance of 
glutamine in trained immunity.
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 The effect of BCG on cellular metabolism has been little studied so far. In 
a BCG-vaccination trial, PBMCs showed a decreased expression of glycolysis 
genes two days after vaccination, but they were upregulated at 7 and 14 days 
post vaccination (34). In our trial we see upregulation of glycolysis genes and a 
trend for glutaminolysis genes up to 3 months after vaccination.  However, this was 
performed in only 19 volunteers at one fixed time point after ex-vivo stimulation. 
Given the strong variation in the human population, a larger trial with sequencing 
data (and preferably also genetic analysis) is strongly warranted. Furthermore, in 
infection models with Mycobacterium tuberculosis and M. avium, an overall shift of 
glucose metabolism from oxidative phosphorylation to fermentation (Warburg effect) 
has been reported, and this was linked to pro-inflammatory cytokine production and 
bacterial survival (35-37). However, how long these shifts last and whether they are 
only an expression of the acute immune reaction to the mycobacteria is unknown. 
 One of the important conclusions of the present study is that these changes 
in cellular metabolism contribute to the long-term epigenetic reprogramming of 
trained monocytes. Previously, we have already shown how β-glucan induced 
trained immunity results in metabolic changes (Warburg effect), which is the result 
of epigenetic modulation, e.g. increased H3K4me3 and H3K27ac at promoters 
sites of essential glycolytic genes (16). We have now confirmed that comparable 
epigenetic changes are induced in BCG-induced trained immunity. Interestingly 
however, these epigenetic changes are in turn dependent on the induction of 
the metabolic pathways: if glycolysis or glutaminolysis are inhibited, changes in 
H3K4me3 and H3K9me3 at promoter sites of IL6 and TNFA are reversed, showing a 
link between these two regulatory cellular processes. The relation between cellular 
metabolism and the epigenetic landscape of cells has recently received increased 
attention (38-40). Methylation of histone tails is regulated by lysine demethylases 
and histone methylstransferases, whose activity is influenced by cellular metabolites 
functioning as co-factors. For histone (and also DNA) methylation S-adenosyl 
methionine (SAM), derived from methionine, serves as a methyl donor and cofactor 
(40). More than 200 mammalian genes have been predicted to encode for SAM-
dependent methyltransferases (41). Unfortunately, the regulation of SAM in BCG-
induced trained immunity is still unkown. Histone demethylation KDMs of the JmjC 
and JmjD family need α-ketoglutarate as a cofactor for the demethylation process 
(42). Metabolites with a similar molecular structure, such as fumarate, succinate, 
or 2-hydroxyglutarate, can in turn serve as antagonizing factors (42, 43), thereby 
inhibiting the demethylation process. Moreover, these metabolites do not only affect 
histone demethylases, but also affect DNA demethylases (43), which therefore leaves 
DNA methylation and the effect of the changing metabolism on DNA methylation 
as an intriguing topic for future research. In this respect, it is important to point out 
Chapter 7
  122 | 
that glutaminolysis, which can lead to succinate accumulation (32), when inhibited 
abolished upregulation of cytokine production by BCG. These data argue that the 
metabolic and epigenetic modifications are intertwined, and positive feedback loops 
are likely to strengthen the trained immunity phenotype. While we here demonstrate 
the impact of cellular metabolism on histone modifications at the level of immune 
gene promoters, epigenetic changes may be also induced in rate-limiting metabolic 
enzymes. Further study is needed to examine these possible effects. 
 In order to further demonstrate the importance of mTOR-dependent glycolysis for 
induction of trained immunity, we show in a clinical trial that metformin (an mTOR 
inhibitor) administration can inhibit the induction of trained immunity. Finally, we 
demonstrate that genetic polymorphisms in genes encoding for the rate-limiting 
glycolysis enzymes HK2 and PFKP influence induction of trained immunity in 
monocytes from two cohorts of healthy volunteers. Also several SNPs in mTOR 
showed a tendency towards modulation of trained immunity, but their importance 
remains to be demonstrated in larger studies. 
 In conclusion, we show essential roles for glycolysis and glutamine metabolism 
for the induction of trained immunity in human monocytes by BCG. Induction of 
these pathways is regulated by epigenetic mechanisms at the level of chromatin 
organization. The next step should investigate the potential therapeutic role that 
modulation of these pathways may have during vaccination.
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Figure S1. Glucose metabolism, Related to Figure 1. Human monocytes were trained for 24h with 
BCG or left in medium as control. After 2 subsequent days rest, cells were restimulated with LPS. Glucose 
consumption and lactate production in the medium were assessed at different time points for 2 donors 
and lactate:glucose ratios were calculated.
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Figure S2. Related to Figure 1 
and S3. (A) Spectrum of culture 
media. Representative 13C-1H-HSQC 
spectrum of the culture media of human 
monocytes trained for 24h with BCG 
(BCG; red) or left in medium as control 
(CTL; black) following a subsequent 24h 
incubation with LPS in the presence of 
2-13C-labeled glucose. The 2D-spectrum 
shows the proton resonances (X-axis) 
directly linked to 13C (Y-axis), with the 
resonances of 2-13C-glucose (Gluc-2) 
and 2-13C-lactate (Lact-2) being the more 
intense (see below). The chemical shift 
is expressed in parts per million (ppm). 
The spectrum displays other peaks 
corresponding to other compounds that 
are not resulting from the metabolism of 
2-13C-labeled glucose. Gluc = glucose; 
Glutm = glutamine; Lact = lactate; etha 
= ethanol.
(B) Spectrum of cell extracts. Highlight 
of a representative 2-lactate 1H-NMR 
spectrum of cell extracts from human 
monocytes trained for 24h with BCG 
(BCG; red) or left in medium as control 
(CTL; black) following a subsequent 
24h incubation with LPS in the 
presence of 2-13C-labeled glucose. The 
presence of a 13C splits the resonances 
of the protons directly linked in two by 
a J-coupling constant, allowing the 
calculation of the 13C incorporated 
in each position in comparison with 
12C-lactate abundance (≈ 4.15-4.10 
ppm). In the case of the position 2 of 
lactate, the total incorporation of 13C 
from the 2-13C-glucose is 19 % in the 
control macrophages and 46% in the 
BCG-trained macrophages.
(C) 13C-labeled glucose incorportation 
in Rybosyl. Human monocytes were 
trained for 24h with BCG or left in 
medium as control. After 2 subsequent 
days rest, cells were restimulated 
with LPS in medium with 13C-labeled 
glucose. After 24h incorportation in 
intracellular metabolites was assessed. 
(Mean ± SD, n=3). 
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Figure S4. Related to Figure 1. Amino acid consumption from 
medium. Human monocytes were trained for 24h with BCG or left 
in medium as control. After two subsequent days rest, cells were 
restimulated with LPS. Amino acid consumption from the medium was 
assessed at the indicated time points.
Figure S3. Related to Figure 1C,D. (A) Complete human Seahorse data. Monocytes were incubated for 
24h with culture medium or BCG. At day 6 (prior to restimulation) extracellular acidification rate (ECAR) 
and oxygen consumption rate (OCR) were determined by Seahorse. (Mean ± SEM, n=6,  * p < 0.05, 
Wilcoxon signed-rank test). (B) Complete mice Seahorse data. Mice were vaccinated with BCG. After 7 
days splenocytes were isolated and ECAR and OCR were determined by Seahorse. (Mean ± SEM, n=6, 
* p < 0.05, ** p < 0.01, Mann-Whitney U test).
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Figure S5. Related to Figure 5. Effect of MTOR SNPs on induction of trained immunity. Blood 
was drawn of healthy volunteers in 2011 (cohort 1) and SNPs were determined. Adherent monocytes 
were cultured in vitro as described in figure 1A. The indicated SNPs in MTOR were found to affect the 
production of IL-6 and TNFα  upon LPS restimulation after BCG training. (Mean ± SEM, * P < 0.05, 
Wilcoxon signed-rank test). Linkage disequilibria of the displayed MTOR SNPs. Calculated according to 
the methods of Machiela and Chanock (1).
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Epigenetic promoter primers
Gene Forward (5’-->3’) Reverse (5’-->3’)
MYO AGCATGGTGCCACTGTGCT GGCTTAATCTCTGCCTCATGAT
H2B TGTACTTGGTGACGGCCTTA CATTACAACAAGCGCTCGAC
GAPDH CCCCGGTTTCTATAAATTGAGC AAGAAGATGCGGCTGACTGT
ZNF UTR AAGCACTTTGACAACCGTGA GGAGGAATTTTGTGGAGCAA
TNFA GTGCTTGTTCCTCAGCCTCT ATCACTCCAAAGTGCAGCAG
IL6 AGGGAGAGCCAGAACACAGA GAGTTTCCTCTGACTCCATCG
MTOR ATAAAGAGCGCTAGCCCGAA  GACCCCTCCCGGTGTAATTC  
HK2 GAGCTCAATTCTGTGTGGAGT ACTTCTTGAGAACTATGTACCCTT
PFKP CGAAGGCGATGGGGTGAC  CATCGCTTCGCCACCTTTC  
GLS CCAGAGCCCCTAGTACCCAA  TTGGCGATTAGGGCAGTCAA  
GLUD GAAGTCCGTCCTCCCCGTTA  TTTTAAGCCGCAGCTTCCTG  
qPCR primers
Gene Forward (5’-->3’) Reverse (5’-->3’)
HPRT CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA
MTOR TCCGAGAGATGAGTCAAGAGG CACCTTCCACTCCTATGAGGC
HK2 TTGACCAGGAGATTGACATGGG CAACCGCATCAGGACCTCA
PFKP ATTGCGGTTTTCGATGCCAC GCCACAACTGTAGGGTCGT
GLS AGGGTCTGTTACCTAGCTT ACGTTCGCAATCCTGTAGA
GLUD TCGTGGAGGACAAGTTGGT TTGCAGGGCTTGATGATCC
Table S1. Related to Figure 3. Primers.
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ABSTRACT
Induction of trained immunity (innate immune memory) is mediated by activation 
of immune and metabolic pathways that result in epigenetic rewiring of cellular 
functional programs. Through network-level integration of transcriptomics and 
metabolomics data, we identify glycolysis, glutaminolysis, and the cholesterol 
synthesis pathway as indispensable for the induction of trained immunity by β-glucan 
in monocytes. Accumulation of fumarate, due to glutamine replenishment of the 
TCA cycle, integrates immune and metabolic circuits to induce monocyte epigenetic 
reprogramming by inhibiting KDM5 histone demethylases. Furthermore, fumarate 
itself induced an epigenetic program similar to β-glucan-induced trained immunity. In 
line with this, inhibition of glutaminolysis and cholesterol synthesis in mice reduced 
the induction of trained immunity by β-glucan. Identification of the metabolic pathways 
leading to induction of trained immunity contributes to our understanding of innate 
immune memory and opens new therapeutic avenues. 
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Recent studies demonstrated that certain infections and vaccinations induce innate 
immune memory (also termed trained immunity (1)) in monocytes, macrophages, 
and natural killer cells, resulting in non-specific protection against reinfection (2, 
3). The biological relevance of innate immune memory is demonstrated by its 
broad presence in nature, with studies in organisms as diverse as plants, insects, 
cephalopods, and mammals reporting its impact for resistance to infections (4-6). 
Many of the studies reporting adaptive characteristics embedded in innate immune 
responses predate the modern era of molecular biology: the lack of understanding 
the molecular mechanisms underlying their effects impaired however the capacity 
to fully understand the importance of this process. This situation has changed 
profoundly over the last few years, when several studies demonstrated that 
epigenetic reprogramming forms the basis of innate immune memory in both plants 
(7, 8) and mammals (3, 9-11). 
 Genome-wide changes in histone modifications have been shown to underlie 
trained immunity in monocytes, but the molecular mechanisms linking the 
immunological signals induced by microbial stimuli or vaccines to the epigenetic 
changes have not been deciphered. Changes in cellular metabolism, with a shift 
from oxidative phosphorylation to aerobic glycolysis (Warburg effect), are crucial 
for the induction of β-glucan-induced trained immunity (12). Interestingly, increasing 
evidence links cellular metabolism to the regulation of gene transcription, as several 
metabolites from glycolysis and the TCA cycle have been shown to act as cofactors 
for epigenetic writers and erasers such as DNA and histone methyltransferases 
and demethylases, and histone acetyltransferases and deacetylases (13, 14). 
These circuits have important functional consequences based on how cells use 
metabolic substrates: for example, type 1 inflammatory macrophages (M(IFNγ)) rely 
on increased glycolysis (15-17), whereas tolerant macrophages (M(IL-4)) rely on 
oxidative phosphorylation and β-oxidation (17, 18). Interestingly, not only glucose 
metabolism, but also other metabolic pathways play important roles in reprogramming 
and polarizing cells (13, 14, 19). 
 Based on this growing body of evidence, we hypothesized that changes in 
cellular metabolism in trained immunity not only reflect enhanced energetic needs, 
but also connect with immune pathways and epigenetic reprogramming, through the 
accumulation of specific metabolites modulating epigenetic processes that impact 
the functional program of the cell. We combined transcriptomic, metabolomic, and 
epigenomic studies to identify important metabolic processes activated in β-glucan-
trained monocytes. We validated the role of these processes in induction of trained 
immunity, identifying an important function for glutamine metabolism and fumarate 
accumulation. The importance of these processes was also demonstrated in in-vivo 
models of trained immunity.
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MATERIALS AND METHODS
PBMC and monocyte isolation - Buffy coats from healthy donors were obtained 
after written informed consent (Sanquin Blood Bank, Nijmegen, The Netherlands). 
Peripheral blood mononuclear cell (PBMC) isolation was performed by dilution 
of blood in pyrogen-free PBS and differential density centrifugation over Ficoll-
Paque (GE healthcare, UK). Cells were washed twice in PBS. Training of adherent 
monocytes was performed as previously described (3); see also below. Percoll 
isolation of monocytes was performed as previously described (20). Briefly, 150-
200x10^6 PBMCs were layered on top of a hyperosmotic Percoll solution (48.5% 
Percoll (Sigma-Aldrich, St Louis, MO, USA), 41.5% sterile H2O, 0.16 M filter-sterilized 
NaCl) and centrifuged for 15min at 580xg. The interphase layer was isolated and 
cells were washed with cold PBS. Cells were resuspended in RPMI culture medium 
(Roswell Park Memorial Institute medium, Invitrogen, CA, USA) supplemented with 
50μg/ml gentamicin, 2mM Glutamax, and 1mM pyruvate and counted. An extra 
purification step was added by adhering Percoll-isolated monocytes to polystyrene 
flat bottom plates (Corning, NY, USA) for 1h at 37°C; a washing step with warm PBS 
was then performed to yield maximal purity. 
Monocyte training and inhibition experiments - 100μl cells were added to flat 
bottom 96-well plates. After washing with warm PBS, monocytes were incubated 
with culture medium only as a negative control or 5μg/ml of β-glucan, (β-1,3-(D)-
glucan, kindly provided by Professor David Williams), 100µM mono methyl-fumarate 
or dimethyl-2-oxoglutarate (Sigma) for 24h (in 10% pooled human serum). Cells 
were washed once with 200μl warm PBS and incubated for 5 days in culture medium 
with 10% serum and medium was changed once. Cells were restimulated with 
200μl RPMI,  Escherichia coli LPS (serotype 055:B5, Sigma-Aldrich, 10ng/ml), or 
Pam3Cys (EMC microcollections, L2000, 10μg/ml). After 24h, supernatants were 
collected and stored at -20°C (see Figure S1). In some experiments, cells were 
pre-incubated (before β-glucan training) for 1h with 10nM rapamycin (Sigma), 50μM 
BPTES (Sigma), 2μg/ml Ceruline (Sigma), 100μM 6-aminonicotinamide (Sigma), 
20μM fluvastatin sodium hydrate (Sigma). Concentrations were selected as being 
the highest non-cytotoxic concentrations.
Cytokine and lactate measurements - Cytokine production was determined in 
supernatants using commercial ELISA kits for TNFα (R&D systems, MN, USA) 
and IL-6 (Sanquin, Amsterdam, The Netherlands) following the instructions of the 
manufacturer. Lactate concentration was measured using a Lactate Fluorometric 
Assay Kit (Biovision, CA, USA).
HPLC and NMR - Amino acids were quantified by high-performance liquid 
chromatography (HPLC) in a Gilson UV/vis_155 detector (338nm) after precolumn 
derivatization with ortho-phthalaldehyde (OPA with methanol ≥99.9%, potassium 
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borate 1M pH=9.5, and 2-mercaptoethanol ≥99.0%) 1:5 (Sigma Aldrich). Culture 
supernatants were filtered by Acrodisc 13mm syringe filters with 0.2μm supor 
membrane (Pall Corporations, USA). Inorganic mobile phase pH=7.8 was 
composed by Na2HPO4.2H2O3 50mM : propionic acid 250mM (1:1) mixture (Merck, 
Germany) with acetonitrile HPLC grade in water (10:2:13). Organic mobile phase 
was composed by acetonitrile, methanol and water (3:3:4) (HPLC grade, HiPerSolv 
Chromanorm, VWR Chemicals, USA). All mobile phases for elution were degasified 
for 30 minutes previously to analysis. Amino acids were quantified using the Gilson 
Uniprot Software, version 5.11 accordingly to standard solutions were prepared in 
MilliQ water (Millipore, Germany).
 For NMR spectroscopy, methanol/water extracts and cell culture supernatants 
were analyzed. The aqueous and chloroform extracts were dried in a SpeedVac 
Plus system. The aqueous extract was suspended in 600μL D2O with 0.262mM of 
TSP-d4 as chemical shift indicator and the organic extract in 600μL CD3Cl. To 550μL 
of cell culture media were added 50μL D2O, with a TSP-d4 final concentration of 
0.262mM.
 The samples were analyzed at 25°C by 1H-NMR and by 2D 13C-1H- heteronuclear 
single quantum coherence (HSQC) spectroscopy in a UltrashiedTM 800 Plus 
(Bruker) operating at 800.33MHz, equipped with a TXI-Z H C/N/-D (5mm) probe. 
The 1H-NMR pulse sequence used has a NOESY-presaturation (noesygppr1d) with 
irradiation at the water frequency (ns 124, TD 64K, SW 20ppm, d1 4s, d8 0.01s); 
while in the 13C-1H-HSQC was used the hsqcetgpsisp2 pulse sequence (ns 16, TD1 
512, TD2 2K, SW2 16ppm, SW1 165ppm, d1 1s). The chemical shifts in aqueous 
sample were referred to TSP, while the samples in chloroform-d were referred to the 
solvent signal. Spectra were acquired and processed using TopSpin 3.2 software 
(Bruker); assignments were made by comparison with chemical shifts found in the 
literature for metabolic intermediates and Human Metabolome Database (www.
hmdb.ca). The quantifications of the signals were performed by integration of the 
peaks in the 1H-NMR spectra and of the volumes in the 13C-1H-HSQC spectra, using 
the resonance due to the TSP as reference. 
Metabolite measurements - Cells were cultured as described above. At day 6, cells 
were detached from the plate with Versene (Life Technologies) and counted. At least 
1x10^6 cells were lysed in 60μl 0.5% Triton-X in PBS. Metabolite concentrations were 
determined by commercial assay kits for Acetyl CoA, fumarate, glutamate, malate, 
NADPH, α-ketoglutarate (all Sigma), following the instructions of the manufacturer. 
mRNA extraction and RT-PCR - Cells were cultured as described above, after 4h, 
12h and 24h for fumarate stimulation or after 6 days after β-glucan training mRNA was 
extracted by Trizol (Life technologies), according to the manufacturer’s instruction 
and cDNA was synthesized using iScript reverse transcriptase (Invitrogen). Relative 
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mRNA levels were determined using the Applied Biosciences Step-one PLUS and 
the SYBR Green method (Invitrogen). Values are expressed as fold increases in 
mRNA levels, relative to those in non-trained cells, with β-2-microglobulin or HPRT 
as housekeeping genes. Primers are listed in Table S4. RNA sequencing was 
performed as described before (9). Data accession codes: GSE86940 and GSE 
85246.
Chromatin immunoprecipitation - 10x10^6 monocytes were trained in vitro in 10 
cm-Petri dishes (Greiner) in 10ml-medium volumes. Cells were isolated and trained as 
described above. After resting for 5 days in culture medium, the cells were detached 
from the plate with Versene and fixed in methanol-free 1% formaldehyde. Cells were 
then sonicated and immunoprecipitation was performed using antibodies against 
H3K4me3 (Diagenode, Seraing, Belgium). After ChIP, DNA was processed further 
for qPCR analysis using SYBR green. Samples were analyzed by a comparative Ct 
method in which myoglobulin was used as a negative control and H2B as a positive 
control according to the manufacturer’s instructions. Primers are listed in Table S4. 
ChIP sequencing was performed as described before (9). Data accession codes: 
GSE86940 and GSE 85246.
Metabolome assessment - Cells were cultured as described above. At 0h, 4h, 24h, 
and 6d, cells were harvested and cell pellets were snap frozen and stored at -80°C until 
metabolite analysis. Measurement of metabolites was performed by LC-MS. Polar 
metabolites were extracted in 80% methanol. Metabolic profiles were obtained using 
three LC-MS methods. Two separate hydrophilic interaction liquid chromatography 
(HILIC) methods were used to measure polar metabolites in positive and negative 
ionization mode MS, and one reversed phase method was used to profile lipids in the 
positive ion mode. Polar metabolites were profiled in the positive ion MS mode using 
an LC system comprising a 1200 Series Pump (Agilent Technologies) and an HTS 
PAL autosampler (Leap Technologies) that was coupled to a 4000 QTRAP mass 
spectrometer (AB SCIEX) equipped with an electrospray ionization source. Samples 
were prepared by drying 100 ml of cell extracts under nitrogen and re-suspending the 
residue in 100 ml of 10/67.4/22.4/0.2 v/v/v/v water/acetonitrile/methanol/formic acid 
containing stable-isotope labeled internal standards (valine-d8, Sigma-Aldrich; and 
phenylalanine-d8, Cambridge Isotope Laboratories). The samples were centrifuged 
(10min, 1610xg, 4μC), and the supernatants were injected directly onto a 150mm 
3μm 2.1mm Atlantis HILIC column (Waters). The column was eluted isocratically with 
5% mobile phaseA (10mMammoniumformate/0.1%formic acid) for 1min followed 
by a linear gradient to 40% mobile phase B (acetonitrile/0.1% formic acid) over 
10min. The ion spray voltage was 4.5kV and the source temperature was 425μC. 
All metabolites were measured using several reaction monitoring scans (MRM). MS 
settings, including declustering potentials and collision energies, for each metabolite 
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were optimized by infusion of reference standards before sample analyses.
 MultiQuant software (version 1.2; AB SCIEX) was used to process all raw LC- 
MS data and integrate chromatographic peaks. The processed data were manually 
reviewed for quality of integration and compared against known standards to confirm 
metabolite identities.
Metabolomics preprocessing - Missing values: If no peak was detected for a 
certain metabolite in a particular sample, its concentration was assumed to be below 
the detection limit. A value of half the minimum value of that metabolite over all 
samples was used for these metabolites. In doing this, we assume that the minimum 
value found for a particular metabolite is close to the detection limit. Data scaling: 
The metabolomics data were log2 transformed before most of the analyses were 
performed (exceptions are mentioned in the next sections). Depending on the type 
of analysis, different additional scaling steps were performed.
Metformin proof-of-principle trial - The oral metformin study was performed in 
twelve healthy volunteers, all of whom provided written informed consent. Exclusion 
criteria consisted of obesity, kidney failure, or metabolic disorders. Volunteers 
received increasing dosages of metformin for a total of five days (500mg on day 1, 
2000mg on day 6). Blood sampling was performed one day before start of metformin 
(day 0), during metformin intake (day 6), on day 9, and on day 20. The study was 
approved by the local institutional review board (Arnhem-Nijmegen Medical Ethical 
Committee) and conducted according to the principles of the International Conference 
on Harmonisation–Good Clinical Practice guidelines.
Animal experiments - C57Bl/6J mice were trained by intraperitoneal injection with 
1mg β-glucan as previously described (3). 1h before and 2h after intraperitoneal 
injection of β-glucan or PBS, mice received an intraperitoneal injection of PBS, 
200μg BPTES, or 125μg atorvastatine. After 7 days, mice were challenged with 
10μg LPS intraperitoneally; after 3h, mice were sacrificed and circulating IL-1β and 
TNFα concentrations were measured by ELISA (R&D systems) according to the 
manufacturer’s instructions. The study was approved by the ethical animal committee 
of the University of Colorado, Denver.
KDM5 activity assay - Nuclear extracts were prepared according to the method 
of Schreiber et al (21). Cells were cultured as described above, 24h for fumarate 
or α-ketoglutarate stimulation and 5 days after 24h stimulation with β-glucan or 
LPS in 10cm-Petri dishes. 1x10^6 cell were resuspended in 400µl cell lysis buffer 
(10mM HEPES; pH 7.5, 10mM KCl, 0.1mM EDTA, 1mM dithiothreitol (DTT), 0.5% 
Nonidet-40 and 0.5mM PMSF along with the protease inhibitor cocktail (Sigma)) 
and allowed to swell on ice for 20min with intermittent mixing. Tubes were vortexed 
and then centrifuged at 12,000xg at 4°C for 10min. The pelleted nuclei were washed 
twice with the cell lysis buffer and resuspended in 25µl ice cold nuclear extraction 
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buffer (20mM HEPES (pH 7.5), 400mM NaCl, 1mM EDTA, 1mM DTT, 1mM PMSF 
with protease inhibitor cocktail) and incubated in ice for 30min with intermitted 
sonication. Nuclear extract was collected by centrifugation at 12,000xg for 15min 
at 4°C. The supernatant was used immediately in a fluorometric KDM5/JARID 
Activity Quantification Assay Kit (Abcam), performed following the instructions of the 
company.
Analysis methods - Principal Component Analysis (PCA): In the PCA analysis of the 
metabolomics data, the data were first mean-centered. PCA was performed using 
the function “prcomp” from the “stats” package, part of the “R” language. Univariate 
statistical testing: For the univariate statistical tests no further scaling was performed. 
P-values were calculated using a two-sided paired t-test, using the function “t.test”, 
part of the “R” language. P-values were corrected using the Benjamini-Hochberg 
false discovery rate procedure (as implemented in R). Pathway enrichment analysis: 
Pathway enrichment analysis was performed using two different methods. The first 
was “Pathway-tools” (22), the stand-alone version of the tool integrated into the 
Biocyc online resource (23). This tool allows additional visualization of the data on 
a metabolic pathway map (both metabolomic and transcriptomic), but this tool does 
not allow the definition of a background metabolic set (all metabolites measured 
by the used platform. Pathway-tools requires the definition of a set of significantly 
differentially expressed metabolites/genes. Metabolites and genes were defined as 
significantly changed between two conditions if they had a FDR < 0.1. The second 
method used to perform pathway-enrichment analysis is “MetaboAnalyst” (24), 
which does allow the definition of such a background set. MetaboAnalyst additionally 
has the advantage of performing a quantitative enrichment analysis instead of 
using a hard threshold, however, it does not allow the type of visualization that is 
provided by Pathway-tools. This complementary set of options was the reason for 
using both tools. A quantitative enrichment analysis was performed using the peak 
intensities as an input (before log2 transform). The settings were as follows: missing 
values were imputed as explained in the section “Metabolomics preprocessing” and 
no data filtering or scaling was applied. The pathway-associated metabolite sets 
were used to check for enrichment (before and after log transformation), using all 
metabolites measured with mass spectrometry as a custom reference set. Pathways 
of less than four compounds were filtered from our analysis. P-values for enriched 
pathways in both methods were corrected using the Benjamini-Hochberg false 
discovery rate procedure. Data visualization: The first explorative visualization was 
performed using Pathway-tools, which allows visualization of both transcriptomic 
and metabolomic data. Based on the pathways that were significantly differentially 
expressed in either the metabolomic or transcriptomic data, the interesting parts 
of the map were explored. Next, using the tool “Escher” (25), a pathway map was 
Immunometabolism in Trained Immunity
| 139
 8
created, containing just the parts found to be of interest. A schematic overview of 
the pathways is depicted in Figure 1C (the complete map as created by Escher is 
depicted in Figure S1).
Statistics - Ex-vivo and in-vitro monocyte experiments were analyzed using a 
Wilcoxon signed-rank test or one-way ANOVA, where applicable. A P-value below 
0.05 was considered statistically significant. These data were analyzed using 
GraphPad Prism 5.0 (La Jolla, CA, USA). *p < 0.05, **p < 0.01. Data are shown as 
means ± SEM.
RESULTS
Cellular metabolic pathways in monocytes during induction of trained immu-
nity
β-glucan and bacterial lipopolysaccharide (LPS) induce different long-term functional 
programs in monocytes and macrophages, i.e. enhanced function and tolerance, 
respectively; with transcriptomic and epigenomic analyses revealing major differences 
in glucose metabolism pathways (9, 12). To elucidate whether additional metabolic 
pathways are differentially expressed between trained and tolerant cells, RNAseq 
expression data at different time points after stimulation with β-glucan and LPS were 
analyzed for metabolic pathways, and full intracellular metabolome assessment was 
performed. We used the previously described in-vitro model of trained immunity 
(12) in which purified monocytes are stimulated for 24h with RPMI, β-glucan, or 
LPS, after which cells are washed and rested for 5 days in culture medium, followed 
by a second 24h stimulation with either medium or LPS (Figure S1). Distinct RNA 
expression patterns between β-glucan-trained and non-trained (RPMI) cells were 
visible after 24h of stimulation, with the largest differences observed at the day 
6-time point in LPS-treated cells (Figure 1A, Table S1). Metabolome data of trained 
and tolerant cells showed that at early time points (4h and 24h after stimulation), 
only small differences existed between the three conditions (RPMI, LPS, β-glucan). 
On day 6 however, the intracellular metabolome of β-glucan-trained cells was clearly 
different from the RPMI and LPS-treated cells, with major differences observed in 
TCA cycle metabolites, fatty acid metabolism, and other pathways (Figure 1B, S1, 
and Table S2, S3). Altogether, these data indicate that the majority of transcriptional 
changes associated with metabolic pathways occur early (24h) in β-glucan-exposed 
cells, and precede the metabolic phenotype observed in fully differentiated β-glucan-
trained macrophages on day 6. 
 Integration of the transcriptome and metabolome data in a network-level 
context, revealed an upregulation of several major metabolic pathways in β-glucan-
trained macrophages, including glycolysis, pentose phosphate pathway (PPP), 
and cholesterol metabolism (Figure 1C, S1). Interestingly, several important TCA 
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metabolites were strongly increased, such as succinate, malate, and fumarate, as 
well as 2-hydroxyglutarate, leading us to hypothesize that TCA metabolites were 
being replenished through glutaminolysis (Figure 1C, S1). 
Glycolysis, but not PPP, is an essential metabolic pathway in trained immu-
nity
Glucose consumption is increased in β-glucan-trained macrophages (12), and our 
metabolome analysis supports an increase in glycolysis. To obtain further insight 
into the major accumulated products of glucose metabolism, we performed NMR 
experiments with 13C-labeled glucose in trained monocytes. First, glucose was 
converted into lactate, validating the upregulation of glycolysis with concomitant 
lactate production in β-glucan-trained monocytes that we reported previously (12). 
In addition, labeled purines were also detected, showing the activation of the PPP 
(Figure 2A, S2). In contrast, neither 13C-labelled metabolites of the TCA cycle were 
detected after incubation of trained monocytes with 13C-labeled glucose, nor 3-13C 
lactate, indicating that the non-oxidative branch from the PPP back to glycolysis was 
inactive (Figure 2A, S2).
 As glucose can be metabolized by aerobic glycolysis and PPP, we assessed which 
of these pathways was important for induction of trained immunity. Inhibition of mTOR 
and glycolytic flux by rapamycin inhibited monocyte training, as previously shown 
(12), whereas inhibition of the oxidative branch of the PPP by 6-aminonicotinamide 
(6-AN) had no effect (Figure 2B). The increase in cytokine production by β-glucan-
induced trained immunity is accompanied by epigenetic changes, including an 
increase of H3K4 trimethylation (H3K4me3) at promoter sites of inflammatory genes 
(9). Consistent with similar observations in cytokine production, epigenetic changes 
in H3K4me3 induced by β-glucan at the promoter sites of IL6 and TNFA were 
abolished by rapamycin, but not by 6-AN (Figure 2B, S3). Thus, whereas glycolysis 
is central for induction of trained immunity, inhibition of PPP does not have a direct 
effect on increased cytokine production by trained monocytes.
 Metformin activates AMPK and inhibits mTOR activity (Figure S3) (19). We 
have previously shown that inhibition of the mTOR pathway that controls glucose 
metabolism by metformin counteracts the induction of trained immunity by β-glucan 
in mice (12). We now also show that metformin inhibits lactate production, 5 days 
the average metabolite intensities in the metabolomics data. Rows indicate different metabolites; columns 
indicate different conditions. Log transformed metabolite intensities were first z-scored/standardized and 
then averaged over all replicates. A PCA score plot of PC1 vs PC2 of the standardized metabolomics data 
is shown. Samples are color-coded according to the stimulus that was used; labels indicate time points 
after stimulation. (C) Schematic pathway map depicting gene expression (arrows) and metabolic changes 
(filled circles) in cells treated with β-glucan vs LPS at day 6. Transcripts and metabolites marked in red 
were significantly upregulated in β-glucan vs LPS. The complete map as created by Escher is depicted 
in Figure S1.
C
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Figure 2 - Glucose metabolism in trained immunity. (A) Accumulation of the 13C label that was 
incorporated in 2-13C labeled glucose was determined in lysates from β-glucan vs non-trained monocytes 
by NMR, therefore showing to which products glucose is metabolized. Arrows in grey are not active. 
HSQC-NMR spectra are shown in Figure S2. (n=2). (B) Human monocytes were trained with β-glucan or 
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after β-glucan training (Figure S3). To assess whether metformin has a similar effect 
in vivo in humans, we initiated a proof-of-principle clinical trial in which healthy 
volunteers received an incremental dose of metformin for 6 days (up to 1000mg 
twice daily on day 6). In line with the in-vitro and murine experimental data, in-vivo 
administration of metformin in humans decreased the ex-vivo β-glucan-induced 
training of circulating monocytes, which was accompanied by a lower capacity 
to mount glycolysis and release lactate (Figure 2C). When the study participants 
stopped taking metformin, the capacity of monocytes to undergo β-glucan training 
was fully restored (day 9 and 20), thereby confirming the importance of glucose 
metabolism changes for inducing trained immunity in humans (Figure 2C).
Glutamine and cholesterol metabolism are important metabolic pathways in 
trained immunity
In addition to glycolysis and PPP, glutamine metabolism, cholesterol, and fatty 
acid synthesis pathways were also upregulated after β-glucan training. Glutamine 
metabolism has been shown to play an important role in immune activation (26-28). 
Incubation of trained monocytes with 13C-labeled glutamine resulted in increased 
production of glutamate, a substrate that can replenish the TCA cycle (Figure 3A, 
S2). Although no labeled succinate, fumarate, or malate were identified due to their 
relatively low concentrations and the limited sensitivity of the assay, we were able 
to measure increases in these TCA cycle metabolites using classical biochemical 
methods (Figure S1, S4). Interestingly, no labeled lactate was detected, suggesting 
that glutamine is not a source of pyruvate for lactic fermentation (Figure 3A, S2). This 
interpretation was supported by the near 1:2 molar ratio of glucose:lactate observed 
in the 13C-glucose experiment, suggesting that glucose is the sole source of lactate; 
the ratio would have been lower if also other sources of lactate would have been 
used. 
 Aspartic acid was also consumed in large amounts from the medium, indicating 
that metabolism of amino acids other than glutamine may also be involved in trained 
immunity (Figure S4). In line with this notion, production of 2-hydroxyglurate from 
α-ketoglutarate was also significantly increased, just as methionine (Figure S1). 
Finally, in addition to the well-known pathway in which glutamate enters the TCA 
cycle via α-ketoglutarate, glutamate catabolism also enters the TCA cycle via 
succinate semialdehyde metabolism (Figure 1C). 
left in culture medium for 24h in the presence or absence of mTOR inhibitor (rapamycin) or PPP inhibitor 
(6-AN). After 6 days, DNA was isolated for epigenetic analysis or cells were restimulated with LPS to 
determine cytokine production. (n=5, * p < 0.05, ** p < 0.01, Wilcoxon signed-rank test). (C) Healthy 
human volunteers received a twice-daily increasing dose (1-2 g) of metformin for 6 days. At indicated time 
points, monocytes were trained ex vivo with β-glucan; after 5 days of rest, cells were restimulated with 
P3C and cytokine production was assessed. For the effect of metfomin on the AMPK-mTOR pathway and 
lactate production see Figure S3. (n=11, * p < 0.05, Wilcoxon signed-rank test).
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Figure 3 - Other metabolic pathways in trained immunity. (A) Accumulation of the 13C label that was 
incorporated in 2-13C labeled glutamine was determined in supernatants and cell lysates from β-glucan vs 
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 In an additional set of experiments, we sought to establish the role of glutamine, 
fatty acid, and cholesterol synthesis in trained immunity by adding inhibitors of these 
pathways (BPTES, cerulenin, and fluvastatin, respectively) to the in-vitro trained 
immunity model. Inhibition of glutaminolysis or cholesterol synthesis inhibited 
trained immunity, whereas blockade of fatty acid synthesis had no effect (Figure 3B, 
S3). In line with these results, H3K4me3 was downregulated by inhibition of either 
glutaminolysis or cholesterol synthesis (Figure 3B). We next tested the relevance of 
these pathways in an in-vivo model of trained immunity by assessing the effects of 
BPTES that inhibits glutaminolysis, and atorvastatin, which inhibits the rate-limiting 
enzyme in cholesterol syntheses HMG-CoA-reductase. Mice were treated with 
1mg of β-glucan or vehicle control intraperitoneally, followed one week later by an 
injection of 10μg LPS. 4h After the LPS challenge, induction of cytokine synthesis 
was measured by ELISA in the circulating blood. We found that LPS induced a 
significantly higher IL-1β concentration in plasma of β-glucan-trained mice than of 
controls (Figure 3C), as previously reported (3). Importantly, when glutaminolysis was 
inhibited by BPTES or cholesterol synthesis was inhibited by atorvastatin, trained 
immunity, measured by IL-1β production, was significantly downregulated (Figure 
3C). The plasma concentrations of TNFα at this time point after LPS injection were 
low and not different between the various conditions. Together, these data show that 
glutaminolysis and the cholesterol synthesis pathway are two metabolic pathways 
that, in addition to glycolysis, are essential for the increased cytokine production and 
epigenetic changes observed in β-glucan-induced trained immunity.
Fumarate induces epigenetic changes and trained immunity
Analysis of the metabolome of trained monocytes showed that succinate, fumarate, 
and malate were strongly induced in these cells (Figure 1, S1). We first assessed 
whether any of these metabolites by themselves can induce trained immunity. Training 
of monocytes with fumarate on day 0 dose-dependently induced increased cytokine 
production upon restimulation on day 6, whereas malate and succinate did not 
induce this effect (Figure 4A). Inhibition of glycolysis or glutaminolysis by rapamycin 
or BPTES, respectively, both pathways that inhibit β-glucan-induced trained 
immunity, also decreased fumarate concentrations in trained monocytes (Figure 
non-trained monocytes by NMR, therefore showing to which products glutamine is metabolized. HSQC-
NMR spectra can be found in Figure S2. (B) Human monocytes were trained with β-glucan or left in 
culture medium for 24h in the presence or absence of glutaminase inhibitor (BPTES), fatty acid synthesis 
inhibitor (cerulenin), or HMG-CoA reductase inhibitor (fluvastatin). After 6 days, DNA was isolated for 
epigenetic analysis or cells were restimulated with LPS to determine cytokine production. (n=5, * p < 0.05, 
** p < 0.01, Wilcoxon signed-rank test). (C) Mice were intraperitoneally trained with β-glucan or PBS in 
the presence or absence of glutamine (BPTES) or cholesterol (atorvastatin) metabolism inhibitors. After 
7 days, an intraperitoneal LPS challenge was performed and IL-1β production was assessed 3h later. 
The fold of increase of IL-1β production of β-glucan trained mice to non-trained mice is shown. (n=4, * p 
< 0.05, paired t test).
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Figure 4 - Fumarate-induced trained immunity.(A) Human monocytes were stimulated for 24h with 
different concentrations of methyl-fumarate. At day 6, cells were restimulated for 24h with LPS and 
cytokine production was assessed. (n=8, * p < 0.05, One-way ANOVA, Dunnett’s post test). (B) Human 
monocytes were trained with β-glucan in the presence or absence of metabolic inhibitors for 24h. On day 
6, cells were lysed and intracellular fumarate concentrations were determined.  (n=9, * p <0.05, ** p < 
0.01, one-way ANOVA). (C) Human monocytes were stimulated for 24h with 50μM methyl-fumarate. At 
day 6, cells were fixed, chromatin was isolated, and H3K4me3 at the promoters of TNFA and IL6 were 
determined. (n=5, * p < 0.05,  Wilcoxon signed-rank test). (D) Experimental setup for the generation of 
A
B C
E F
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4B). In addition, fumarate induced H3K4me3 at the promoters of pro-inflammatory 
cytokines, as observed during induction of trained immunity by β-glucan (Figure 4C). 
Considering these effects, we performed a whole-genome assessment of the histone 
marks H3K4me3 and H3K27ac by ChIP sequencing in fumarate and β-glucan-
trained monocytes (Figure 4D). In total, 124 dynamic H3K4me3 regions (Figure 4E) 
and 332 dynamic H3K27ac regions (Figure 4F) were identified in fumarate-trained 
macrophages, with a log2 fold change >2.5 compared to non-trained macrophages 
(RPMI). By the same criteria, β-glucan exposure induced 2,688 dynamic H3K27ac 
changes (Figure S5), indicating that fumarate-induced chromatin remodeling 
recapitulates only a small fraction of the total trained epigenome. However, 95% 
of the genomic regions differentially regulated by fumarate were also differentially 
regulated by β-glucan (>1 log2 fold change). If for β-glucan a log2 fold change of >2 
were being used, this would account for 63% of the regions. Genes associated with 
fumarate dynamic epigenetic regions were enriched in pathways involved in immune 
response and leukocyte migration (Figure 4E,F), consistent with previous reports in 
β-glucan-trained monocytes (3, 9). 
 Citric acid cycle metabolites (e.g. fumarate and succinate) have previously been 
reported to regulate HIF-1α stabilization, by inhibiting hydroxylation and therefore 
stabilizing HIF-1α (29, 30). We firstly assessed whether fumarate inhibited HIF-1α 
hydroxylation in our in-vitro model. Incubation of human monocytes with fumarate 
for 2h inhibited HIF-1α hydroxylation (Figure 5A), and HIF-1α targets (31) were 
induced on transcriptional level (Figure 5B). This provides a first mechanism how 
fumarate could induce the observed phenotypical changes, but it does not explain 
the observed effects on histone modifications. 
 Therefore, given our finding that fumarate induces H3K4me3, we investigated 
whether it could induce transcription of methyltransferases. However, none of the 
detectable methyltransferases were differentially expressed between trained and 
non-trained samples (Figure S6). We therefore assessed whether the activity of 
KDM5 family of histone demethylases, which are responsible for demethylation of 
H3K4 (32), was different in β-glucan trained macrophages. As shown in Figure 5C, 
β-glucan training of monocytes resulted in decreased biological activity of KDM5 
demethylases on day 6 after training, which corresponds to the time point with the 
highest intracellular fumarate concentrations (Figure S1), an effect that was not 
observed in LPS-induced immunotolerant macrophages (Figure 5C). Interestingly, 
a similar effect was observed at transcription level (Figure S6). We also assessed 
fumarate-treated macrophages for epigenomic analysis.  (E) Heat map of H3K4me3 reads (purple) over 
fumarate-specific peaks. The intensity over the center of the peak +/- 12kb is depicted for RPMI-Mf, 
BG-Mf, and fumarate-Mf, with each row (x-axis) corresponding to a peak. (F) Heat map of H3K27ac 
reads (red) over fumarate-specific peaks. The intensity over the center of the peak +/- 12kb is depicted 
for RPMI-Mf, BG-Mf, and fumarate-Mf. The top GO pathways (from DAVID) associated with the nearest 
genes to dynamic H3K4me3 and H3K27ac are shown, with adjusted p values.
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expression of KDM3a/JMJD1a (a H3K9 demethylase) and KDM6b/JMJD3 (a H3K27 
demethylase), but these genes were not significantly influenced during induction 
of training (Figure S6). Finally, as α-ketoglutarate is a known cofactor for lysine 
demethylases, whereas metabolites that have a comparable molecular structure 
to α-ketoglutarate (e.g. fumarate or succinate) are natural antagonists (33), we 
also determined whether the effect of fumarate on KDM5 activity is influenced by 
α-ketogluterate. KDM5 activity was significantly inhibited by fumarate, and that was 
restored by the addition of α-ketoglutarate (Figure 5D). Also  at the level of cytokine 
production α-ketoglutarate was able to partially counteract the training effect of 
fumarate (Figure 5E).
DISCUSSION
In this study we provide the first mechanism linking stimulation of innate immune 
Figure 5 - Fumarate modulates HIF-1α degradation and epigenetic modulators. (A) Human 
monocytes were stimulated for 2h with 50μM fumarate, after which cells were lysed and HIF-1α 
hydroxylation was assessed by Western blot. Representative example of 5 experiments. (B) Human 
monocytes were stimulated for 24h with 50μM fumarate, then mRNA was isolated and expression of HIF-
1α targets were determined. (n=8, * p < 0.05,  Wilcoxon signed-rank test). (C) Human monocytes were 
trained with β-glucan or tolerized with LPS for 24h. At day 6, nuclear extracts were isolated and KDM5 
activity was determined. (n=6, * p < 0.05, One-way ANOVA, Dunnett’s post test). (D)  Human monocytes 
were incubated for 24h with fumarate or/and α-ketoglutarate after which nuclear extracts were isolated 
and KDM5 activity was determined. (n=6, * p < 0.05, One-way ANOVA, Dunnett’s post test). (E) Human 
monocytes were incubated for 24h with fumarate or/and α-ketoglutarate. At day 6, cells were restimulated 
for 24h with LPS and cytokine production was assessed. (n=6, * p < 0.05, One-way ANOVA, Dunnett’s 
post test).
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pathways with the induction of epigenetic and metabolic changes in trained immune 
cells. We show that training of monocytes with β-glucan induces a rewiring of 
cellular metabolism that modulates the epigenetic programming of metabolic genes. 
Glycolysis, glutaminolysis, and cholesterol synthesis are non-redundant metabolic 
pathways important for trained immunity in monocytes and macrophages. Among the 
detailed metabolite changes, we identify fumarate as a key metabolite that induces 
trained immunity (innate immune memory), an effect mediated at least partially by 
induction of histone modifications such as H3K4me3 and H3K27Ac. 
 The role of cellular metabolites acting as cofactors for epigenetic enzymes has 
only recently been revealed in several cell types and tissues (13, 34). By assessing 
the interaction between transcriptional and metabolic profiles, we identified several 
major metabolic pathways specifically activated in trained monocytes, compared 
with naive and tolerant cells. Glucose enters both glycolysis and PPP during 
activation of trained monocytes. Whereas glycolysis has been previously reported 
to be important for trained immunity (12), very little is known regarding the role of 
glucose
Dectin-1 
G-6-PAkt
Fatty acids 
phospholipids
stimulation
PPP
purinesX X
pyruvate
TCA
cycle
mTOR
Acetyl-CoA
HIF-1α
PDH
citrate
NADPH
malate
Malonyl CoA
X
Lactic acid Histone acetyl 
transferases
glutamate
fumarate
H3K4me3
cholesterol
glutamine
H3K27Ac H3K27Ac
Figure 6 - Overview figure showing the metabolic and epigenetic pathways through which 
β-glucan induces trained immunity. Training of monocytes by β-glucan induces complex metabolic 
pathways: while glycolysis, glutaminolysis and cholesterol synthesis are important for induction of trained 
immunity, the pentose phosphate pathway (PPP) and fatty acid synthesis have no direct effect. Fumarate 
accumulation through glutaminolysis has a central role for induction of histone modifications and induction 
of trained immunity.
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the PPP in this process. Here we validate several previous studies of the role of 
the mTOR pathway and glycolysis, and extend them in a proof-of-principle clinical 
trial. By using metformin, an activator of AMP kinase and thus inhibitor of mTOR, 
in healthy volunteers, we demonstrate a role for the mTOR pathway in trained 
immunity in humans. This observation goes beyond answering a biological question, 
as metformin is a widely used drug in patients with type 2 diabetes (35). Indeed, its 
inhibition of trained immunity might have undesired consequences on antimicrobial 
host defense; on the other hand, it may represent a potential new drug to be 
employed in certain inflammatory diseases with excessive inflammation (16, 36, 37). 
In contrast to glycolysis, the oxidative branch of PPP does not seem to have a major 
impact on trained immunity.
 Using a systems biology approach, our analysis of intracellular metabolites 
of trained monocytes identified additional pathways that are involved in trained 
immunity (Figure 6). The metabolism of several amino acids was enhanced, 
including glutamine. Metabolism of glutamine into glutamate, α-ketoglutarate and 
succinate semialdehyde provides substrates for the TCA cycle such as fumarate and 
succinate. Interestingly, fumarate itself induces trained immunity as well. Trained 
immunity induced by fumarate results in increased trimethylation of histones at H3K4, 
and interestingly also acetylation at H3K27, linking immunometabolic activation 
with long-term epigenetic changes. Importantly, the epigenetic program induced by 
fumarate partially reproduces that of β-glucan-induced training, demonstrating its 
likely involvement in mediating at least part of the effects of β-glucan. 
 KDMs of the JmjC and JmjD family need α-ketoglutarate as a cofactor for the 
demethylation process (33), whereas metabolites with a similar molecular structure, 
such as fumarate, can act as antagonizing factors (33, 38), thereby inhibiting 
demethylation. The KDM5 family of demethylases (that is responsible for H3K4 
demethylation) has been shown to be inhibited by fumarate (33, 38). Recently, locally 
produced fumarate has also been shown to play a role in DNA repair by inhibition 
of KDM2B histone demethylase activity, which resulted in enhanced H3K36me2 
(39). We now show that fumarate inhibits the bioactivity of KDM5s in our model of 
trained immunity and that α-ketoglutarate can counteract this effect. In addition to 
fumarate, the concentration of 2-hydroxyglutarate, which has similar antagonizing 
effects on α-ketoglutarate-dependent demethylases (40), is greatly increased in 
β-glucan-trained macrophages too (Figure S1). Therefore, 2-hydroxyglutarate may 
serve as another essential factor in modulating histone marks in trained immunity 
induced by β-glucan. Xiao et al. have previously shown that fumarate (and potentially 
2-hydroxyglutarate) does not only affect histone demethylases, but also affect DNA 
demethylases (38). The effect of β-glucan training and metabolic alterations on DNA 
methylation is therefore an intriguing topic for future research. In addition to the effects 
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of fumarate on epigenetic enzymes, fumarate also inhibits proteasomal degradation 
of HIF-1α, an essential transcription factor in β-glucan-induced trained immunity (12, 
29, 41). In this process, α-ketoglutarate is a cofactor for the hydroxylation necessary 
for HIF-1α degradation; fumarate is a natural antagonist of this reaction, thereby 
stabilizing HIF-1α.
 In conclusion, we show that β-glucan-induced trained immunity in monocytes 
induces profound changes in cellular metabolism. The three most prominent 
metabolic pathways involved in trained immunity are glycolysis, glutaminolysis, and 
cholesterol synthesis, which are linked to enrichment in H3K4me3 that is essential 
for trained immunity by β-glucan. Finally, we provide proof-of-principle of metabolo-
epigenomic circuits in innate immune memory by demonstrating an essential role for 
fumarate in modulating HIF-1α degradation, histone methylation and acetylation. The 
identification of the metabolic pathways contributing to induction of trained immunity 
improves understanding of innate immune memory and opens new therapeutic 
avenues.
Accession codes
GSE85246: RNA sequencing time course of control, β-glucan trained, and LPS 
immunotolerant monocytes.
GSE86940: RNA sequencing and ChIP sequencing data of control, and fumarate 
and β-glucan trained monocytes, at day 6. 
Digital versions of Tables S1-3 can be obtained by sending a request to the author.
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Figure S1. Related to Figure 1-5. 
Experimental setup. Monocytes were 
isolated from buffy coats and plated to flat-
bottom plates. Cells were left to adhere for 
1h and were washed once with warm PBS 
to reach maximum purity. Then, depending 
on the experiment inhibitors and/or β-glucan 
were added. After 24h incubation, cells were 
washed once with warm PBS and were left to 
rest in culture medium for five days (with one 
medium change half way). At day six, cells 
were restimulated for 24h with RPMI of 10ng/
ml LPS. The experiment was terminated at 
several time points as depicted. Metabolome 
and RNAseq samples were taken directly 
after 4h, 24h and 6 days. Epigenetic analysis 
was always performed on day six, prior to 
restimulation. And cytokines were always 
determined after the whole protocol was 
finished. 
At day 6, cells were lysed and intracellular 
concentrations of metabolites were 
determined. Metabolites are shown as circles; 
reactions are shown as arrows. Significantly 
upregulated (red), downregulated (green), and 
unchanged (gray) reactions/metabolites are 
shown. Metabolites that were not measured 
are depicted as small-unfilled circles. Figure 
was created using the tool “Escher.”
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Figure S2. Related to Figure 2A and 3A. 1H-13C HSQC-NMR spectra. The destination of 13C labeled 
glucose (left) or glutamine (right) was determined in β-glucan vs non-trained monocytes by NMR both in 
cells (upper) and culture medium (lower panels).
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Figure S3. Related to Figure 2&3. Human monocytes were incubated for 24h with β-glucan in the 
presence of absence of metabolic inhibitors in 10cm petri dishes. After 24h cells were washed and 10% 
serum in RPMI was added, on day 3 medium was changed. On day 6 cells were washed once with 
warm PBS. The adherent macrophages were deattached and 50.000 cells were reseeded in 96-well flat-
bottom plates and stimulated with RPMI or 10ng/ml LPS for 24h and cytokine and lactate production were 
assessed. RPMI restimulated cells did not produce TNFα or IL-6. 
Metformin activates AMPK and inhibits mTOR. Human monocytes were incubated for 2h with 3mM 
of metformin, then cells were lysed and phosphorylation of ACC (downstream target of AMPK) and S6K 
(downstream target of mTOR) were assessed by Western Blotting.
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Figure S4. Related to Figure 3. Amino acid consumption during β-glucan-induced trained immunity. 
Monocytes were trained with β-glucan for 24h. Post-treatment amino acid concentrations in the culture 
medium were determined at indicated time points. Culture medium was changed once after 24h.
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Figure S5. Related to Figure 4E,F. Epigenetic analysis of fumarate-induced trained macrophages. 
β-glucan- and fumarate-induced epigenetic changes. (A) Boxplots of H3K4me3 and H3K27ac reads/
peak for fumarate “up” and fumarate “down” peaks. (B) Dynamic H3K4me3 and H3K27ac peaks (genomic 
regions with signal) were assigned to the nearest protein-coding gene using GREAT (http://bejerano.
stanford.edu/great/public/html/). The top pathways from GREAT or DAVID gene ontology tools are shown 
as a table. Selected genes in the top pathways are also shown. (C) Heat map showing H3K27ac signal 
intensity at regions that are modulated by β-glucan (“BG up” and “BG down”) or fumarate (“Fumarate up” 
and “Fumarate down”). Each row of the heat map is a peak, and the y axis shows distance from the center 
of the peak (+/- 12kb). The height of the heat map corresponds to the number of peaks.
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Figure S6. Related to Figure 5. Modulatation of epigenetic enzymes by fumarate. Human monocytes 
were stimulated for 4h, 12h, and 24h with 50μM fumarate, after which mRNA was isolated and expression 
of histone methyltransferases or demethylases was determined. Or human monocytes were trained with 
β-glucan. After 24h cells were washed and after 5 days of rest KDM5 expression was determined.
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Supplemental Tables
Table S1, related to Figure 1 and Figure S1. Pathway enrichment based on the metabolomics data 
constructed with the MetaboAnalyst tool (with all  measured metabolites as a background). Raw data 
intensities were used for analysis. Details of the procedure are described in Methods.
Table S2, related to Figure 1 and Figure S1. Pathway enrichment of upregulated metabolites based on 
the metabolomics data constructed with the Pathway-tools tool. Metabolites were considered significant 
if they have a FDR (Benjamini-Hochberg) of < 0.1. Details of the procedure are described in Methods.
Table S3, related to Figure 1 and Figure S1. Pathway enrichment based on the transcriptomics data 
constructed with the Pathway-tools tool. Genes were considered significant if they have a FDR (Benjamini-
Hochberg) of < 0.1. Details of the procedure are described in Methods.
Digital versions of Tables S1-3 can be obtained by sending a request to the author.
Table S4. Primers used for qPCR.
Epigenetic promoter primers
Gene Forward (5’-->3’) Reverse (5’-->3’)
MYO AGCATGGTGCCACTGTGCT GGCTTAATCTCTGCCTCATGAT
H2B TGTACTTGGTGACGGCCTTA CATTACAACAAGCGCTCGAC
TNFA GTGCTTGTTCCTCAGCCTCT ATCACTCCAAAGTGCAGCAG
IL6 AGGGAGAGCCAGAACACAGA GAGTTTCCTCTGACTCCATCG
qPCR primers
Gene Forward (5’-->3’) Reverse (5’-->3’)
B2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
HPRT CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA
HK2 TTGACCAGGAGATTGACATGGG CAACCGCATCAGGACCTCA
ALDOA CAGGGACAAATGGCGAGACTA GGGGTGTGTTCCCCAATCTT
ENO1 TGGTGTCTATCGAAGATCCCTT CCTTGGCGATCCTCTTTGG
LDHA ATGGCAACTCTAAAGGATCAGC CCAACCCCAACAACTGTAATCT
KDM5A AGCCGAGTTGGGAGGAGTT TGGACTCTTGGAGTGAAACGA
KDM5B CCATAGCCGAGCAGACTGG GGATACGTGGCGTAAAATGAAGT
KDM5C GGGTCCGACGATTTCCTACC ATGCCCGATTTCTCTGCGATG
KDM5D CAAGACCCGCTTGGCTACATT TTGGACGCGAGGAGTAAATCT
KDM3A GTGCTCACGCTCGGAGAAA GTGGGAAACAGCTCGAATGGT
KDM6B CACCCCAGCAAACCATATTATGC CACACAGCCATGCAGGGATT
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ABSTRACT
Innate immune cells can display functional adaptation characteristics after infections 
or vaccinations, a process designated trained immunity, which is mediated by 
intimate interactions between immunological, metabolic, and epigenetic pathways. 
Metabolome and transcriptome analysis of human trained monocytes identified the 
cellular cholesterol synthesis pathway to play an important role in trained immunity. 
Pharmacological and genetic modulation of the cholesterol synthesis pathway 
revealed that the metabolite mevalonate is a crucial mediator of trained immunity. 
Mevalonate induces a trained immunity phenotype in human primary monocytes via 
IGFR and mTOR activation, accompanied by whole-genome histone modifications 
in inflammatory pathways. HMG-CoA-reductase inhibitors (statins) that block 
mevalonate generation prevent trained immunity with regards to cytokine production, 
activation of glycolysis, and enrichment of H3K4me3 histone marks. Finally, 
monocytes of patients with hyper IgD syndrome (HIDS), which are mevalonate 
kinase deficient and accumulate mevalonate, demonstrate a trained immunity 
phenotype at both immunological and epigenetic level, which could likely explain 
the attacks of fever and inflammation of these patients. In conclusion, unraveling 
the role of the mevalonate pathway for the induction of trained immunity contributes 
to our understanding of the pathophysiology of HIDS, and identifies potential novel 
therapeutic strategies in clinical conditions linked with excessive induction of trained 
immunity.
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The immune system is classically divided into the innate and the adaptive immune 
system. The innate immune system is rapid, relatively non-specific and cannot 
build immunological memory, whereas the adaptive immune system, in turn, is 
slower, specific, and can build memory. However, the recent observation that 
innate immune cells can exert adaptive characteristics and can build a non-specific 
memory challenged this paradigm (1). This is supported by a wide variety of recent, 
but also older studies, in plants, invertebrates and mammals (2, 3). Cells of the 
innate immune system, such as monocytes and NK-cells, are able to build memory, 
a process that is dependent on epigenetic changes (4). Once these cells encounter 
a secondary stimulus, either similar or unrelated to the first insult, their response is 
altered, which could result both in a stronger or attenuated response. The induction 
of a non-specific memory resulting in an enhanced function of the innate immune 
system was termed ‘trained (innate) immunity’ (1, 2). 
 Analysis of differentially regulated pathways in trained monocytes and 
macrophages already revealed an important role for changes in intracellular 
metabolism. A shift from oxidative phosphorylation to aerobic glycolysis (the Warburg 
effect), regulated via the mTOR/HIF-1α pathway was identified as a central regulatory 
mechanism for β-glucan-induced trained immunity (5). Shifts in cellular metabolism 
are known to be important drivers of cell phenotype and activation (6). Interestingly, 
not only glucose metabolism, but also other metabolic pathways play an important 
role in reprogramming and polarization of cells. Recently, we described that also 
glutaminolysis and accumulation of fumarate contributes to the trained-immunity 
phenotype, by inhibiting KDM5 demethylases and thus influencing the epigenetic 
remodeling (7). Here, we sought to unravel how the cholesterol synthesis pathway 
modulates trained immunity and epigenetic reprogramming, combining transcriptomic 
and epigenomic studies in both β-glucan and oxLDL trained monocytes. We validated 
the role of these processes in patients with hyper IgD syndrome (HIDS), who have a 
defective cholesterol synthesis pathway due to mevalonate kinase deficiency. 
MATERIALS AND METHODS
Study subjects - Inclusion of healthy controls and HIDS patients was approved 
by the local institutional review board (CMO region Arnhem-Nijmegen, #2299 
2010/104) and conducted according to the principles of the International Conference 
on Harmonization-Good Clinical Practice guidelines. 
Cells and reagents - Buffy coats from healthy donors were obtained after written 
informed consent (Sanquin blood bank, Nijmegen, The Netherlands). β-glucan (β-1,3-
(D)-glucan) was kindly provided by Professor David Williams (College of Medicine, 
Johnson City, USA). oxLDL was freshly prepared as previously described (8). Stimuli 
and pharmacological inhibitors used include lipopolysaccharide (LPS; Sigma-
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Aldrich, St. Louis, MO; from E. coli serotype 055:B5, further purified as described 
(9)), Pam3Cys (EMC microcollections, Tübingen, Germany), PolyI:C (Invivogen, 
San Diego, CA, USA), Macrophage-activating lipopeptide-2 (MALP2; Sigma-
Aldrich), Phytohemagglutinin (PHA; Sigma-Aldrich), fluvastatin sodium hydrate 
(Sigma-Aldrich), (R)-mevalonic acid lithium salt (Sigma-Aldrich), zaragozic acid 
(SantaCruz Biotechnology), 6-fluoromevalonate (Sigma-Aldrich), 2-deoxyglucose 
(Sigma-Aldrich), rapamycin (Sigma-Aldrich), methyltioadenosine (Sigma-Aldrich), 
IGF1-R inhibitor Picropodophyllin (IGFR-i, Sigma-Aldrich), LXR-inhibitor GSK2033 
(Axon Medchem), or PPARδ-inhibitor GSK3787 (Tocris).
PBMC and monocyte isolation - PBMC isolation was performed by dilution of blood 
in pyrogen-free PBS and differential density centrifugation over Ficoll-Paque (GE 
healthcare, UK). Cells were washed thrice in PBS. Percoll isolation of monocytes 
was performed as previously described (10). Briefly, 150-200x10^6 PBMCs were 
layered on top of a hyperosmotic Percoll solution (48,5% Percoll (Sigma-Aldrich, St 
Louis, MO, USA), 41,5% sterile H2O, 0.16M filter sterilized NaCl) and centrifuged 
for 15min at 580 g. The interphase layer was isolated and cells were washed with 
cold PBS. Cells were resuspended in RPMI culture medium (Roswell Park Memorial 
Institute medium; Invitrogen, CA, USA) supplemented with 50μg/ml gentamicin, 2mM 
glutamax, and 1mM pyruvate and counted. An extra purification step was added by 
adhering Percoll-isolated monocytes to polystyrene flat bottom plates (Corning, NY, 
USA) for 1h at 37°C; subsequently a washing step with warm PBS was performed 
to yield maximal purity. 
Monocyte training and inhibition experiments - Monocytes were trained as 
described before (11). Briefly, 1x10^5 cells were added to flat-bottom 96-well plates. 
After washing with warm PBS, monocytes were incubated either with culture medium 
only as a negative control or 5μg/ml of β-glucan, 10μg/ml oxLDL or 100-1000 μM (R)-
mevalonic acid for 24h (in 10% pooled human serum). Cells were washed once with 
200μl of warm PBS and incubated for 5d in culture medium with 10% pooled human 
serum, and medium was changed once. Cells were restimulated with either 200μl 
RPMI, LPS 10ng/ml, or Pam3Cys 10μg/ml. After 24h supernatants were collected 
and stored at -20oC. In some experiments, cells were pre-incubated (before β-glucan, 
mevalonate or oxLDL training) for 1h with 20μM fluvastatin sodium hydrate, 1-5µM 
zaragozic acid, 200µM 6-fluoromevalonate, 10μM GSK2033, or 10μM IGFR-i. 
Concentrations were chosen as being highest non-toxic concentrations, based on 
pilot-experiments (not shown).
Mouse experiments - Blood mononuclear cells from wild type mice were isolated 
using the density gradient cell separation medium histopaque 1083 (Sigma). Cells 
were incubated with β-glucan (5μg/ml) or mevalonate (500μM) for 24h in the presence 
of 20ng/ml recombinant mouse granulocyte-macrophage colony-stimulating factor 
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(GM-CSF, PeproTech). Cells were then washed with PBS and were cultured until 
day 6 in 10% fetal bovine serum. Afterwards, they were stimulated with LPS (10ng/
ml) for 24h in RPMI without fetal bovine serum. Concentrations of TNFα and IL-6 
were measured in cell culture supernatants.
 The effect of fluvastatin (20μM) and potent inhibitors for LXR (1μM, 10μM; 
GSK2033, Axon Medchem) or PPARδ (1μM, 10μM; GSK3787, Tocris) on β-glucan-
induced training was examined. Compounds were added during the first 24h. 
Treatment of cells with dimethyl sulfoxide (DMSO; Sigma) served as control in the 
case of LXR and PPARδ antagonism.
Cytokine and lactate measurements - Cytokine production was determined in 
supernatants using commercial ELISA kits for human IL-1β, TNFα (R&D systems, 
MN, USA), human IL-6 (Sanquin, Amsterdam, The Netherlands), and mouse TNFα 
and IL-6 (Meso Scale Discovery) following the instructions of the manufacturer. 
Lactate concentration was measured using a Lactate Fluorometric Assay Kit 
(Biovision, CA, USA). 
Foam cell formation - To induce foam cell formation at day 6, trained macrophages 
were incubated with RPMI alone or RPMI containing oxidized LDL at 50µg/mL for 
24h. Incubation with this concentration of oxLDL alone caused no secretion of IL-
6, TNFα or MCP-1, compatible with absence of endotoxin in the prepared LDL 
fractions. Accumulation of oxLDL was visualized by Oil-Red-O staining as described 
before (12).
Western blotting - 10x10^6 monocytes were trained in vitro with (R)-mevalonate 
with or without 10μM IGFR-i in 10cm-Petri dishes in 10ml-medium volumes. After 
resting for 5 days in culture medium, the cells were harvested for Western blotting. 
Total protein amounts were determined by BCA assay (Thermo Fisher Scientific) and 
equal amounts of proteins were loaded on pre-casted 4-15% gels (Biorad, CA, USA). 
The separated proteins were transferred to a nitrocellulose membrane (Biorad), 
which was blocked in 5% BSA (Sigma). Incubation overnight at 4°C with rabbit 
polyclonal antibodies against p-S6K, p-4EBP1, p-mTOR (Cell Signaling, Danvers, 
MA, USA), and actin (Sigma) were used to determine the protein expression, 
which was visualized using a polyclonal secondary antibody (Dako, Belgium) and 
SuperSignal West Femto Substrate (Thermo Fisher Scientific).
RNA sequencing and chromatin immunoprecipitation - 10x10^6 monocytes 
were trained in vitro with β-glucan, oxLDL or (R)-mevalonate in 10cm-Petri dishes 
in 10ml-medium volumes. After resting for 5 days in culture medium, the cells were 
harvested for RNA extraction or chromatin immunoprecipitation.
 RNA extraction and cDNA synthesis: Monocytes isolated from HIDS patients 
and controls, and in-vitro derived naive and mevalonate exposed macrophages, 
were lysed in Trizol reagent and stored at -80°C (Life Technologies). Total RNA 
Chapter 9
  166 | 
was extracted from cells using the Qiagen RNeasy RNA extraction kit (Qiagen, 
Netherlands), using on-column DNAseI treatment. Ribosomal RNA was removed 
using the riboZero rRNA removal kit (Illumina). RNA was then fragmented into 
200bp fragments by incubation for 4min at 95°C in fragmentation buffer (200 mM 
Tris-acetate, 500mM Potassium Acetate, 150mM Magnesium Acetate, pH 8.2). First 
strand cDNA synthesis was performed using SuperScript III (Life Technologies), 
followed by synthesis of the second cDNA strand. Library preparation was performed 
using the KAPA hyperprep kit (KAPA Biosystems), using the USER enzyme to 
degrade the second cDNA strand. Quality of cDNA and the efficiency of ribosomal 
RNA removal was confirmed using quantitative RT-PCR using the IQ Sybr Supermix, 
with primers for GAPDH, 18S and 28S rRNA. 
 Chromatin immunoprecipitation (ChIP): Purified cells were fixed with 1% 
formaldehyde (Sigma-Aldrich) at a concentration of approximately 15x10^6 cells/
ml. Fixed cell preparations were sonicated using a Diagenode Bioruptor Pico 
sonicator using 5 cycles of 30s on, 30s off. One µg of chromatin (approx. 0.5-1 
million cells) was incubated with dilution buffer, 12µl protease inhibitor cocktail and 
1µg of H3K27ac antibody or H3K4me3 (Diagenode) to a final volume of 300µl, and 
incubated overnight at 4oC with rotation. Protein A/G magnetic beads were washed 
in dilution buffer with 0.15% SDS and 0.1% BSA, added to the chromatin/antibody 
mix and rotated for 60min at 4oC. Beads were washed with 400µl buffer for 5min at 
4oC with five rounds of washes. After washing, chromatin was eluted using 200 µl 
elution buffer for 20min. Supernatant was collected, 8µl 5M NaCl, 3µl proteinase 
K were added and samples were incubated for 4 hours at 65oC. Finally, samples 
were purified using Qiagen Qiaquick MinElute PCR purification Kit and eluted in 20µl 
elution buffer. 
 For qPCR analysis, samples were analyzed using a comparative Ct method 
in which myoglobulin was used as a negative control and H2B as a positive 
control according to the manufacturer’s instructions. The following primers 
were used for this analysis: MYO forward AGCATGGTGCCACTGTGCT; 
MYO reverse GGCTTAATCTCTGCCTCATGAT; H2B forward 
TGTACTTGGTGACGGCCTTA; H2B reverse CATTACAACAAGCGCTCGAC; 
TNFA forward GTGCTTGTTCCTCAGCCTCT; TNFA reverse 
ATCACTCCAAAGTGCAGCAG; IL6 forward AGGGAGAGCCAGAACACAGA; IL6 
reverse GAGTTTCCTCTGACTCCATCG.
 Library preparation for sequencing: Illumina library preparation was done using 
the Kapa Hyper Prep Kit (Kapa Biosystems). For end repair and A-tailing double 
stranded DNA was incubated with end repair and A-tailing buffer and enzyme and 
incubated first for 30min at 20oC and then for 30min at 65oC. Subsequently adapters 
were ligated by adding 30µl ligation buffer, 10 Kapa l DNA ligase, 5µl diluted adaptor 
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in a total volume of 110µl and incubated for 15min at 15oC. Post-ligation cleanup 
was performed using Agencourt AMPure XP reagent and products were eluted in 
20µl elution buffer. Libraries were amplified by adding 25µl 2x KAPA HiFi Hotstart 
ReadyMix and 5µl 10x Library Amplification Primer Mix and PCR, 10 cycles. Samples 
were purified using the QIAquick MinElute PCR purification kit and 300bp fragments 
selected using E-gel. Correct size selection was confirmed by BioAnalyzer analysis. 
Sequencing was performed using the Illumina NextSeq500 machine and generated 
43bp paired end reads. Samples for RNAseq were treated to the above protocol 
exactly, except for a single additional step: After post-ligation cleanup, and before 
library amplification, samples were incubated with 3μL USER enzyme for 15min at 
37°C to digest the second cDNA strand. 
 RNAseq data analysis: To infer gene expression levels, RNAseq reads were 
aligned to the Ensembl v68 human transcriptome using Bowtie 1 (13). Quantification 
of gene expression was performed using MMSEQ (https://github.com/eturro/mmseq) 
(14). Differential expression was determined using DEseq (http://bioconductor.org/
packages/release/bioc/html/DESeq.html) (15). Differentially expressed genes were 
determined using pair-wise comparison between treatments, with a fold change 
>1.5, adjusted p value of <0.1, and RPKM >1. 
The metabolic maps were created based on output generated with Escher (16).
 ChIPseq data analysis: Sequencing reads were aligned to human genome 
assembly hg19 (NCBI version 37) using bwa (17). Duplicate and low quality reads 
were removed after alignment using Samtools and Bamtools (18, 19). For peak calling 
the BAM files were first filtered to remove the reads with mapping quality less than 15, 
followed by fragment size modeling (http://code.google.com/p/phantompeakqual-
tools/). MACS2 (http://github.com/taoliu/MACS/) was used to call the peaks (20). 
H3K27ac peaks were called using the default (narrow) setting. Reads/peak tables 
were merged using Bedtools (21). Data were normalized using the R package 
DESeq1 and then pair-wise comparisons were performed (fold change 1.5, adjusted 
p-adj value <0.1 and reads/peal ≥10 in at least in any condition) to determine the 
differential peaks. 
Statistics - In-vitro monocyte experiments were performed at least 6 times and 
analyzed using a Wilcoxon signed-rank test or one-way ANOVA, where applicable. 
A P-value below 0.05 was considered statistically significant. All data were analyzed 
using Graphpad prism 5.0 (La Jolla, CA, USA). * p < 0.05, ** p < 0.01. Data are 
shown as means ± SEM. 
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Figure 1 - The cholesterol synthesis pathway in trained immunity. (A) Transcriptional expression 
of macrophages five days after β-glucan exposure. Red arrow = significant upregulation. Overview of 
the cholesterol synthesis pathway and the used inhibitors. (B) Monocytes were trained with β-glucan +/- 
inhibitors of the cholesterol synthesis pathway. Five days after β-glucan exposure, lactate concentrations 
were measured in the supernatants and macrophages were restimulated for 24h with LPS and TNFα 
concentrations were measured in the supernatant. (n=6, mean ± SEM). (C) Mouse blood mononuclear 
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RESULTS
Activation of the cholesterol synthesis pathway, but not the synthesis of cho-
lesterol itself, is essential for induction of trained immunity
β-glucan can induce a long-term reprogramming in monocytes and macrophages, 
resulting in enhanced function (22). Integration of the transcriptome and metabolome 
of β-glucan-trained macrophages revealed an upregulation of several major metabolic 
pathways, such as glucose metabolism, glutaminolysis, and the cholesterol synthesis 
pathway (5, 7). The expression of several key enzymes in the cholesterol synthesis 
pathway was strongly increased by β-glucan training (Figure 1A), leading to the 
hypothesis that the cholesterol synthesis pathway contributes to trained immunity. 
 Pharmacological inhibition of the rate-limiting enzyme HMG-CoA-reductase with 
fluvastatin prevented the induction of trained immunity by β-glucan, illustrated by 
decreased cytokine production upon re-stimulation. Moreover, lactate production 
was also decreased, indicating reduced glycolysis, which is an important component 
of the trained immunity phenotype (Figure 1B) (7). Additionally, when mouse blood 
mononuclear cells were trained with β-glucan, the induction of cytokine production 
upon LPS restimulation could also be inhibited with fluvastatin (Figure 1C). To further 
unravel which part of the cholesterol synthesis pathway is essential for this effect, 
several inhibitors of enzymes downstream of HMG-CoA-reductase were assessed 
for their capacity to modulate trained immunity (Figure 1A,B). To study whether 
cholesterol synthesis itself is necessary for training, cells were preincubated with 
zaragozic acid A, which inhibits squalene synthase. Preincubation of monocytes 
with zaragozic acid, however, did not inhibit the induction of pro-inflammatory 
cytokine production (Figure 1B), indicating that cholesterol itself is not essential 
for trained immunity. Secondly, 6-fluoromevalonate was used to inhibit mevalonate 
pyrophosphate (PP) decarboxylase. Mevalonate PP decarboxylase catalyzes the 
formation of isopentenyl-PP from mevalonate-5-PP. Pre-incubation of monocytes 
with 6-fluoromevalonate augmented the induction of pro-inflammatory cytokine 
production by β-glucan (Figure 1B), indicating that the accumulation of a molecule 
upstream of 6-fluoromevalonate plays a role in the induction of cytokine production, 
and excluding a role for protein prenylation. 
 We have previously reported that brief exposure to oxLDL also induces trained 
immunity (23). Pre-incubation of cells with fluvastatin also prevented oxLDL-induced 
cells were trained with β-glucan +/- fluvastatin on day 1. At day 6, cells were stimulated for 24h and 
cytokines were determined in the supernatants. (n=6, mean ± SEM). (D) Monocytes were trained with 
oxLDL +/- fluvastatin for 24h. Five days later, epigenetic (H3K4me3) changes at the TNFA promoter and 
lactate concentrations in the supernatant were measured. Macrophages were also restimulated for 24h 
with LPS to determine TNFα concentrations in the supernatant. (n=6, mean ± SEM). (E) Monocytes were 
trained with oxLDL +/- fluvastatin for 24h. Five days later foam cell formation was induced by exposure to 
high concentration of oxLDL. After 24h cells were stained with Oil-Red-O. (* p < 0.05).
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Figure 2 - Mevalonate induces trained 
immunity.  (A) Adding mevalonate during the 
first 24h can rescue the inhibition of oxLDL/β-
glucan-induced training by fluvastatin. (n=6, 
mean ± SEM). (B) Human and (C) mouse 
monocytes were trained with mevalonate 
for 24h and restimulated with LPS at day 6. 
TNFα concentration was measured in the 
supernatants. (n=6, mean ± SEM). (D) When 
6-fluoromevalonate was added during the 
first 24h, training with mevalonate could be 
enhanced. (n=6, mean ± SEM). (E) Lactate 
production of RPMI or LPS re-stimulated mevalonate-trained macrophages at day 6. (n=10, mean ± 
SEM). (F) Adding a methyltransferase inhibitor (MTA) inhibits the induction of trained immunity. (N=6, 
mean ± SEM). (G) H3K4me3 at promoters of TNFA and IL6 was assessed at day 5 of mevalonate-trained 
macrophages. (n=6, mean ± SEM, * p < 0.05, ** p < 0.01).
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trained immunity, both in terms of cytokine production upon restimulation and 
decreased lactate production and glycolysis. Incubation with fluvastatin prevented 
epigenetic reprogramming of both oxLDL and β-glucan-induced training (Figure 1D, 
(7)), and prevented increased foam cell formation, which was induced by training 
with oxLDL (Figure 1E). OxLDL- and β-glucan-induced training was associated 
with enrichment of H3K4me3 on the promoter of TNFA, which was prevented by 
fluvastatin (Figure 1D, (7)).
Mevalonate induces trained immunity by epigenetic reprogramming
As the induction of trained immunity is inhibited by fluvastatin and increased with 
6-fluoromevalonate, we hypothesized that mevalonate is the metabolite from the 
cholesterol synthesis pathway that drives the development of the trained immunity 
phenotype. Indeed, addition of exogenous mevalonate recaptured the β-glucan- and 
oxLDL-induced trained phenotype in the presence of fluvastatin (Figure 2A). We 
further investigated the induction of training by mevalonate and found that incubation 
of monocytes with mevalonate on day 0 augmented cytokine production upon 
restimulation 6 days later (Figure 2B). Again, this could be reproduced in mouse 
monocytes (Figure 2C). Furthermore, pre-incubation with 6-fluoromevalonate 
potentiated the effect of mevalonate (Figure 2D). Interestingly, lactate production 
was also increased in mevalonate-trained macrophages (Figure 2E). In addition, 
to determine the role of histone methylation in the induction of trained immunity by 
mevalonate, we added methyltioadenosine (MTA, a non-selective methyltransferase 
inhibitor) to the in-vitro system during the first 24h. Addition of MTA prevented 
mevalonate-induced trained immunity in terms of increased cytokine production 
(Figure 2F). Indeed, mevalonate induced an enrichment of H3K4me3 on the 
promoters of IL6 and TNFA (Figure 2G), similar to the training by β-glucan and 
oxLDL (22, 23). The increase in lactate suggested activation of the glycolytic 
pathway similar to β-glucan-trained macrophages (5). Indeed, inhibition of glycolysis 
with 2-deoxyglucose and inhibition of mTOR with rapamycin prevented mevalonate-
induced trained immunity (Figure 3A). Western blot analysis showed an increase 
in phosphorylated mTOR upon training with mevalonate, as well as an increase in 
phosphorylated mTOR-targets: S6K and 4EBP1 (Figure 3B). This shows a crucial 
role for glucose metabolism and mTOR signaling in mevalonate-induced trained 
immunity. In contrast, induction of training by mevalonate could not be counteracted 
by inhibition of LXR or PPARδ (data not shown). 
 Previous studies have shown that mevalonate signals via the IGF1 receptor 
(IGF1-R) (24). To study whether mevalonate exerts its effects extracellularly in 
an autocrine fashion, we inhibited the IGF1-R during the 6 days resting period of 
β-glucan training. IGFR-i diminished the effect of β-glucan training (Figure 3C). Next, 
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we inhibited mevalonate training itself with this inhibitor and showed that the IGF1-R 
is responsible for signal-transduction of mevalonate training (Figure 3D). When the 
IGF1-R was blocked, also the increase in mTOR, S6K and 4EBP1 phosphorylation 
was diminished (Figure 3B), as well as the increased H3K4me3 (Figure 3E), indicating 
that mevalonate induces epigenetic changes via IGF1-R and subsequently mTOR, 
S6K and 4EBP1 (Figure 3F).  
 To further elucidate the mechanism through which mevalonate induces trained 
immunity, we performed RNA sequencing and a whole-genome assessment of the 
histone mark H3K27ac by ChIP sequencing in mevalonate-trained macrophages. 
Monocytes were trained as described above, and after 5 days of rest (before 
restimulation), monocyte-derived-macrophages were harvested for ChIP and RNA 
sequencing (Figure 4A). Similar to fumarate-trained macrophages (7), no consistent 
differences were found in transcription profiles at this time point. This is consistent with 
previous observation for β-glucan-trained macrophages that the major differences 
in gene expression are present during the first 24h after β-glucan stimulation, 
whereas at later time points transcriptional differences are less pronounced (25). 
Whole genome epigenetic analysis of mevalonate-trained macrophages, by 
chromatin immunoprecipitation of histone 3 lysine 27 acetylation (H3K27ac) did 
reveal noticeable differences between trained and non-trained macrophages. In total 
233 defined peaks showed an upregulation of H3K27ac and 554 peaks showed 
a downregulation in mevalonate-trained macrophages (Figure 4B-D, Table S1). 
When these peaks were compared with β-glucan-trained macrophages, of the 
233-upregulated peaks only few were also found in β-glucan-trained macrophages. 
However, of the 554 downregulated peaks 397 were also found in the β-glucan-
trained macrophages. Of these peaks 45% also showed a downregulation of at least 
2-fold, showing a comparable signature in mevalonate and β-glucan-induced trained 
immunity (Table S1). Pathway analysis of these differentially regulated peaks in 
mevalonate-trained monocytes, can be found in Figure 4E and shows the modulation 
of several important inflammatory pathways.
Monocytes of HIDS patients with mevalonate kinase deficiency have a trained 
immunity phenotype with higher cytokine production 
Mevalonate kinase deficiency in humans leads to Hyper-IgD syndrome (HIDS), an 
Figure 3 – Signaling in mevalonate-trained monocytes. (A) When 2-deoxyglucose (2-DG) or rapamycin 
were added during the first 24h, mevalonate and β-glucan-induced training could be inhibited. (n=6, mean 
± SEM). (B) Western blot showing increased p-mTOR, p-S6K and p-4EBP1 upon mevalonate training. 
Treatment with IGF1-R inhibitor (IGFR-i) inhibited these effects. (C) Inhibition of the IGF1-R (IGFR-i) 
during resting of β-glucan-induced training inhibits the induction of trained immunity. (D) When IGFR-i was 
added to mevalonate training, the induction of trained immunity was diminished. (n=6, mean ± SEM). (E) 
Blocking the IGF1-R inhibits the epigenetic changes induced by mevalonate training. (n=6, mean ± SEM). 
(F) Proposed working mechanism of mevalonate-induced trained immunity. (* p < 0.05).
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Figure 5 - HIDS patients display a trained-immunity 
like phenotype. (A) Monocytes from HIDS patients and 
matched healthy volunteers were exposed ex vivo to 
several ligands for 24h. Cytokine were measured in the 
supernatants. (n=4, mean ± SEM). (B) Heatmap showing 
expression data of monocytes of HIDS patients versus 
healthy volunteers either unstimulated, or 24h stimulated 
with RPMI or LPS. (n=3 vs n=3). (C) Top pathways 
associated with genes that show higher expression in HIDS patients exposed to 24h RPMI compared to 
controls. (n=3 vs n=3). (D) Monocytes of 3 HIDS patients and 3 healthy volunteers were exposed to RPMI/
LPS for 24h or left unstimulated (unstim). Fold increases of HIDS/controls were calculated for genes in the 
glycolysis pathway, mTOR pathway or cytokines. (n=3 vs n=3, * p < 0.05).
Chapter 9
  176 | 
autoinflammatory disorder characterized by an accumulation of mevalonate (26, 27). 
HIDS patients experience periodic attacks of sterile inflammation with symptoms 
such as fever, skin lesions, lymphadenopathy, and arthralgia (28). Interestingly, white 
blood cells of HIDS patients were described to produce more cytokines, unstimulated 
as well as stimulated, indicating a pre-activated state (29). We hypothesized that this 
is due to a trained immunity phenotype of HIDS monocytes, likely induced by the 
accumulation of mevalonate. We investigated the cells of 3 adult HIDS patients (2 
male, 1 female), all three with V377I mutations. In line with our hypothesis, purified 
monocytes from these patients produced significantly more TNFα, IL-6 and IL-1β 
upon stimulation with several ligands compared to healthy controls (Figure 5A). 
RNAseq analysis revealed that HIDS monocytes incubated in medium for 24h in 
the absence of exogenous stimulation display an overexpression of multiple genes 
(Figure 5B, Table S2), although with substantial interdonor variation (Figure S1). 
Pathway analysis of these expression data is displayed in Figure 5C and shows 
upregulated inflammatory pathways, such as NFκB signalling, supporting the 
hypothesis of a hyperinflammatory state. We performed whole-genome assessment 
of the histone mark H3K27ac by ChIP sequencing in non-stimulated monocytes from 
the HIDS patients and controls. Due to variation between the three HIDS patients, 
only 147 upregulated and 69 downregulated peaks were found to be different 
comparing HIDS patient to healthy controls (Table S3). The overlap between 
the in vitro mevalonate-trained macrophages and HIDS circulating monocytes in 
terms of H3K27ac peaks was limited, due to differences in the cell types analysed 
(Figure S2). When specifically comparing peak-related genes between HIDS and 
mevalonate-activated samples one upregulated gene and 22 downregulated genes 
were found (Table S3), but these could not be allocated to certain cellular pathways, 
because of the low number. When specifically assessing the expression data of 
HIDS patients for trained immunity-related genes an interesting comparison can 
be made. Expression profiles of pathways known to be important for induction of 
trained immunity such as glycolysis, mTOR pathway, and (innate) cytokines were 
assessed (4, 5, 22), comparing HIDS patients and healthy controls. This shows a 
clear increased induction of glycolysis and mTOR pathway in HIDS patients when 
their monocytes are stimulated with LPS (Figure 5D). Moreover, transcription of 
cytokines was evidently increased in monocytes of HIDS patients after 24h in RPMI 
medium (Figure 5D).
DISCUSSION
Trained immunity is associated with an upregulation of several cellular metabolic 
pathways, including glycolysis and glutamine metabolism. In this paper, we explored 
the role of the cholesterol synthesis pathway in the induction of trained immunity. 
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We show that the cholesterol synthesis pathway is essential for inducing trained 
immunity, and its inhibition by statins down-regulated the increased cytokine 
production and epigenetic reprogramming induced by either β-glucan or oxLDL. We 
also show that not the synthesis of cholesterol itself is essential, but the accumulation 
of the metabolite mevalonate. Epigenome analysis showed that incubation of healthy 
monocytes with mevalonate alone results in trained macrophages that resemble the 
β-glucan-induced trained immunity phenotype, especially on the genes that were 
epigenetically down-regulated. This indicates that next to fumarate, mevalonate 
is an essential metabolite in the metabolo-epigenetics of trained immunity. RNA 
sequencing analysis showed that monocytes from patients with HIDS due to 
mevalonate kinase deficiency exhibit a trained immunity phenotype. 
 The cholesterol synthesis pathway has been shown to affect epigenetic 
remodeling via induction of LXRα, which is induced by intermediates downstream 
in the cholesterol synthesis pathway (30, 31). Furthermore, downregulation of 
geranylgeranylation suppresses HDAC1 activity and FPP and GGPP have been 
shown to inhibit the lysine specific demethylase 1 (32, 33). However, surprisingly in 
the present study, we show that intermediates downstream in the pathway are not 
essential for inducing trained immunity, while metabolites in the proximal part of the 
pathway, especially mevalonate, play an important role. We, thus, show that it is 
unlikely that isoprenylation plays a major role for the induction of trained immunity.
 HIDS is one of the prominent hereditary autoinflammatory (‘periodic fever’) 
syndromes. HIDS patients carry mutations in mevalonate kinase that are responsible 
for the clinical picture of febrile attacks, skin lesions, arthritis and lymphadenopathy. 
The mutation in mevalonate kinase leads to accumulation of mevalonate and results 
in elevated excretion of mevalonic acid during attacks (27). In the treatment of HIDS, 
inhibition of IL-1 with anakinra has become one of the cornerstones of the therapy (34), 
but HIDS is considered more and more a ‘multi-cytokine disease’, as also inhibition 
of IL-6 with tociluzimab and even anti-TNF treatment with etanercept have shown 
promising results in specific cases (35-38). We thus hypothesized that induction of 
a trained immunity phenotype, characterized by exaggerated cytokine production by 
monocytes due to mevalonate accumulation, could play a role in the pathophysiology 
of HIDS. This hypothesis was validated by demonstration of exaggerated cytokine 
production in HIDS monocytes, accompanied by transcriptional and epigenetic 
changes. Interestingly, statin treatment showed a reduced excretion of mevalonic 
acid in HIDS patients, and a decreased number of febrile days, supporting the 
concept that lowering mevalonate levels is beneficial for disease activity (39).  
 Kastner et al. have shown that isoprenylation is an important mechanism that 
is deficient in HIDS patients and causative to the disease symptoms. The absence 
of protein geranylgeranylation results in compromised PI(3)K activity, which allows 
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an unopposed TLR-induced inflammatory response with constitutive activation 
of the pyrin inflammasome. Moreover, due to prenylation defects the GTPase 
RhoA is inactivated, which also results in pyrin inflammasome activation (40, 41). 
Interestingly, it was also shown that isoprenylation is not defective in HIDS patients 
due to increased flux through the isoprenoid/cholesterol biosynthesis pathway by 
elevating intracellular mevalonate levels (42). However, we now show that next to 
this mechanism based on defective prenylation, also the accumulation of mevalonate 
itself seems to play a causative role in developing the hyperinflammatory state 
observed in HIDS. 
 A crucial aspect relates to the mechanisms through which mevalonate induces 
and modulates trained immunity. In T-cells, activation induces a shift from oxidative 
phosphorylation to aerobic glycolysis, similar to trained monocytes. In these cells 
it was shown that the increased glycolysis also fuels mevalonate metabolism (43). 
Glucose is increasingly taken up and converted into pyruvate. Subsequently, via 
a truncated TCA cycle, pyruvate is converted into acetyl-CoA and citrate, which is 
exported to the cytosol. There, the citrate is converted back into acetyl-CoA by ATP 
citrate lyase (44) and enters either the mevalonate pathway or fatty acid biosynthesis 
(43). Previously we have shown an increase in intracellular citrate in β-glucan 
trained cells, which might provide evidence of a similar mechanism in monocytes 
(7). An interesting observation of our study is the involvement of glycolysis and 
mTOR for the induction of trained immunity by mevalonate. Mevalonate-induced 
training can be counteracted by inhibiting glycolysis and mTOR signaling. We 
identified the IGF1-receptor as the responsible receptor through which mevalonate 
can signal extracellularly, activating the mTOR pathway and subsequently inducing 
epigenetic changes. This would then fuel a self-reinforcing activating mechanism in 
which glycolysis promotes mevalonate accumulation, which subsequently activates 
glycolysis via IGF1 signaling (Figure 3F). However mevalonate could theoretically 
also exert an effect intracellularly. 
 Clinically, the discovery of a role for mevalonate for the induction of trained 
immunity, and for a hyperinflammatory phenotype in specific diseases, has important 
consequences. Inhibition of the cholesterol synthesis pathway in inflammatory 
conditions is thus potentially very relevant. Earlier studies have already shown 
that statins can improve survival from sepsis in mice (45) and also human studies 
demonstrate that statin use may be associated with better survival in sepsis (46). 
Also the development of rheumatoid arthritis is thought be reduced by statin 
treatment (47). Inhibition of the cholesterol synthesis pathway could therefore be 
an effective therapy in other hyperinflammatory disorders in which trained immunity 
plays a role (1). However, to fully implement inhibition of the mevalonate pathway as 
a therapeutic option, the exact role of trained immunity and mevalonate accumulation 
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in these conditions should first be elucidated further. 
 In conclusion, the cholesterol synthesis pathway, and in particular the intermediate 
mevalonate, is essential for inducing trained innate immunity. Incubation of 
monocytes with mevalonate induces a trained immunity phenotype, which covers 
a part of the β-glucan trained immunity phenotype, similar to fumarate. Patients 
with mevalonate accumulation acquire a trained immunity phenotype, characterized 
by an increased expression of cytokines and genes in the glycolysis pathway. 
Furthermore, inhibition of the cholesterol synthesis pathway by statins prevents the 
trained immunity phenotype. Statins could therefore be used as a treatment option 
for diseases, which are mediated via trained immunity, until more specific drugs for 
inhibiting trained immunity are available. 
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Digital versions of Tables S1-3 can be obtained by sending a request to the author.
Table S1, related to Figure 4 – Differentially regulated H3K27ac peaks in mevalonate-trained 
monocytes. In the first tab genes related to peaks induced by mevalonate-induced trained immunity 
can be found. In the second tab these peaks are compared with H3K27ac peaks from β-glucan-induced 
trained immunity from Arts et al. (7).
Table S2, related to Figure 5 – RNA sequencing analysis of monocytes of HIDS patients versus 
healthy controls. Up- and down-regulated expression is shown in separate tabs for non-stimulated 
monocytes and monocytes that were cultured in RPMI medium for 24h. 
Table S3, related to Figure 5 – ChIP sequencing of monocytes of HIDS patients versus healthy 
controls. In the first tab H3K27ac peaks comparing HIDS patients to healthy controls is shown. In the 
second tab the overlap between the in-vitro mevalonate-trained macrophages and HIDS circulating 
monocytes in terms of H3K27ac peaks are shown. 
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Figure S1, related to Figure 5 - HIDS expression analysis. Heat map of individual donors for genes 
that show LPS responses in controls and HIDS patients. Monocytes were either unstimulated (=baseline) 
or stimulated for 24h with RPMI or LPS.
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Figure S2, related to Figure 5 - Comparison of H3K27ac peaks in HIDS monocytes versus 
mevalonate-trained macrophages. At the left, graphs display the median and mean read counts of the 
H3K27ac peaks that were significantly up or down in HIDS patient monocytes. At the right, graphs display 
median and mean read counts at the same H3K27ac peaks.
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ABSTRACT
The acute phase of sepsis is characterized by a strong inflammatory reaction. 
At later stages in some patients immune paralysis may be encountered, which is 
associated with poor outcome. By transcriptional and metabolic profiling in human 
sepsis patients we showed that a shift from oxidative phosphorylation to aerobic 
glycolysis is an important component of initial activation of host defense. Blocking 
metabolic pathways with metformin reduced cytokine production and increased 
mortality in systemic fungal infection in mice. In contrast, in leukocytes rendered 
tolerant by exposure to lipopolysaccharide or after isolation from patients with sepsis 
and immune paralysis, a generalized metabolic defect at the level of both glycolysis 
and oxidative metabolism was apparent, which was restored after recovery of the 
patients. Finally, the immunometabolic defects in humans could be partially restored 
by therapy with recombinant interferon-γ, suggesting that metabolic processes could 
represent a therapeutic target in sepsis. 
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The immune response during the acute phase of sepsis is characterized by 
inflammation and activation of immune effector mechanisms (e.g. phagocytosis, 
intracellular killing) aimed at eliminating the pathogen. During the late phase, the 
immune system shifts towards an anti-inflammatory state to reduce inflammation and 
initiate tissue repair. This chain of events can be distorted with dire consequences 
for the outcome: an exaggerated systemic release of cytokines in the acute phase 
(cytokine storm) can cause hypotension, cardiovascular dysfunction, tissue damage 
and multi-organ failure, while during the later phases of the disease activation 
of modulatory pathways may prematurely inhibit host defense (innate immune 
tolerance or innate immune paralysis) (1). However, recent studies demonstrated 
that these functional states can occur simultaneously. In agreement, a recent 
study showed that phagocytes from sepsis patients who had survived the infection 
displayed both decreased inflammation and increased expression of genes involved 
in phagocytosis, microbial killing and tissue repair, which was found to be mediated 
by a HIF-1α transcription factor-dependent pathway (2). Nevertheless, exaggerated 
inhibitory effects on leukocytes during the late phase of sepsis can lead to immune 
paralysis, associated with an increased susceptibility to secondary infections and 
a poor outcome (3). Understanding the mechanisms that regulate inflammatory 
responses in sepsis is crucial to identify new therapeutic strategies for reversing 
immune dysregulation in severely ill septic patients.
 Studies have identified a crucial role for cellular metabolism of glucose in the 
functional fate of immune cells. In this respect, naive or tolerant cells mainly rely on 
oxidative phosphorylation and β-oxidation as energy sources, while after stimulation 
leukocytes shift their metabolism towards aerobic glycolysis (attuned to the Warburg 
effect) (3, 4). Defects in tissue metabolism have been reported in sepsis, and 
seemed correlated with outcome. Elevated ATP concentration in muscle biopsies 
of sepsis patients are associated with better survival (5), whereas mitochondrial 
dysfunction and energy shortage have been hypothesized to be an underlying cause 
of organ dysfunction (6, 7). In addition, two small studies reported mitochondrial 
dysfunction (8) and redox imbalance (9) in leukocytes of sepsis patients. However, 
a comprehensive investigation of cellular metabolism of leukocytes in sepsis and its 
impact on immune function and outcome has not been performed.
 In this study we aimed to assess energy metabolism of immune cells in two 
clinically relevant infection models, namely bacterial sepsis caused by the Gram-
negative bacterium Escherichia coli and fungal sepsis caused by the opportunistic 
fungal pathogen Candida albicans. On the one hand we investigated the role for host 
defense of a metabolic shift towards aerobic glycolysis during acute infection, and 
on the other hand, the relationship between the dysregulation of cellular metabolism 
and innate immune paralysis (or innate immune tolerance) in patients with severe 
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sepsis. 
MATERIALS AND METHODS
PBMC and monocyte isolation - Buffy coats from healthy donors were obtained after 
written informed consent (Sanquin blood bank, Nijmegen, The Netherlands). PBMC 
isolation was performed by dilution of blood in pyrogen-free PBS and differential 
density centrifugation over Ficoll-Paque (GE healthcare, UK). Cells were washed 
twice in PBS and resuspended in RPMI culture medium (Roswell Park Memorial 
Institute medium; Invitrogen, CA, USA) supplemented with 50μg/ml gentamicin, 
2mM Glutamax, and 1mM pyruvate (Gibco). PBMCs were counted in a Coulter 
counter (Coulter Electronics) and adjusted to 5×10^6 cells/ml. A 100μl volume was 
added to round bottom 96-well plates (Greiner, Frickenhausen, Germany) for PBMC 
experiments.  For monocytes experiments, monocytes were separated from other 
cells by hyperosmotic density gradient centrifugation over Percoll (Sigma-Aldrich, St. 
Louis, MO, USA), and afterwards washed once with PBS. Monocytes were counted 
and adjusted to 1×10^6 cells/ml. A 100μl volume was added to flat bottom 96-well 
plates (Corning, NY, USA) and cells were let to adhere for 1h at 37°C; subsequently 
a washing step with 200μl warm PBS was performed to yield maximal purity. 
Monocyte isolation from septic patients was performed by CD14 positive magnetic 
beads (MACS Miltenyi) isolation after the PBMC isolation step.
Monocyte/PBMC stimulation - Cells were stimulated with RPMI, Escherichia coli 
LPS (serotype 055:B5, Sigma-Aldrich, 10ng/ml), or 1x10^6/ml Candida albicans 
ATCC MYA-3573 (UC 820) for 24h or 7 days (in the presence of 10% serum for 
lymphocyte derived cytokines) and supernatants were stored at -20oC until cytokine/
lactate measurements were performed. For NAD+ measurements, cells were lysed in 
lysis buffer and stored at -800C. To induce tolerance, monocytes were pre-incubated 
with LPS (10ng/ml) or C. albicans (10^4 CFU/ml) in the presence of 10% serum. After 
24h cells were washed once with warm PBS and let to rest for 24h in 10% serum 
supplemented medium. Thereafter, cells were restimulated with RPMI or 10ng/ml 
LPS for 2h (for Western blot) or for 24h (for cytokines/lactate/NAD+ production). 
Supernatants and lysates were stored as described above. In some experiments, 
cells were pre-incubated for 1h with the mTOR pathway inhibitors 10nM rapamycin 
(Sigma), 100nM torin1 (Tocris, Bristol, UK), or the AMPK inducer 3mM metformin 
(R&D, Abingdon, UK), after which the stimulus was added. For the IFNγ experiments 
were preincubated for 1h with 1µg/ml of recombinant IFNγ (Immukine, Boehringer 
Ingelheim, Vienna, Austria) before restimulation.
Cytokine, lactate, NAD+, and ATP measurements - Cytokine production was 
determined in supernatants using commercial ELISA kits for TNFα, IL-17, IL-22 (R&D 
systems, MN, USA) and IL-1β, IL-6, IFNγ (Sanquin, Amsterdam, The Netherlands) 
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following the instructions of the manufacturer. Lactate concentration was measured 
using a Lactate Fluorometric Assay Kit (Biovision, CA, USA) and NAD+ by a NAD+/
NADH Fluorometric Quantification Kit (Biovision). Lactate results are depicted as 
increase (Δ) lactate production: the difference of lactate production between RPMI 
and LPS stimulated samples. ATP was measured by a bioluminescence ATP 
determination kit (Thermo Fisher Scientific, Waltham, MA, USA).
Western blots - Cells were cultured, lysed and stored as described above. Monocytes 
from septic patients were directly lysed after CD14 positive MACS isolation and 
stored at -20°C. Total protein amounts were determined by BCA assay (Thermo 
Fisher Scientific) and equal amounts of proteins were loaded on pre-casted 4-15% 
gels (Biorad, CA, USA). The separated proteins were transferred to a nitrocellulose 
membrane (Biorad), which was blocked in 5% BSA (Sigma). Incubation overnight at 
4°C with rabbit polyclonal antibodies against p-S6K, p-4EBP1, p-Akt (Cell Signaling, 
Danvers, MA, USA), CPT1, CD36 (Santa Cruz, TX, USA), and actin (Sigma) were 
used to determine the protein expression, which was visualized using a polyclonal 
secondary antibody (Dako, Belgium) and SuperSignal West Femto Substrate 
(Thermo Fisher Scientific) or ECL (Biorad).
Oxygen consumption - 5x10^6 PBMCs were incubated for 48h with RPMI, LPS or 
C. albicans in the presence of 10% serum. Culture medium was collected after which 
the cells were washed, and resuspended in 60μl of the collected culture medium. 
Oxygen consumption for septic patients or healthy volunteers was performed on 
5x10^6 freshly isolated PBMCs collected in  50μl RPMI. The cell suspensions 
were then used for cellular O2 consumption analysis. Oxygen consumption was 
measured at 37°C using polarographic oxygen sensors in a two-chamber Oxygraph 
(OROBOROS Instruments, Innsbruck, Austria). First, basal respiration was measured. 
Next, leak respiration was determined by addition of the specific complex V inhibitor 
oligomycin A (OLI; 2.5µM). Then, maximum oxygen consumption was quantified by 
applying increasing concentrations of the mitochondrial uncoupler p-trifluoromethoxy 
carbonyl cyanide phenyl hydrazone (FCCP 0.5 to 14µM final concentration). Finally, 
non-mitochondrial oxygen consumption (ROX) was assessed by adding the specific 
complex I inhibitor rotenone (ROT; 30nM) and the complex III inhibitor antimycin A 
(AA; 2.5µM). 
Animal experimental models - Animals experiments were conducted in accordance 
at the Center of Animal Use for Research Purposes of ATTIKON University hospital 
in accordance with the 56/2013 EU law (license 4/2013). Forty C57Bl6 male mice 
7-9 weeks old weighting 25-27g were studied. Mice were staying at cages with a 
constant flow air exchange, they were fed standard lab chow and they had access 
to water ab libitum. Mice were randomly assigned to each of three groups and 
interventions were performed after ether anesthesia. Researchers were blinded 
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for the interventions: a) treated intraperitoneally (ip) on days -1, 0, 1, 2, 3, 4, 5, 6 
and 7 with 200μl PBS. These mice were challenged with one log-phase 5x10^6/
mice inoculum of C. albicans intravenously (iv) by the tail vein on day 0; b) treated 
intraperitoneally (ip) on days -1, 0, 1, 2, 3, 4, 5, 6 and 7 with 250mg/kg of metformin 
(Glucophage, Bristol, Athens, Greece) diluted in PBS. These mice were challenged 
with one log-phase 5x10^6/mice inoculum of C. albicans intravenously (iv) by the tail 
vein on day 0. Survival was monitored for 28 days for 10 mice/group and animals 
were sacrificed as 5/group on days 3 and 7. During sacrifice, one midline abdominal 
incision was performed under aseptic conditions and tissue samples were taken 
from the liver, spleen and right kidney. Once weighed, segments of liver and right 
kidney were homogenized with 1ml RPMI-1640 (Biochrom, Berlin, Germany) 
nutrient broth and 100μl of the homogenate were four times serially diluted 1:10 in 
0.9% NaCl. A 0.1-ml aliquot of each dilution was plated onto Sabouraud (Becton 
Dickinson, Cockeysville Md) agar. Plates were incubated at 37oC for 48h and the 
number of viable colonies in each dilution was multiplied by the appropriate dilution 
factor. Results were expressed in log10 CFU/g. The lower detection limit was 10 
CFU/g. The spleen was gently squeezed and then passed through a sterile filter 
(250μm, 12x13cm, Alter Chem Co) for splenocytes collection. After counting the 
splenocytes with tryptan blue exclusion of dead cells, splenocytes were incubated 
into sterile flat wells at a density of 5x10^6/ml in 1ml of RPMI-1640 supplemented 
with 2mM glutamine, 10% fetal bovine serum, 100U/ml of penicillin G, and 0.1mg/ml 
of streptomycin in the absence or presence of 10ng/ml LPS, Escherichia coli O55:B5 
(24h), or 1x10^6 CFU/ml of heat-killed yeasts Candida albicans (5d) at 37°C in 5%. 
At the end of incubation, the plates were centrifuged and the supernatants were 
collected. Cytokines were measured in supernatants by an enzyme immunoassay 
(R&D Inc, Minneapolis, USA). 
Human endotoxemia - Eight healthy men (mean age 22.9, SE ± 0.5 years) were 
intravenously administered with LPS (from E. coli;  U.S. standard reference endotoxin, 
kindly provided by the National Institutes of Health, Bethesda, MD; 4ng/kg body 
weight). Blood was collected before and 4h after LPS administration in PAXgene 
tubes (Becton-Dickinson, Breda, the Netherlands) for microarray analysis of total 
RNA isolated using the PAXgene blood RNA kit (Qiagen) according to manufacturer’s 
instructions. Blood was also collected in heparin tubes (Becton-Dickinson, Breda, 
the Netherlands) for whole blood and PBMC restimulation with 100ng/ml LPS for 
h. After re-stimulation, cytokine release was assessed by Luminex-based multiplex 
assay. The study was approved by the institutional scientific and ethics committees, 
and written informed consent was obtained from all subjects (NCT01014117). 
Patient studies - Clinical samples were obtained from patients with blood culture 
proven E. coli or C. albicans sepsis who had been enrolled in the MARS (Molecular 
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Diagnosis and Risk Stratification of Sepsis) cohort, a large prospective observational 
study in the ICUs of two tertiary teaching hospitals (Academic Medical Center, 
Amsterdam and University Medical Center Utrecht, Utrecht) in the Netherlands that 
took place from 2011 to 2014 (ClinicalTrials.gov identifier NCT01905033). Blood 
was collected in PAXgene tubes and total RNA isolated by means of the PAXgene 
blood RNA kits using the QIAcube system (Qiagen) according to manufacturer’s 
instructions. The Medical Ethical Committees of both study centers gave approval 
for an opt-out consent method (IRB no. 10-056C). PAXgene blood was also obtained 
from 42 healthy controls (age range 30-63 years; 24 males, 18 females) after providing 
written informed consent. For ex-vivo cytokine and lactate production of septic 
patients, blood was drawn via an arterial catheter from eight newly admitted septic 
patients within 24h after admission to the intensive care unit of Radboud University 
Medical Center Nijmegen. Once a patient had recovered, blood was drawn before 
release from the ICU and if possible once more at a later time point. For the IFNγ 
pilot study the primary end point data have been published elsewhere (10). In short, 
eight patients with an invasive Candida spp and/or Aspergillus fumigatus infection 
were next to the standard antifungal therapy treated with recombinant IFNγ (100mg 
thrice a week, for 2 weeks), at indicated time points blood was drawn, and ex-vivo 
PBMC stimulations were performed (10). From the 24h cultured supernatants lactate 
was measured.
Microarray analysis - Genome-wide blood gene expression analysis of the human 
endotoxemia cohort was done using the Illumina HumanHT-12 V3.0 expression 
beadchip (GSE48119); whereas the sepsis patients from the MARS cohort were 
analyzed by hybridizing to the human genome U219 96-array plate and scanned 
using the GeneTitan® instrument (Affymetrix) (GSE65682). Genome-wide gene 
expression analysis of in-vitro stimulated PBMCs from healthy volunteers was done 
by using the Illumina HumanHT-12 V4.0 expression beadchip (GSE42606), further 
details can be found from Smeekens, et al. (11). 
Statistics - Differences in cytokine/lactate/NAD+ were analysed using a Wilcoxon 
signed-rank test or one way Anova, where applicable. Survival curves were analysed 
by a log-rank test and for oxygen consumption a student t test was used. All these 
analyses were performed in Graphpad prism 5 (CA, USA). * p < 0.05, ** p < 0.01, 
*** p < 0.0001. Data are shown as means ± SEM. Dichotomous and continuous 
clinical data were assessed by Fisher’s exact test and Wilcoxon’s rank sum test, 
respectively. Microarray data are presented in the form of volcano plots (integrating 
log2 fold changes and multiple-test adjusted probabilities) and heat map plots, 
generated in R studio (12).
Study design and patient selection - The study was performed within the context 
of the Molecular diAgnosis and Risk stratification of Sepsis (MARS) project in the 
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mixed ICUs of two tertiary referral centers in the Netherlands (Academic Medical 
Center, Amsterdam, and University Medical Center Utrecht, Utrecht; clinicaltrials.
gov identifier NCT01905033).(13, 14) The Medical Ethics committees of both 
participating centers approved an opt-out consent method (IRB no. 10-056C).
 MARS patient cohort: The MARS ICU patient cohort was enrolled between 
January, 2011 and July, 2012, comprised of 46 sepsis patients with blood culture 
proven infection  Escherichia coli (E. coli) (n=33) or Candida species (n=13, C. 
albicans (n=7), C. glabrata (n=5), C. lusitaniae (n=1), and C. tropicalis (n=1)). 
Severity was assessed on a daily basis from ICU admission by means of the Acute 
Physiology and Chronic Health Evaluation (APACHE IV) score (15). Shock was 
defined as hypotension requiring the use of noradrenaline in a dose of >0.1 µg/kg/min 
during at least 50% of the day. Blood was collected in PAXgene blood tubes (Becton-
Dickinson, Breda, the Netherlands) for RNA isolation. Total RNA was isolated by 
means of the PAXgene blood mRNA kit (Qiagen) and Qiacube automated system 
(Qiagen). Blood was also obtained from 42 healthy controls (age range 30-63 years; 
24 males, 18 females) after providing written informed consent.
 RUMC cohort: Eight newly admitted sepsis patients (age range 33-76 years, 
3 males, 5 females) were included after informed consent. Shock was defined as 
described above. Blood was drawn via an arterial catheter within 24h after admission 
to the intensive care unit of the Radboud university medical center Nijmegen. Blood 
cultures were positive for E. coli (n=2) or C. albicans (n=1), and in other patients 
pathogens were cultured from urine, or pleural effusion, containing E. coli (n=4), or 
C. glabrata (n=1).
Microarray data processing and normalization - MARS cohort in-vivo blood 
gene expression data: Quality and integrity of RNA was assessed by Nanodrop 
spectrophotometry (260:280nm) and bioanalysis (Agilent, Amstelveen, the 
Netherlands). RNA (RIN > 6.0) was processed and hybridized to the Human 
Genome U219 96-array plate using the GeneTitanR instrument (Affymetrix) as 
described by the manufacturer at the Cologne Center for Genomics (CCG), 
Cologne, Germany. Raw data scans (.CEL files) were read into the R language and 
environment for statistical computing (version 2.15.1; R Foundation for Statistical 
Computing, Vienna, Austria; http://www.R-project.org/). Pre-processing and quality 
control was performed by using the Affy package version 1.36.1.(16) Array data were 
normalized using the Robust Multi-array Average (RMA) method and summarized by 
medianpolish. The resultant 49,386 log-transformed probe intensities were filtered 
by means of a 0.5 variance cutoff using the genefilter method (17) to recover 24,646 
probes in at least one sample. The occurrence of non-experimental chip effects was 
assessed by means of the Surrogate Variable Analysis (18) and corrected using 
the ComBat method (19). Differential gene expression across healthy subjects, E. 
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coli and Candida blood culture positive patient samples was done by means of the 
limma method (20, 21). We adjusted for the potential impact of age in our model 
(additive). Throughout Benjamini-Hochberg (BH) (22) multiple comparison adjusted 
probabilities, correcting for 24,646 tests, defined significance. Probes were annotated 
using the U219 annotation database available through R/Bioconductor (23). 
 Human endotoxemia in-vivo blood gene expression data: PAXgene blood total RNA 
was isolated by means of the Qiacube automated system (Qiagen) using PAXgene 
blood RNA kits according to manufacturer’s instructions. Synthesis, amplification and 
purification of anti-sense RNA was performed by using the Illumina TotalPrep RNA 
Amplification Kit (Ambion art. No. AM-IL1791) following the Illumina Sentrix Array 
Matrix expression protocol at ServiceXS (Leiden, the Netherlands). A total of 750ng 
biotinylated cRNA was hybridized onto the HumanHT-12v3 Expression BeadChip 
(Illumina). The raw scan data were read using the beadarray package (version 1.16.0) 
(24), using the R statistical environment (version 2.11.0) (25). Illumina’s default pre-
processing steps were performed using beadarray. Briefly, estimated background was 
subtracted from the foreground for each bead. For replicate beads, outliers greater 
than 3 median absolute deviations from the median were removed and the average 
signal was calculated for the remaining intensities. Log-transformation was applied 
to summarized data in order to remove mean-variance relationship in intensities. 
Resulting data were then quantiles normalized (26). Quality control was performed 
both on bead level and on bead summary data using the arrayQualityMetrics package 
(v2.6.0) (27). For each of the 48,804 probes a detection score was calculated by 
comparing their average signals with the summarized values for the negative control 
probes. This step filtered the non-expressed probes, thus yielding 20,700 probes. 
Probes were re-annotated using the illuminaHumanv3BeadID.db package available 
from Bioconductor. Assessment of differential gene expression was done by means 
of the limma method (20, 21). Throughout Benjamini-Hochberg (BH) (22) multiple 
comparison adjusted probabilities, correcting for 20,700 tests, defined significance. 
Human in-vitro gene expression data: Genes pertaining to metabolic signaling 
pathways were selected and analyzed for differential expression in RPMI (control), 
LPS and candida stimulated samples (4h and 24h) as described before (11) by using 
limma (20, 21). Multiple-comparison BH-adjusted p-value < 0.05 defined significance.
Gene expression pathway analysis - Ingenuity pathway analysis (IPA, www.
ingenuity.com) was used to identify significant enrichment of canonical signaling 
pathways. Genes were stratified as over- or under-expressed and analyzed by 
selecting the Ingenuity gene knowledgebase as reference and specifying human 
species. All other parameters were kept default. Association significance was 
measured by Fisher’s exact test BH-adjusted p-values. Transcription factor binding 
site motif analysis was performed on all multiple-comparison significant genes (BH 
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p < 0.05) per comparison using the oPossum methodology (28, 29). The initial 
2000bp of DNA sequence upstream and downstream of the gene transcription start 
site was used. All other parameters were default. Fisher’s scores above median 
and percent TFBS hits of all input DNA sequences > 50% were used as cutoffs for 
transcription factor pathway analysis using the ToppGene bioinformatics suite (30, 
31). Significance was demarcated using Fisher’s exact test BH-adjusted p-values 
(BH p < 0.05).
RESULTS
The shift towards aerobic glycolysis in acute inflammation 
The first aim of the study was to investigate cellular metabolism during stimulation 
of leukocytes by pathogens. Microarray assessment of human peripheral blood 
mononuclear cells (PBMCs) stimulated for 4h and 24h with either C. albicans (11) 
(Figure S1A,B) or E. coli-derived lipopolysaccharide (LPS) (Figure S1C) revealed 
a strong upregulation of mRNA pertaining to genes involved in glycolysis, whereas 
expression of rate-limiting enzymes in the tricarboxylic acid (TCA; Krebs) cycle was 
downregulated. In addition, expression of key genes involved in the mTOR/HIF-1α 
pathway (important for regulation of glycolysis (25)) were also upregulated (Figure 
S1A). These gene transcription data were validated by a strong increase in lactate 
production and NAD+ concentration when cells were stimulated with C. albicans or 
LPS (Figure 1A) demonstrating a shift towards aerobic glycolysis, thus illustrating 
the induction of the Warburg effect (32). This shift towards glycolysis has been 
shown to be driven by mTOR activation as an intracellular sensor of glucose (33). In 
line with this, both C. albicans- and LPS-induced phosphorylation of the mTORC1 
(mTOR complex 1) downstream targets S6K and 4EBP1 (33) after 2h of stimulation 
(Figure 1B), showing that an mTOR regulated increase in anaerobic glycolysis is a 
key metabolic pathway in acute inflammation.
The mTOR pathway is essential for survival in sepsis 
Inhibition of the mTOR pathway in human PBMCs by metformin (an AMPK activator 
(34)) inhibited S6K and 4EBP1 phosphorylation (Figure 1B); in addition, inhibition 
of mTOR with metformin, rapamycin or torin1 (35) decreased cytokine production 
induced by C. albicans after stimulation for 24h (TNFα, IL-1β, but not IL-6) or 5 
days (IFNγ, IL-17, IL-22) (Figure 2A,B). In-vivo inhibition of metabolic pathways by 
metformin resulted in a significantly lower survival in Candida sepsis in mice, lower 
ex-vivo cytokine production by splenocytes and an increased fungal outgrowth in 
kidneys but not liver. Taken together these results attest to the importance of the 
mTOR pathway for robust cytokine production and an effective host defense (Figure 
2C-E).
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Regulation of cellular metabolism pathways in sepsis 
After showing the important role of mTOR-induced glycolysis for host defense 
during the acute phase of infection, we aimed to assess glycolysis and oxidative 
phosphorylation in leukocytes of patients with sepsis. We assessed genome-
wide gene expression of whole blood leukocytes isolated from healthy volunteers 
undergoing experimental endotoxemia, a human model of the inflammatory 
response observed during sepsis, induced by intravenous administration of low-
Figure 1 – Immunometabolism is upregulated during the acute inflammatory phase. (A) Stimulation 
of human PBMCs with LPS or C. albicans for 24h induces pro-inflammatory cytokine, lactate and NAD+ 
production (n=8). (B) Stimulation of human PBMCs for 2h with LPS or C. albicans upregulates the mTOR 
complex 1 pathway targets p-S6K and p-4EBP1. 1h preincubation with the AMPK activator metformin 
reverses activation of mTOR targets. (* p < 0.05, ** p < 0.01, Wilcoxon signed-rank test).
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dose E. coli LPS (4ng/kg) (36). This model is commonly characterized by robust 
blood transcriptome alterations after LPS administration e.g. elevated expression of 
typical pro- (IL-1, IL-6 signaling) and anti-inflammatory (IL-10 signaling) as well as 
Toll-like receptor signaling genes at 4h post-LPS administration  (Figure S2B) (36-
38).Genes from glycolysis I and mTOR pathways, but also oxidative phosphorylation 
and fatty acid oxidation were under-expressed in blood leukocytes 4h after LPS 
administration (Figure 3A), a time point at which the cytokine production capacity 
of leukocytes was strongly reduced (Figure S2C,D). Metabolic regulators HIF1A, 
NAMPT and EPAS1 (HIF2A) were over-expressed after LPS administration, 
whereas no differences were uncovered for PPARA, PPARG and HIF1AN (HIF-1A 
inhibitor) (Figure S3A-C). Moreover, M1 macrophage-like markers were largely over-
Figure 2 – Inhibition of the mTOR pathway reduces cytokine production and increases mortality. 
(A) Inhibition of the mTOR pathway by rapamycin, torin-1, or metformin blocks the induction and release 
of the pro-inflammatory cytokines TNFα and IL-1β after 24h by C. albicans in human PBMCs.  (B) mTOR 
inhibitors block human lymphocyte-derived cytokines IFNγ, IL-17 and IL-22 in vitro upon 7d RPMI or 
C. albicans stimulation (n=6, each first bar represents a negative (RPMI) control). (C-E) In-vivo mTOR 
inhibition with metformin (daily i.p. injection with PBS or metformin starting 1 day before C. albicans 
inoculum until 7 days afterward) increases mortality for C. albicans sepsis in mice (C), increases fungal 
outgrowth in the kidneys of the mice (D), and reduces pro-inflammatory cytokine production (at day 7) 
upon restimulation of splenocytes for in vitro (E) with LPS (IL-1β, IL-6, TNFα after 24h) or C. albicans 
(IFNγ, IL-17, IL-22 after 5 days) (each first bar represents a negative (RPMI) control). (n=5 mice per group 
and for survival experiments 10 mice per group). (* p < 0.05, Wilcoxon singed-rank test, or Kaplan-Meier 
curve).
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Figure 3 – Blood transcriptome analysis of human endotoxemia and sepsis patients with Candida 
and E. coli systemic infection. (A) Eight healthy male subjects were administered 4ng/kg E. coli LPS in 
a clinically controlled setting and genome-wide blood transcriptional profiles were assessed before and 
4h after LPS administration. (B-E) Clinically well-defined sepsis patients with E. coli or Candida blood 
stream infections were enrolled (Table S1). Genome-wide blood transcriptome analysis of sepsis patients 
revealed a pronounced alteration in gene expression compared to healthy subjects (B), which was a 
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E. coli sepsis, demonstrating changes in metabolic pathways and macrophage differentiation markers.
Chapter 10
  198 | 
expressed after LPS administration, in contrast to predominant under-expression of 
M2 macrophage-like markers (Figure 3A). 
 To assess whether these changes could be identified in actual sepsis patients 
as well, genome-wide blood microarray analysis was performed in a cohort of 33 
patients with bacterial sepsis (positive blood cultures for E. coli) and in 13 patients 
with fungal sepsis (positive blood cultures for Candida spp.) (Figure 3B-E and Table 
S1). Both bacterial and fungal sepsis induced strong changes in transcriptome 
profiles, encompassing more than 2000 genes (fold change ≥ 2 or ≤ -2) for each 
infection (Figure 3B). Most of the genes modified were common for both bacterial and 
fungal sepsis, although specific gene sets for either infection could also be identified 
(Figure 3C). Among the common pathways that were influenced in both types of 
sepsis, changes in the expression of genes involved in cellular metabolism were 
very prominent, including oxidative phospohorylation, glycolysis and mTOR signaling 
pathways (Figure 3D). Sepsis patients manifested over-expression of glycolysis and 
oxidative phosphorylation genes coupled with mitochondrial dysfunction, whereas 
fatty acid oxidation and mTOR signaling genes were under-expressed (Figure 3E). 
Furthermore, sepsis patients presented overexpression of M2-like genes and under-
expression of M1-like genes (Figure 3E). Analysis of transcription factor binding site 
motifs in promoter regions of genes altered during sepsis revealed a clear role for 
the mTOR-dependent HIF-1α axis in leukocyte gene regulation during both E. coli 
and Candida sepsis (Figure S3D). This is in line with the findings of others, who 
have shown the importance of HIF-1α in other processes than metabolism during 
functional reprogramming of human monocytes in sepsis (2). These data show that 
during sepsis profound changes in metabolism of leukocytes are encountered.
Tolerant monocytes display defective energy metabolism
In a following set of experiments we assessed whether induction of innate immune 
tolerance in human monocytes modulates cellular metabolism. We used an in-vitro 
model of innate immune tolerance induced by stimulation of monocytes with high 
concentrations of LPS or C. albicans (in contrast with the low level stimulation that 
induces priming (25, 39, 40)). When monocytes were rendered immunotolerant, 
pro-inflammatory cytokine production upon restimulation was almost completely 
abolished (Figure 4A). In line with this, restimulation of tolerant monocytes with 
LPS resulted in reduced lactate and enhanced NAD+ production compared with 
control cells, indicative of defective capacity to mount a Warburg effect (Figure 
4A). Immunoblotting of the mTOR pathway showed decreased phosphorylation of 
mTORC1 targets (Figure 4B). When glycolysis is impaired, β-oxidation of fatty acids 
is often used as an alternative source of energy (41). However, monocytes that 
were rendered tolerant by LPS pre-exposure were also characterized by decreased 
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Figure 4 – In vitro innate immune tolerant monocytes have impaired metabolism. (A) To induce 
immunotolerance, monocytes were pre-incubated with LPS (10 ng/ml) or C. albicans (10^4 CFU/ml). After 
resting for 24h, cells were restimulated with RPMI (first 2 or 3 grouped bars) or 10ng/ml LPS (last 2 or 3 
grouped bars) for 24h. Tolerant monocytes produced less pro-inflammatory cytokines and lactate (n=6 
individual donors). (B) Activation of the downstream mTOR targets S6K and 4EBP1 is downregulated 
in tolerant monocytes (24h stimulation, 24h rest), as are the fatty acid transporters CD36 and CPT1 
(representative Western blot of 4 separate individual donors). (C) Tolerant monocytes (24h stimulation, 
24h rest) display decreased oxygen consumption (n=6 first 2 panels display a representative donor). 
basal = basal respiration, leak = proton leak after inhibition of ATP synthase, max = maximal oxygen 
consumption, rox = residual oxygen consumption or non-mitochondrial oxygen consumption. (* p < 0.05, 
** p < 0.01, *** p < 0.001. Wilcoxon signed-rank test).
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amounts of fatty acid transporters CD36 and CPT1 compared to the control 
cells exposed to culture medium alone (Figure 4B). Finally, the assessment of 
immunotolerant monocytes also showed a marked decrease in oxygen consumption 
compared with naive monocytes (Figure 4C). Therefore, a decrease in all major 
metabolic pathways (glycolysis, OxPhos, β-oxidation) is seen in immunotolerant 
monocytes.
Severe metabolic defects in leukocytes of sepsis patients 
To assess whether similar defects of cellular metabolism characterize leukocytes 
from patients with sepsis, we assessed cytokine production capacity and glycolysis 
in cells from a separate set of sepsis patients who either responded normally to 
stimulation (Figure 5A; high responders, n=6), or those who lacked the capacity to 
produce cytokines upon ex vivo stimulation with LPS (Figure 5A; immunotolerant, 
n=5). Stimulation of PBMCs from healthy controls and high responder sepsis patients 
showed normal secretion of cytokines. These cells were also able to mount lactate 
and NAD+ release. In contrast, PBMCs of immunotolerant sepsis patients were 
unable to produce lactate and NAD+ upon LPS stimulation (Figure 5A). Metabolic 
processes in monocytes of patients during septic shock and recovery were also 
assessed. When immunotolerant sepsis patients were followed in time (> 7 days), 
ex-vivo cytokine and lactate production was restored upon patient recovery (Figure 
5B). 
 Assessment of the mTOR pathway and fatty acid transporters (CD36 and CPT1) 
in monocytes by immunoblot showed reduced activation in patients with sepsis. 
These effects were reverted once patients recovered (Figure 5C). Consistent with 
the data above showing severe metabolic disturbances in sepsis patients, maximum 
oxygen consumption of PBMCs was also significantly impaired in sepsis patients, 
compared to healthy controls (Figure 5D). These data demonstrate that both 
glycolysis and oxidative metabolism pathways are strongly downregulated in sepsis 
patients, leading to what we term here as ‘immunometabolic paralysis’ (Figure S4).
IFNγ partially restores cellular metabolism 
Restoring energy metabolism might represent a potential therapy in sepsis patients 
with immunometabolic paralysis. IFNγ is a cytokine with the capacity to potently 
stimulate monocyte function and recombinant IFNγ therapy in septic patients has 
been shown to (partially) reverse immunoparalysis both in vitro and in vivo (10, 42, 
43). Moreover, IFNγ polarizes macrophage differentiation towards an M1 macrophage 
phenotype, which is associated with increased glycolysis (44) and mTOR/HIF-1α 
regulated metabolic switch from oxidative phosphorylation to glycolysis in mouse 
dendritic cells (DC) and splenocytes, is dependent on autocrine IFNγ production (45). 
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We therefore hypothesized that IFNγ might be able to restore glycolysis in tolerant 
monocytes. Firstly, we showed that treating LPS tolerant human monocytes in vitro 
with IFNγ restored lactate production upon stimulation with LPS (Figure 6A), while 
oxygen consumption was not influenced (Figure 6B). The inhibition of the mTOR 
pathway with rapamycin abrogated the effect of IFNγ (Figure 6A). To further assess 
the mTOR pathway in IFNγ therapy, tolerant and non-tolerant (naive) monocytes 
were exposed to IFNγ for 2h, after which the phosphorylation of the mTOR pathway 
was assessed by immunoblot. IFNγ was able to induce phosphorylation of the mTOR 
pathway in both tolerant and non-tolerant monocytes (Figure 6C). Furthermore, in a 
proof of concept trial (10), eight fungal sepsis patients were treated with recombinant 
IFNγ three times a week. Ex-vivo stimulation of isolated PBMCs after subcutaneous 
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Figure 5 – Tolerant monocytes from septic patients show impaired metabolic pathways. (A) Cytokine 
production, as well as lactate and NAD+ synthesis was strongly downregulated in a subgroup of patients 
defined as immunotolerant or displaying immune paralysis, compared to healthy controls and patients 
with normal cytokine responsiveness (‘high responders’) (healthy volunteers = 11, high responders  = 
6, low responders = 5). (B) Tolerant monocytes from septic patients have reduced cytokine production 
upon ex vivo LPS stimulation, as well as reduced lactate and NAD+ production, which are restored upon 
patient recovery (healthy volunteers = 10, patients = 8). (C) Activation of the mTOR targets S6K and 
4EBP1 and fatty acid transporters CD36 and CPT1 are downregulated during sepsis and are restored 
once patients have recovered. The last value for each patient represent the samples after recovery, while 
the other samples are collected during the phase of immune paralysis. (D) Maximal oxygen consumption 
is decreased in PBMCs of sepsis patients (red line) compared with PBMCs from healthy controls (black 
line). basal = basal respiration, leak = proton leak after inhibition of ATP synthase, max = maximal oxygen 
consumption, rox = residual oxygen consumption or non-mitochondrial oxygen consumption (last panel 
are pooled data of the 3 patients). (* p < 0.05, ** p < 0.01, *** p < 0.001, One-way ANOVA).
Chapter 10
  202 | 
administration of recombinant IFNγ showed an increase in lactate production, that 
accompanied the upregulation of cytokine production capacity (10), indicating a 
restoration of the capacity to mount glycolytic responses (Figure 6D). Therefore, 
IFNγ is able to partially restore the metabolic defects in innate immune tolerance by 
promoting glycolysis, which is impaired in immunotolerant monocytes.
DISCUSSION
Collectively, our study supports three main conclusions. Firstly, during an acute 
phase of infection the shift from oxidative phosphorylation to aerobic glycolysis 
(Warburg effect) is an important mechanism of host defense. Secondly, leukocytes 
of patients with severe sepsis display severe defects in cellular energy metabolism 
Figure 6 – Immune therapy with IFNγ partially restores the metabolic defects by induction of the 
mTOR pathway. (A) When LPS-induced tolerant purified monocytes (24h stimulation, 24h rest) were 
treated in vitro with IFNγ in various concentrations, the capacity of the cells to mount aerobic glycolysis 
and respond with lactate release upon LPS stimulation was restored. In addition, lactate production 
restored by 1000 or 100ng/ml IFNγ can be inhibited by rapamycin. (n=6) (B) Tolerant monocytes (24h 
stimulation, 24h) were treated for 3h with PBS, or 1µg/ml IFNγ and oxygen consumption was measured. 
(n=4) (C) Treating tolerant and normal monocytes with 1µg/ml IFNγ for 2h induces phosphorylation of the 
mTOR pathway (n=6). (D) The impaired lactate production can be (partially) restored with recombinant 
IFNγ therapy, when administered s.c three times a week (100 mg). Ex-vivo restimulation of PBMCs for 
24h (with LPS, PHA or C. albicans) from sepsis patients (11) before (day 1=D1) and after (from day 2=D2) 
start of therapy shows that IFNγ partially restores the capacity of cells to release lactate (n=5). (* p < 0.05, 
** p < 0.01, *** p < 0.001, One-way ANOVA, or Wilcoxon signed-rank test).
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that are associated with impaired capacity to respond to secondary stimulation, a 
process that is equivalent to a true ‘immunometabolic paralysis’. Thirdly, therapeutic 
approaches that restore this metabolic defect might represent a novel therapeutic 
approach for the treatment of sepsis.  
 In our experiments, tolerant leukocytes had broad defects in metabolic pathways, 
failing to increase not only glycolysis, but also displaying decreased oxygen 
consumption and lower fatty acid transport. This observation is somewhat unexpected, 
as it shows that leukocytes of sepsis patients not merely reverse glucose metabolism 
from glycolysis to oxidative phosphorylation, but display multiple energy metabolism 
defects. These defects correlated with the loss of cytokine production capacity, which 
were reversed upon recovery. Mitochondrial dysfunction has been previously shown 
to correlate with a poor outcome in sepsis, but these studies mainly focused on non-
hematopoietic cells (46), with only one study reporting defects in leukocytes (8). Here 
we show that the defects comprise several metabolic pathways and correlate with 
immune function. A remaining point of discussion is whether the metabolic defects 
are one of the main causes of the immunological phenotype or whether they are a 
feature of adaptation of the immune cells during infection. However, there are strong 
suggestions that infection and metabolic defects are intertwined for example on the 
one hand we show that inhibition of metabolic pathways influences the immunologic 
response, and on the other it has been shown that IL-10 downregulates glycolysis 
in a murine model (47), suggesting a relation between cytokine production and 
metabolism. Finally, an important aspect regards the cell populations in which these 
metabolic changes occur during sepsis. Our experiments showing the importance 
of regulation of metabolic pathways in innate immune tolerance were performed in 
a whole blood stimulation assay that mimics the interplay of all cells of the immune 
system. Although additional experiments were performed to assess the effects on 
more specific cell populations (monocytes) in vitro, a comprehensive analysis of the 
in-vivo changes in different cell subpopulations in sepsis patients is warranted. 
 An important discussion point is the fact that metformin, used as a modulator 
of metabolic pathways, displays more effects than only activation of AMPK and 
inhibition of the mTOR pathway. We have nevertheless decided to investigate its 
effects due to the broad clinical use, making these experiments relevant from a 
translational perspective. The mTOR inhibitor rapamycin could not be used to study 
cellular metabolism in the live infection model, due to its well-known antifungal effect 
(48). However, our use of more specific mTOR inhibitors in vitro such as torin-1 
and rapamycin validated the mTOR effect on inflammation. Furthermore, a number 
of studies reported that rapamycin inhibits TNFα production suggesting an anti-
inflammatory effect, similar to our observations. In contrast, other studies have shown 
rapamycin to upregulate IL-12 production and downregulate IL-10 production, thus 
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resulting in immunostimulatory effects, as seen for IL-6 in our in-vitro experiments. 
Several hypotheses have been raised to explain these differences, most likely 
the Akt/mTOR/HIF-1α pathway has differential effects on the various cytokines, 
depending on the cell type and stimulus or infection present (49).
 The present study identifies cellular metabolic processes as a potential therapeutic 
target in sepsis. So far only very few agents with known metabolic regulatory capacity 
have been tested in sepsis models. Among them, PPARγ transcription factor 
activation, that is associated with increased glycolysis and fatty acid metabolism 
(50-52), has been shown to have a beneficial effect on mortality in murine sepsis 
models (53-55). Furthermore, several therapeutic agents capable of restoring 
mitochondrial activity have been studied in sepsis rodent models with beneficial 
outcomes (56). In the present study we investigated IFNγ as it has been known to 
upregulate cytokine production in innate immune tolerance (10, 42, 43). Autocrine 
IFNγ production is involved in the mTOR/Hif-1α-dependent metabolic switch from 
oxidative phosphorylation to glycolysis in mouse DCs and splenocytes (45). Indeed, 
our data show that in-vitro exposure of immunotolerant monocytes to IFNγ activates 
the mTOR pathway and partially restores the capacity of leukocytes to mount a 
glycolytic response. These data and our findings differ from a recent report which 
shows the downregulatory capacity on mTORC1, with methodological differences 
and different cell populations as likely causes for this (57). Thus, metabolic and 
immunologic recoveries seem to be correlated, and improved strategies to correct 
the metabolic abnormalities should be considered in patients with sepsis and immune 
paralysis.
 Apart from the IFNγ effects on mTOR, other potential mechanisms might play 
a role as well. Firstly, IFNγ induces sustained occupancy of transcription factors 
STAT1 and IRF1, as well as induces histone acetylation at promoter and enhancer 
sites of pro-inflammatory cytokines (58), and possibly metabolic genes. Secondly, 
miRNA-146 plays an important role in disruption of pro-inflammatory cytokine 
synthesis in innate immune tolerance (59), and IFNγ could potentially influence 
its expression, as shown for other miRNAs (60, 61). Thirdly, restoring metabolism 
pathways by IFNγ could potentially lead to an increase of succinate, an important 
positive regulator of IL-1β production via HIF-1α (62). Finally, sirtuins have been 
shown to play an important role in the regulation of the immunotolerant phenotype 
of monocytes, and inhibition of SIRT1 can restore the immunotolerant (metabolic) 
features of monocytes (41). Promisingly, IFNγ has also been shown to repress the 
expression of SIRT1 in muscle cells (63).
 In conclusion, the switch from oxidative phosphorylation to aerobic glycolysis 
is an important component of the cellular response to infection. Broad defects in 
the energy metabolism of leukocytes comprising both glycolysis and oxidative 
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mechanisms characterize a state of immunometabolic paralysis in patients with 
severe sepsis, and this gives both important new insights in the pathophysiology 
of the disease, and may represent a novel therapeutic target. Immunotherapy with 
recombinant IFNγ is one of the potential approaches to correct these defects.
Accession codes.
GSE65682: MARS sepsis patient samples;
GSE48119: Human endotoxemia model (4ng/kg E. coli LPS);
GSE42606: Healthy volunteer in-vitro stimulation gene expression data.
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ICU patients
Healthy 
subjects 
(n=42)
Fungal sepsis 
(Candida)
(n=13)
Bacterial sep-
sis (E. coli)   
(n=33) p
Demographics
Age, years (IQR) 35 (30-63) 60 (47-66) 67 (56 -74) 0.065a
Gender, % male 57 62 58 1b
Severity and complications
APACHE IV score, median (IQR) - 110 (89-113) 87 (69-102) 0.35a
Septic shock % - 46 49 1b
Comorbities
Diabetes mellitus % - 0 27 0.044b
COPD % - 8 9 1b
Congestive heart failure % - 8 6 1b
Hypertension % - 15 21 1b
Hematological malignancy % - 0 3 1b
Treatment
Mechanical ventilation % - 85 76 0.70b
Outcome
ICU mortality % - 46 15 0.051b
Hospital mortality % - 54 27 0.17b
30 day mortality % - 38 18 0.25b
90 day mortality % - 54 30 0.18b
ICU length of stay, days (IQR) - 22 (8-27) 5 (2-11) 0.0051a
Hospital length of stay, days 
(IQR) - 34 (18-61) 47 (18-72) 0.58
a
Table S1 - Characteristics and demographics. Characteristics and demographics of the MARS 
intensive care unit (ICU) patient cohort with blood culture positive Escherichia coli (E. coli) or Candida 
species and healthy control subjects. Significance in comparisons was demarcated at p < 0.05. COPD, 
chronic obstructive pulmonary disease. APACHE, Acute Physiology and Chronic Health Evaluation. a 
Wilcoxon rank sum test probability; b Fisher’s exact test probability.
Chapter 10
  208 | 
Figure S1 - Gene expression profiles. A. Heatmap representation of multiple-comparison adjusted 
significant glycolysis and mTOR signaling gene expression analysis of healthy human donor PBMC 
samples stimulated for 4h or 24h with (a) C. albicans, and (b) E. coli LPS.
A 
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10Figure S2 - Endotoxin administration in healthy volunteers. Genome-wide blood gene expression analysis in healthy volunteer samples before and 4h after intravenous administration of E. coli LPS. 
(a) Volcano plot representation of gene expression alterations post-LPS (integrating log2 fold changes and 
multiple-comparison adjusted p-values). Red denotes over-expressed genes  (log2 fold change ≥ 1); blue 
denotes under-expression (log2 fold change ≤ -1). Horizontal line depicts multiple comparison adjusted 
p=0.05. (b) Ingenuity canonical signaling pathway enrichment of over-expressed (red) and under-
expressed (blue) genes showing over-expression of prototypical pro-inflammatory and anti-inflammatory 
pathways concomitant with under-expression of predominantly metabolic signaling pathways. Whole 
blood (c) and PBMCs (d) isolated before (pre-LPS) and 4h after in-vivo LPS administration (post-LPS) 
were re-stimulated with RPMI medium or LPS. Supernatants were used to measure the abundance of 
TNFα and IL-6. *** p < 0.0001, ** p < 0.01.
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Figure S3 - Transcription factor analysis. (a, b) HIF1A, EPAS1 (HIF2A), NAMPT, PPARA, PPARG and 
HIF1AN expression in the human endotoxemia model (c) as well as E. coli and Candida sepsis (d). blue, 
under-expression; red, over-expression. (c) Diagrammatic representation of the mTOR signaling pathway 
with gene expression log2 fold changes overlaid (green = under-expressed). (d) Overrepresentation 
analysis of transcription factor binding site motifs showed the mTOR-dependent HIF1A transcription 
factor was predicted as highly active in both E. coli and Candida sepsis. (TF, transcription factor).
Figure S4 - Overview of metabolic states during sepsis. During the acute hyperinflammatory 
phase, immunometabolism is upregulated by means of the Warburg effect (upregulated glycolysis and 
downregulated oxidative phosphorylation), while during the immune paralysis state all major metabolic 
pathways are downregulated; metabolic paralysis.

Chapter 11
Transcriptional and metabolic 
reprogramming induce an inflammatory 
phenotype in non-medullary thyroid 
carcinoma-induced macrophages
Rob J.W. Arts*, Theo S. Plantinga*, Sander Tuit, Thomas Ulas, Bas Heinhuis, 
Marika Tesselaar, Yvette Sloot, Gosse J. Adema, Leo A.B. Joosten, Johannes W.A. 
Smit, Mihai G. Netea, Joachim L. Schultze, Romana T. Netea-Maier.
*These authors have contributed equally
Oncoimmunol 2016;12:e1229725
Chapter 11
  214 | 
ABSTRACT
Tumor associated macrophages (TAMs) are key components of the tumor 
microenvironment in non-medullary thyroid cancer (TC), the most common 
endocrine malignancy. However, little is known regarding the regulation of their 
function in TC. Transcriptome analysis in a model of TC-induced macrophages 
identified increased inflammatory characteristics and rewiring of cell metabolism 
as key functional changes. This functional reprogramming was partly mediated by 
TC-derived lactate that induced upregulation of cytokine production through an Akt/
mTOR-dependent increase in aerobic glycolysis. This led to epigenetic modifications 
at the level of histone methylation, and subsequently long-term functional changes. 
Immunohistochemistry assessment validated the increase in glycolysis enzymes 
and lactate receptor in TAMs in tissue samples from patients with TC. In conclusion, 
Akt/mTOR-dependent glycolysis mediates TC-induced reprogramming of TAMs and 
inflammation, and this may represent a novel therapeutic target in TC.
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Tumor associated macrophages (TAMs) and cancer cells have an important 
mutual relationship: on the one hand the tumor modulates the function of infiltrating 
macrophages, and thus contributes to reprogramming of TAMs, while on the other 
hand TAMs influence the behavior of cancer cells (1). Theoretically, macrophages 
have the potential to play an effective role in elimination of tumor cells; however, 
there are also important lines of evidence that TAMs promote cancer cell survival, 
proliferation, metastases, angiogenesis and immune suppression (2).  The impact 
of TAMs on tumor progression very likely depends on their specific reprogramming 
within the tumor, a process influenced by factors of the local microenvironment such 
as hypoxia, release of local mediators (e.g. cytokines, growth factors), as well as 
metabolic products released by either the cancer cells and/or other immune and 
stroma cells (1-4). The pathways and mechanisms involved in the reprogramming 
of TAMs are incompletely understood and in the present study we aimed to 
investigate the phenotypic and functional characteristics of TAMs in a model of 
non-medullary thyroid cancer (TC). TC is the most common endocrine malignant 
tumor and of all cancer types has the highest rise in incidence (5). Previous studies 
have shown that particularly anaplastic and poorly differentiated TCs, which have 
a very poor prognosis, are highly infiltrated with TAMs and that this correlates with 
prognosis. In these tumors TAMs represent the most prominent component of the 
tumor microenvironment (6, 7). Pharmacological depletion of TAMs using CSF-1R 
inhibition in a murine model of TC has been reported to reduce tumor development 
and progression (8). These data suggest that TAMs have protumorigenic effects in 
TC and might represent promising therapeutic targets for tumors that are resistant 
to conventional treatment. Nevertheless, little is known about the role of the TAMs in 
TC and on the factors driving the functional reprograming the macrophages within 
the context of TC. To this end, we used a complementary approach that combines a 
discovery-based methodology on transcriptome analysis of human monocytes that 
have been co-cultured with TC cells and differentiated into TC-induced macrophages 
to reveal essential pathways in specific reprogramming of these macrophages, 
with immunological, metabolic and genetic approaches to validate the pathways 
identified. We show that TC-induced macrophages are characterized by important 
immunological and metabolic rewiring that impacts their function and that these 
metabolic changes are being recapitulated in the TAMs in tissue samples from 
patients with TC. These findings may help the identification of novel therapeutic 
approaches for TC and potentially for other malignant processes as well.
MATERIALS AND METHODS
Co-culture model of TC cell lines and human monocytes - The TC cell line in-
vitro experiments were performed using TPC1 (papillary, RET/ PTC rearrangement), 
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BC-PAP (papillary, BRAF V600E mutation), and FTC133 (follicular, PTEN deficient) 
cell lines (9). The human glioblastoma cell lines U87 and U251 were kindly provided 
by Prof. G.J. Adema and drs P. Gielen, Radboud umc Nijmegen.  Peripheral blood 
mononuclear cells were isolated by density gradient centrifugation using Ficoll-
plaque (GE Healthcare, Diegem Belgium) from buffy coats (Sanquin bloodbank, 
Nijmegen, The Netherlands), or healthy volunteers after informed consent (ethical 
approval CMO 2010-104). After adhesion for 1h in the 96-well plates, the non-
adherent cells comprising mainly lymphocytes were discarded, and the adherent 
monocytes were incubated further with the tumor cell lines. In selected experiments 
such as those assessing cell transcriptome, an additional step of purification using 
CD14-labelled magnetic beads was performed in order to obtain a highly purified 
monocyte population.
 The cancer cell lines were grown in culture medium RPMI-1640 Dutch 
modification (Life Technologies, Carlsbad, California, USA) supplemented with 
gentamycin 50µg/ml, glutamax 2mM, pyruvate 1mM, and 10% Fetal Calf Serum 
(Gibco, Life Technologies). A trans-well system used ThinCertTM cell culture inserts 
on a 24-well plate (Greiner Bio-One GmbH, Austria). Cell counts were performed 
in a Coulter particle counter (Beckman Coulter Inc.). A total of 1x10^5 TPC1 cells 
(or the other TC cell lines, as indicated) in 250µl culture medium were added to the 
upper compartment of the trans-well system, while RPMI was added to the lower 
compartment. The cells were incubated for 24h at 37°C, 5% CO2. Next, the cells 
were washed with PBS and PBMCs were prepared in culture medium: RPMI  (Life 
Technologies, Carlsbad, California, USA) supplemented with glucose 5mM, pyruvate 
1mM, glutamine 2mM, gentamicin 50µg/mL and HEPES 10mM (Life Technologies, 
Carlsbad, California, USA).  A total of 1x10^6 PBMCs in 500µl were added to the 
lower compartment of the trans-well system. PBMCs and cancer cell lines were 
co-cultured for 24h at 37°C. In some experiments the mTOR inhibitor rapamycin 
(100nM, Bio Connect, Huissen, The Netherlands), glutaminase inhibitor BPTES 
(50µM, Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands), G6PD inhibitor 
6-aminonicotinamide (100nM, Sigma), CPT-1 inhibitor etomoxir (10µM, Sigma), 
ATP synthase inhibitor oligomycin (1µM, Sigma), 500µM 5’-deoxy-5’(methylthio) 
adenosine (MTA, sigma), lactate receptor antagonist α-cyano-4-hydrocycinnamioic 
acid (1mM, Sigma) or VEGF receptor antagonist Sorafenib (100nM, Bio Connect) 
were added to the medium.  
 After 24h incubation, the cell culture inserts containing RPMI control medium or 
TPC1 cells were discarded and the PBMCs were stimulated for 24h with RPMI or 
10ng/ml LPS (E. coli strain O55:B5, Sigma Chemical Co, St. Louis, MO), as substitute 
for endogenous TLR4 ligand signaling, 10µg/ml Pam3Cys (EMC microcollection) or 
10ng/ml IL-1α (Hoffman/Roche). At the end of the incubation period, supernatant 
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was collected and stored at -20oC until further analysis, or cells were collected for 
further analysis.
RNA isolation followed by deep sequencing - Total RNA was extracted from 
24h TPC1 co-cultured macrophages and 24h RPMI cultured monocyte controls (4 
donors) after 4h and 24h of additional incubation in RPMI only, using RNeasy Mini 
and Microkits (Qiagen). 50ng of RNA was converted into cDNA libraries according 
to the TruSeq RNA library preparation kit v2 and libraries were sequenced on the 
HiSeq 1500 system and demultiplexed using CASAVA v1.8 (Illumina).  Detail of the 
further analysis can be found in the Supplementary data. The detailed data have 
been deposited in the GEO database with accession number GSE76445. 
Cytokine, chemokine, VEGF and lactate production - IL-6, IL-8 (Sanquin, 
Amsterdam, Netherlands), TNFα (R&D, the Netherlands) concentrations in the 
culture supernatant were measured by commercial ELISA kits according to the 
instruction of the manufacturer. Granulocyte macrophage colony-stimulating factor 
(GM-CSF), monocyte chemotactic protein 1 (MCP-1), and vascular endothelial 
growth factor (VEGF, all Bio-rad, Veenendaal, the Netherlands) were measured by 
Magpix (Luminex Corporation). Lactate was measured by a Lactate Fluorometric 
Assay Kit (Biovision, CA, USA).
Metabolic assays using the Seahorse system - TC-induced macrophages were 
cultured as described above and after 24h detached with Versene (ThermoFisher 
Scientific) from the culture plates. 1x10^5 cells in triplicate were plated onto overnight-
calibrated cartridges in assay medium (RPMI with 0.6mM glutamine, pH adjusted to 
7.4. For OCR also 5mM glucose and 1mM pyruvate was added) and incubated 
for 1h in a non-CO2 corrected incubator at 37
oC. Oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) were analysed using a cell mito stress 
(OCR) or glycolysis stress test (ECAR) kit in a XFp analyser (Seahorse bioscience, 
Copenhagen, Denmark) with final concentrations of 1μM oligomycin, 1μM FCCP, 
0,5μM Rotenone/Antimycin A, 10mM glucose, and 50mM 2-DG.
Western blot assessments - TC-induced macrophages were cultured as described 
above and lysed after 24h being relieved from the tumor cells. Total protein amounts 
were determined by BCA assay (Thermo Fisher Scientific) and equal amounts of 
proteins were loaded on pre-casted 4-15% gels (Biorad, CA, USA). The separated 
proteins were transferred to a nitrocellulose membrane (Biorad), which was blocked 
in 5% BSA (Sigma). Incubation overnight at 4°C with rabbit polyclonal antibodies 
against p-S6K, p-4EBP1, p-mTOR (Cell Signaling, Danvers, MA, USA), and actin 
(Sigma) were used to determine the protein expression, which was visualized using 
a polyclonal secondary antibody (Dako, Belgium) and SuperSignal West Femto 
Substrate (Thermo Fisher Scientific) or ECL (Biorad).
Chromatin immunoprecipitation (ChIP) - Cells were isolated and cultured 
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as described above. After being relieved 24h from the TPC1 cells, TC-induced 
macrophages were detached from the plate with 500μl Trypsin per well and fixed 
in methanol-free 1% formaldehyde and stored at 4oC until further processing. Fixed 
cells were sonicated for 10min in a Bioruptor pico sonicator (Diagenode, Seraing, 
Belgium). Immunoprecipitation was performed using antibodies against H3K4me3 
and H3K9me3 (Diagenode, Seraing, Belgium). After ChIP, DNA was processed 
further for qPCR analysis using the SYBR green method. Samples were analyzed 
by a comparative Ct method. Primer sequences can be found in Table S1.
Immunohistochemistry - Glycolytic enzymes third human isoform of 
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and pyruvate kinase 2 
(PFKFB3, PKM2), lactate receptor GPR81 and CD68 protein expression was 
evaluated by immunohistochemical staining of formalin-fixed paraffin-embedded 
(FFPE) TC tissue sections. To remove the paraffin, tissues were incubated twice 
in xylene and successively in 100%, 96% and 70% of alcohol for 5min each step. 
Antigens were retrieved with citrate buffer for 2min in the microwave (800 W) and 
10min at RT (Citrate buffer: pH=6.0, 16.4ml sodium citrate (0.1 M) with 3.6ml citric 
acid (0.1M) in 180ml H2O). The endogenous peroxidase activity was blocked with 
3% of H2O2 in methanol for 15min at RT. Furthermore, since tumor-like tissues 
contain endogenous biotin, this was blocked in the tissue sections by an avidin/
biotin blocking kit according to the manufacturers’ protocol (Vector Laboratories, 
CA, USA). Sections were incubated with 20% goat serum diluted in PBS for 10min 
and subsequently with the first antibody (PFKFB3 (ab96699, Abcam, 1:100), PKM2 
(3198, Cell Signalling, 1:100), GPR81 (ab188647, Abcam, 1:50), CD68 (KP1, DAKO, 
1:8000) all diluted in PBS supplemented with 5% goat/rabbit serum, overnight at 4°C. 
After washing with PBS, sections were incubated with a second HRP-conjugated 
antibody 1:200 diluted in PBS for 1h at RT. The ABC-HRP complex (ABCkit-HRP 
Vector PK-6101), 1:500 diluted in PBS, was applied to the sections for 30 minutes 
at RT. The substrate solution was added for 7min at RT: 0.5 ml of DAB in 9.5 ml of 
PBS and 10μl of H2O2. Tissues were counterstained with haematoxylin for 30s at RT. 
Slides were dehydrated with consecutive incubation in 70%, 96%, 100% of alcohol 
and xylene (two times) for 5’ each step. Sections were mounted in Permount.
Statistical analysis - Differences in cytokine, lactate, VEGF production, trimetylation, 
and phosphorylation were analyzed using Wilcoxon signed-rank test. All analyses 
were performed in Graphpad prism 5 (CA, USA). * p < 0.05, ** p < 0.01. Data are 
shown as means ± SEM. Information on additional statistical analyses can be found 
in the supplementary experimental procedures.
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RESULTS
Transcriptome analysis: inflammatory and metabolic rewiring in TC-induced 
human macrophages
To enable a detailed analysis of the effect of TC cells on monocyte reprogramming, 
we generated genome-wide transcriptome data by RNA sequencing of TC-induced 
macrophages and RPMI cultured control monocytes (24h of culture), both of which 
were relieved for either 4h or 24h in RPMI after co-culture with the tumor cells (TPC1 
cell line). We performed an extensive bioinformatics analysis as outlined in (Figure 
1A). A total of 13,047 transcripts were identified as present throughout 4 conditions 
represented by 16 samples. Employing a two-way ANOVA model (Table S1), we 
identified 372 (4h) and 353 (24h) genes being differentially expressed between 
TC-induced macrophages and RPMI controls (Figure S1A). Next we visualized the 
degree of variance between TPC1 co-cultured monocytes and control cells at both 
time points by performing hierarchical clustering (HC) based on the top 1000 variable 
genes (Figure 1B). HC revealed that TPC1 co-cultured monocytes exert significant 
transcriptomic changes compared to control monocytes. Moreover, there was also 
a clear difference in gene expression between monocytes co-cultured with TPC1 for 
4h respectively 24h, suggesting that the observed changes are dynamic. To validate 
these findings, we applied co-regulation analysis (CRA) and visualized the gene 
network of the top 500 variable genes within the data (Figure 1C). The topology of 
the network was defined by two major clusters (C1, C2), with cluster C1 showing 
a clear substructure (C1a, C1b). Overlaying differentially regulated genes onto the 
network revealed that the cluster C1a represented genes increased in expression 
in monocytes co-cultured with TPC1 at the 4h time point, while C1b was associated 
with genes elevated at the 24h time point. Additionally, employing Self-Organizing 
Map (SOM) clustering to identify and visualize conditions-specific genes within the 
network (Figure S1B), we were able to validate the condition-specific sub-networks. 
Together, these data support a model suggesting transcriptional programming of 
monocytes by TPC1 tumor cells in a dynamic fashion. To investigate the biological 
relevance of the observed transcriptomic changes in both 4h and 24h TC-induced 
macrophages, we applied Gene Set Enrichment Analysis (GSEA) using two well-
established pathway gene sets (10). Computing enrichment for hallmark pathways 
(Figure 1D), ‘PI3K/Akt/mTOR’ and ‘fatty acid metabolism’ pathways were enriched 
at the 4h time point. In contrast, the TPC1 co-cultured monocytes taken at the 24h 
time point showed enrichment of “interferon gamma response” and “angiogenesis” 
related pathways. Using reactome pathways to compute enrichment, we detected 
even more inflammation-related pathways to be enriched at the 24h time point 
(e.g. inflammasome activation, TLR responses, interferon signaling, etc) (Figure 
S1C, Table S2). It is known that cellular metabolism of macrophages is crucial for 
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Figure 1 - Transcriptome analysis of TC-induced macrophages. (A) Scheme outlining the experimental 
setup (upper scheme) and bioinformatics analysis (lower scheme). (B) HC map of the top 1000 variable 
genes between TC-induced macrophages and RPMI controls. (C) Network visualization of gene-centered 
CRA (Pearson correlation ≥ 0.7). FC over mean of all conditions is mapped onto the network for TC-
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inflammatory function, with a shift from oxidative phosphorylation towards mTOR-
dependent aerobic glycolysis playing a central role (11, 12). Therefore, we extracted 
the gene sets from PI3K/Akt/mTOR- and glycolysis-related pathways (both hallmark 
and reactome) and mapped them onto the CRA network (Figure 1E). Indeed 16 of 
23 genes were found in cluster C1 (Figure 1E) and were elevated at the 4h (12/16) 
and 24h (10/16) time points, respectively (Table S3). To determine whether potential 
transcriptional regulators (TR) of mTOR-dependent aerobic glycolysis might also 
be part of the network, we mapped TR information onto the CRA network (Figure 
S1D). Surprisingly, 23 TRs were downregulated (cluster C2) in TPC1 co-cultured 
monocytes, while only 7 TRs were upregulated. Indeed, among the upregulated 
transcription factors we identified hypoxia-inducible factor-1 alpha (HIF-1A, orange 
node), which was previously shown to be involved in mTOR-dependent aerobic 
glycolysis (11) in cluster C1a. RelA, a NF-kB transactivating subunit that has been 
shown to counteract reprogramming to aerobic glycolysis (13) was found to be 
downregulated in TPC1 co-cultured monocytes. Moreover, the reactome pathway 
“NF-kB is activated and signals survival” was found to be depleted in TPC1 co-
cultured monocytes at the 4h time point (Figure S1C).  We next validated the findings 
for the 24h time point employing Gene Ontology Enrichment Analysis (GOEA) on 
genes elevated in TPC1 co-cultured monocytes (fold change (FC) over mean: ≥ 1, 
present in the CRA network). Network visualization of enriched GO-Terms revealed 
terms related to ‘immune cell proliferation’ and ‘activation of innate immune response’ 
(Figure 1F) further supporting reprogramming of monocytes at the later time points 
towards immune activation. Taken together, our data analysis supported a model 
of transcriptional regulation of genes involved in mTOR-dependent glycolysis early 
after exposure to TC cells, while further reprogramming towards an inflammatory 
response was seen at the later time point. 
TC-induced macrophages are reprogrammed by the secretome of TC cells
Transcriptome analysis suggested a pro-inflammatory profile of TC-induced 
macrophages. We aimed to validate this finding by functional assessments: human 
primary monocytes were co-incubated in a trans-well system with the three types 
of TC cell lines (TPC1, FTC133 and BC-PAP) for 24h, followed by restimulation for 
induced macrophages (4h, left network; 24h, right network). (D) Volcano plots of normalized enrichment 
scores (NES) and enrichment p-values based on GSEA using Hallmark pathway gene sets (MSigDB, 
Broad Institute). Data are shown for TPC1 co-cultured macrophages (4h and 24h). Dark (NES ≥ 1; p 
value ≤ 0.05) and light (NES ≥ 1; p value > 0.05, ≤ 0.1) red circles show gene sets positively enriched. 
Dark and light blue circles show gene sets depleted (NES ≤ -1). (E) Hallmark and reactome pathway 
genes (MSigDB, Broad institute) related to PI3K/Akt/mTOR and glycolysis mapped onto the CRA network 
(orange nodes). (F) Network visualization of GOEA of genes derived from the “TPC1 co-cultured (24h) vs. 
mean all conditions” comparison (FC: ≥ 1; present in CRA network) using BiNGO and EnrichmentMap. 
Red nodes represent the enriched GO-terms, node size and color represents corresponding FDR-
adjusted enrichment p-values (p-value: 0.05 ≤).
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Figure 2 – TC-induced macrophages have a pro-
inflammatory phenotype. (A) Outline of the culturing 
methods. (B) Monocytes were incubated for 24h with 
TC cells in a trans-well system and restimulated with 
LPS for 24h. (n=7). (C) TAMs derived from coculture 
with TPC1 and two glioblastoma cell lines were 
restimulated with LPS for 24h. (n=4). (D) Medium from 
three thyroid cell lines was added to human monocytes 
for 24h and subsequently stimulated with RPMI or 
LPS for 24h. (n=4). (E,F) Lactate and VEGF were 
determined in naive macrophage and tumor medium. (n=6). (G) A lactate receptor antagonist was added 
to the culture system. (Mean ± SEM, n=5, * p < 0.05, by Wilcoxon signed-rank test). (H) Monocytes were 
incubated with 1µM of lactic acid for 24h and restimulated with LPS for 24h. (n=8). (* p < 0.05, ** p < 0.01 
by Wilcoxon signed-rank test).
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24h with either culture medium (RPMI), or Toll-like receptor (TLR) ligands (TLR4 
ligand lipopolysaccharide (LPS), TLR2 ligand (Pam3CKS4 (P3C), or IL-1α) (Figure 
2A). The production of TNFα and IL-6 by TC-induced macrophages was significantly 
increased compared to the control naive macrophages (Figure 2B, S2A). Production 
of IL-10 and IL-1β was low and in most conditions below detection limit. Additional 
experiments using TPC1-induced macrophages showed also increased IL-8 
production, whereas no differences in granulocyte macrophage colony-stimulating 
factor (GM-CSF), monocyte chemotactic protein 1 (MCP1) were found (Figure 
S2B). Co-culture of human monocytes with two glioblastoma cell lines showed less 
strongly upregulated cytokine production upon restimulation, suggesting a degree of 
specificity for the effect of the TC cell lines (Figure 2C). 
 The identification of the pro-inflammatory profile induced by TC cells in monocytes 
lead to the hypothesis that soluble factors released by TC cells impact on the 
differentiation of these monocytes into macrophages with a specific phenotype. To 
reveal whether a soluble factor in the medium produced by the cancer cells was 
responsible for the upregulated cytokine production, medium from TC cell line cultures 
was added to human monocytes for 24h, after which cells were restimulated with 
LPS. In line with previous experiments, this increased production of cytokines from 
macrophages as well (Figure 2D). Two factors known to be released by tumor cells 
and which have immunologic effects are vascular epithelial growth factor (VEGF) 
and lactate, the end-metabolite of glycolysis. Indeed, both VEGF (Figure 2E) and 
lactate (Figure 2F) concentrations were significantly increased in TC conditioned 
media. In order to determine whether lactate or VEGF could serve as soluble factors 
that are necessary for the specific reprogramming of the TC-induced macrophages, 
antagonists of the cellular receptors for these molecules were added to the culture 
system. Blockade of lactate receptor significantly reduced cytokine release by TC-
induced macrophages, while blockade of the VEGF receptor had no effects on 
cytokine release (Figure 2G, S3). These data suggest that TC cell-derived lactate 
contributed to the induction of the inflammatory profile of TC-induced macrophages. 
In line with this, preincubation for 24h with 1µM of lactate also increased cytokine 
production upon TLR stimulation (Figure 2H). 
TC-induced macrophages display increased glucose metabolism that is ne-
cessary for increased cytokine production 
Transcriptome analysis of TC-induced macrophages also revealed that several 
metabolic pathways were upregulated at transcriptional level. We, and others have 
shown that cellular metabolism of macrophages is crucial for their inflammatory 
function, with a shift from oxidative phosphorylation towards mTOR-dependent 
aerobic glycolysis (Warburg effect) playing a central role (11, 12). To investigate the 
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activation of glycolysis and oxidative phosphorylation in TC-induced macrophages, 
extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of TC-
induced macrophages (before restimulation by TLR engagement) were measured 
by Seahorse technology. Interestingly, maximal ECAR was increased in TC-induced 
macrophages and OCR was increased at both basal and maximal level (Figure 3A). 
The intracellular concentration of acetyl CoA was increased, which could be used 
both to fuel the TCA cycle and for fatty acid synthesis. The glutamate concentration 
was decreased, likely caused by the replenishment of the TCA cycle through 
glutamine metabolism (Figure S4). These data demonstrate strong activation of 
metabolic activity in the TC-induced macrophages.
 To assess which of the metabolic pathways is essential in the upregulation of 
cytokine production, specific metabolic pathways were inhibited and cytokine 
production was assessed. Inhibition of the pentose phosphate pathway 
(6-aminonicotinamide, 6-AN), glutamine metabolism (BPTES), β-oxidation of fatty 
acids (etomoxir), or the electron transport chain complex V (oligomycin) did not 
influence cytokine production. However, exposure to mTOR inhibitor rapamycin 
significantly decreased IL-6 production by TC-induced macrophages, demonstrating 
a role for mTOR/glycolysis pathway in this process (Figure 3B, S5). This was further 
supported by assessing phosphorylation of mTOR and its downstream products 
(S6K and 4EBP1) in TC-induced macrophages before restimulation. Indeed, we 
observed enhanced activation of this pathway in TC-induced macrophages (Figure 
3C).
 In order to validate activation of glycolysis in TC-derived TAMs in patients with 
TC, formalin-fixed paraffin-embedded (FFPE) tissue sections of six thyroid tumors 
were immunohistochemically prepared and TAMs were stained by CD68 staining. 
To investigate the extent of glycolysis in these TAMs, expression of the third human 
isoform of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and pyruvate 
kinase 2 (PFKFB3, PKM2), and the lactate receptor GRP81 were determined. Both 
these key enzymes of glycolysis and the expression of the lactate receptor were 
highly upregulated in at least 80% of CD68-positive TC-associated macrophages 
present in these tissues. (Figure 3D, S6A). In contrast, virtually no macrophages 
could be detected in normal thyroid tissues from the same individuals (Figure S6B). 
TC-induced macrophages undergo epigenetic reprogramming regulated by 
the mTOR pathway
In the following set of experiments, we wanted to assess whether TC cell-macrophage 
co-incubation induced a stable inflammatory phenotype over time. To assess this, 
after the initial preincubation with TPC1 cells, the TC-induced macrophages were 
left in culture medium for an additional 24h before restimulation (Figure 4A). The 
Reprogramming of TAMs
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Figure 3 – Metabolism of TC-induced macrophages is changed. (A) Extracellular acidification rate 
(ECAR) and oxygen consumption rate (OCR) from TC-induced macrophages and naive macrophages 
were determined after TC-induced macrophages were relieved for 24h from the TPC1 cells. (n=4) (B) 
Inhibitors of mTOR (rapamycin), pentose phosphate pathway (6-AN), glutamine metabolism (BPTES), 
fatty acid β oxidation (etomoxir) and complex V ATP synthase (oligomycin) were added to the culture 
system and cells were restimulated for 24h with LPS. (n=4). (C) Monocytes were incubated for 24h with 
TPC1 cells, after 24h rest cells were lysed and p-mTOR, p-S6K, and p-4EBP1 induction were determined. 
(D) Immunohistochemical analysis of PFKFB3, PKM2 and GPR81 in CD68-positive TAMs. Results are 
representative of stained FFPE tissue material from six anaplastic TC patients. (* p < 0.05, by Wilcoxon 
signed-rank test).
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restimulation with LPS showed that the cytokine production was still upregulated 
in the TC-induced macrophages even if they were relieved from the TPC1 cells, 
demonstrating a long-term stable phenotype (Figure 4B). This suggests a putative 
epigenetic rewiring of the transcriptional program, as shown in other types of long-
term functional reprogramming of macrophages for example during trained immunity 
(11). In order to test this hypothesis, a broad histone methylation inhibitor (MTA) 
was added during the first 24h of co-culture. This brought cytokine production back 
to baseline (Figure 4C), showing that histone methylation plays an important role in 
the specific reprogramming of TC-induced macrophages. H3K4me3 is an important 
histone marker of open (accessible) promoters shown to be associated with high 
cytokine production (14). To assess whether increased H3K4me3 plays a role in 
the long-term inflammatory phenotype of TC-associated macrophages, monocytes 
were preincubated for 24h with TPC1 cells, after which the tumor cells were removed 
and the macrophages were incubated for an additional 24h in culture medium. 
Chromatin immunoprecipitation was performed to determine the H3K4me3 status 
of the promoters of IL6 and TNFA in TC-induced macrophages. Indeed, a significant 
increase of H3K4me3 was observed in the TC-induced macrophages.  
 Additionally, when rapamycin was added to the culture medium, the increase 
of H3K4me3 was abolished, which corresponded to the observed decrease of IL-6 
after mTOR inhibition with rapamycin (Figure 4D). This suggested that the induction 
of the mTOR-dependent pathway plays an important role for long-term epigenetic 
reprogramming of TC-induced macrophages. H3K9me3 is a histone mark that 
induces heterochromatin and therefore decreases DNA accessibility (14), which was 
also found to be important in trained immunity (15). A potential role of H3K9me3 was 
assessed, but no significant downregulation of H3K9me3 was found after co-culture 
with TPC1 tumor cells (Figure 4E). 
DISCUSSION
The process through which monocytes infiltrate tumors, differentiate into TAMs, and 
influence the immune responses towards the malignant cells is believed to play 
a crucial role in carcinogenesis. TC is the most common endocrine malignancy, 
and TAMs have been shown to be strongly present in the tumor and impact the 
prognosis (6, 7). However, despite this, very little is known about the phenotype of 
TAMs in TC and the pathways that influence macrophage differentiation in TC. In the 
present study we initiated transcriptome analysis of TC-induced macrophages, and 
we demonstrate that soluble factors released by TC (among which lactate) induce 
a strong inflammatory phenotype and a rewiring of the cellular metabolism of TC-
induced macrophages. Activation of mTOR-dependent glycolysis induced long-term 
epigenetic histone modifications (especially H3K4me3) and upregulated cytokine 
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Figure 4 – The pro-inflammatory phenotype is epigenetically regulated. (A) Outline of the culturing 
methods. (B) Monocytes were coincubated with thyroid tumor cell lines for 24h. After 1 day additional rest 
they were restimulated with LPS for 24h. (n=5). (C) MTA, an inhibitor of histone methylation was added to 
the culture system and cells were restimulated for 24h with LPS. (n=6). (D,E) Monocytes were incubated 
for 24h with TPC1 cells, after 24h rest DNA was isolated to determine H3K4me3 (D) and H3K9me3 (E) 
expression at the promoter site of IL6 and TNFA. (n=6, n=5). (* p < 0.05 by Wilcoxon signed-rank test).
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production. The role of the lactate-glycolysis-inflammation circuit for TC was also 
further supported in patients through immunohistological and genetic approaches.
 The assessment of the transcriptome of the TC-induced macrophages identified 
complex circuits of immunological and metabolic pathways. One of the strongest 
sets of cellular functions highly upregulated in the TC-induced macrophages were 
those related to inflammation. Pathways related to pattern-recognition receptors, 
chemokine synthesis and cytokine-cytokine receptor interaction were upregulated, 
suggesting a strong inflammatory phenotype of the cells. This was validated by 
experiments demonstrating that macrophages differentiated in the presence of 
TC cell lines displayed much stronger inflammatory function upon stimulation. An 
inflammatory phenotype has been demonstrated to characterize TAMs in many 
tumors (16), and inflammation stimulates carcinogenesis through multiple pathways: 
excretion of epidermal growth factor, pro-angiogenic signals such as VEGF and 
fibroblast growth factor 2, several pro-inflammatory cytokines and chemokines, and 
factors such as matrix-degrading enzymes, metalloproteinases, cysteine cathepsin 
proteases and heparanases all contribute to a tumor-promoting environment (17, 
18). These data strongly suggest that TAM-derived inflammation has an important 
impact on TC development. Indeed, it has been previously shown that the presence 
of inflammatory mediators in TC, including cytokines such as IL-1β and TNFα, 
negatively influence the expression of sodium iodine symporter, the major protein 
responsible for the uptake of radioactive iodide in thyroid cells which represents the 
main targeted therapy for patients with TC (19). Also processes that limit inflammation 
such as autophagy are defective in TC (20, 21). In addition to TAMs, also the function 
of regulatory T-cells has been shown to be dependent on glycolysis, as the induction 
of their suppressive function was tightly dependent on mTOR-induced glycolysis 
(22). This is especially interesting as more aggressive forms of TC are associated 
with increased numbers of regulatory T-cells in peripheral blood (23) and TAMs 
are able to induce regulatory T-cells (24, 25). The interaction and balance between 
the pro-inflammatory macrophages and inhibitory regulatory T-cells, whose activity 
is both dependent on glycolysis, might therefore be an interesting topic for future 
research.
 In addition to the inflammatory pathways induced by TC in TAMs, a second 
important set of biological processes strongly modulated were the metabolic 
pathways, with strong upregulation of the mTOR signaling pathway, carbohydrate 
digestion, but also fatty acid and pyrimidine biosynthesis. Changes in cellular 
metabolism, and especially a shift towards aerobic glycolysis through mTOR-
dependent mechanisms, have been recently demonstrated to be crucial for the 
activation of macrophages (11, 12). Moreover, inflammatory (M(IFNγ), formely M1) 
macrophage metabolism is associated with an increased glucose consumption 
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11and lactate production, whereas the more anti-inflammatory (M(IL4), formally M2) 
macrophages depend preferentially on oxidative phosphorylation. On the other 
hand, M(IL-4) macrophages typically express more arginase, which is necessary 
in amino acid metabolism (26, 27) and M(IL-4) macrophages also show more fatty 
acid uptake and β-oxidation compared to M(IFNγ) macrophages (28). Interestingly, 
the transcriptome and functional phenotype of TC-induced macrophages did not 
display a clear M(IFNγ) or M(IL-4) phenotype, with both pathway characteristics of 
M(IFNγ) (inflammation, glycolysis) and M(IL-4) (oxidative phosphorylation) being 
upregulated. 
 Interestingly, when we compared our results to the transcriptome of a panel of 
29 different macrophage profiles as reported by Xue et al. (29), the transcriptional 
Lactate  
Other tumor-derived  
factors 
	
Tumor	cell	survival	and	prolifera2on	
Lactate	 TNFα	 IL-6	
Figure 5 – Soluble tumor-derived signals change the phenotype of the tumor-associated 
macrophage, by induction of the mTOR pathway and glycolysis, and epigenetic changes.
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program of 4h TC-induced macrophages was defined by gene modules associated 
with macrophage stimulation by fatty acids (linoleic, oleic, lauric acid), LPS or a 
combination of TNFα, prostaglandin E2 and Pam2Cys (TPP). The transcriptional 
program of 24h TC-induced macrophages was mainly described by IL-4 defined gene 
modules in combination with an inflammatory gene module linked to stimulation with 
palmitic acid (PA) (Figure S1E). Therefore, this mixed gene signature in TC-induced 
macrophages cannot be considered as an archetypical M2 macrophage. We thus 
propose that the functional program induced by TC in TAMs is distinct and combines 
elements from both M(IL-4) macrophages, and inflammatory characteristics. In 
addition to IL-4, another important anti-inflammatory cytokine is IL-37, which could 
be especially relevant due to its capacity to inhibit the Akt/mTOR pathway (30, 31). 
While no IL-37 expression could be found in the TC-induced macrophages, future 
studies should investigate it in in-vivo samples from TC patients. 
 One of the most relevant findings of metabolic pathways activated in TC-
induced macrophages is mTOR-dependent glycolysis. Indeed, we demonstrate an 
essential role for the Akt/mTOR pathway for the inflammatory phenotype of the TC-
induced macrophages and this could represent an important therapeutic target. In 
TAMs induced by other tumors it has been shown that lactic acid produced by the 
cancer cells is essential for TAM reprogramming, by induction of the transcription 
factor HIF-1α (3), and a similar dependency on lactate release was observed for 
the cytokines released in our system. As HIF-1α activation is highly dependent on 
mTOR activation, our observation that HIF-1α is one of the main TFs in TC-induced 
macrophages fits with this picture. Interestingly, inhibiting mTOR with rapamycin 
abolished IL-6 upregulation induced by TC cells, while TNFα production was not 
affected. In addition, mTOR inhibition was accompanied by downregulation of the 
histone marks associated with open chromatin and increased transcription. 
 This role of the mTOR pathway provides a link between cellular metabolism and 
epigenetic programming of gene transcription. The field of metabolo-epigenomics 
is an emerging field within immunology (32), with important roles demonstrated 
for various metabolites (especially of glycolysis and TCA cycle) in modulating 
epigenetic processes. For examples, acetyl-CoA influences histone acetylation by 
functioning as a substrate for histone acetylation, succinate and fumarate inhibit 
histone demethylases, and NAD+ induces histone deacetylation through activation 
of sirtuins (32-34). Recently, the rate of glycolysis was directly associated with the 
acetylation of specific histone sites, which appeared to be mostly dependent on 
acetyl-CoA levels (35). We show an upregulation of glycolysis, and an increased 
intracellular concentration of acetyl Co-A in TC-induced macrophages. Moreover, 
glycolysis has been shown to be a source (together with folic acid and methionine) 
for S-adenosylmethionine (SAM), which serves as a methyl donor for histone and 
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DNA methylation (33). This is especially interesting because of increased TCA cycle 
metabolism and oxidative phosphorylation in TC-induced macrophages. All in all, 
these data strongly suggest that the metabolic rewiring induced in macrophages 
by TC-derived compounds (such as lactate) induces epigenetic reprogramming 
(as demonstrated by enhanced H3K4me3), which in turn results in increased gene 
transcription of inflammatory mediators (see scheme Figure 5). We hypothesize that 
this enhanced inflammation will in turn influence tumor progression and outcome.
In addition to glycolysis, other metabolic pathways were also modulated in TC-induced 
macrophages. Interestingly, inhibition of glutamine metabolism that can contribute to 
replenishment of the TCA cycle did not reduce cytokine production in TAMs, but 
showed a tendency toward increased cytokine production. This is an interesting 
observation, which has not been further investigated, but should be addressed in 
future research. In addition, fatty acid synthesis was very strongly increased in TC-
induced macrophages: although an effect on inflammation and cytokine production 
was not observed, this may very well impact other aspects of tumor and macrophage 
biology such as cell survival and proliferation.
 Our observation that reprogramming of tumor stroma cells (in our case TAMs) is 
associated with changes in metabolism is reminiscent of a process termed “reverse 
Warburg effect” (36, 37). In this process it has been suggested that cancer cells 
reprogram metabolism of tumor stroma cells toward aerobic glycolysis (Warburg 
effect), and this will result in fuel for mitochondrial metabolism (e.g. lactate and 
ketones), which is beneficial for tumor growth and survival. Using oxidative 
phosphorylation instead of glycolysis reduces the speed of cell aging and is therefore 
beneficial for tumor cell survival, growth and metastasis (37). Whether these changes 
are a result of local reprogramming of myeloid cells in the tumor microenvironment 
or whether soluble factors excreted by the tumor (stroma) already reprogram 
circulating monocytes, or even the myeloid precursors in the bone marrow, remains 
unanswered and should be investigated in future studies. 
 In conclusion, we show that TC-induced macrophages display broad changes in 
cellular metabolism and have an increased inflammatory profile. Reprogramming of 
the TC-induced macrophages is dependent on activation of the Akt/mTOR pathway, 
which is also essential for reshaping the epigenetic landscape. 
Digital versions of Tables S1-3 can be obtained by sending a request to the author.
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Supplementary experimental procedures
Preprocessing of sequenced data 
All reads were aligned against the human hg19 reference genome by TopHat2 
v2.0.11 (1) using default parameters. The data was imported into Partek Genomics 
Suite v6.6 (PGS) to deduct gene and transcript information before performing 
normalization using statistical software R (v3.0.2) and the DESeq2 package (http://
dx.doi.org/10.1101/002832). Normalized read counts were floored to a value of at 
least 1 after correcting for donor introduced variance. Subsequent to flooring, the 
dataset was trimmed by defining a gene as expressed if the maximum value over all 
group means was higher than 10.  
Identification of differentially expressed genes 
To calculate the top variable genes (TPC1 vs. RPMI) and differentially expressed 
(DE) genes within the dataset between TC-induced macrophages and RPMI controls 
(4h and 24h) a two-way Analysis Of Variance (ANOVA) was performed using PGS. 
Genes were defined to be DE when having a fold change (FC) of ≥ 1.5 and an 
unadjusted p-value of ≤ 0.05. Based on the ANOVA model, Hierarchical clustering 
(HC) was performed on the top 1000 variable genes within the dataset (TPC1 vs. 
RPMI) using default settings in PGS to observe the transcriptome similarity between 
the samples on a more detailed level.  
Gene set enrichment analysis 
Gene Set Enrichment Analysis (GSEA) was performed by PGS using 10,000 
permutations utilizing the hallmark and reactome pathway gene-sets (http://software.
broadinstitute.org/gsea/msigdb/index.jsp) to find enriched pathways in TPC1 co-
cultured macrophages (4h and 24h, compared to RPMI controls). To identify to which 
polarization state the TC-induced macrophages relate the most, GSEA was also 
performed utilizing 49 gene sets reflecting a continuum of macrophages activation-
states (2). All GSEA results were visualized by volcano plots. 
Generation of a co-regulation network based on the DE genes among condi-
tions 
In order to identify similarities between gene expression throughout all conditions 
(n=16), we employed co-regulation analysis (CRA) based on Pearson correlation 
coefficients (≥ 0.70) by using BioLayout Express3D (3) on the top 500 variable genes 
within the dataset (TPC1 vs. RPMI). For visualization purposes, the obtained network 
was imported in Cytoscape (http://www.cytoscape.org/). To identify subnetworks 
specific for the conditions within the dataset, the FC over mean of all conditions 
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was computed for each condition and subsequently mapped onto the CRA network. 
As validation to this approach, using the mean expression values, Self-Organizing 
Map (SOM) clustering (map height: 10 by 10) was performed in PGS to identify 
condition specificity of genes. To validate GSEA results, all PI3K/Akt/mTOR- and 
glycolysis-related gene lists were extracted from hallmark and reactome pathway 
gene sets (http://software.broadinstitute.org/gsea/msigdb/index.jsp). These genes 
were subsequently mapped onto the CRA network to identify condition specificity for 
these pathways. Transcriptional regulators within the dataset were identified using a 
TF list (4) and subsequently mapped onto the CRA network.  
Gene ontology enrichment analysis and GO network visualization 
To link condition-specific genes to prior knowledge, we applied Gene Ontology 
Enrichment Analysis (GOEA) on a gene set specific (FC condition vs. mean all 
conditions: ≥ 1; present in CRA network) for the TPC1 co-cultured macrophages (24h). 
Subsequently, to visualize the data we employed the BiNGO (5), EnrichmentMap 
(6), and Word Clouding (7) plug-ins in Cytoscape.  
Forward Reverse
MYO (positive control 
H3K4me3) AGCATGGTGCCACTGTGCT GGCTTAATCTCTGCCTCATGAT
H2B (negative control 
H3K4me3) TGTACTTGGTGACGGCCTTA CATTACAACAAGCGCTCGAC
TNFA GTGCTTGTTCCTCAGCCTCT ATCACTCCAAAGTGCAGCAG
IL6 AGGGAGAGCCAGAACACAGA GAGTTTCCTCTGACTCCATCG
ZFN274_3UTR 
(positive control 
H3K9me3)
AAGCACTTTGACAACCGTGA GGAGGAATTTTGTGGAGCAA
GAPDH (negative 
control H3K9me3) CACCGTCAAGGCTGAGAACG ATACCCAAGGGAGCCACACC
Table S1 - Primer sequences for ChIP experiments
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Figure S1. Transcriptome analysis of TC-induced macrophages. (A) Scheme outlining DE gene 
numbers derived from various comparisons. Arrow indicates direction of differential expression 
(upregulated, red; downregulated, blue; FC ≥ 1.5, unadjusted p-value ≤ 0.05). (B) For each gene within 
the dataset, condition specificity is computed applying SOM clustering and subsequently mapped onto 
the CRA network. (C) Volcano plots of normalized enrichment scores (NES) and enrichment p-values 
based on GSEA using reactome pathway gene sets (MSigDB, Broad Institute). Data are shown for TPC1 
co-cultured macrophages (4h and 24h). Dark (NES ≥ 1; p value ≤ 0.05) and light (NES ≥ 1; p value > 
0.05, ≤ 0.1) red circles show gene sets positively enriched. Dark and light blue circles show gene sets 
depleted (NES ≤ -1). (D) Transcriptional regulators are mapped onto the CRA network (yellow and orange 
node(s)). (E) Volcano plots of normalized enrichment scores (NES) and enrichment p-values based on 
GSEA using stimuli-specific gene sets (2). Data are shown for TPC1 co-cultured macrophages (4h and 
24h). Red circles (NES ≥ 1; p value ≤ 0.05) show gene sets positively enriched. Blue circles show gene 
sets depleted (NES ≤ -1).
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Figure S2. TC-induced macrophages have a pro-inflammatory phenotype. (A) Monocytes were 
incubated for 24h with thyroid cancer cell lines in a trans-well system and restimuled with RPMI, P3C 
or IL-1α for 24h. (B) In the LPS restimulated TC-induced macrophages, also IL-8, MCP-1 and GM-CSF 
concentrations were measured in the culture medium.
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Figure S3. A VEGF antagonist does not reduce the pro-inflammatory 
phenotype. A VEGF receptor antagonist was added to the culture system 
during coculture with TPC1 tumor cells. After 24h coculture, macropaghes 
were restimulated with LPS and TNFα and IL-6 production was determined 
in the supernatants.
Figure S4. Intracellular Acetyl CoA and glutamate.  Monocytes were 
incubated for 24h with TPC1 thyroid cancer cells in a trans-well system. After 
being relieved from the TPC1 cells for 24h, macrophages were lysed and 
intracellular concentrations of Acetyl CoA and glutamate were determined.
Figure S5. Inhibition of metabolic 
pathways, TNFα  results. Monocytes were 
incubated for 24h with TPC1 thyroid cancer 
cells in a trans-well system with or without 
inhibitors of mTOR (rapamycin), the pentose 
phosphate pathway (6-AN), glutamine 
metabolism (BPTES), β-oxidation of fatty 
acids (etomoxir), or the electron transport 
chain complex V (oligomycin). After being 
relieved from the TPC1 cells and inhibitors for 
24h, were restimulated with LPS and TNFα 
production was determined.
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CD68	(400x)	 PFKFB3	(400x)	
CD68 (400x) GPR81 (400x) 
CD68 (400x) PFKFB3 (400x) 
Figure S6.  Metabolism of 
TC-induced macrophages is 
changed.  
(A) Immunohistochemical 
analysis of PFKFB3, PKM2 and 
GPR81 and their colocalization 
with CD68 positive TAMs in 
differentiated TC. Results 
are representative of stained 
FFPE tissue material derived 
from five patients. (B) 
Immunohistochemical analysis 
CD68 positive macrophages in 
healthy thyroid tissue. Hardly any 
positively stained cells can be 
found. 200x magnification.
A
B
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ABSTRACT
The classical view that only adaptive immunity can build immunological memory has 
recently been challenged. Both in organisms lacking adaptive immunity as well as in 
mammals, the innate immune system can adapt to mount an increased resistance 
to reinfection, a de facto innate immune memory, termed trained immunity. Recent 
studies have revealed that rewiring of cellular metabolism induced by different 
immunological signals is a crucial step for determining the epigenetic changes 
underlying trained immunity. Processes such as a shift of glucose metabolism from 
oxidative phosphorylation to aerobic glycolysis, increased glutamine metabolism 
and cholesterol synthesis, play a crucial role in these processes. The discovery of 
trained immunity opens the door for the design of novel generations of vaccines, for 
new therapeutic strategies for the treatment of immune deficiency states, and for 
modulation of exaggerated inflammation in autoinflammatory diseases.
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Classically, the immune system can be divided into innate and adaptive immunity, 
with monocytes, macrophages, neutrophils, and NK-cells as the main cellular 
effectors of innate immune responses, while T- and B-lymphocytes mediate adaptive 
immunity. Until recently it was assumed only the adaptive immune system possesses 
the capacity to mount a memory response and therefore improve the immunological 
reaction to a second infection. However, an increasing amount of evidence 
accumulates, suggesting that also the innate immune system possesses adaptive 
characteristics. In plants and non-vertebrates, both lacking an adaptive immune 
system, it has already been know for several decades that a memory response 
could be build that would protect from a secondary infection (1, 2). Interestingly, this 
improved secondary response is not always strictly specific, as infection with one 
pathogen can sometimes also protect from infections with non-related pathogens 
(3). This process has been shown to be epigenetically regulated (4). In retrospect, 
this (non-specific) memory, mediated by the innate immune system, was also seen 
in mice strains with known deficiencies in adaptive immune responses (3, 5). 
 More recently, this same process of innate immune memory was also been shown 
to occur in human monocytes and macrophages. β-glucan, a major component of the 
C. albicans cell wall, was shown to ex vivo enhance cytokine production to a second 
unrelated stimulus, a process that was also epigenetically regulated (6, 7). Also in 
mice, an in-vivo challenge with β-glucan protected from subsequent C. albicans or S. 
aureus infection (6, 8), and infection with cytomegalovirus induced improved effector 
function of NK-cells after the infection (9). In humans, vaccination with Bacillus 
Calmette-Guérin (BCG) showed non-specific protection from all-cause mortality, 
mainly a result of reduced mortality from infections, in low-weight birth children in 
West-Africa (10, 11). In a vaccination study in healthy adult volunteers, BCG markedly 
increased ex-vivo cytokine responses by inducing epigenetic reprogramming in 
myeloid cells (12). These studies demonstrate that the innate immune system can 
adapt after a previous challenge through functional and epigenetic reprogramming, 
a process that has been termed trained immunity or innate immune memory (13, 14). 
On the one hand, trained immunity is likely an important host defense mechanism 
contributing to the maturation of the innate immune system of infants and mediating 
protection after certain infections or vaccinations. On the other hand, when induced 
inappropriately by endogenous stimuli, trained immunity may play a role in the 
pathogenesis of autoinflammatory and/or autoimmune diseases (14, 15). Therefore, 
better understanding of the molecular mechanisms of trained immunity is crucial for 
developing new ways of immunotherapy and targeting inflammatory disorders (14). 
 In the last years an increasing amount of evidence has been accumulated in 
support of the concept that cellular metabolism is correlated with the functional 
state of immune cells (16). Some of the first observations reported that different 
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subsets of lymphocytes had distinctly different cellular metabolic states. Activated 
T-lymphocytes have high rates of both glycolysis and oxidative phosphorylation 
(OxPhos) and metabolize glucose to lactate (17, 18), whereas memory T-lymphocytes 
are more dependent on lipid synthesis via mitochondrial citrate production. These 
lipids can be used to produce triacyglycerides (TAGs) which are being degraded by 
β-oxidation to fuel OxPhos via acetyl-CoA production (19). In contrast, regulatory 
T-cells fuel β-oxidation and OxPhos through exogenously derived fatty acids (20). 
This shows that the phenotype of lymphocytes highly correlates with the source of 
energy that they use (21, 22). Subsequent studies showed that different phenotypes 
of macrophages retrieve energy from very distinct metabolic pathways: the more 
inflammatory (M(IFNγ) or formerly M1) macrophages depend largely on glycolysis 
and show impaired OxPhos and disruption of the tricarboxylic acid (TCA) cycle (23, 
24), while in the more anti-inflammatory (M(IL-4) or formerly M2) macrophages the 
TCA cycle is intact as they rely on OxPhos (25, 26) and furthermore show increased 
β-oxidation as a result of fatty acid uptake (27).
 In this review we will focus on the metabolic pathways induced by innate immune 
training. We will discuss glycolysis, TCA cycle, glutamine, and cholesterol metabolism 
and discuss their (potential) effect on epigenetics and how these clues could be used 
as therapeutic targets. 
METABOLIC PATHWAYS IN TRAINED IMMUNITY
Glycolysis
A metabolic switch from oxidative phosphorylation to glycolysis resulting in more 
lactate production has been described in the highly metabolically active cancer 
cells already in the beginning of the last century by Otto Warburg, thus called the 
‘Warburg effect’ (28). Glycolysis is often increased during immune cell activation: 
activated T-cells show increased rates of glycolysis (17, 18) and pro-inflammatory 
macrophages increase glucose metabolism resulting in increased lactate production 
(24). This switch is assumed to be important as glycolysis, although being less 
efficient in generating adenosine triphosphate (ATP), can be upregulated multiple 
folds and therefore results in a faster production of ATP compared to OxPhos (28). 
 A similar switch is seen in β-glucan trained monocytes (29) (Figure 1). 
Transcriptional and epigenetic (H3K4me3 and H3K27ac) analysis of β-glucan 
induced trained immunity in monocytes revealed that genes in the mTOR signaling 
pathway and several metabolic pathways, especially glycolysis, were highly induced 
(7, 29). When human monocytes are stimulated in vitro with β-glucan for 24h and 
let to rest for 6 subsequent days, the amounts of glucose consumption and lactate 
production increased over time. In contrast, oxygen consumption 6 days after 
β-glucan training is significantly decreased compared to control macrophages (29). 
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These effects of β-glucan-induced training were mediated by activation of the Akt/
mTOR/HIF-1α pathway. Inhibiting this pathway at several levels, or making use of 
myeloid cell specific Hif-1α knockout mice, abrogated induction of trained immunity 
both at cytokine and epigenetic level (29) (Figure 1).
 Induction of glycolysis results in higher ratios of NAD+/NADH ratio, which was 
also the case in β-glucan trained monocytes/macrophages (29). In LPS stimulated 
monocytes the vast increase in NAD+/NADH ratio has been shown to activate 
sirtuin 1 and 6, supporting a switch from a pro-inflammatory state with high rates 
of glycolysis to a more anti-inflammatory state with increased fatty acid oxidation 
(30). Interestingly, in β-glucan trained monocytes, sirtuin 1 expression appeared to 
be decreased and activation of sirtuin 1 by resveratrol inhibited training (29). This 
suggests that decreased expression of sirtuin 1 might play a role in the significant 
increase of H3K27ac induced by monocyte training by β-glucan. However, apart from 
the classical role as histone deacetylases, sirtuins were also shown to deacetylate 
nonhistone structutes, such as NF-κB or HIF-1α (31), and this should be taken into 
consideration too. Moreover, lactate, the end product of anaerobic glycolysis, is also 
able to inhibit histone deacetylase (HDAC) activity and therefore cause increased 
gene accessibility (32).
 In addition to its direct role in energy production, induction of glycolysis might also 
play a role in posttranslational modification of effector molecules. Glyceraldehyde 
3-phosphate dehydrogenase (gapdh), one of the enzymes in glycolysis can bind 
Glucose 
TCA 
Pyruvate Lactate 
OxPhos 
Glucose 
TCA 
Pyruvate Lactate 
OxPhos 
A B 
mTOR 
Hif1α 
Non-trained macrophage Trained macrophage 
Figure 1 - Glucose metabolism in trained immunity. Induction of trained immunity by β-glucan 
causes activation of the mTOR pathway, by signalling via the dectin-1 receptor, which results in HIF-1α 
activity. HIF-1α is a central regulating transcription factor of for example glycolysis-related genes. This, 
therefore, results in an upregulation of glycolysis. Pyruvate, the end product of glycolysis, can be used to 
either fuel the TCA cycle to produce NADH or FADH2, metabolic components that could be used in the 
electron transport chain for oxidative phosphorylation (OxPhos). However, in β-glucan trained monocytes 
pyruvate is converted into lactate, a reaction, although less efficient than OxPhos, that results in more ATP 
production, as it can be upregulated to a great extent.
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the 3’ UTR of ifng RNA and therefore decreasing ifnγ production. In activated T-cells 
gapdh is used in glycolysis and therefore more ifnγ can be produced. Also decreasing 
gapdh expression by RNA interference increased ifnγ production (33). A similar 
mechanism has been reported in murine and human monocytes and macrophages 
in relation to TNFA mRNA induction. GADPH can posttranscriptionally repress TNFA 
mRNA in monocytes in low glycolysis state, e.g. immunotolerant monocytes as seen 
in sepsis (34) (Figure 2). Whether reversal of such effects plays a role in trained 
immunity remains to be elucidated.
Tricarboxylic acid cycle 
A crucial pathway of energy metabolism in the cell is represented by the TCA cycle, 
leading to oxidation of various substrates, including pyruvate coming from glycolysis. 
After induction of trained immunity by β-glucan, trained macrophages display a 
decreased basal and maximum oxygen consumption, suggestive for a decrease 
in use of OxPhos (29). However, although OxPhos is decreased, the TCA cycle is 
not completely shut down, with concentrations of several metabolites in the TCA 
cycle such as citrate, succinate and fumarate being increased compared to non-
trained macrophages. Increased citrate concentrations might serve as a source 
for fatty acid synthesis, as citrate was shown to inhibit glycolysis and TCA cycle 
metabolism, whereas gluconeogenesis and lipid and sterol synthesis were induced 
(35-41). Citrate can either be produced from glycolysis via pyruvate, or it can be 
derived from other metabolites, such as glutamine, which can be converted into 
α-ketoglutarate and enter the TCA cycle (35, 42). The latter pathway is especially 
important in conditions where the mTORC1 pathway is active which results in HIF-
1α induction (e.g. trained immunity) (43), as HIF-1α inhibits pyruvate dehydrogenase 
(PDH) and therefore carbon incorporation of glycolysis into the TCA cycle (43, 44) 
(Figure 2). When citrate is being used as a source for lipid or sterol synthesis, it first 
should be transported from the mitochondrion into the cytosol by the citrate carrier 
(CIC) where it can be converted into acetyl-CoA by ATP citrate lyase (45) (Figure 2). 
Acetyl-CoA is a acetyl donor for histone acetylation (a histone mark that facilitates 
transcription) (46). Moreover, it has been shown that acetyl-CoA derived from both 
glycolysis and glutamine induces histone acetylation of genes of glycolytic enzymes, 
such as hexokinase 2, phosphofructokinase, and lactate dehydrogenase (LDH) 
(47), therefore promoting glycolysis. Inhibition of, or mutations in, CIC limit histone 
acetylation, showing the importance of citrate in histone acetylation (48).
 Succinate and fumarate concentrations are also higher in β-glucan trained 
monocytes and macrophages and both have been shown to play an important role 
in inflammation (49). Accumulation of succinate and fumarate has been shown to 
have a stabilizing effect on HIF-1α (by inhibiting Prolyl hydroxylases), and thus 
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12lead to an increase in glycolysis and IL-1β transcription (23, 50, 51). Apart from the 
effect on HIF-1α, succinate also signals through the succinate receptor, which in 
dendritic cells results in intracellular calcium mobilization and synergism with Toll-
like receptor 3 (TLR3) and TLR7 and promote their activity (52, 53). Succinate also 
results in succinylation of several proteins, e.g. GAPDH, malate dehydrogenase, 
LDH and the glutamate carrier 1. However, how this posttranslational modification 
affects the activity of these proteins remains to be elucidated (23). Lastly, succinate 
and fumarate can act as an antagonist of histone and DNA demethylases. Lysine 
TCA cycle 
Glucose 
Pyruvate 
Acetyl-CoA 
Hexokinase 
GAPDH 
PKM 
Lactate LDH 
Oxaloacetic 
acid 
Citrate 
α-ketoglutarate 
Succinate 
Fumarate 
Malate 
Malate 
Malate  
aspartate 
shuttle 
NADP 
NADPH 
Glutamate 
Glutamine 
GABA 
CIC 
Citrate 
Acetyl-CoA 
NADP 
NADPH 
Cholesterol 
NAD NADH 
NAD 
NADH 
PDH 
NAD 
NADH 
Aspartate 
Malate 
Mitochondrial cytosol  
shuttle 
Enzymatic reaction(s) 
Reduction/oxidation Mitochondrium 
Cytoplasm 
Glutamate 
Figure 2 - Overview of the complex metabolic pathways that could play a role in trained immunity. 
Induction of glycolysis resulting in lactate production is one of the central hall marks in trained immunity 
metabolism. However, also glutamine metabolism, which fuels the TCA cycle is essential, just as 
accumulation of certain TCA cycle metabolites, such as fumarate. Aspartate consumption from the medium 
is also increased in trained monocytes and macrophages. Lastly, the cholesterol synthesis pathway 
appears to be an essential metabolic pathway as well, as at transcription level it is greatly induced, 
and inhibiting this pathway by statins inhibits the induction of trained immunity. Several metabolites 
that accumulate in trained monocytes and macrophages could play a role in the induction of epigenetic 
modulators, such as succinate and fumarate for antagonizing histone or DNA demethylation and acetyl-
CoA as an essential substrate for acetylating processes. Further research to determine the exact role of 
these pathways in trained immunity and also their effects on epigenetics is warranted.
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demethylases (KDMs) of the JmjC family need α-ketoglutarate as a cofactor for 
the demethylation process (54) and succinate and fumarate are known to serve as 
antagonizing factors (54, 55). For fumarate it has also been shown that it can inhibit 
activity of KDM5 demethylases (12, 56).
 2-hydroxyglutarate concentrations are also higher in trained monocytes, and 
this also has antagonizing effects on α-ketoglutarate-dependent demethylases (57). 
Hence, 2-hydroxyglutarate could also serve as an additional factor in modulating 
epigenetic marks induced by β-glucan. 
FUTURE DIRECTIONS TO STUDY TRAINED IMMUNITY
Glutamine metabolism
The metabolite glutamine has been shown to be an essential source of succinate 
and fumarate by glutamine anaplerosis and the GABA shunt (23), and also for citrate 
via the reverse TCA cycle route (35). It should therefore also be determined whether 
glutamine metabolism is an important component of trained immunity as well (Figure 
2). In addition, other effects of glutamine metabolism may influence cell activation 
during trained immunity. Firstly, glutamate could be used for ATP production, as well 
as NADPH by conversion of cytosolic malate to pyruvate. Therefore, mitochondrial 
malate needs to be transported into the cytosol by the malate shuttle. In addition, 
cytosolic pyruvate could also be used to maintain the NADH redox balance by 
conversion to lactate. Secondly, glutamate could be used to produce acetyl CoA, 
which acts as a substrate for histone acetyltransferases (58); notably, H3K27Ac is 
an important histone mark accompanying active promoters in trained monocytes 
(7). Thirdly, in a glioblastoma cell line, glutamine has been shown to contribute to 
the production of cholesterol and fatty acids, two pathways that were significantly 
upregulated in trained monocytes (7, 59). Glutamine enters the TCA cycle via 
α-ketoglutarate or succinate and is metabolized to citrate (or goes in the reverse 
direction (60)) that can be converted into cytosolic acetyl CoA, which can be used 
as a direct fuel for cholesterol and fatty acid synthesis. Fourthly, glutamine could be 
used to produce malate, which can be used for fueling the malate-aspartate shuttle. 
In this way the reducing equivalents of mitochondrial NADH can be transported 
to the cytoplasm for NADPH production, where it might serve as a cofactor in the 
cholesterol synthesis pathway, which is highly induced in β-glucan-induced trained 
immunity (Figure 2). Finally, inhibition of glutamine uptake in breast cancer cell 
lines has been strongly correlated with reduction of H3K4me3 of essential genes, 
modulated by reduced expression of the methyltransferases SETD1 and ASH2L 
(61).
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Aspartate metabolism
When consumption of amino acids from the medium of non-trained and β-glucan-
trained human macrophages was compared, consumption of aspartate was shown 
to be highly induced in trained macrophages. Metabolism of aspartic acid serves 
several roles, as it is part of the urea cycle, gluconeogenesis, and the malate-
aspartate shuttle, it is important for inosine formation in purine metabolism, and 
is a precursor for several amino acids, including methionine (62). Aspartate could 
therefore contribute in several ways to the induction of trained immunity. Firstly, 
aspartate might act by upregulating the malate-aspartate shuttle, which would 
result in a transition of the reducing equivalents of mitochondrial NADH to NADPH 
production in the cytoplasm, where it might serve as an essential metabolite for 
upregulated cholesterol synthesis (Figure 2). Secondly, aspartate might serve as fuel 
for purine production, which is upregulated in β-glucan-trained cells via the penthose 
phosphate pathway (PPP) (63). Thirdly, aspartate can be used as a source, via 
transamination of oxaloacetic acid, which together with acetyl-CoA forms citrate 
(35) (Figure 2). Finally, aspartate might serve for the production of essential amino 
acids such as methionine, which also serves, just as other metabolic pathways, 
such as folate and choline metabolism, as an essential cofactor for DNA and histone 
methyltransferases (64, 65).
Cholesterol synthesis
Analysis of transcriptome data of β-glucan trained macrophages revealed that 
also the cholesterol synthesis pathway was also highly induced (7, 59). How the 
cholesterol synthesis pathway contributes to the phenotype of trained immunity is 
still to be elucidated. However, a plausible hypothesis for this effect is that cholesterol 
remodels the cell membrane of trained cells, which could mediate increased 
signal transduction upon restimulation, for example by disrupting cholesterol and 
sphingolipid raft formation (66). 
FUTURE DIRECTIONS TO TARGET DISEASE
Immunometabolism is a field that has gained more interest the last several years, 
and has been shown to be involved in immune activation in several diseases such 
as infections (67, 68), autoinflammatory disorders and cardiovascular diseases 
(69). Moreover, in post-sepsis immunoparalysis, we have shown that the cellular 
metabolism of monocytes had broad defects and that reversing these defects 
could at least partially restore the immunological function of these cells (8, 70). 
Therefore, modulation of cellular metabolism has great potential as a therapeutic 
in immune-mediated diseases. In autoinflammatory diseases, atherosclerosis or 
insulin resistance and diabetes in which monocytes and macrophages are thought 
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to be skewed towards a pro-inflammatory profile, inhibition of certain metabolic 
pathways may represent a valid approach to target disease activity (14, 69, 71-74). 
Moreover, the role played by cellular metabolic pathways for the induction of trained 
immunity may also represent a novel therapeutic approach in immunodeficiencies. 
Induction of metabolic pathways important for trained immunity should be attempted 
to restore immune function during sepsis-induced immunoparalysis. In addition, 
these approaches could also be used to improve the immune responsiveness in 
vulnerable groups such as elderly and infants that have decreased immune function 
and are more prone to infectious diseases (75, 76). 
 In conclusion, boosting or inhibiting the innate immune system has several 
potential beneficial effects in different kinds of medical settings and modulating 
cellular metabolism of immune cells is a promising new approach to reach this goal.
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Trained innate immunity, a de facto memory of the innate immune system, has gained 
attention over the last years as an important immunological process. Especially as 
its implications appear to reach further than generally was thought on first hand. 
 In the present thesis I addressed two main topics. In the first part of this thesis 
the non-specific effects of the BCG vaccine were determined and discussed. Here 
I show the underlying molecular mechanisms for the induction of trained immunity 
by BCG, just as its immunomodulatory potential, which could have important 
implications for management of infectious diseases, immunodeficiency disorders 
and vaccination strategies. We furthermore advocate that this is not just true for 
BCG but holds for other vaccines and potentially vitamine A supplementation too. In 
the second part of this thesis I focus on the metabolic changes that occur through 
the induction of trained immunity. Metabolic changes are well known to correlate 
with cellular function in other cell types. We now show that this is also true for trained 
and tolerant monocytes and macrophages. This gives an important insight in new 
potential treatment strategies for immunological disorders.
 This final chapter addresses the main findings of this thesis, puts them in context 
with other literature, describes the potential implications of these findings, and finally 
points out future research challenges. 
BCG and trained immunity
The hypothesis that BCG is able to induce non-specific protective effects started 
with the observation that vaccination of neonates in developing countries with a 
high infectious disease burden resulted in lower mortality from other infectious 
diseases than tuberculosis (1). This shows a non-specific adaptation (memory) of 
the immune system. This non-specific memory could hypothetically be the result 
of two mechanisms: (a) trained immunity that concerns the innate host defenses, 
or (b) cross-reactivity of T-lymphocytes, a process termed ‘heterologous immunity’ 
that is mostly attributed to T-cell cross reactivity (2). Heterologous immunity has 
been especially well described in viral infections, but in mice it has also been shown 
that vaccination with BCG can protect against infection with vaccinia virus through 
a mechanism dependent on T-cell receptor signaling and IFNγ production of CD4 
cells (3). Furthermore, via a different mechanism, CD4 and CD8 memory cells could 
be activated in an antigen-independent manner, and they can therefore boost both 
Th1 and Th17 responses upon secondary non-related infections (4-9). Also, BCG 
vaccination has been shown to enhance the antibody titer and T-cell responses to 
other vaccines such as hepatitis B, polio and pneumococcal conjugate vaccination 
(10, 11).
 Next to the non-specific effects on the adaptive immune system, the effect of BCG 
on the innate immune system has been studied in several models. A mouse study 
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showed that BCG/PPD-activated macrophages were able to produce more H2O2 
and were better capable in killing Candida albicans (12). In an experimental model 
in hamsters, BCG vaccination increased the lytic activity of peritoneal macrophages 
against herpes simplex infected cells (13). Also severe combine immunodeficiency 
(SCID) mice that lack functional lymphocytes showed an increased survival from 
Candida sepsis and less fungal outgrowth after BCG vaccination, with spleen 
monocytes producing more TNFα upon ex-vivo restimulation (14). BCG vaccinated 
B-cell deficient mice were as effectively protected from Schistosoma mansoni 
infection as the wild type controls (15). Administration of muramyldipeptide (MDP), 
which is a component of mycobacterial cells walls, resulted in protection against 
infection with vaccinia virus and herpes simplex virus in mice, and this effect was 
mediated by peritoneal macrophages and was independent of IFNγ (16). 
 Important non-specific beneficial effects of BCG were also observed in humans. 
BCG vaccination was shown to induce potentiation of the activity of NK-cells (17, 
18), just as in mice where the protective effect of BCG vaccination on disseminated 
candidiasis was partially dependent on NK-cells (17). Compared to cord blood 
monocytes from unvaccinated neonates, cells from vaccinated infants showed 
increased expression of granulysin and perforin upon stimulation (19). The ration 
between M1 versus M2 macrophages is modulated and appeared to correlate with 
the risk of cancer recurrence after intravesical BCG therapy, which supports an 
important role of innate immune cells for the non-specific effects of BCG in bladder 
cancer (20). Also an increase in antimicrobial peptide production in infants vaccinated 
with OPV and BCG was observed in stool samples (21).
 In a first human proof-of-principle vaccination trial, these non-specific effects 
could at least partially be attributed to the innate immune system, by showing that 
BCG vaccination led to higher production of innate cytokines up to three months 
after vaccination when PBMCs were stimulated with BCG-related and non-related 
ligands. This was accompanied by an increase of the activation markers CD11b, 
TLR4 and CD14 on monocytes. The increased cytokine production was a result of 
higher mRNA expression, which was accompanied by epigenetic modulation, in this 
case increased H3K4me3 at IL6 and TNFA promoters of monocytes (14). 
 Given the promising results of this trial, more studies on the non-specific effects 
of the BCG vaccine were performed. In a trial in Guinea Bissau with 467 low birth-
weight newborns, ex-vivo cytokine production was upregulated upon stimulation 
with several TLR agonists (22), showing that trained immunity can also be elicited 
in newborns. Furthermore, the boosting effect of BCG on other vaccines was 
determined in a trial were it was shown that BCG is able to enhance antibody 
induction of influenza strains (23). 
 Interestingly, BCG revaccination of two-year-old children in Guinea Bissau resulted 
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in lower TNFα and higher IL-10 responses to LPS, PHA and PPD (24). This effect 
might be dependent on T-regulatory cells induction by the second BCG vaccination, 
as it was shown that mice that were presensitized with mycobacteria developed 
more Treg induction and higher IL-10 response upon subsequent vaccination with 
BCG (25).
 The studies presented in the first part of this thesis were designed to contribute 
to better understand these non-specific effects of BCG vaccination. 
 Chapter 2 and 3 directly aim for a clinically relevant application of trained 
immunity induced by BCG. BCG vaccination would be very suitable in situations 
in which patients suffer from immunodeficiencies and could be boosted by BCG. 
Examples that could be thought of are immunoparalysis after sepsis, HIV infection, 
or inherited immunodeficiencies. However, the presence of an immunodeficiency 
is a contraindication for BCG administration, as the microorganism may cause 
disseminated disease. Hence, we assessed the potential of a γ-irradiated BCG 
vaccine (γBCG, which thus contains inactivated, but intact M. bovis) to induce 
trained immunity. In the in-vitro culture system γBCG was able to induce trained 
immunity, both at the level of increased cytokine responses upon restimulation, 
as on the epigenetic level. This gave the incentive to continue with two trials to 
further elucidate the potential induction of trained immunity by γBCG in vivo. In a 
first trial, presented in chapter 2, fifteen healthy volunteers were vaccinated with 
γBCG. 2 Weeks and 3 months later, blood was drawn and PBMCs were ex vivo 
stimulated with several stimuli to assess the induction of non-specific memory. 
However, in contrast to the in-vitro experiments, vaccination with γBCG increased 
only heterologous T-cell responses, but did not enhance the production of monocyte-
derived pro-inflammatory cytokines. In a second trial that was performed at the same 
time, healthy volunteers were vaccinated with γBCG or placebo and five days later 
the subjects were hospitalized and received an intravenous injection of LPS. Main 
outcome measures were clinical parameters and in-vivo cytokine production: also 
in this trial no differences were found between the placebo and γBCG vaccinated 
group. 
 Hence, from these two studies it can be concluded that γBCG is not capable of 
inducing trained immunity in vivo and it is unlikely that it can be used as immunotherapy 
in immunodeficient patients. Several considerations have to be taken into account 
while interpreting these results. One question that remains unanswered is whether 
γBCG could induce trained immunity in immunocompromised patients. It could be 
hypothesized that the effect of γBCG is smaller compared to BCG (that replicates 
at the site of vaccination) and is therefore not capable of inducing an enhanced 
function of myeloid cells in healthy volunteers, but it might still be able to do so in 
immunocompromised subjects (e.g. post-sepsis immunotolerant patients). Also the 
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idea of repeated γBCG vaccinations to improve γBCG stimulation, which happens 
with normal BCG by replication of the bacterium at the site of vaccination, could be 
a way to induce better innate immune training. 
 In Chapter 4 I addressed a clinically important question for the effectiveness of 
BCG vaccination. WHO recommends high-dose vitamin A supplementation (VAS) 
in countries at risk of vitamin A deficiency (26). However, some studies have noted 
interactions between VAS and routine vaccinations, just as potential effects of VAS 
itself (27, 28). We therefore assessed the long-term effects of vitamin A in our in-
vitro system and showed that incubation of monocytes with vitamin A resulted in 
an immunotolerant phenotype. Moreover, addition of vitamin A to BCG training of 
monocytes decreased the induction of trained immunity in vitro. We furthermore 
found that this effect of vitamin A is the result of increased H3K9me3 (a repressive 
histone mark) at the promoters of pro-inflammatory genes. Interestingly, also BCG-
induced trained immunity is regulated by H3K9me3, which is decreased at the 
promoter sites of pro-inflammatory cytokines after stimulation with BCG.  Hence, this 
gives us an important novel insight in the effects of vitamin A on the innate immune 
system, an effect that also should be tested in vivo. 
 These in-vitro studies give us very interesting and necessary insights in the 
molecular mechanism of BCG-induced trained immunity, but they are not easy to 
extrapolate for the in-vivo effects of BCG on infection. Therefore, we designed a 
trial to directly assess the impact of BCG vaccination, on the training of the innate 
immune system and clinical outcome measures. In Chapter 5 I made use of 
a surrogate model of infection; vaccination of healthy individuals with the yellow 
fever vaccine, as vaccination with this live-attenuated vaccine results in viraemia. 
Volunteers were randomized to receive either placebo or BCG. After 4 weeks they 
all received yellow fever vaccination. Indeed, volunteers that received the BCG 
vaccine showed lower viraemia and even more importantly, the amount of viraemia 
was negatively correlated with the induction of trained immunity for IL-1β production 
to non-related stimuli. In other words, when monocytes of a healthy volunteer after 
BCG vaccination produced more IL-1β when they were stimulated with a non-related 
pathogen/ligand, this volunteers showed lower amounts of circulating yellow fever 
virus. Hence, induction of trained immunity by BCG correlated with lower viraemia. 
This is a very important finding, as this is the first trial to show that the lower mortality 
numbers observed after BCG vaccination can indeed be linked to the enhanced 
function of the innate immune system that we have seen in our previous trials.  
 Lastly, in Chapter 6 I reviewed the literature for potential non-specific effects 
of other vaccines and whether they could be due to reprogramming the innate 
immune system. We concluded that it is likely that many of the non-specific effects 
of vaccines are at least partially mediated by reprogramming of the innate immune 
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system. This conclusion has several implications that warrant further research into 
the effects of vaccination on the innate immune system. A few points have therefore 
to be taken into account. In the first place, by taking into account the non-specific 
effects of vaccines, there is an incentive for a more rational design of vaccination 
policies, by delivering vaccines in an order that gives the maximum beneficial effects 
(29). Furthermore, if currently used vaccines with strong beneficial non-specific 
effects but moderate specific protective effects, such as BCG, are to be replaced by 
newer vaccines that have a greater specific protective effect, these new vaccines 
should also be evaluated for their non-specific effects. The old vaccine should not 
be withdrawn and substituted by a new vaccine without evaluation of the effect of 
this change on overall mortality. At the same time, we should be aware of the non-
specific effects of vaccines that have been phased out of vaccination policies due to 
the eradication of their target disease, such as vaccinia (worldwide), BCG (developed 
world), or perhaps in the future will be phased out, such as polio vaccine and measles 
vaccine: they could still have beneficial effects without protecting against their target 
diseases. Lastly, the study of the beneficial non-specific effects of vaccines might 
lead to the development of new strategies to use them in target patient groups at 
increased risk for infections, such as newborns, patients with inherited or acquired 
immunodeficiencies, immunosenescence in the elderly, immunotherapy in cancer, or 
other situations where boosting of the innate immune system could be helpful. 
The network of immunometabolic pathways in trained immunity
Over the last years, more and more evidence has become available that supports 
the concept that cellular metabolism is correlated with the functional state of 
immune cells (30). The field started with experiments showing that different subsets 
of lymphocytes use different cellular metabolic pathways to retrieve their energy 
from. Activated T-lymphocytes depend on high rates of glycolysis and oxidative 
phosphorylation (OxPhos) and metabolize glucose to lactate (31, 32). Memory 
T-lymphocytes depend more on lipid synthesis via mitochondrial citrate production. 
These lipids can be used to produce triacyglycerides that are being degraded by 
β-oxidation to fuel OxPhos via acetyl-CoA production (33). Furthermore, regulatory 
T-cells fuel β-oxidation and OxPhos through exogenously derived fatty acids (34). 
This, hence, shows that the phenotype of lymphocytes correlates with the source of 
energy that they use (35, 36). Subsequent studies showed that different macrophage 
functional states are associated with very distinct metabolic pathways as well, with 
the more inflammatory (M(IFNγ) or formerly M1) macrophages depending largely 
on glycolysis and showing impaired OxPhos and disruption of the tricarboxylic 
acid (TCA) cycle (37, 38), and the more anti-inflammatory (M(IL-4) or formerly 
M2) macrophages relying on OxPhos (39, 40) with an intact TCA cycle and also 
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increased β-oxidation as a result of fatty acid uptake (41). Furthermore, it is not only 
glucose metabolism, but also other metabolic pathways that play important roles in 
reprogramming and polarizing cells (42-44).
 Based on these considerations it is very likely that metabolic changes also 
occur in trained monocytes and macrophages, as there is a clear change in cellular 
phenotype. In a first study, genome-wide changes in histone modifications have 
shown to underlie trained immunity in monocytes, but the molecular mechanisms 
linking the immunological signals induced by microbial stimuli or vaccines to the 
epigenetic changes have not been deciphered. Changes in cellular metabolism, 
with a shift from OxPhos to aerobic glycolysis (Warburg effect) were shown to be 
crucial for the induction of β-glucan-induced trained immunity (45). Interestingly, 
increasing amounts of evidence links cellular metabolism to the regulation of gene 
transcription, as several metabolites from glycolysis and the TCA cycle have been 
shown to act as cofactors for epigenetic writers and erasers such as DNA and 
histone methyltransferases and demethylases, and histone acetyltransferases and 
deacetylases (42, 43). Based on this growing body of evidence, we hypothesized that 
changes in cellular metabolism in trained immunity not only reflect enhanced energetic 
needs, but also connect with immune pathways and epigenetic reprogramming, 
through the accumulation of specific metabolites modulating epigenetic processes 
that impact the functional program of the cell. 
In the second part of this thesis I focussed on the metabolic pathways induced by 
innate immune training, such as glycolysis, TCA cycle, glutamine, and cholesterol 
metabolism and discussed their effects on epigenetics and how these interactions 
could be used as therapeutic targets. 
 In Chapter 7 I assessed whether changes in cellular glucose metabolism 
accompany the induction of trained immunity by BCG, using both an in-vitro system, 
as well as the in-vivo human vaccination model. Here we showed that in BCG-
induced trained immunity glycolysis is upregulated in monocytes, which is regulated 
by the Akt/mTOR axis. Interestingly, there appeared to be a strong link between 
the metabolic and epigenetic changes. When the shift in glucose metabolism was 
inhibited, the induction of trained immunity by BCG was reduced. Also, the metabolic 
changes were epigenetically regulated, as shown by histone changes at the promoter 
sites of metabolic genes. These observations show that metabolic and epigenetic 
changes induced in trained immunity by BCG are dependent on each other. 
 In Chapter 8 we show that apart from the glycolysis pathway, also other 
metabolic pathways are essential for the induction of trained immunity. Here we 
show that glutamine metabolism is essential and that fumarate is a central regulatory 
metabolite. Fumarate, a TCA cycle intermediate, accumulated in β-glucan-trained 
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macrophages and this accumulation was essential for the induction of β-glucan-
induced trained immunity. Interestingly, when monocytes were trained with fumarate 
alone, trained immunity was induced as well and this was accompanied by genome-
wide epigenetic changes. This shows that fumarate could account for at least a 
part of the epigenetic changes induced in trained immunity. α-Ketoglutarate (another 
TCA cycle intermediate) is a known cofactor for histone lysine demethylases (KDM), 
whereas metabolites that have a comparable molecular structure to α-ketoglutarate, 
such as fumarate, are natural antagonists (46). In line with this, fumarate-induced 
trained immunity inhibited KDM5 activity, just as was seen in β-glucan trained 
macrophages. 
 In Chapter 9 I addressed the role of the cholesterol synthesis pathway for the 
induction of trained immunity. Inhibition of the cholesterol synthesis pathway inhibits 
the induction of trained immunity, and the first reactions of the pathway appear 
most important for this effect. We demonstrated that accumulation of mevalonate 
is one of the central mechanisms in the induction of trained immunity. Incubating 
monocytes with mevalonate also resulted in a trained phenotype of these cells, 
which was reflected by epigenetic changes that partially overlapped the epigenetic 
changes induced in β-glucan trained macrophages. As clinical validation we used 
monocytes from hyper IgD syndrome (HIDS) patients that due to a germline mutation 
accumulate mevalonate. Their monocytes show a pro-inflammatory phenotype and at 
expression level these monocytes showed several trained immunity characteristics, 
which strengthens the hypothesis that mevalonate accumulation could play a role in 
disease development.
 If metabolic changes play a major role in the induction of trained immunity, it is a 
plausible hypothesis that metabolism could also be involved in the development of 
innate immune tolerance: the opposite state from trained immunity, when monocytes 
are less pro-inflammatory and where cytokine responses are downregulated. In 
Chapter 10 I assessed the metabolic changes that occur in tolerance in vitro and in 
vivo during the course of sepsis and we show that during immunotolerance all major 
metabolic pathways are downregulated, resulting in ‘immunometabolic paralysis’. 
Interestingly, when tolerant monocytes of sepsis patients were treated with IFNγ, 
the metabolic paralytic state could be partially abrogated, which also resulted in 
increased cytokine production. This, hence, shows that restoring the metabolic 
state of a cell could also restore its functional effects. This observation creates new 
therapeutic options, and opens the way for metabolic modulators to enhance or 
suppress metabolic pathways in certain diseases. Recently, we have for example 
also shown that the epigenetic changes induced in immunotolerant monocytes can 
be reversed by treating these cells with β-glucan (47).
 To further extent trained immunity in other (disease) models, I investigated 
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the immunological and metabolic phenotype of tumor-associated macrophages 
(TAMs) in a model of thyroid cancer in Chapter 11. Functional analysis of thyroid 
cancer-induced TAMs show a pro-inflammatory phenotype, with increased cytokine 
production upon stimulation. Transcriptional analysis of these TAMs also shows 
major reprogramming at the level of metabolism. mTOR-induced glycolysis is 
upregulated in TAMs, and is shown to be essential for the epigenetic reprogramming 
that results in the pro-inflammatory phenotype of these cells. Inhibition of glycolysis 
(and therefore the epigenetic reprogramming) of TAMs could therefore be envisaged 
as a new therapeutic approach in thyroid cancer.
 Finally, in Chapter 12 I summarize the findings of the chapters in this second 
part of this thesis and give an overview of how glycolysis, glutaminolysis, cholesterol 
metabolism and fumarate accumulation contribute to the induction of trained 
immunity and the related pro-inflammatory phenotype. 
 In conclusion, boosting or inhibiting the innate immune system has several 
potential beneficial effects in different medical settings and modulating cellular 
metabolism of immune cells is a promising new approach to reach this goal.
FUTURE PERSPECTIVES
Immunometabolism is a field that has gained much interest the last several years, 
and has been shown to be involved in immune activation in several diseases 
such as infections, autoinflammatory disorders, and cardiovascular diseases (48-
50). Moreover, in post-sepsis immunoparalysis, we have shown that the cellular 
metabolism of monocytes has broad defects and that reversing these defects 
could at least partially restore the immunological function of these cells (44, 47, 
51). Therefore, modulation of cellular metabolism has great potential as a therapy 
in immune-mediated diseases. In autoinflammatory diseases, atherosclerosis or 
insulin resistance and diabetes in which monocytes and macrophages are thought to 
be skewed towards a pro-inflammatory profile, apart from modulating the epigenetic 
changes induced, inhibition of certain metabolic pathways may represent a valid 
approach to target disease activity (52). Moreover, the role played by cellular 
metabolic pathways for the induction of trained immunity may also represent a 
novel therapeutic approach in immunodeficiencies. Induction of metabolic pathways 
important for trained immunity should be attempted to restore immune function 
during sepsis-induced immunoparalysis. In addition, these approaches could also 
be used to improve the immune responsiveness in vulnerable groups such as the 
elderly and infants that have decreased immune function and that are more prone 
to infections (53, 54). 
 However, apart from modulating immunometabolism, inducing trained immunity 
itself could be a potential therapeutic target as well. It has for example already been 
Chapter 13
  264 | 
shown that vaccination with BCG might reduce the risk of developing lymphoma 
(55) or melanoma (56, 57) and BCG is used as immunostimulant in bladder cancer 
treatment and experimentally as adjuvant in tumor vaccination models (58). 
Furthermore, there are the observations in high-infectious disease burden countries 
where BCG protects from other infectious diseases (1). It could therefore be argued 
to reintroduce BCG in developed countries, because of its beneficial non-specific 
effects. However, a recent trial in Denmark in over 4000 babies randomized to 
receive either BCG or not, showed no differences on hospitalization. This could 
of course be due to the low infectious disease burden and the relatively high 
frequency of hospitalization due to other causes (59, 60), but it also shows that 
reintroduction in Denmark does not have overall benefits.  However, application in 
determined high(er) risk groups could therefore be of use, as for example shown 
in an Indonesian study where repeated BCG vaccination in elderly subjects (60-75 
years) reduced upper respiratory tract infections (61). It has for example been shown 
that topical therapy with BCG is very potent in the treatment of common and genital 
warts (62-64). Also in a case report of diffuse cutaneous leishmaniasis, leishmania-
BCG combined vaccination initiated healing of all lesions (18), and in a randomized 
controlled trial in localized cutaneous leishmaniasis it was shown to be as effective as 
chemotherapy (65). Hence, in situations where the immune system cannot eliminate 
chronic infection, induction of trained immunity, and therefore enhancing the immune 
response, could be a potential treatment. 
 Apart from infectious diseases, induction of trained immunity could also be of use 
in cancer treatment. Induction of trained immunity has for example been suggested 
as a therapy in haematological malignancies (66), with a small study showing 
beneficial effects of BCG on remission duration and survival after treatment of acute 
myelogenous leukemia (67). 
 Another interesting hypothesis is the combination of checkpoint inhibitors in 
cancer therapy and trained immunity. A combination of systemic anti-CTLA-4 and 
intravesical BCG has been suggested in bladder cancer (68), but this could be 
applicable to other tumors as well. Checkpoint inhibitors (e.g. anti-CTLA-4, or PD-1 or 
PD-1L inhibitors) are antibodies that block inhibitory checkpoints and thereby restore 
the immune defense against cancer cells. Hypothetically, if the blockade of inhibitory 
checkpoints would be combined with the induction of trained immunity of the innate 
immune system, this would results in an even more effective immune response 
against the cancer. Moreover, BCG vaccination has been shown to enhance NK-cell 
function, which could contribute to a more effective immune response as well (17). 
 However these hypotheses should be put into the context of chapter 11 were 
we show that tumor-associated macrophages in thyroid cancer dysplay a trained 
phenotype, and were actually the inhibition of trained immunity would be of benefit.
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 There are still several questions that remain to be answered regarding trained 
immunity. A first question that needs to be addressed is how BCG vaccination can 
result in the long-term effects on the innate immune system. Monocytes stay only 
for a few days in the peripheral blood, whereas the pro-inflammatory ‘trained’ profile 
of monocytes remains for at least 3 months in peripheral blood (14). This results 
in the assumption that the progenitor cells of the myeloid lineage in bone marrow 
are reprogrammed as well. Therefore, to test this hypothesis a trial with analysis 
of bone marrow before and after BCG vaccination should be performed. Myeloid 
precursors should be assessed for their functional profile, as well as epigenetic, 
transcriptional, and metabolic analysis to determine their trained phenotype. Apart 
from more knowledge on the mechanism how trained immunity preserves its effect, 
such a study may contribute to development of additional therapeutic applications. 
When BCG vaccination indeed results in trained bone marrow, this could be applied 
in bone marrow transplantations, where a graft versus tumor effect is essential. 
 A second question that needs to be addressed in future studies is the differential 
effect of BCG in separate volunteers in the vaccination studies. In some volunteers 
trained immunity is clearly induced with higher cytokine responses to non-related 
pathogens, whereas in others there is hardly an induction. Mutations or variations 
in the NOD2 receptor, autophagy (ATG2b), or glycolysis enzymes (14, 69, 70) have 
been shown to be of influence, but this does not explain all observed variance. 
Hence, to determine important pathways and molecular mechanisms in trained 
immunity a cohort study should be performed with sufficient power to perform genetic 
variants analysis in BCG-vaccinated individuals. This will lead to genetic variations 
that influence the induction of trained immunity by BCG; subsequently these should 
be tested in functional experiments. Also this study could lead to direct clinical 
applications. If certain genetic variants are determined, these should be tested in 
bladder cancer patients that are being treated with BCG installations, just as was 
done for the ATG2b variant (69).
 Finally, the induction of trained immunity in vivo should be optimized. Now the 
only way to induce trained immunity in humans is BCG vaccination. This comes 
with disadvantages, as the respons differs greatly between subjects, proper 
administration of the vaccine needs experience, and repeated administrations are 
not always possible due to severe local reactions. In the recent years intravenous 
administration of β-glucan has been developed as a potential novel cancer treatment 
(71). It is likely that such administarion of β-glucan is more effective and can be 
better regulated to induce trained immunity. Also with MDP (the causative componant 
of BCG) a comparable approach could be attempted. And specific direction to the 
myeloid cell line or bone marrow could even more increase effectiveness.
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In conclusion, in this thesis I have shown that BCG and β-glucan can induce trained 
immunity in human monocytes and macrophages, resulting in a pro-inflammatory 
phenotype. Trained immunity can have an impact on infections in humans, as shown 
by the reduction of yellow fever vaccine viraemia. This process is epigenetically 
mediated. Furthermore, changes in cellular metabolism are essential for the induction 
of trained immunity, with glycolysis, glutaminolysis and cholesterol synthesis as 
important pathways involved. Interestingly, this is not only true for the induction of 
trained immunity by BCG or β-glucan, but also for tumor-associated macrophages 
that show a pro-inflammatory phenotype. Also in immune tolerant monocytes from 
sepsis patients a clear modulation in metabolism is seen. Overall, this demonstrates 
that immune-metabolic pathways regulate the induction of innate immune memory. 
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Trained immunity, ofwel het geheugen van het aangeboren immuunsysteem, is 
het onderwerp van dit proefschrift. Voorheen werd gedacht dat de cellen van het 
aangeboren immuunsysteem (wij onderzochten specifiek monocyten en macrofagen) 
geen geheugen hebben en niet sterker kunnen worden. De afgelopen jaren is echter 
duidelijk geworden dat dit niet waar is en dat deze cellen wel degelijk effectiever 
kunnen worden middels een mechanisme dat we trained immunity hebben gedoopt. 
Trained immunity heeft de laatste jaren steeds meer aandacht gekregen. Dit heeft 
er met name mee te maken dat de toepassingen en gevolgen verder reiken dan in 
eerste instantie werd verwacht. 
 In mijn proefschrift bespreek ik twee onderwerpen. In het eerste deel beschrijf 
ik de niet-specifieke effecten van het BCG-vaccin. Het BCG-vaccin is gemaakt om 
tegen tuberculose te beschermen, maar gebleken is dat het naast dit specifieke 
effect, ook voordelige niet-specifieke effecten heeft. BCG beschermt ook tegen 
andere infectieziekten die niet aan tuberculose verwant zijn, een effect dat deels 
toegeschreven kan worden aan trained immunity. In dit deel van het proefschrift 
beschrijf ik de onderliggende moleculaire mechanismen voor BCG-geïnduceerde 
trained immunity en onderzoek ik of we het beïnvloeden van het aangeboren 
immuunsysteem ook toe kunnen passen bij patiënten met een immuunstoornis, bij 
de behandeling van infectieziekten, of voor het verbeteren van vaccinaties. In het 
tweede deel van mijn proefschrift focus ik vooral op de metabole veranderingen 
die in de cellen optreden tijdens het induceren van trained immunity. Het is bekend 
dat metabole veranderingen (op welke manier de cel aan zijn energie komt) 
samenhangen met de functie van een cel. Hier laat ik zien dat dat ook geldt voor 
getrainde macrofagen. Dit geeft een belangrijk inzicht voor potentiële nieuwe 
behandelingsstrategieën voor immunologische ziekten. 
BCG en trained immunity
De hypothese dat BCG ook niet-specifieke beschermende effecten heeft, kwam 
voort uit de observatie dat vaccinatie van baby’s in ontwikkelingslanden met een 
hoge infectieziektedruk resulteerde in lagere sterfte door andere infectieziekten 
dan tuberculose. Dit laat zien dat er dus een niet-specifiek geheugen binnen het 
immuunsysteem bestaat. Dit niet-specifieke geheugen kan hypothetisch gezien 
het gevolg zijn van twee mechanismen. Enerzijds trained immunity die plaatsvindt 
binnen het aangeboren immuunsysteem, of anderzijds heterologe immuniteit 
die een gevolg is van kruisreactiviteit van T-lymfocyten, dus via het verworven 
immuunsysteem. In dit proefschrift zal ik met name ingaan op de effecten op het 
aangeboren immuunsysteem, dus trained immunity. 
 In een eerste vaccinatietrial met gezonde vrijwilligers werd aangetoond dat 
BCG-vaccinatie leidt tot een hogere cytokineproductie (signaalstoffen) wanneer 
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witte bloedcellen van deze vrijwilligers in het laboratorium werden gestimuleerd met 
verschillende ziekteverwekkers. Daarnaast werd er aangetoond dat er epigenetische 
veranderingen plaatsvonden in cellen van het aangeboren immuunsysteem; dit zijn 
veranderingen in de manier waarop het DNA verpakt is. Hierdoor worden delen van 
het DNA beter of juist slechter bereikbaar, maar wordt de DNA-sequentie zelf niet 
aangepast. Dit was een belangrijke bevinding die aantoonde hoe de niet-specifieke 
effecten van BCG zouden kunnen werken. 
 Op deze bevindingen heb ik voortgebouwd in dit eerste deel van mijn proefschrift. 
In hoofdstuk 2 en 3 bekijk ik of we deze effecten van BCG-vaccinatie toe kunnen 
passen bij patiënten met een immuunstoornis. Bij patiënten met een verzwakt 
immuunsysteem zou het nuttig kunnen zijn om het aangeboren immuunsysteem 
te trainen middels een BCG-vaccinatie en het daardoor effectiever te maken.  Het 
probleem is echter dat het BCG-vaccin levende bacteriën bevat en daarom niet 
aan patiënten met een verzwakt immuunsysteem toegediend kan worden, daar dit 
in een gevaarlijke infectie zou kunnen resulteren. Derhalve hebben we het BCG-
vaccin bestraald, zodat alle bacteriën dood waren. Dit bestraalde vaccin hebben we 
vervolgens getest op de potentie om trained immunity te induceren. In hoofdstuk 
2 deden we dit allereerst in het laboratorium en lieten we zien dat monocyten en 
macrofagen inderdaad getraind konden worden met het bestraalde vaccin en dat dat 
tot dezelfde epigenetische veranderingen leidde. Vervolgens hebben we gezonde 
proefpersonen met dit vaccin gevaccineerd om te onderzoeken of hetzelfde in de 
mens gebeurde. Helaas bleek dat niet het geval te zijn. Tegelijkertijd werd er een 
tweede trial verricht waarin gezonde proefpersonen met het bestraalde vaccin werden 
gevaccineerd en een week later een experimentele bloedvergiftiging ondergingen 
op de intensive care. Ook in deze trial werd aangetoond dat vaccinatie met dit vaccin 
geen effect had op de reactie van het aangeboren immuunsysteem. Daarmee is 
dus aangetoond dat voor het beïnvloeden van het aangeboren immuunsysteem het 
levende BCG-vaccin nodig is.
 In hoofdstuk 4 bekijk ik een andere klinisch belangrijke vraag naar de effectiviteit 
van het BCG-vaccin. De Wereld Gezondheidsorganisatie (WHO) adviseert een hoge 
dosis vitamine A-supplementen in landen waar het risico op een vitamine A-tekort 
hoog is. Er zijn echter studies die laten zien dat deze supplementen ook een effect 
hebben op de niet-specifieke effecten van vaccins en dat het supplement mogelijk 
zelf ook niet-specifieke effecten heeft. In dit hoofdstuk laat ik zien dat als ik in het 
laboratorium monocyten blootstel aan vitamine A de effectiviteit van deze cellen 
langdurig afneemt. Als ze bijvoorbeeld een week later worden gestimuleerd, maken 
ze veel minder cytokines. Dit is het gevolg van epigenetische veranderingen die 
door vitamine A worden veroorzaakt. Naast dit effect van vitamine A zelf, laat ik zien 
dat vitamine A de training van BCG remt en dat daardoor het positieve effect van 
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BCG wordt tenietgedaan. Dit geeft ons dus belangrijke informatie over de potentiële 
langdurige effecten van vitamine A; iets dat ook getest zou moeten worden in 
kinderen die vitamine A-suppletie krijgen. 
 De studies in de vorige hoofdstukken geven ons interessante en belangrijke 
inzichten in het moleculaire mechanisme van BCG-geïnduceerde trained immunity, 
maar ze laten nog geen direct bewijs zien dat de training van het aangeboren 
immuunsysteem gelinkt kan worden aan de lagere sterfte door andere infectieziekten, 
zoals wordt gezien in de observationele studies. Daarom hebben we een trial met 
gezonde proefpersonen opgezet om deze hypothese te testen. In hoofdstuk 5 
maken we gebruik van het gelekoortsvaccin, omdat dit na vaccinatie een kleine 
infectie geeft met dit virus en daarom als een model voor een virale infectieziekte 
beschouwd kan worden. In dit hoofdstuk laat ik zien dat het immuunsysteem van 
gezonde vrijwilligers die met BCG zijn gevaccineerd inderdaad beter reageert op 
het gelekoortvirus en dat deze proefpersonen een kleinere hoeveelheid virus in hun 
bloed hebben. Daarnaast laat ik zien dat hoe beter het aangeboren immuunsysteem 
getraind is door BCG, hoe lager de hoeveelheid gelekoortsvirus in het bloed. 
Daarmee laten we dus zien dat er een directe link is tussen trained immunity en hoe 
het lichaam op een infectieziekte reageert.
 In hoofdstuk 6 geef ik tot slot een overzicht van alle vaccins en hun potentiële 
niet-specifieke effecten. Voor de meeste vaccins zijn er aanwijzingen dat zij meer 
teweegbrengen dan enkel bescherming tegen de ziekte waarvoor zij toegediend 
worden. Voor een aantal vaccins bestaat er ook bewijs dat deze extra bescherming 
ten minste partieel door het aangeboren immuunsysteem veroorzaakt zou kunnen 
worden. Een belangrijke conclusie die in dit hoofdstuk wordt getrokken, is dat er te 
weinig onderzoek gedaan wordt naar de niet-specifieke effecten van vaccins en via 
welke mechanismen zij werken. Aangezien deze niet-specifieke effecten belangrijke 
gevolgen teweeg kunnen brengen, zowel positief als negatief, is meer kennis 
essentieel. Daarbij dient opgemerkt te worden dat ook bij het ontwikkelen van nieuwe 
vaccins, of het vervangen of verwijderen van vaccins uit het vaccinatieschema 
rekening gehouden dient te worden met de niet-specifieke effecten. 
Immunometabolisme in trained immunity
De laatste jaren is steeds meer duidelijk geworden dat immunometabolisme (hoe komt 
een witte bloedcel aan zijn energie en welke voedingsstoffen gebruikt hij hiervoor) 
essentieel is voor de functie van een witte bloedcel. Bij cellen van het verworven 
immuunsysteem, bijvoorbeeld T-lymfocyten, is de laatste jaren duidelijk geworden 
dat geactiveerde cellen veel glucose gebruiken en lactaat (melkzuur) produceren, 
en veel meer zuurstof nodig hebben dan rustende cellen. Geheugen T-cellen 
daarentegen gebruiken juist meer vetzuren om aan hun energie te komen. Ook 
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voor macrofagen is onlangs aangetoond dat inflammatoire macrofagen veel glucose 
consumeren en veel lactaat produceren, terwijl anti-inflammatoire macrofagen dit 
veel minder doen en juist zuurstof gebruiken om de kleinere hoeveelheid glucose die 
zij opnemen efficiënter te verwerken.
 Al met al is het dus erg waarschijnlijk dat veranderingen in metabolisme van 
monocyten en macrofagen een rol zouden kunnen spelen in de inductie van trained 
immunity. Deze informatie is belangrijk, omdat het remmen of juist stimuleren van 
bepaalde metabole veranderingen trained immunity zou kunnen remmen of juist zou 
kunnen stimuleren. Op deze manier zouden we dus in bepaalde ziekteprocessen 
kunnen interveniëren.
 In hoofdstuk 7 bekijk ik daartoe allereerst de rol van het glucose- en 
glutaminemetabolisme in BCG-geïnduceerde trained immunity. Ik laat zien dat 
BCG-getrainde macrofagen inderdaad meer glucose gebruiken en meer lactaat 
produceren. Dit geldt zowel voor getrainde macrofagen in het laboratorium, als voor 
monocyten van BCG-gevaccineerde gezonde vrijwilligers. Deze veranderingen 
in het metabolisme van de getrainde cellen zijn het gevolg van epigenetische 
veranderingen. Daarnaast laat ik zien dat de epigenetische veranderingen die door 
BCG geïnduceerd worden afhankelijk zijn van de metabole veranderingen. Dit toont 
aan dat er een complexe interactie is tussen de epigenetische en de metabole 
veranderingen. 
 In hoofdstuk 8 maak ik gebruik van β-glucan; dit is een component van de Candida 
albicans (een schimmel) celwand die ook trained immunity induceert. Voor β-glucan- 
geïnduceerde trained immunity is reeds eerder aangetoond dat het glucoseverbruik 
toeneemt en dat er meer lactaat geproduceerd wordt. In dit hoofdstuk laat ik zien 
dat ook het metabolisme van glutamine en cholesterol belangrijk zijn. Daarnaast 
vindt er accumulatie van fumaraat (een metaboliet uit de citroenzuurcyclus) plaats. 
Opmerkenswaardig: als monocyten aan fumaraat worden blootgesteld, wordt er 
ook trained immunity geïnduceerd. Bovendien overlapt het epigenetische profiel dat 
door fumaraat wordt geïnduceerd met het profiel van β-glucan (alhoewel β-glucan 
meer veranderingen teweegbrengt). Dit toont aan dat fumaraataccumulatie voor een 
deel een rol speelt in de inductie van trained immunity door β-glucan.
 In hoofdstuk 9 wordt ingegaan op de tweede metabole verandering die in 
het vorige hoofdstuk wordt beschreven, het cholesterolmetabolisme. Ik laat zien 
dat een toename van cholesterolmetabolisme essentieel is voor de inductie van 
trained immunity door β-glucan. Ook in dit hoofdstuk gaan we op zoek naar een 
metaboliet uit het cholesterolmetabolisme dat een centrale rol speelt in de inductie 
van trained immunity. Dit blijkt mevalonaat te zijn. Stimulatie van monocyten met 
enkel mevalonaat induceert ook een trained immunity-fenotype met epigenetische 
veranderingen, die opnieuw deels overlappen met die in β-glucan-geïnduceerde 
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trained immunity. In dit hoofdstuk maken we ook een belangrijke stap naar de kliniek. 
Bij patiënten met het hyper IgD-syndroom (HIDS) zou namelijk trained immunity 
een verklaring kunnen zijn voor hun ziektebeeld. HIDS is een aandoening waarbij 
er door een genetische mutatie accumulatie van mevalonaat in cellen plaatsvindt. 
Deze toename van mevalonaat zou daardoor trained immunity kunnen induceren 
hetgeen ervoor kan zorgen dat de monocyten van deze patiënten te heftig reageren 
op prikkels. Analyse van monocyten van HIDS-patiënten laat inderdaad zien dat 
er overeenkomsten zijn met getrainde monocyten in het laboratorium. Dit biedt 
perspectieven voor nieuwe behandelmethoden. 
 In hoofdstuk 10 gaan we in op immunotolerantie. Dit is een functionele 
status van monocyten die als de tegenovergestelde status van trained immunity 
beschouwd kan worden. Immunotolerante monocyten zijn namelijk minder effectief 
en   immunotolerantie gaat gepaard met een hogere mortaliteit door infectieziekten. 
Dit geldt bijvoorbeeld voor patiënten na een bloedvergiftiging. Bovendien wordt 
immunotolerantie net als trained immunity gemedieerd door epigenetische 
veranderingen. Om die reden hadden wij de hypothese dat metabole veranderingen 
ook een rol zouden kunnen spelen in immunotolerantie. In dit hoofdstuk analyseren 
we daarom monocyten en macrofagen die in het laboratorium immunotolerant zijn 
gemaakt, en we analyseren ook monocyten van patiënten met een bloedvergiftiging. 
We laten zien dat cellen in de immunotolerante status een te traag werkend 
metabolisme hebben, waarbij geen enkele van de metabolieten die potentieel voor 
energie kan zorgen gebruikt wordt. Wij denken dat hierdoor de cel niet goed kan 
functioneren. Het activeren van het cellulair metabolisme zou daarom een goede 
therapeutische ingreep kunnen zijn. Wij hebben derhalve gepoogd met IFNγ het 
glucosemetabolisme weer te activeren. Dit lukte zowel in het laboratorium als in 
patiënten, waarbij ook de mogelijkheid van deze cellen om cytokines te produceren 
toenam. Dit geeft dus aan dat modulatie van metabolisme inderdaad als therapie 
gebruikt zou kunnen worden.
 In hoofdstuk 11 maken we een stap naar een ander ziektebeeld, 
namelijk schildklierkanker. Ik bekijk welke veranderingen macrofagen in 
schildklierkankerweefsel ondergaan. We laten in dit hoofdstuk zien dat deze 
macrofagen, ook wel tumor-geassocieerde macrofagen (TAMs) genoemd, een 
trained immunity-profiel aannemen. Zij produceren namelijk meer cytokines, er 
is een toename in glucosemetabolisme, zij produceren meer lactaat en dit alles 
wordt gemedieerd door epigenetische veranderingen. Aangezien meer TAMs in 
het tumorweefsel geassocieerd is met een slechtere prognose, zou remming van 
trained immunity (bijvoorbeeld door remming van het glucosemetabolisme) een 
interessante nieuwe therapeutische methode kunnen zijn.  
 In hoofdstuk 12 vat ik tot slot de metabole veranderingen die een rol spelen in 
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trained immunity samen en geeft ik een overzicht van hoe glucose, glutamine en 
cholesterol metabolisme een rol spelen in de inductie van trained immunity.
 Concluderend, ik heb laten zien dat immunometabolisme een rol speelt in trained 
immunity en daarmee dus belangrijk zou kunnen zijn in verschillende ziektebeelden 
als infectieziekten, auto-inflammatoire aandoeningen, cardiovasculaire ziekten, of 
kanker. Daarnaast heb ik laten zien dat ook in immunotolerantie, na bijvoorbeeld 
een bloedvergiftiging, het cellulair metabolisme een belangrijk falend mechanisme 
is. Dat maakt modulatie van het immunometabolisme en het moduleren van trained 
immunity een potentieel belangrijke nieuwe therapie om in deze ziektebeelden te 
interveniëren. 
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